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Abstract 
 
Chronic venous disorder (CVD) is common affecting 30-40% of the general 
population. The symptoms include pain, ambulatory discomfort and cosmetic 
embarrassment with signs of varicose veins, gaiter pigmentation and leg ulceration. 
The post-thrombotic syndrome (PTS) occurs as the aftermath of a deep vein 
thrombosis. 
 Standard evaluation tools are used to assess CVD so that the severity of 
disease and the beneficial effects of treatment can be recorded. This is an essential 
ingredient for all controlled trials. Measurements of effectiveness allow different 
treatments, similar treatments between different hospitals and the natural history of 
untreated disease to be assessed and compared. Cost is an important component of a 
cost-effective analysis.  
 This thesis provides a critical analysis on the ways in which patients are 
assessed with novel suggestions for improvement. 
 The aim of this work is to examine the following scoring 
systems/questionnaires and to provide evidence as to how they can be improved: 
 1. The clinical part of the CEAP classification 
 2. The venous clinical severity score 
 3. The Aberdeen varicose vein questionnaire 
 4. The Villalta scale 
The following haemodynamic tests will also be assessed together with novel 
applications: 
 1. Duplex 
 2. Air-plethysmography 
 6 
Normal controls, patients with primary CVD and patients with PTS are the subjects 
used in this research. Most belong to 2 controlled trials. The first compares 
endovenous laser ablation (EVLA) with ultrasound-guided foam sclerotherapy 
(UGFS) and the second compares stockings of different lengths and compression 
strengths in treating PTS patients. 
 The main innovations in assessment are the saphenous treatment score, the 
saphenous pulse and the venous filling time to 90% of the venous volume (VFT90) in 
the identification of patients with mild clinical disease. The main validation is the 
clinical and haemodynamic correlations with the Villalta scale, and the main 
limitation is the use of the C of CEAP in the assessment of clinical severity. 
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SPJ  Sapheno-popliteal junction 
SSV  Small saphenous vein 
STS  Saphenous treatment score 
SVI  Superficial venous insufficiency 
T-UGFS Tumescence-assisted UGFS 
TAMV Time average mean velocity 
TED  Thrombo-embolic deterrent 
TV  Tricuspid valve 
UGFS  Ultrasound-guided foam sclerotherapy 
U/S  Ultrasound 
VAS  Visual analogue scale 
VCSS  Venous clinical severity score 
VCT  Valve closure time 
VEINES VEINES-QOL/Sym. Veins insufficiency epidemiological and  
  economic study 
VER  Venous elastic recoil 
VF  Volume flow 
VFI  Venous filling index 
VFT90 Venous filling time to 90% of the VV 
VFT100 Venous filling time to 100% of the VV 
VM  Valsalva manœuvre 
VPG  Venous pressure gradient 
VS  Villalta scale 
VSDS  Venous segmental disease score 
VV  Venous volume 
VVs  Varicose veins 
 
* Refers to the same questionnaire but different practices usually choose one 
abbreviation over the other. Both are included in this thesis.  
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PART  I 
 
 
 
CHAPTER  1 
 
 
 
REVIEW OF THE LITERATURE 
 
 
What gets measured gets managed. 
 
-- Unknown 
 
 
1.1 Introduction 
1.11 The need for improving assessments 
Almost all vascular surgeons and phlebologists know the best way to treat varicose 
veins from techniques they have developed over many years. Similarly, they are also 
aware of the causes of recurrent varicose veins. Historical phrases include: “failure to 
perform a flush ligation and interruption of all the tributaries”, “that’s what happens if 
you don’t strip the vein”, and “inadequate groin surgery by juniors”. These phrases 
have now been superseded to reflect the endovenous revolution: “failure to ablate the 
below-knee part of the GSV”, and “failure to eliminate all areas of reflux”. It is 
extraordinary that the SFJ is now avoided purposefully by about 2 cm which is a 
major shift in the treatment paradigm. Accurate assessments may have prevented 
these misconceptions.  
 Another cause of recurrence can be failure to select the correct treatment 
method. There are several to choose from including laser, foam, steam, 
radiofrequency, cryotherapy, hooks, strippers, endothelial abrasion and glue. In the 
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hand of “experts” the results are very good with little to discriminate one treatment 
from the other. Advances in assessment may help to determine which method is 
better. 
 The treatment aims are also blurred. Is the preferred endpoint occlusion or the 
abolition of reflux with saphenous conservation? It is also extraordinary that some 
phlebologists do not consider reflux a failure if it serves as a drainage pathway even 
though there is reversal of venous flow towards the foot. Should the intervention be 
tailored to the pathophysiology? For example, saphenous and junction treatments for a 
descending aetiology, tributary treatments for an ascending aetiology. 
 The focus of this thesis is on assessment rather than another treatment 
technology because investment in assessment is likely to have a greater impact for 
patients. It will help in the selection of the correct instrument option, define the aims 
of treatment and evaluate the causes of recurrence. 
 Regarding PTS there is controversy as to its definition and as to how severe 
the symptoms and signs should be before patients can be labelled. Haemodynamic 
assessments of outflow resistance are in their infancy and therefore the efficacy of 
treatments at relieving iliac obstruction remains subjective. Should the afterload of the 
calf-muscle pump (reflux) contribute to increased outflow resistance? Stockings are 
the mainstay of treatment but which are the best in haemodynamic terms and should 
they be customised for the patient? Furthermore, the mechanisms of venous return at 
rest needs clarification since their impairment is the cause of most venous disorders in 
the leg. If this can be measured then the efficacy of treatment can be assessed with 
more clarity. These and many more questions can be answered only with investment 
into assessment technology rather than newer treatments. 
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1.12 Standardisation 
 
Uniform reporting standards are a major step towards improving assessment. This 
facilitates comparision between different treatments at different centers, a prime 
element in all clinical studies. This was highlighted in a special communication from 
the Society of Interventional Radiology and the American Venous Forum in 2007 
(Kundu, Lurie et al. 2007). Their main objective was to improve the quality of 
research on venous disease. However, heterogeneity of reporting standards is a 
common occurrence (Thakur, Shalhoub et al. 2010). In that manuscript which 
reviewed 28 studies the proportion of patients with C2 disease ranged from 6.3% to 
83.5% and a total of 31 different outcome measures were used. Furthermore, duplex 
ultrasound was used in only 21/28 trials to assess recurrence and quality of life was 
only evaluated in 11/28. The need for the use of a prospectively agreed population 
was suggested and the recommendations by the SIR and AVF were supported. The 
importance of a uniform venous terminology in reporting was summarised in a recent 
article (Vasquez and Munschauer 2010).  
 Standard definitions are equally important. Perhaps the most controversial and 
blurred definition is that of recurrence. Discrimination between clinical recurrence 
and duplex recurrence of varicose veins is important. Then there is also the grey area 
between residual veins, recurrent veins, new veins, neovascularisation and how to 
evaluate staged treatments. Of course recurrent QoL impairment and return to 
baseline severity are different assessment parameters but should they be included as 
recurrence? This leads on to defining the aim of treatment. Should this be directed at 
relieving CVD or obliterating varices? The REVAS consensus document 
acknowledges the problems and the need for a standard definition (Perrin, Guex et al. 
2000). It states at the outset that the frequency of recurrence is between 20% and 80% 
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depending on the definition of the condition. It endorsed the following blurred 
definition: “the presence of varicose veins in a lower limb previously operated on for 
varices”. However, despite the statement “it is time to move to a precise terminology” 
the impact of the report was a list of recommendations for future studies. Currently, 
the report is undergoing a revision to include endovenous treatment modalities. 
 The terminology of CVD has been updated to prevent non-uniform use or 
misuse of a number of venous terms (Eklof, Perrin et al. 2009). It defines chronic 
venous insufficiency as advanced chronic venous disorder, the later of which includes 
the full spectrum of morphological and functional abnormalities in the venous system. 
The greatest confusion in venous haemodynamics relates to the word proximal, which 
should be avoided to prevent ambiguity unless the context of the sentence does not 
depend on this word.     
 Standardisation of induction tests to augment venous flow is necessary in most 
situations. These help to minimise error by the removal of confounding variables. 
Unlike the arterial circulation veins to do not have a standardised cyclical force 
driving venous return. Consequently induction tests are required to challenge flow to 
determine how this behaves under normal and pathological conditions. The manual 
calf compression and release manoeuvre (MCCR) for example is performed manually 
by the vascular ultrasound specialist. Differing hand sizes, compression sites and 
duration and speeds of release are confounding variables. The use of an automated 
pump would standardise these variables (Kakkos, Lin et al. 2009). Similarly, a 
Valsalva manoeuvre can be standardised using a ball and a tube during restricted 
exhalation (Jeanneret, Labs et al. 1999). The measuring point when recording the 
diameter of the GSV should also be performed using a standardised technique 
(Mendoza, Blattler et al. 2013).  
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1.2 Assessing clinical severity  
 
1.21 Introduction 
The importance of this cannot be overestimated. Accurate measurement of severity 
permits evaluation of the disease geographically, its natural history, between different 
treatments and the same treatment in different hospitals. If it can be measured then it 
can be managed. However, the assessment must be accurate. 
 Rationing treatment for varicose veins is a driving force for improving the 
accuracy in assessing severity. In a questionnaire study completed by 307/411 
vascular surgeons, 54% had local referral guidance and 46% restricted access to 
outpatient consultation (Lindsey and Campbell 2006). One-hundred and thirty 
consultants did not see patients with only cosmetic concerns despite the fact many 
may have had gross interference with their lives. Unsurprisingly, the introduction of 
rationing has been shown to reduce the workload by 37% (Harris, Davies et al. 2006). 
This followed the introduction of criteria to control the cosmetic demand. The 
selection was based on the presence of ulceration, skin changes, bleeding and 
thrombophlebitis. One could argue that these are not routine elective conditions, each 
following a different treatment pathway, and that they distract attention from the main 
issue of elective rationing. A report on rationing surgery based on the presence or 
absence of varicose veins was more focussed (Tiwari, Douek et al. 2002). It took into 
account aching, throbbing, itching and cramps alongside cosmesis and suggested that 
ranking symptoms would be more usefull. NICE are currently updating their 
guidelines (Varicose veins in the legs. 2012). 
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1.22 Assessing quality of life 
This section is perhaps the most important because CVD affects the QoL of patients 
and the main aim of treatment is to improve QoL. To this end the AVVQ was 
developed as a postal questionnaire using measures of health status specific to the 
condition. It has been shown to be reliable and has been validated to measure what is 
intended (Garratt, Macdonald et al. 1993). That work included measures of internal 
consistency using Cronbach’s alpha and the “eigenvalue” to explain variation between 
patients. Since then the AVVQ has been benchmarked against the SF-36 and a 
patients’ symptoms and concerns questionnaire (Smith, Garratt et al. 1999). That 
study confirmed reliability and validity as well as improvement in 137 patients, 6 
weeks following surgery. Similar studies in the Netherlands have confirmed reliability 
and validity (Klem, Sybrandy et al. 2009b) as well as responsiveness following 
treatment (Klem, Sybrandy et al. 2009a). 
 Four further studies on AVVQ responsiveness are worthy of note. The first 
examined patient, operative and surgeon factors in 203 consecutive patients, C2-6, 
following saphenous and perforating vein surgery (Mackenzie, Lee et al. 2002). They 
concuded that this led to an improvement in the AVVQ in 87% at 2 years. They 
stressed the importance of a multivariate analysis because this revealed recurrent 
surgery, C4-5 as a significant negative factor and GSV surgery as the only significant 
positive factor. Furthermore, pre-operative AVVQ scores had the largest effect on 
post-operative improvement.  
 The second study compared 7,167 post treatment AVVQ questionnaires to 
their pre-treatment scores (Nesbitt, Wilson et al. 2012). The average pre-operative and 
post-operative AVVQ scores were 18.75 and 10.76, respectively. They noticed that 
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the lowest improvements were witnessed in patients with the lowest pre-operative 
scores (least severe symptoms).  
 The third study compared the AVVQ, before and at 6 weeks, with clinical, 
anatomical and haemodynamic assessments in 443 legs from 317 patients following 
EVLA, RFA and open surgery (Shepherd, Gohel et al. 2011). They concluded that all 
measurements were responsive to change but correlations between the AVVQ, 
clinical and haemodynamic outcomes were weak.  
 Finally, Ted King’s and his team experience, with concomitant UGFS and 
EVLA on 1,114 legs in 924 consecutive patients revealed a significant improvement 
in AVVQ at 2 years (King, Coulomb et al. 2009). The mean baseline AVVQ 
improved from 11.8 to 2.2 (P < 0.001).  
 Generic QoL questionnnaires remain important in assessments because they 
allow comparison with interventions for other chronic conditions. This was illustrated 
in a study on 284 patients using the Short Form-12 and a questionnaire enquiring 
about lower limb symptoms (Darvall, Bate et al. 2012). They concluded that physical 
and mental QoL was significantly worse in varicose vein patients with lower limb 
symptoms irrespective of the clinical stage of the disease, measured using the C of 
CEAP. They also stated that VVs are not primarily a cosmetic problem and rationing 
treatment to C4-6 excludes many patients who would benefit from intervention.  
 Questions which focus on QoL but are not part of a validated questionnaire are 
also important. Two studies reflect this statement. The first examined the outcome of 
VV surgery at 10 years on clinical findings, symptoms and patient satisfaction in a 
consecutive cohort of 100 patients (Campbell, Vijay Kumar et al. 2003). Only 30% of 
patients were free of recurrent VV at 10 years: 44% had “just a few” varicosities 
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while 26% had VVs “as badly as before”. Only 34% were not “generally pleased” 
because of continuing symptoms, recurrent VVs and other miscellaneous reasons.  
 The second study assessed the effects of CVD on activities of daily living and 
QoL on 5,187 subjects. They discovered that most of the respondents had some CVD 
symptoms with women being 1.5 to 3 times more likely to report leg symptoms. The 
risk of developing the most frequent subjective symptoms such as heaviness and 
tiredness in the legs was not statistically different for younger subjects. 
 There are several other QoL questionnaires besides the AVVQ, the validity of 
which has also been proven. These include the CIVIQ, VEINES-QOL/Sym and the 
EQ-5D. Each will be discussed in turn. The CIVIQ is a disease specific questionnaire 
which was finalised in a study involving 2,001 subjects (Launois, Reboul-Marty et al. 
1996). It was validated in subjects who were asked to score both the severity of their 
problems and the importance they attributed to each problem on a 5-point Likert scale 
(Edwards and Kenney 1946). Tests were made for internal consistency and 
reproducibility and this was then validated in a randomised clinical trial on 934 
patients in order to demonstrate responsiveness to change. The result was a 20-item 
self-administered questionnaire which explored psychological, physical, social 
functioning and pain components. Like the AVVQ, in a subsequent study on 291 
patients, there were significant discrepancies between this instrument and clinician 
reported outcomes of CVD (Chassany, Le-Jeunne et al. 2006).  
 The VEINES-QOL/Sym is a 26-item patient reported QoL questionnaire 
tested in 166 general practices and 116 specialist clinics in Belgium, France, Italy and 
Canada (Quebec) for reliability, validity, reproducibility and responsiveness. The 
authors claim that it is the only fully validated measure of QoL across the full 
spectrum of CVD, and not just VVs (Lamping, Schroter et al. 2003).         
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 The EQ-5D is a generic PROM. It is a standardised instrument for measuring 
health outcomes. It is designed for self completion and suited as a postal questionnaire 
and face-to-face interviews in a clinical setting. It was evaluated using a considerable 
amount of data generated from a study commissioned from the DoH and this has been 
reported recently (Devlin, Parkin et al. 2010). The study used 2 novel methods of 
analysing and displaying the EQ-5D data, from which they were able to show striking 
QoL differences between surgical procedures. The advantages of using generic 
PROMS are therefore supported when comparing procedures on hips, knees, hernias, 
veins and cataracts. 
 Quality of life assessments are also important in regard to evaluating the PTS 
and compression therapy. In a study of 41 patients with a previous DVT, of which 
46% had PTS, the generic SF-36 was compared to the disease specific VEINES-
QOL/Sym (Kahn, Hirsch et al. 2002). In this study there was no difference in the SF-
36 scores between the 2 groups. However, the mean VEINES-QOL scores were 
significantly worse in the PTS subjects, 44.5 versus 54.8, P < 0.001. The mean 
VEINES-Sym was also worse in this group, 45.6 versus 54.1, P = 0.003. They 
concluded that generic QoL assessments may not capture impact on disease specific 
QoL. Another study evaluating the effect of a venous-return assist device in 26 severe 
PTS patients revealed an improvement in the mean VEINES scores from 50.2 in the 
control group to 52.5 in the study group P = 0.004. The differences in both studies, 
though statistically significant, are small in absolute numbers which may question the 
clinical significance of these findings. 
 Compression therapy is rarely quantified using validated QoL questionnaires 
however, compliance may be a surrogate QoL marker and questions enquiring about 
QoL may yield important information. Analysis of 110 returned detailed 
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questionnaires in 200 consecutive patients with C2-6 disease receiving compression for 
>2 weeks revealed that 29.1% voted the therapy as comfortable and 37% had an 
improvement of their leg symptoms (Reich-Schupke, Murmann et al. 2009). 
However, patients with a leg ulcer and longer duration of therapy experienced a worse 
QoL.  In another study on 3,144 new patients with CVD only 21% reported using 
stockings on a daily basis and 63% did not use them at all (Raju, Hollis et al. 2007). 
Compliance was better at 50% in patients who gave a prior history of DVT compared 
to 35% in those without such history.  
 
1.23 Assessing clinical stage 
Quality of life alone is not sufficient for assessing patients. Objective assessments 
using markers of disease or clinical evidence of impairment are necessary because, as 
stated previously, correlations against QoL are usually poor (Shepherd, Gohel et al. 
2011). In clinical practice there are patients with excellent improvement in an 
objective assessment but report no change in QoL and vice versa (Davies 2003). The 
C of the CEAP classification is the most well known and popular benchmark in 
assessing objectively the stage of the disease. 
 It was developed in 1994 in Hawaii by an ad hoc committee of the AVF led by 
Bob Kistner, Bo Eklöf and Andrew Nicolaides (Moneta 2003). It was likened to the 
Tumour-Nodes-Metastasis staging system in cancer in providing a classification 
system of CVD. The C part – clinical features, the E part – etiological factors, the A 
part – anatomical distribution and the P part – underlying pathophysiology. The C part 
is the most used part of CEAP. It is now an essential component of reporting 
standards and has been published in 13 languages and on 5 continents. It paved the 
way for realising the importance of uniform venous terminology in reports on 
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varicose veins (Vasquez and Munschauer 2010). However, weaknesses were 
recognised and these have been addressed in a revision (Eklof, Rutherford et al. 
2004).  
 There were several definitions that were reinforced. Three of interest were the 
size of the varicose vein as 3 mm or greater, the inclusion of saphenous veins as 
varicose if they demonstrated reflux and the loose definition of pigmentation as 
brownish darkening of the skin resulting from extravasated blood. This implies that 
callipers, duplex and histology are required in the clinical classification which is not 
strictly “based solely on clinical appearance” requiring duplex and other 
investigations to “largely define the E, A, and P categories”.  The essential change in 
the classes was the division of class C4 into two subgroups: C4a (pigmentation or 
eczema) and C4b (lipodermatosclerosis or atrophie blanche). Also of importance was 
the affirmation that CEAP was not a static classification. Assessments using changes 
in CEAP before and after treatment have been reported (Kakkos, Rivera et al. 2003; 
Bountouroglou, Azzam et al. 2006). 
 Predictably, the global recognition of CEAP has opened up the opportunity for 
comments. One such study published in the first issue of a journal, which 
subsequently terminated, examined the reproducibility of the C classes of CEAP (Uhl, 
Cornu-Thenard et al. 2001). They tested the intra-observer reproducibility on 25 
patients and the inter-observer reproducibility on 27. The former was good with a 
kappa coefficient of 0.85 but the later was worse with a kappa coefficient of only 
0.47. They highlighted the problematic area as the assessment of varices, 
telangectasiae and mild cases of oedema and pigmentation. They concluded that the 
definition of each C class was not sufficiently accurate from an operational point of 
view.  
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 In a review article on the gold standards and limits on CEAP a further point 
was raised that CEAP is not a severity classification (Rabe and Pannier 2012). This 
was repeated again in the discussion with evidence to the contrary. They stated that 
reflux prevalence increases with higher C stages (Maurins, Hoffmann et al. 2008), that 
patients’ QoL decreases with higher C classes (Kahn, M'Lan C et al. 2004) and the C 
class correlates significantly with foot volumetry (Danielsson, Norgren et al. 2003). In 
another study with 16,251 subjects, the presence of reflux correlated likewise with 
increasing C class (P < 0.0001) (Chiesa, Marone et al. 2007). Furthermore, the advice 
in using basic C was to use the “single highest descriptor” which implies a hierarchy 
of some type. This was also stated in the UIP world conference in Rome in 2001 that 
“a limb will be represented by the most severe clinical class present in that limb” 
(Allegra, Antignani et al. 2003). Given the number of clinical trials which use the C of 
CEAP as a benchmark of severity this leaves the reader somewhat confused. Perhaps 
they meant to say that the C class was not a “progressive” classification with 
telangectasiae developing into varicose veins then pigmentation and later into ulcers, 
without missing a step.  
 Other issues raised include the suggestion that corona phlebectatica 
paraplantaris should be C3 and not C1 (Uhl, Cornu-Thenard et al. 2005), that the 
development of computer software would help the classification (Cornu-Thenard, Uhl 
et al. 2004) and that most reseach into refinements should be directed towards the 
problematic early C stages (Antignani, Cornu-Thenard et al. 2004).     
  
1.24 Assessing severity of disease 
The VCSS arose from the AVF’s ad hoc committee on venous outcomes assessment 
(Rutherford, Padberg et al. 2000). It was developed because of a need to compare the 
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outcomes of 2 or more treatments in a clinical trial, or the same treatment in 2 or more 
reports from the literature. The CEAP classification was not considered fit for this 
purpose because many of its components are relatively static whilst others use 
detailed alphabetical designations. The VCSS is based on the best gradable and 
responsive elements of CEAP. They claim the scoring system is a 30-point flat scale 
meaning that each grade of each element has the same weight. Once developed field 
testing was required for iterative improvements.  
 The next 3 publications in the JVS tested the VCSS. The performance 
characteristics were studied in 128 legs from 64 consecutive patients with CVD and 
compared to CEAP (Meissner, Natiello et al. 2002). The scores for pain, inflammation 
and pigmentation showed significant inter-observer variability (P < 0.05). However, 
the interobserver agreement on the absence or presence of severe disease, scores < 3 
versus scores > 8, was good with kappa values of 0.59 and 0.65, respectively. They 
concluded, unsurprisingly, that there was a good correlation with CEAP: r = 0.84; P < 
0.0001. 
 The second publication examined the changes in the VCSS in 48 legs 
following superficial venous surgery. Six months after surgery, the median percentage 
change in VCSS and the 18-point CEAP clinical score were 73% and 70% 
respectively. The corresponding change in the CEAP clinical class was only 17%, 
thus confirming the hypothesis that then VCSS was more responsive to treatment. As 
in the previous publication, there was an excellent correlation between the VCSS and 
CEAP clinical class: r = 0.83; P < 0.001. It has been pointed out that these high 
correlations were not just expected, but a certainty, because the VCSS is derived from 
the CEAP clinical score, itself derived from the CEAP clinical class (Beresford 2003). 
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 The third publication tested the VCSS against duplex abnormalities in 420 
legs from 210 subjects as part of a screeing project for protein C deficiency (Ricci, 
Emmerich et al. 2003). The VCSS was 0 in 283 legs and ≥1 in the remainder. Legs 
with a VCSS ≥1 had a 26-fold greater chance of duplex abnormaities, and when it was 
0 there was a high likelihood that the patient did not have CVD.  
 In 2007, the response of the individual components of the VCSS were assessed 
in 682 legs at baseline, 4 days, 4 weeks, 4 months and 12 months following RFA 
(Vasquez, Wang et al. 2007). There was a step wise improvement in all 10 
components at these time points. The authors concluded that the VCSS was an 
excellent stand alone tool for assessing outcomes after saphenous RFA. Three years 
later the same author led the revision of the VCSS as part of a special communication 
of the AVF ad hoc outcomes working group (Vasquez, Rabe et al. 2010). Although 
the basic structure remained unchanged the revision focussed on clarifying 
ambiguities, updating terminology and simplifying application. The main changes 
related to the distribution of oedema rather than a time point (Q.3), introducing the 
perimalleolar area (Q.4, 5, 6), and including corona phlebectatica paraplantaris 
(Q.2). An instruction sheet is now supplied for using the revised VCSS. The rVCSS 
has been assessed for repeatability (k = 0.68; P < 0.0001) and reproducibility (k = 
0.72; P < 0.000001) in 136 legs. As before, the rVCSS correlated well (P < 0.0001) 
with the CEAP clinical class (Marston, Vasquez et al. 2013).  
 A detailed study assessing 5,814 legs in 2,907 participants as part of the 
National Venous Screeing Programme was performed to validate the VCSS with other 
assessment tools (Passman, McLafferty et al. 2011). These included CEAP clinical 
stage, the CIVIQ quality of life instrument and duplex scanning. The CEAP clinical 
stage was: C0: 26%; C1: 33%; C2: 24%; C3: 9%; C4: 7%; C5: 0.5%; C6: 0.2%. The 
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study concluded that, as there were correlations which were driven by the individual 
components of the VCSS, this may reflect that the VCSS has a more global 
application in determining overall severity of venous disease. Interestingly, this work 
summarised the statistical properties of CEAP clinical stage as “consecutive ordinal 
variables of increasing severity” and that of the VCSS which “stratifies severity of 
each attribute and may be more accurate in determining severity distribution”. 
 The global application of the VCSS for CVD stated in the publication above 
can be questioned. Firstly, it is not a QoL instrument and the only question regarding 
symptoms is question 1 about pain. Secondly, it was validated on varicose veins 
patients and not the full spectrum of CVD, which includes acute DVT and PTS. These 
deficiencies are covered by the VEINES-QOL/Sym which encompasses acute DVT 
(Kahn, Lamping et al. 2006) and PTS (Kahn, Shbaklo et al. 2008). Its strength is that 
the questions are global and about “your leg problem” and do not focus on varicose 
veins or ulcers as in the AVVQ and VCSS, respectively (Lamping, Schroter et al. 
2003). 
 The PTS has developed its own scoring system. Out of the competition 
between the Villalta (Villalta, Bagatella et al. 1994), Ginsberg (Ginsberg, Turkstra et 
al. 2000), Brandjes (Brandjes, Buller et al. 1997) and Widmer (Widmer, Stathelin et 
al. 1981) systems, the VS seems to be the most popular based on a systematic review 
(Soosainathan, Moore et al. 2013). The authors state that it was able to fulfil all the 
criteria described: interobserver reliability, association with ambulatory venous 
pressures, ability to assess severity of PTS, ability to assess change in conditions over 
time and association with patient-reported symptom severity.  
 The VS was proposed by Prandoni in 1992 and first published in abstract form 
by Sabina Villalta (Villalta, Bagatella et al. 1994). It is a clinical scale to diagnose and 
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classify the severity of PTS and its measurement properties have been published in a 
review article (Kahn 2009). It was shown to have good physician-physician inter-rater 
reliability with a kappa of 0.78, 0.77, 0.80 and 0.75 for the total score, signs score, 
symptoms score and PTS severity category (Villalta, Bagatella et al. 1994). There was 
a good correlation with QoL demonstrated in a study of 41 out-patients with a DVT 
(Kahn, Hirsch et al. 2002). In that study patients with severe PTS, measured by the 
VS, had VEINES-QOL scores that were on average 21 points lower than patients 
without PTS (P < 0.001).  The VS was also responsive to changes in PTS severity in 2 
studies. The first analysed 359 patients 4 months after DVT and noticed that 
worsening of the VS was associated with a deterioration in generic physical QoL (P < 
0.001) and disease specific QoL (P < 0.001) (Kahn, Ducruet et al. 2005). The second 
was a RCT that evaluated a novel venous return device for severe PTS in 32 patients 
(O'Donnell, McRae et al. 2008). In that study, the effect of a mean 3.1 improvement 
in the VS was paralleled by greater patient reported benefit and a significant 
improvement in venous disease-specific QoL. The review concluded that information 
on assessing the reliability of the symptom component, the value of assigning 
numerical points for ulceration, and further assessing the responsiveness in groups of 
patients with different severity categories is needed (Kahn 2009).  
 The frequency of PTS diagnosed using the VS was assessed in a RCT as part 
of the CaVenT study (Enden, Haig et al. 2012). In this study the 2 year outcomes in 
189 patients after catheter-directed thrombolysis were compared to 108 patients 
receiving standard treatment for acute iliofemoral DVT. In the control group 55.6% 
developed PTS versus only 41.1% in the CDT group (P = 0.047), representing an 
absolute risk reduction of 14.4%.  
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 The VS has been recommended for use in defining PTS as part of a 
standardisation on behalf of the subcommittee on control of anticoagulation of the 
scientific and standardisation committee of the international society on thrombosis 
and haemostasis (Kahn, Partsch et al. 2009). However, there are limitations to the VS 
which may need to be addressed in order to improve the measurement properties 
(Strijkers, Wittens et al. 2011). These include incorporation of venous claudication as 
a patient symptom and further evaluations on assessing intra-rater reliability. 
 The power of any scoring instrument for CVD is its ability to record venous 
symptoms. The Edinburgh vein study addresses this point (Bradbury, Evans et al. 
1999). This was a cross sectional survey of men and women between 18 and 64 years 
who were asked to fill in a questionnaire on the presence of leg symptoms which was 
then followed up by a clinical examination. In men only itching was related to trunk 
varices (P = 0.011). In women only, heaviness or tension (P ≤ 0.001), aching (P ≤ 
0.001), and itching (P ≤ 0.005) were related. They concluded that even in the presence 
of trunk varices most leg symptoms probably have a non-venous cause.  
  
1.3 Assessing haemodynamic severity 
 
1.31 Introduction 
 
It is generally accepted that the worse the reflux, the more the obstruction and a 
deteriorating calf muscle pump (CMP) all represent failure of the anti-gravitational 
mechanisms of the leg. These are the three main categories of haemodynamic 
impairment which may lead to CVD, on their own, or in combinations. The words 
“worse”, “more” and “deteriorating” are imprecise and require exact definitions in 
order to measure these 3 categories. Their widespread use may reflect the difficulty in 
qnantifying pathology. 
 52 
 Colour duplex, plethysmographic techniques, (strain-gauge, air and photo-
plethysmography) and direct imaging with CTV, IVUS or ascending/descending 
venography are the main tools used to assess haemodynamic severity. Since this work 
involves duplex and air-plethysmography alone, this section will be focused on these 
2 investigations. 
 Air-plethysmography was introduced as an upgrade to the 2 dimensional 
strain-gauge plethysmography currently in existence (Christopoulos, Nicolaides et al. 
1987). It records acute changes in calf volume thus summarising the net effect of 
antegrade flow, reflux, obstruction and calf-muscle pump function. The ideas of 
Andrew Nicolaides and the development skills of Edward Arkans combined with the 
innovative elements from Dimitri Christopoulos led to the working prototype. This 
was tested in the space station in a situation of zero gravity and on the author in 1987 
as a normal control in Hull by Dimitri.  
 The use of strain-gauge plethysmography was developed as a non-invasive 
way of quantifying ambulatory venous pressure. Up until then this was measured with 
dorsal foot vein cannulation connected to a pressure transducer. In a study on 50 legs 
in 27 subjects using strain-gauge plethysmography compared to pressure 
measurements from foot vein cannulation the results indicated that it was possible to 
differentiate between normal legs, those with SVI only, those with DVI only and 
those with DVI and occlusion (Fernandes, Horner et al. 1979). A similar experiment 
was performed using APG in 104 legs (Christopoulos, Nicolaides et al. 1988b). Using 
the VFI in mL/sec it was possible to discriminate between normal, varicose veins, 
varicose veins with skin changes and legs with popliteal vein reflux. However, 
judging by the published charts, there was considerable overlap and the report was 
conspicuous by its lack of P values.  
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   In a study on 294 legs in 154 patients with varicose veins categorised by the 
C of CEAP there were significant differences in the VFI between C0-1 compared to C2-
6, P < 0.05 (Nishibe, Kudo et al. 2006). That study concluded that the VFI of APG 
was a reasonable method for distinguishing the presence or absence of CVD but it 
could not discriminate clinical severity. However, this is not too surprising because 
there were only 8 legs in C5-6 and the deep veins were intact. This made the 
distribution of venous disease skewed and of narrow range in comparison to the 2 
earlier studies mentioned above. 
 A study on 274 legs from 149 patients and 56 legs from 28 volunteers 
attempted to correlate clinical severity with haemodynamic severity using APG 
(Welkie, Comerota et al. 1992). From C0 to C2 the VV and VFI increased with a 
reduction in EF, but there was no further deterioration with the development of 
oedema, pigmentation or ulceration. Poor values were also found in patients with 
venous obstruction compared to those without. Interestingly, RVF correlated with 
AVP better in patients without obstruction than those with obstruction, r = 0.86 versus 
r = 0.40, respectively. Another study on 103 patients with CVD and 10 controls failed 
to detect any relationship between RVF and AVP by venous cannulation, r = 0.04 
(Payne, Thrush et al. 1993). However, there was a correlation between the VFI and 
the AVP, r = 0.58. 
 The value of APG in predicting clinical outcomes after surgery was reported 
in a study of 73 legs, C3-6, using APG and the 18-point clinical symptom score 
(Owens, Farber et al. 2000). The mean CSS decreased from 7.35 before surgery to 
1.79 at a mean follow-up of 44.3 months (P < 0.001). A normal post-operative VFI (≤ 
2 mL/s) predicted a good clinical outcome (CSS ≤ 2) with a positive predictive value 
of 94%, a specificity of 89%, and a sensitivity of 70%. 
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 There is one study of note correlating APG parameters with duplex. That study 
evaluated 122 legs in 61 consecutive patients at various stages of CVD (Weingarten, 
Czeredarczuk et al. 1996). The APG parameters of VFI, EF and RVF were compared 
to 6 duplex parameters of total reflux time and mean reflux time, in deep, superficial 
and both systems. The correlation of all the reflux times with the VFI ranged from r = 
0.35 to r = 0.43, (Pearson bivariate). There was no significant correlation between 
duplex against the EF or the RVF.  
 Finally, there are 2 studies in CVD patients which examined reproducibility, 
variability and reliability of APG measurements. The first study assessed 15 legs on 2 
occasions, 7-10 days apart with 1 measurement on the first day and 2 measurements 
on the second (Asbeutah, Riha et al. 2005). Values obtained were OF, VFI, EF and 
RVF. Satisfactory reproducibility was concluded since the mean coefficient of 
variation for within-subject measurements of all APG parameters was < 10%. The 
second study assessed 18 legs, 3 or 10 times each, on 2 separate occasions, 1-6 weeks 
apart (Yang, Vandongen et al. 1997). The coefficients of variation for the repeated 
measurements ranged from 7.5-27% for the majority of the APG parameters. The 
differences between the means of 3 tests and the means of 10 tests were < 10%. The 
coefficients of variation of method error were approximaterly 10% in test-retest 
measures.  
 
1.32 Assessing antegrade flow 
Venous return or antegrade flow is the prime function of leg veins. This force from 
behind, vis-a-tergo, is the least studied. Current research is towards quantifying the 
forces hampering venous return like reflux rather than measuring their net effect on 
antegrade flow. Ambulatory venous pressure is considered the gold standard 
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assessment of antegrade flow. Although it does not measure flow directly, low 
pressures indicate that the venous return is good and vice-versa. However, 2 
manuscripts discredited the value of a single AVP measurement. The dorsal foot, 
saphenous and popliteal veins exhibit different pressure waveforms during exercise 
concluding that these 3 veins represent 3 separate hydraulic compartments in normal 
individuals (Neglen and Raju 2000a; Neglen and Raju 2000b). Ambulatory foot 
dorsal venous pressure was not considered representative of pressure changes in the 
popliteal or saphenous veins. Despite the absence of similar pressure changes, a 
substantial increase in antegrade flow occurs during foot movements (Erika Mendosa 
– Wunstorf manoeuvre – personal communication). Flow up the saphenous veins on 
calf-muscle pump activity remains elusive because the flow should be directed 
inwards from superficial, through perforating veins and then into the deep system 
(Lurie 2009).  
  Intermittent pneumatic compression devices increase venous return and this 
has been studied with duplex in patients with venous ulcers and congestive cardiac 
failure (a relative contra-indication) in comparison to healthy controls. Popliteal total 
volume flow and peak ststolic velocity increased three-fold with IPC in 20 legs with 
venous ulceration (Kalodiki, Ellis et al. 2007). Peak and mean flow velocities of 
popliteal and soleal veins in 19 patients with congestive cardiac failure were 
attenuated resting, with less of an increase with IPC in comparison to 19 healthy 
controls (Nose, Murata et al. 2010). Flow has shown also to increase with IPC 
measured using MRV performed in supine volunteers (Pierce, Gatehouse et al. 2012). 
Ambulatory venous pressure like-wise decreases with IPC and this has been used as a 
way of optimising the compression rate and duration (Delis, Azizi et al. 2000). 
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However, GEC stockings do not seem to have any effect on venous blood velocity in 
supine hospitalised patients (Stein, Matta et al. 2013). 
 Venous return has been assessed with electrical provocation manoeuvres using 
direct calf muscle stimulation (Griffin, Nicolaides et al. 2010) and peroneal nerve 
stimulation (Tucker, Maass et al. 2010) in 24 and 30 healthy volunteers, respectively. 
The feedback on venous hemodynamics using duplex recorded volume flow and flow 
velocities has provided useful information on the optimisation of these devices. Their 
flow characteristics, if used as induction tests, may also prove useful in quantifying 
venous disease. 
 
1.33 Assessing reflux 
Reflux is the most popular and universal flow characteristic used to define a normal 
vein from a pathological vein. The parameter measured using duplex is reflux 
duration (van Bemmelen, Bedford et al. 1989). The cut-off points on normal and 
pathological values have been summarised by Labropoulos (Labropoulos, Tiongson et 
al. 2003; Labropoulos 2008). Abnormal retrograde flow duration was defined as >500 
ms for superficial veins, deep femoral veins and calf veins. In perforating veins it was 
>350 ms. In the common femoral and popliteal vein is was >1000 ms.  
 Interestingly, the common assumption that all reflux starts from a failed valve 
at the SFJ and progresses downwards was questioned in a landmark article 
(Labropoulos, Giannoukas et al. 1997). That study examined 125 legs with early 
superficial vein incompetence. The below-knee GSV was the commonest site of 
reflux (68%) followed by the above-knee GSV (55%) and the SFJ (32%). They 
concluded that below-knee GSV reflux is frequent in asymptomatic individuals or 
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patients with prominent or varicose veins. Reflux progression can be descending, 
ascending or multifocal (Labropoulos, Leon et al. 2005). 
 The method used to induce reflux and the positioning of the leg both influence 
assessments on reflux. Reflux assessed with Valsalva and pneumatic cuff techniques 
were compared in the 15 degrees reverse Trendelenburg and standing positions of 22 
CVI legs and 21 normal legs (Masuda, Kistner et al. 1994). That study demonstrated 
that the Valsalva method was best performed at 15 degrees reverse Trendelenburg and 
the cuff technique was best in the standing position. However, there was much 
variability between the techniques in the diagnosis of reflux and they were unable to 
identify one technique as better than the other. Interestingly, Valsalva testing 
produced reflux times >1.5 sec in normal legs representing a physiological reflux.   
     A manual calf compression and release manoeuvre (MCCR) is the usual 
method for inducing reflux in a dependent leg. A pneumatic cuff release manoeuvre 
has been proposed as a better technique. Venous reflux using both methods was 
studied in 94 venous segments of 54 legs with SVI by measuring the duration of 
reflux and the peak reflux velocity (Yamaki, Nozaki et al. 2006). That study 
demonstrated that there was no significant difference in the duration of reflux between 
the 2 methods at the SFJ and the SPJ. However, a MCCR produced significantly 
higher peak reflux velocities. Another study comparing both techniques in 63 venous 
segments in 18 C2-5 patients, also found no difference in diagnosing reflux (Kakkos, 
Lin et al. 2009). That study revealed that there was a higher coefficient of variation 
with MCCR regarding antegrade flow up the superficial veins but no significant 
differences in reflux duration. Peak reflux velocity was higher also using MCCR (P 
=.037). Both studies raise a question regarding release times. A faster release may 
result in a higher peak reflux velocity which may be achieved quicker by hand. 
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 An interesting study compared GSV diameters and reflux times in 22 legs 
from 11 healthy subjects after activity versus prolonged standing for 4 – 6 hours in a 
surgical operating room (Criado, Daniel et al. 1995). Reflux duration in the GSV 
remained <333 ms in 97.5% of all measurements. In the proximal GSV there was a 
significant increase in diameter (P = 0.0001) and reflux duration (P = 0.048) after 
stationary standing. This study confirms that gravitational stresses are applied to veins 
in healthy subjects. 
 Quantification of reflux using duration may not be the most appropriate way to 
assess reflux. Although short durations <0.5 sec are considered normal, longer 
durations are associated with less severe disease. Evaluations using peak reflux 
velocity and peak reflux volume have been shown to improve discrimination power 
between early and advanced CVD (Yamaki, Nozaki et al. 2002). That study assessed 
1,132 legs in 914 patients with CVD and concluded that reflux duration was unable to 
discriminate between C1-3 and C4-6. A similar study by the same first author quantified 
venous reflux parameters and APG assessments in 686 legs from 574 patients by 
comparing C1-3 versus C4-6 (Yamaki, Nozaki et al. 2007). As before, reflux duration 
did not improve the discrimination power between the 2 groups. In contrast, peak 
reflux velocity and peak reflux flow was significantly higher in C4-6 patients. They 
concluded that peak reflux velocity and peak reflux flow are better parameters than 
reflux duration for the discrimination of clinical severity in both superficial and deep 
venous insufficiency. Furthermore, the VFI of APG was significantly higher in 
patients with secondary CVI than primary CVI. 
 The lack of value of quantifying reflux duration has been reported in other 
studies. A study using duplex and APG in 69 legs from 45 patients with varying 
degrees of CVI failed to demonstrate a correlation between reflux duration versus 
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flow volume or peak reflux velocity at any of the anatomical locations studied 
(Rodriguez, Whitehead et al. 1996). Similarly there was no correlation between reflux 
duration and the APG derived VFI. They concluded that reflux duration was 
extremely useful in determining the presence of reflux but was of no value in 
quantifying the degree of reflux. Another study evaluated 403 legs with duplex at 
varying stages of CVD (Weingarten, Branas et al. 1993). Total limb reflux time was 
determined by summing the reflux times of all the venous segments in the leg. The 
mean superficial segment reflux time was unable to distinguish between the groups. 
However, the mean deep segment reflux time was prolonged in legs with venous 
ulcers. Another study comparing different venous reflux parameters with duplex 
likewise concluded that reflux time was the least useful variable compared to average 
and peak velocity, average and peak flow, and reflux volume (Valentin and Valentin 
1999). A detailed study on 244 refluxive legs in 182 patients confirmed that the 
duration of reflux cannot be used to quantify severity of reflux and is purely a 
qualitative measurement (Neglen, Egger et al. 2004).  
 The above studies on reflux duration were all assessed in dependent legs with 
a full venous reservoir. Assessment of reflux duration using a gravitational challenge 
test by way of an elevation-dependency manoeuvre may give different results. A 
study examining the rate of reflux in mL/s using duplex in 45 legs concluded that a 
rate >10 mL/s was associated with a high incidence of skin changes (66%) 
irrespective of whether this was in the superficial or deep veins (Vasdekis, Clarke et 
al. 1989). Reflux <10 mL/s was not associated with skin changes.          
 A longitudinal study using photo-plethysmography to quantify refilling time 
from childhood to adulthood is notable (Stucker, Reich et al. 2005). PPG data were 
obtained from pupils of 11 secondary schools at 4 different time periods in response 
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to dorsal extension of the foot. The median venous filling times increased from 24 
seconds to more than 45 seconds after 8 years and represented maturation of venous 
system physiology. The decrease in venous reflux or calf-mucle-pump afterload may 
be due to the maturation of venous valves. That study concluded that PPG was not a 
means of assessing malfunction of the venous system during childhood and 
adolescence.  
 The Bonn Vein Study examined the distribution and prevalence of reflux in 
the superficial and deep veins in the general population (Maurins, Hoffmann et al. 
2008). This was a population-based cross-sectional study of 1,350 male and 1,722 
female subjects with a response rate of 59%. Using clinical CEAP, 9.6% were 
classified as C0, 59% C1, 14.3% C2, 13.5% C3, 2.9% C4 and 0.7% C5-6. Reflux >0.5 
sec was found in 35.3% of subjects with 21% showing reflux in at least one 
superficial vein and 20% in at least one deep vein. This study demonstrated a high 
prevalence of reflux in superficial and deep veins which was associated with age and 
clinical stage.  
  
1.34 Assessing obstruction 
Obstruction to antegrade flow is the least well understood component of venous 
insufficiency and therefore it is the hardest to quantify in physiological terms. 
Measurements of outflow resistance (OR) which are reliable and reproducible with a 
high sensitivity and specificity are the current challenge in CVD. Factors responsible 
for an increase in OR are multifactorial and include luminal causes like thrombus, 
mural causes like fibrosis from PTS, extramural causes like May-Thurner syndrome 
(Kalu, Shah et al. 2013) and intra-abdominal causes like obesity. In a dependent leg, 
the afterload of the CMP is also contributory and the prime determinants of a high 
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afterload are reflux, immobility and CMP failure, for whatever reason. Furthermore, a 
reduced cardiac output will reduce the vis-a-tergo which may also contribute to an 
impaired venous return.  
 The influence of obesity on CVD was investigated in 401 legs from 272 
patients. The 61% of patients that were overweight with a BMI of 25 kg/m2 had more 
severe CVD (Danielsson, Eklof et al. 2002). Clinical CEAP correlated with BMI (P < 
0.001) even after adjustments were made for total peak reflux velocity and the total 
reflux score (P < 0.001). Overweight patients were more likely to have skin changes 
and ulceration (P < 0.001) than patients with a BMI < 25 kg/m2 despite similar values 
for total reflux time (P = 0.92) and total peak reflux velocity (P = 0.98). That study 
concluded that an elevated BMI was a separate risk factor for increased severity. 
 In a retrospective review, 20 ambulatory patients (39 symptomatic legs) with a 
mean BMI of 52 and a mean weight of 164 Kg were assessed by clinical CEAP and 
examined with duplex (Padberg, Cerveira et al. 2003). There was no evidence of 
reflux in 24/39 legs. Ulceration was present in 25/39 legs. Increasing clinical CEAP 
correlated with increasing BMI (P < 0.05). This suggested that the obesity itself 
contributes to the CVD. The finding that clinical CEAP was more severe in obese 
limbs (P < 0.001) was confirmed in another study in 934 consecutive patients (van 
Rij, De Alwis et al. 2008). That study noticed that although venous reflux was worse 
in the obese, the CMP function was better. The patterns of venous incompetence were 
comparable but there was greater reflux, increased vein diameter and higher foot 
AVPs with obesity. The authors concluded that this may be the result of increased 
abdominal pressure.  
 An experimental study measuring the response to the inflation of an 
abdominal-cuff (initially 20 mmHg and then 40 mmHg) on femoral vein pressure 
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supported the hypothesis in the previous study (Willenberg, Clemens et al. 2011). 
Femoral vein pressure increased with cuff pressure in all the subjects (P < 0.0025). In 
the 10 non-obese subjects the femoral vein diameter increased (P < 0.0001) with a 
decrease in peak velocity and mean velocity (P < 0.0001) which was similar to obese 
subjects without a cuff. The authors concluded that the haemodynamic changes of 
obesity are related to an increase in OR. 
 Detection of outflow obstruction was attempted by comparing 3 different 
techniques in 15 normal legs and 19 legs with a previous DVT (Neglen and Raju 
1993a). These were (i) arm-foot venous pressure differential, (ii) outflow fraction 
determined with APG, (iii) resistance calculations from simultaneously obtained foot 
venous pressure and calf volume curves. These all took place before and after reactive 
hyperaemia was induced. That study concluded that the arm-foot vein pressure 
differential and the foot vein pressure elevation after reactive hyperaemia were the 
most reliable tests for detecting and grading global chronic obstruction. Outflow 
fraction had marked overlapping between the different obstruction grades thereby 
reducing its sensitivity. The reason stated was that the volume shift that occurred on 
thigh-cuff release was filling the thigh area exanguinated by the cuff rather than 
representing a more proximal obstruction to venous return.  
 The value of OF in detecting past DVT was investigated alongside venography 
in 224 legs from 202 patients referred with a suspicion of a past DVT and in 41 legs 
(41 patients) with a clinical DVT but a normal venogram (Kalodiki, Calahoras et al. 
2001). A total of 95% of legs (73/77) that had a proximal DVT were identified using 
the OF enhanced by superficial venous occlusion. The value of < 28% had a 
specificity of 96%, a positive predictive value of 92% and a negative predictive value 
of 98%. The authors concluded that the OF of APG is an accurate, non-invasive 
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method for the diagnosis of haemodynamically significant chronic venous obstruction 
that could replace venography. Recently, a similar study on 29 patients with venous 
claudication were compared to 63 healthy control subjects using the OF of APG 
(Rosfors and Blomgren 2013). These patients (69%) were characterised by a reduced 
venous outflow during the initial 4 seconds following thigh-cuff release. The authors 
concluded that the OF4 of APG can be a valuable tool in the selection of patients with 
iliofemoral obstruction that may benefit from stenting. 
 Another study assessed 39 patients with iliofemoral thrombosis using the OF 
of APG (Delis, Bountouroglou et al. 2004). A total of 43.6% developed venous 
claudication. The OF was significantly lower in this group at 37%, range 32.2-43% 
compared to those without venous claudication 49%, range 44-52% (P < 0.001), 
thereby confirming the usefulness of this test.    
 Measurement of outflow velocity using duplex scanning following rapid calf 
cuff inflation to 100 mmHg has been proposed as a way of indicating a high OR (van 
Bemmelen, Bedford et al. 1990). Outflow velocities <85 cm/s were considered to be 
consistent with incomplete recanalisation of the deep veins. Maximum venous 
outflow velocities were measured in a recent study in 12 patients with clinical May-
Thurner syndrome after a tourniquet induced venous engorgement (Jones, Cassada et 
al. 2012). A mean right to left velocity ratio of 2 occurred in MTS patients in 
comparison to a mean ratio of 1.3 in asymptomatic control subjects. After endovenous 
treatment of MTS the ratio decreased to 1.2, indicating a return to normal. 
 The OF using occlusion APG as well as the venous pressure gradient (VPG) 
was performed in 34 legs with thrombotic chronic venous occlusion, before and after 
stenting (Rosales, Sandbaek et al. 2010). The VPG was obtained by comparing 
venous pressure measurements in a superficial leg vein before and after a thigh-
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tourniquet was inflated to 300 mmHg and sustained for 3 minutes (Clarke, Smith et al. 
1989; Geroulakos and Nicolaides 1995). After release, the reactive hyperaemia 
increases arterial inflow and thus venous outflow. A pressure increase of >8 mmHg 
was used as the cut-off point indicating an elevated OR. Pre-intervention, 
haemodynamic evidence of impaired outflow (OF and VPG) occurred in only 18/34 
(53%) legs.  Successful recanalisation occurred in 32/34 (94%) of legs with clinical 
improvement with a primary patency of 14/21 (67%) at 2 years. Of those with 
impaired OF and VPG pre-intervention, only 4 improved. A high AVP persisted 
unchanged in 16 legs after stenting. This results question the usefulness of measuring 
OF and VPG as an outcome measure after stenting.  
 The OF of APG is not a specific test for OR because the venous elastic recoil 
(VER) is a confounding variable. It is the force driving the venous return after thigh-
cuff release. A reduction of VER is likely to lead to an impaired OF, irrespective of 
whether there is any iliac obstruction. It is known that veins in CVD become more 
compliant (Jeanneret, Jager et al. 2007) and less elastic (Clarke, Smith et al. 1989; 
Geroulakos and Nicolaides 1995). Furthermore, post-phebitic veins are frequently 
scarred which also impairs VER. Therefore OF may represent VER as much as OR.    
       
1.35 Assessing calf-muscle pump function 
The prime factor driving venous return is the heart, vis-a-tergo. This is assisted 
greatly by the calf-mucle-pump (CMP) in the ambulatory subject. Compelling 
evidence for this is provided by an assessment of the risk factors related to failure of 
venous leg ulcers to heal with compression treatment in 189 patients (Milic, Zivic et 
al. 2009). That study included patients with venous leg ulcers >5 cm2 and >3 months 
duration. Non-healing after 52 weeks of multi-layer high compression bandaging 
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occurred in 24 (12.7%) legs. A BMI >33 kg/m2, limited walking (<200 m/day), 
debridement history and penetration > 2 cm were indicators of slow healing. More 
important was that a calf:ankle circumference ratio < 1.3, a fixed ankle joint and a 
reduced ankle range of motion were the only independent parameters associated with 
non-healing (P < 0.001). In this detailed study, the authors concluded that non-healing 
ulcers are related to the impairment of the calf-muscle pump. 
 The deep veins of normal legs have been shown, using serial phlebography, to 
empty with a single calf-muscle contraction (Almen and Nylander 1962). 
Subsequently, it was extrapolated that 60-90 mL were expelled with one contraction 
(Ludbrook 1966). Studies using isotope plethysmography supported this data and 
confirmed the importance of the CMP in venous return (Whitehead, Lemenson et al. 
1983). The introduction of APG provided a simple and effective way of quantifying 
the activity of the CMP using measurements of ejection fraction (EF) and the residual 
volume fraction (Christopoulos, Nicolaides et al. 1989).  That study assessed 30 
normal legs, 110 legs with primary VVs, 34 legs with deep venous reflux and 31 legs 
with deep venous occlusion ± reflux. They noted 3 findings: (i) an increase in 
ulceration with increasing VFI and decreasing EF, (ii) that a poor EF was the primary 
cause of venous ulceration in legs with minimal VFI impairment and (iii) that a good 
EF significantly reduced the incidence of ulceration in legs with a high VFI (P < 
0.05). They recommended the use of APG as a means of quantifying CMP activity. 
 The function of the CMP can also be assessed using duplex and photo-
plethysmography. An interesting study of 84 legs in 44 patients had both these 
investigations plus assessments of ankle movement using goniometry and calf muscle 
strength using dynamometry (Panny, Ammer et al. 2009). They noted 3 findings: (i) a 
higher degree of clinical severity using clinical CEAP with a lower venous pump 
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power, (ii) significant reduction of dosiflexion strength in C6 patients compared to 
controls and (iii) a positive correlation between PPG and the strength of dorsiflection 
as well as total strength (P < 0.05). They concluded that the strength of dorsiflexion 
was the main driver of venous return and that the range of ankle movement was 
impaired in patients with pathological reflux on duplex. They suggested that ankle 
strengthening exercises should be an integral part of treatment. 
 A reduced EF may not be related entirely to an impaired calf muscle. If there 
are incompetent perforating veins whose direction of flow is outward, then calf 
systole causing upward flow may be reduced by these leaking points. Instead, the 
APG sensor cuff may not demonstrate a great reduction in volume because of the 
trade-off between upward and outward flow. Perforating vein incompetence reduces 
the efficiency of the CMP. The haemodynamic performance of these veins were 
studied using duplex in 90 legs from 67 patients with CVD (Delis, Husmann et al. 
2001). Flow velocity waveforms were obtained from 265 perforating veins on the 
release phase of a MCCR manoeuvre in the sitting position. The results were 
interesting. Firstly, incompetent perforating veins had larger diameters, higher peak 
and mean velocities and volume flow with larger outward volumes than competent 
perforating veins (P < 0.0001 for all). Secondly, the flow direction was consistently 
inward on calf compression and outward on release with a greater percentage of 
outward flow on compression versus competent perforating veins (P < 0.01). Finally, 
the volume flow of perforating veins in C3-6 legs outwards was twice that compared to 
C1-2. The authors concluded that the haemodynamics of perforating veins can identify 
those that are clinically relevant. 
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1.36 Assessing vein diameter 
The GSV is oval in shape with the longest axis in line with the saphenous ligament. It 
varies in calibre, with a larger lumen at its point of entry into the common femoral 
vein. It has been proposed that the GSV diameter is a relatively accurate measure of 
haemodynamic impairment and clinical severity (Navarro, Delis et al. 2002). That 
study assessed 112 legs with duplex, APG and clinical CEAP. The GSV diameter was 
measured at 7 separate leg levels from the proximal thigh to the distal calf. The GSV 
diameter increased significantly overall with CEAP severity (P < 0.001) and also 
increased progressively with proximity to the SFJ. A GSV diameter of ≤ 5.5 mm 
predicted the absence of reflux with a sensitivity of 78%, a specificity of 87%, and 
positive and negative predictive values of 78% and an accuracy of 82%. A GSV 
diameter of  ≥ 7.3 mm diameter predicted critical reflux (VFI > 7 mL/sec) with 80% 
sensitivity, 85% specificity, and 84% accuracy.  
 This is in contrast to an earlier publication assessing 32 legs with APG and 
duplex (van Bemmelen, Mattos et al. 1993). That study failed to demonstrate a 
difference in conduit or reservoir vein diameters between varicose vein patients and 
those with venous ulcers. Furthermore, the correlation (Pearson) between the conduit 
(measured at knee level) and the reservoir veins versus the VFI was r = 0.39 and r = 
0.55, respectively.  
 A similar study was performed in 107 legs of patients and 38 normal controls. 
However, GSV reflux was assessed with the Valsalva and Parana manoeuvres instead 
of the VFI (Mdez-Herrero, Gutierrez et al. 2007). The study demonstrated that the 
GSV diameter was greater and the clinical state more severe (C4-6) when the 2 
manoeuvres were positive. 
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 A detailed study on 1,132 legs in 914 patients divided patients into group I 
(C1-3) and group II (C4-6) and compared duplex derived parameters with clinical 
manifestations (Yamaki, Nozaki et al. 2002). The GSV diameter (cm) at the SFJ and 
distally was significantly higher in group II, at 0.96 ± 0.27 and 0.71 ±0.18, 
respectively. The corresponding diameters for group I were 0.82 ± 0.41 (P < 0.0001) 
and 0.61 ± 0.15 (P < 0.0001), respectively. Recently, the suggested measuring point 
for recording the GSV diameter was at the proximal thigh, 15 cm distal to the groin 
(Mendoza, Blattler et al. 2013).   
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PART  II 
 
 
 
CHAPTER  2 
 
 
 
METHODS 
 
 
Scientific Method is a wonderful tool as long as you don't care which 
way the outcome turns. 
 
-- Cristina Marrero 
 
 
2.1 Assessment questionnaires 
 
2.11 Introduction 
 
Questionnaires can be divided into 2 types: those that are patient reported and usually 
completed by the patient and those that are physician recorded and completed by the 
doctor. The AVVQ and the VAS for pain fall into the former category and the C of 
CEAP and the VCSS into the later. The VS has a mixture of both components. 
 The questionnaires were obtained from the literature, photocopied and then 
provided at the time of assessment so once the patient or doctor checked the 
appropriate boxes or circled the appropriate answer they could be collected and stored 
for analaysis later. Samples of the questionnaires used are available in Appendix I. All 
questionnaires were labelled at the time of completion with the participant’s unique 
study number and the side of the leg. They were then dated and filed in chronological 
order in the laboratory. 
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 Questionnaires are not without controversial elements and the results may 
dependent on the method and situation in which they are completed. This section 
examines how the questionnaires were used and interpreted. 
  
2.12 CEAP classification 
 
The C or clinical part of CEAP was the only part used in this research. However, it 
was clearly stated in the respective sections of this work whether the disease under 
evaluation was of primary etiology or secondary to a DVT. It was also stated whether 
the anatomical location of the disease was superficial or deep or the pathophysiology 
was reflux, obstruction or both. 
 The C of CEAP was interpreted as it was intended, as a report of the clinical 
state of the leg. The revised version was used (Eklof, Rutherford et al. 2004). This 
was independent of the history of the patient, the state of the patients’ contralateral leg 
or the duplex findings. However, the history was used in determining whether the 
patient had a venous ulcer in the past. Pigmentation without induration was only 
considered significant in the absence of recent trauma and the presence of reflux on 
duplex. The occurrence of pigmentation with induration, termed LDS, was reported, if 
present, irrespective of the duplex findings. 
 
2.13 Aberdeen varicose vein questionnaire 
 
Although the AVVQ was originally designed as a postal questionnaire survey on 
varicose veins, it was not used as intended in this work (Garratt, Macdonald et al. 
1993). Instead, it was given to patients, with a supplied pen, in a clinical environment 
for them to complete and hand back at the end of the session. The rationale was to 
improve completion rates to near 100% and encourage patients to draw in their 
varicose veins, the least popular question in the AVVQ. Patients also had the 
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opportunity to clarify any questions that they did not understand. It was important to 
ensure that the questionnaire was not perceived by patients as a rationing tool in this 
current climate of health care restriction. To this end all questionnaires were 
completed after clinical decisions had been made. 
 As depicted in Appendix I, the score to each question is weighted to reflect its 
importance in assessing severity, with the higher scores representing greater disease 
specific QoL impairment. This factor is important because all the results which used 
the AVVQ used weighted scores. Further adjustments were made for unanswered 
questions by subtracting the value of those questions from the total possible score and 
then recalculating the final score by multiplying by 100%. Questions 3 and 7 were 
removed from the final instrument because they did not contribute significantly to the 
questionnaire performance. This resulted in a total of 13 remaining questions.  
 
2.14 Venous clinical severity score 
  
The VCSS was used to assess baseline severity and quantify the effects of 
intervention (Vasquez, Rabe et al. 2010). The original scoring instrument was used in 
this thesis (Rutherford, Padberg et al. 2000). Care was taken to ensure the definitions 
of a varicose vein and pigmentation were followed since these definitions are different 
in CEAP. Each question was assessed individually for change as well as the total 
scores. Patients with venous ulceration were not separated out of the questionnaire 
making the total score inclusive of ulcer patients. Question 10 on stocking use was 
answered directly, irrespective of whether they were prescribed temporarily, used to 
alleviate pain, caused discomfort or worn as a matter of compliance.  
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2.15 Villalta Scale 
 
The VS is divided into a patient part recording symptoms and a physician part 
recording signs (Villalta, Bagatella et al. 1994). Both parts were completed by the 
physician. Each element is graded with a score from 0-3 depending on whether the 
condition was absent, mild, moderate or severe. The maximum score for symptoms is 
15 and for signs it is 18. Adjustments were not made to balance up the VS which 
remained weighted in favour of signs. Nor were adjustments made to inflate the score 
to 15 if a patient had a venous ulcer but scored less than 15. Furthermore, the VS was 
not used as recommended for the diagnosis of PTS (Kahn 2009). In the current work 
it was only used to assess the clinical severity of patients.  
  
2.16   Visual analogue pain scale 
 
This instrument (Price, McGrath et al. 1983) was used to determine the amount of 
pain a patient experienced each day during the 7-day period after intervention with 
EVLA or UGFS. This was part of the RCT post-treatment assessment protocol 
presented in detail in Chapter 15. The assessment of pain was non-discriminatory and 
included all forms of leg pain, including discomfort from stockings and phlebitis. 
Patients were handed a sheet of A4 paper just after their treatment consisting of 7 
horizontal black lines representing days. They were each 10 cm long, ungraduated and 
labelled NO PAIN at one end and SEVERE PAIN at the other with a request to mark 
the line with the level of pain experienced on that day (Appendix I). The VAS forms 
were customised and included the day and date before each line as an aide memoire. 
Each form started on the first post-operative day and not on the same day of the 
procedure. They were collected on the follow-up appointment in clinic.  
 Analgesia requirements were also requested as an index of pain because they 
may influence the VAS score for pain. However, it is acknowleged that they may both 
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reduce a pain score by their pain-killing effect as well increase the score by their 
representation of the need to take them. 
          
2.2 Duplex scanning 
 
2.21 Introduction 
 
All colour duplex scans were performed by the same experienced vascular scientist 
dedicated to the assessment of CVD. In most cases the assessments took place 
concurrently with a clinical evaluation in the Tuesday morning venous outpatient 
clinic at Ealing Hospital using a portable Sonosite® Titan colour duplex scanner 
(SonoSite Inc, Bothell, WA, USA). When images or video recordings were required 
the examination took place in the radiology department using a high-end ultrasound 
machine (Philips, iU22, Bothell, WA, USA).  
 Superficial, deep, perforating and varicose veins were assessed for 
competency, reflux, obstruction and occlusion using standard definitions. 
Examinations were performed in the standing position with the majority of the weight 
of the subject supported by the contralateral leg. The manual calf compression and 
release manoeuvre was used to induce antegrade flow and diagnose reflux. 
Obstruction and occlusion were assessed using direct compression with the transducer 
in the standard way. The loss of respiratory phasicity test and Valsalva manoeuvres 
were used as and when required. The VenaPulse® (ACI Medical, CA, USA) rapid 
inflation and deflation pump was not used to standardise the assessment of reflux 
because the benefit of this device in assisting an experienced operator is limited 
(Kakkos, Lin et al. 2009).  
 The results were reported both in a written and graphic format on simple 
standard templates. A GSV template is shown in Fig 2.1. Generally, the arrows 
represent competency and reflux depending on their direction. Occasionally dilated 
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saphenous veins give the appearance of concurrent reflux and antegrade flow as 
shown in Fig 2.2. However, this is an artefact which is recognised from experience. 
Filled in areas represent obstruction and hatched areas occlusion. Additional veins 
named or otherwise can be drawn on the template. Other common notations include 
small circles to depict the origin of significant perforating veins, the Ø sign for 
recording diameters and a numbered small syringe with a needle to illustrate the order 
and sites of foam sclerotherapy. The full reporting system and annotations is beyond 
the scope of this work.   
 
 
 
 
 
Figure 2.1. A partially completed GSV template for reporting a duplex examination.   
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Figure 2.2. Longitudinal (A) and transverse (B) views of aliasing artefact. This gives 
a false conclusion of concurrent reflux and antegrade flow within a dilated GSV. 
   
 
 
2.22 Venous segmental disease score 
 
The VSDS is based on the venous segmental involvement with reflux or obstruction 
or both as determined by appropriate imaging, like duplex (Rutherford, Padberg et al. 
2000). The maximum obstruction score is 10 and the maximum reflux score is also 
10. The footnote of the scoring system, which provides instructions as to its use and 
interpretation, is longer that the score itself. According to the scoring, reflux means 
that all valves in that segment are incompetent. Obstruction means total occlusion at 
some point in the segment or >50% narrowing of at least half of the segment. It was 
also pointed out that treatments designed to abolish saphenous or perforating vein 
reflux would only register as a reduction in the reflux score and not a concurrent 
increase in the obstruction score (Rutherford, Padberg et al. 2000).  
 The instructions were followed precisely. Segments not examined were not 
reported. Reflux was assessed by the presence of significant retrograde flow following 
a MCCR manoeuvre rather than by imaging the valve cusps directly. 
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2.3 Air-plethysmography 
 
2.31  Introduction 
 
Air-plethysmography (APG) was performed in the Josef Pflug vascular laboratory 
within an area designated for this purpose (Fig 2.3). An adjustable couch provided a 
horizontal surface to study the subject in the supine position. A Zimmer frame was 
used for performing the elevation-dependency manoeuvres, asking the subject to bear 
weight on the contralateral leg and for support during tip-toe movements. It was not 
designed for subjects to lean on but as a confidence measure to steady them and 
prevent them falling.   
   
 
 
             Figure 2.3. The APG laboratory 
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     Figure 2.4. Pump/recorder, calibration syringe and sensor cuff 
 
 
 The APG apparatus consists of an air sensor calf-cuff, a 100 mL calibration 
syringe and an air pump as shown in Fig 2.4. The sensor cuff is 36 cm long with an 
upper and lower circumference of 54 cm and 44 cm, respectively. The cuff is wrapped 
around the calf with the smaller end around the ankle and the upper end just below the 
knee. The zip is positioned along the anterior boarder of the tibia.  
 The air-pump is used initially to inflate the sensor cuff to a pressure of 6 
mmHg. This is enough to keep the cuff in place without compressing the superficial 
veins. When the pressure remains at a steady 6 mmHg the pumping mechanism is 
turned off. The air-pump is also a transducer which converts changes in cuff pressure 
into changes in voltage. This can then be displayed on a monitor and recorded onto a 
storage device. When a steady tracing appears on the monitor, the apparatus is 
calibrated using the 100 mL air syringe. At this point the subject is resting on the 
couch, supine, arms at both sides and the foot elevated on a block (Fig 2.5A). 
Injection of 100 mL of air causes an increase in pressure/voltage on the monitor. Thus 
changes in pressure can be converted into changes in volume. This event is recorded 
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on the monitor as a square calibration wave representing 100 mL. Two of these square 
waves are depicted at the start of the tracing in Fig 2.6A.    
 
2.32  Technique 
 
The principle of APG is straightforward. It records acute changes in calf volume 
irrespective of the cause. Validated parameters are derived from these changes using 
thigh compression/release, elevation-dependency manoeuvres and tip-toe movements. 
These provide the outflow fraction (OF), venous filling index (VFI), ejection-fraction 
(EF) and the residual volume fraction (RVF).  
 The VFI in mL/s is the most well known parameter. It is measured during an 
elevation-dependency manoeuvre. It represents the rate of venous filling into the calf 
from retrograde venous flow and antegrade arterial inflow. After calibration the leg is 
elevated with the help of the examiner holding the heel (Fig 2.5B). Emptying of the 
veins is displayed as a decrease in venous volume (Fig 2.6B). When the knee is 
flexed, further emptying is seen because there is no longer any popliteal vein 
impediment to venous drainage caused by knee hyperextension (Fig 2.6C) (Leon, 
Volteas et al. 1992). Next, the subject is asked to stand on the contralateral leg leaving 
the test leg hanging with just the toes touching the floor for stability (Fig 2.5C). 
Baseline emptying is seen first (Fig 2.6D) and then the leg starts to fill until a plateau 
is reached (Fig 2.6E). The VFI is calculated from this slope from D to E such that VFI 
= 90%VV/VFT90. The venous volume (VV) is the volume from D to E. The VFT90 
is the venous filling time from D to 90%VV. The exact point at which the plateau 
starts is ill defined which is why only 90% of the slope is used in the calculation of 
the VFI. 
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Figure 2.5. (A) calibration, (B) emptying (the heel is supported by the examiner, not 
shown), (C) filling, (D) ejection. 
 
 
 
 
 
Figure 2.6. The venous filling index. (A) calibration, (B) leg elevation, (C) knee 
flexion, (D) leg dependency, (E) plateau. The 2 peaks either side of D are movement 
artefacts.  
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 The EF is the percentage of blood expelled form the calf after a single tip-toe 
movement such that EF = ejected volume/VV x 100%. It represents the performance 
of the calf-muscle pump (CMP). The subject is asked to distribute the weight equally 
on both legs to perform the tip-toe movement. This involves raising the heels off the 
floor for 1 second and then returning to the initial position (Fig 2.5D). The residual 
volume fraction (RVF) is the remaining volume of blood, expressed as a percentage, 
after 10 tip-toe movements so that RVF = volume remaining/VV x 100%. It is 
reported as a surrogate of ambulatory venous pressure although direct venous pressure 
measurements have not demonstrated that this is correct (Payne, Thrush et al. 1993). 
The outflow fraction (OF) is the percentage of blood which escapes in 1 second after 
the sudden deflation of an occlusive thigh cuff such that OF = volume released/VV x 
100%. It is reported to measure the degree of proximal obstruction, with lower 
percentages occurring in patients with proximal venous disease like a DVT (Kalodiki, 
Calahoras et al. 2001). The EF, RVF and OF measurements are mentioned for 
completeness but were not used in the main chapters of this thesis. However, the EF 
and RVF were validated separately on normal volunteers in section 2.34. 
 
2.33  Tips and tricks 
 
There is a learning curve associated with performing APG. Subjects should breathe 
quietly during the procedure, avoid coughing and keep their arms by their sides in 
order to avoid increases in intra-abdominal pressure which may hamper venous 
return. They should not wear restrictive clothing.  
 Loss of cuff pressure can be caused by an air leak which is identified by a 
gradual decline in the tracing at rest. Artifactual increases in cuff pressure can be 
caused when the sensor cuff touches the sides of the couch or when clothes fall onto 
the cuff as depicted in Fig 2.7. 
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         Figure 2.7. Venous filling augmentation artefact from clothing 
 
 
 
 
 
2.34  Validation on normal controls 
 
Prior to performing APG in a study environment the technique had to be learned and 
the parameters assessed had to be reliable. The right legs of 21 healthy control 
subjects without clinical evidence of venous disease, 14 of whom were male, were 
used for this purpose. Their median age was 26 (21-46) years. As shown in Table 2.1, 
there was great variation in the EF and the RVF, but the VFI remained below 2.5 
mL/s in all subjects. This is within the 2.0 - 2.5 mL/s upper limit of “normal” for VFI. 
For this reason the EF and the RVF were not included in the ensuing studies. 
However, the wide variations in EF and RVF may reflect real changes in physiology 
rather than errors of technique.  
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Table 2.1.  APG values in 21 healthy volunteers.  
 
 Mean Std Dev Median IQR Range 
VV (mL) 77.7 36.5 67.6  47 - 101  25 - 145 
VFI (mL/s) 1.2 0.6 1.2 0.6 - 1.6 0.4 - 2.4 
EF (%) 76 45 63 48 - 93 26 - 236 
RVF (%) 34 23 28 14 - 48 2 - 94 
VFT90 (s) 74 42 70 38 - 95 12 - 177 
 
 
 
2.4 Stocking interface pressure 
 
Manufacturers of graduated elastic compression stockings specify stockings in terms 
of size and class. In a patient who has been measured for the correct size, the strength 
of compression is determined by the class. A class 1 stocking exerts a pressure at the 
angle region of 18-21 mmHg and a class 2, 23-32 mmHg. However, legs are of 
differing shapes and sizes so an objective in vivo measurement of pressure is required 
for the individual patient. The PicoPress® transducer (Microlab Elettronica, via G 
Rossa 35, 35020 Ponte S, Nicolò PD, Italy) was used to measure the pressure beneath 
a stocking. It has been demonstrated to have a low coefficient of variation and high 
accuracy (Partsch and Mosti 2010a). It comprises of an inflatable diaphragm, 5 cm in 
diameter and 0.2 mm thick, which acts as a sensor. This is attached to a hand held 
transducer via a narrow tube (Al Khaburi, Nelson et al. 2011b) as shown in Fig 2.8.  
 The sensor diaphragm is placed beneath the stocking on the gaiter area 
approximately 5 cm above and 2 cm posterior to the medial malleolus. This site is 
chosen because it avoids the medial boarder of the tibia and the Achilles tendon since 
fulcrum points would result in elevation of the interface pressure (Flaud, Bassez et al. 
2010; Al Khaburi, Nelson et al. 2011a). It is also the narrowest part of the ankle and 
the commonest site likely to develop skin changes. Care is taken also to ensure the 
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sensor is positioned flat prior to any measurements. This is achieved after the stocking 
has been fully applied by pulling and straightening the connecting tube. The pressure 
is displayed on the screen after 2 mL of air has been injected. The syringe is pre-
calibrated and is an integral part of the PicoPress®. 
 
 
 
  Figure 2.8. Interface pressure measuring device (PicoPress®) 
 
 
 
 It has been proposed by the International Compression Club that the ideal site 
of measurement for interface pressure should be at the B1 point (Partsch, Clark et al. 
2006). This is situated at the medial border of the soleus muscle at the level where the 
muscle part of the medial belly of the gastocnemius becomes a flat tendon and is the 
site where the sensor diaphragm should be placed (Fig 2.9). Whilst this point is 
preferred for studies measuring in vivo elastic and inelastic compression, it should be 
noted that it is above the gaiter area and not the usual place where skin changes or 
ulcers develop.  
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Figure 2.9. The B1 measuring point. Circle drawn by G Mosti, supervised by H 
Partsch, at the EVF of 2013, Belgrade, Serbia.   
 
 
2.5 Treatment methods 
  
2.51  Endovenous laser ablation 
 
This is a common procedure performed in many hospitals in the UK. Doctors using 
EVLA have developed their own special individual refinement to the method in order 
to improve efficacy and reduce recurrence and complications. Constraints on 
resources prevent the use of the most up-to-date equipment. In this thesis EVLA was 
used to treat an incompetent GSV. This was performed by a trained vascular registrar, 
the consultant or the author.  
 The EVLA was performed in the day surgery theatre using a laser generator 
delivering intermittent energy at 14 Watts via a foot pedal as shown in Fig 2.10 
(Biolitec, Inc, East Longmeadow, MA, 01028, USA). A 1470 nm wavelength bare-
tipped diode laser fibre (ELVeS®) was used with a graduated fibre sheath. Great 
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saphenous vein (GSV) access was gained using the Seldinger technique at knee level. 
The Micropuncture® Introducer Set, Silhouette™ Transitionless (Cook) was used to 
perform this if the vein was small in calibre (Fig 2.11).      
 
 
 
       Figure 2.10. Laser generator and foot pedal 
 
 
 
 
 
      Figure 2.11. Micropuncture set with graduated laser fibre sheath 
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 The laser fibre sheath was placed over the guide wire up to the 
saphenofemoral junction (SFJ). Then the guide wire was replaced by the laser fibre 
and locked so that its tip remained proud of the sheath. Its position 2 cm short of the 
SFJ was confirmed with ultrasound and the external part of the sheath was attached to 
the patient’s skin with tape to prevent dislodgement. The GSV was prepared with 
tumescence using 40 mL of 0.5% bupivacaine in 1000 mL of 0.9% saline with the aid 
of a spinal needle, tubing, roller pump and foot pedal (Fig 2.12). 
 
 
 
                      Figure 2.12. Tumescence pump and foot pedal 
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 After a final ultrasound check on the position of the laser fibre, lasering 
commenced in the Trendelenberg position under full safety precautions. The pull-back 
rate was 1 cm every 5 seconds and achieved using the graduation marks on the sheath 
and the timed sound interupptions from the generator. The aim was to deliver 70-90 
joules of energy/cm length of vein. Slower pull-backs were aimed for in larger veins 
and vice versa. Concurrent phlebectomies took place using stab incisions and the 
Swiss Oesch® phlebectomy hooks. The leg was wrapped in padding and crepe 
bandages and an anti-embolism stocking was advised for 3 weeks. 
 
2.52  Ultrasound guided foam sclerotherapy 
 
This was performed in a consulting room in outpatients. Foam was prepared by 
agitating 1.2 mL of 1% sodium tetra-decyl sulphate (Fibro-Vein®, STD 
Pharmaceuticals, Hereford, HR4 0EL, UK) in 4.8 mL of air in two 5 mL syringes to 
produce 6 mL of foam. This was prepared immediately prior to injection to keep the 
foam fresh and prevent the small bubbles from uniting into larger bubbles. The three 
way tap was off-set to increase resistance and facilitate foam generation (Fig 2.13).   
 
 
 
Figure 2.13. Foam preparation. Note the tap twist to improve foam quality 
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 Most patients received an injection of up to 12 mL of foam into the GSV at 
knee level using an 18-gauge intravenous cannula. Ultrasound was used to visualise 
the migration of foam within veins as feedback when to stop injecting. Leg elevation 
and an initial injection of 2 mL primed the GSV by causing a reduction in calibre and 
spasm. Then the rest of the foam was administered. Leg elevation during injection 
also encouraged the direction of foam into incompetent tributaries. 
 Tributaries were treated as required on a subsequent occasion using a 21-
gauge butterfly needle. All patients received a class 2 (23-32 mmHg) GEC stocking 
with waist attachement (D-95448, MEDI®, Bayreuth, Germany) for them to wear 
continuously day and night for 2 weeks and only during the day on the third week. 
After 3 weeks all patients had a duplex scan to assess the efficacy of treatment and 
exclude a DVT and were reviewed by a physician.  
 
2.53  Tumescent sclerotherapy 
 
Great saphenous veins ≥ 8 mm in diameter were treated in a clinical room in day 
surgery using tumescence-assisted UGFS (T-UGFS). This involved the cannulation of 
the GSV with a 14-gauge, 25 cm long intravenous central line for foam deployment 
and the injection of tumescence as described above but without local anaesthesia. The 
rational for modifying the standard UGFS technique was to reduce the volume of 
foam required since, in theory, up to 73 mL would be necessary to treat a 12 mm 
diameter GSV, 65 cm in length, as shown in Fig 2.14. The foam volume requirement 
of the GSV was reduced by the following proposed mechanisms: 
 (i) External perivenous compression of the GSV using tumescence 
 (ii) Tributary tumescence at their drainage points into the GSV 
 (iii) GSV spasm and endothelial friction induced by the catheter  
 (iv) Increased surface area/volume ratio with eccentric tumescence 
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 (v) Prior application of a GEC stocking to reduce GSV diameter  
 
 
 
Figure 2.14. Theoretical volumes of foam to fill a large GSV 
 
 
 
 
 Occasionally patients had grossly dilated sacculations of the GSV or a saphena 
varix. These were prepared using eccentric perivenous tumescent compression (Fig 
2.15). The effect was to flatten the walls of the dilated segment so that they were in 
direct opposition. This removes the luminal blood whilst maintaining the surface area 
for sclerotherapy. The differences in the acoustic shadow produced by the foam 
between circumferential compression and eccentric compression are depicted in Fig 
2.15.  
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          Figure 2.15. Circumferential (A) and eccentric (B) tumescence techniques 
 
 
 
 As a rule all patients receiving T-UGFS had their GEC stocking partially 
applied and folded back to just below the injection site as shown in Fig 2.16. Several 
minutes after foam deployment the remainder of the stocking was fitted. The rationale 
for this was to reduce the calibre of the GSV and help prevent bolus foam 
displacement up the GSV and into the common femoral vein during the below-knee 
stage of the stocking application. 
 
 
 
                     Figure 2.16. Partial stocking application prior to sclerotherapy 
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2.54  Stocking 
 
Donning and doffing an open-toe stocking is a technique requiring experience. There 
are 7 stages: 
 (i) Placement of a silk sock to cover the toes and heel 
  (ii) Inversion of the GEC stocking from the heel 
 (iii) Forefoot application 
 (iv) Re-version by pulling up the stocking to expose the covered forefoot 
 (v) Heel effacement 
 (vi) Calf and thigh pull-up 
 (vii) Silk sock removal by pulling on the toe part 
The pull-up movements are facilitated by pinching the stocking between thumb and 
fingers symmetrically at the recess either side of the Achilles tendon. Doffing is much 
easier and merely involves holding the stocking at the mouth and pulling down whilst 
inverting.  
 Stockings were used after sclerotherapy with the intention to reduce the 
amount of hyperpigmentation by keeping the superficial veins collapsed and devoid of 
blood. Furthermore, post procedural SVT can be very uncomfortable and may be a 
mechanism behind early recanalisation.  A firm tender sclero-thrombus 3 weeks after 
UGFS of a GSV tributary is shown in Fig 2.17. This patient complied with stockings.    
 
 
 
 
 
 
 
  Figure 2.17.  Sclero-thrombus causing discomfort and skin 
                        discolouration. 
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2.6 Statistical tests used 
 
2.61 Introduction 
 
Assessments are given value through the use of numbers. These numbers can then be 
evaluated using statistical tests. If these tests demonstrate statistical significance then 
they must be evaluated once again as to whether they represent clinical significance. 
Thus there is a 3 stage process in assessing venous disease: (i) numerical 
transformation; (ii) statistical assessment; (iii) clinical relevance. This is important 
because errors at any of the 3 stages can lessen the impact of any conclusions.  
 Statistical test were performed on data entered into Excel® spreadsheets. Data 
was analyzed using the SPSS statistics. They were imported directly into the IBM® 
SPSS® statistical software package version 17 (SPSS Inc, Chicago, IL 60606, USA) 
or version 19 (IBM Corporation, Armonk, NY, 10504-1722, USA). Charts were 
created from within this program and the data were analyzed for significance which 
was defined when P < 0.05. External help was obtained with statistical tests and these 
experts are acknowleged at the beginning of this thesis.    
 
2.62 Pseudo-randomisation 
Randomization, when required, was performed using sealed envelopes. The treatment 
type or stocking type to be fitted was written on paper and placed in a sealed 
envelope. The envelopes were shuffled by an independent party, placed into a single 
pile and numbered consecutively, starting with 1. A random order of numbers, 
corresponding to the numbers on the envelopes, was obtained externally using the 
MATLAB software programme from MathWorks® (3 Apple Hill Drive, Natick, MA 
01760-2098, US). The envelopes were opened in the order specified by the random 
sequence at the time of treatment or investigation for that patient.  
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 Pseudo-randomisation refers to the restriction imposed upon the randomisation 
process through the specification of equivalence in the ratios obtained. For example 
there was the same number of patients randomised to EVLA as UGFS. In a true 
randomisation process this equivalence is unlikely to have occurred by chance.  
  
2.63 Cardinal and ordinal units 
Part of the numerical transformation process, from a biological observation into a 
number, is defining the category within which the number is situated. Ordinal 
numbers have order and only relative value. For example 6 is greater than 3 but 6 may 
not be twice the value of 3. Cardinal numbers have incremental scalar value making 6, 
for example, twice the value of 3. They can be considered scalar variables. This 
distinction is important in the way assessment questionnaires are handled statistically.  
 The C of CEAP was converted into ordinal numbers for analysis. This made 
C4b, for example greater than C4a, without information as to how much. For this 
reason parametric tests were not used on the C of CEAP since these rely on scalar 
variables. The situation is more complex with the VCSS and the VS. Both make the 
assumption that each of their categories has equivalent biological value and each 
grade within each category is also equivalent. Statistically, therefore, scalar variables 
are permissible. Scalar variables were also used for the AVVQ since this 
questionnaire delivers weighted scores based on the biological importance of each 
question up to 3 decimal places. 
  
2.64 Non-parametric tests 
These were used extensively and in preference to parametric tests because of the 
assumption that biological data will have an order in preference to a scalable metric 
despite the cardinal nature of the questionnaires. Medians, inter-quartile ranges and 
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ranges were used throughout. The Wilcoxon signed rank test was used to determine 
significant differences within the same group, for example changes over time, and the 
Mann-Whitney U test was used to determine significant differences between groups. 
All correlations were exclusively non-parametric using the Spearman rho test since 
this relies on order in preference to value. 
 
2.65 Improvement 
Improvement can be assessed in 2 ways: percentage improvement or absolute 
improvement. The later is simply the mathematical difference between the score 
before treatment and the score afterwards. These techniques give different results in 
the same data set and it is important from the start to decide which of these has more 
clinical meaning. Absolute improvement was chosen for the following 4 reasons: 
 (i) It is unrealistic to assume everyone has 100% disease severity initially. 
 (ii) Changes over several time points are difficult using percentages 
 (iii) 100% improvement of very minor symptoms is a small improvement 
 (iv) Questionnaires were developed to have numerical scales of value 
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PART  III 
 
 
 
CLINICAL STUDIES ON METHODOLOGY 
 
 
 
CHAPTER  3 
 
 
 
CLINICAL STUDY  I 
 
 
 
Inter-observer variations in the C of CEAP 
 
 
...the most important things we need to manage can't be measured. 
 
-- W. Edwards Deming 
 
 
3.1 Introduction 
The CEAP classification (clinical, etiologic, anatomic and pathophysiologic) for 
chronic venous disorder (CVD) was set up following an international ad hoc 
committee (Porter and Moneta 1995; Beebe, Bergan et al. 1996). It was revised in 
2004 when it was stated that revision of CEAP is an ongoing process and that 
recommendations for change in the CEAP standard be supported by solid research 
(Eklof, Rutherford et al. 2004). In 2007, a Joint Statement of the American Venous 
Forum and the Society of Interventional Radiology reported that this revision should 
be included as a baseline patient characteristic prior to endovenous treatments 
(Kundu, Lurie et al. 2007). This would facilitate comparison between the results of 
different studies and improve the overall quality of research on venous disease. 
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 The C component is the most widely used part of the CEAP classification and 
it is based solely on clinical appearance. Skin changes secondary to CVD are 
classified as C4 with C4a representing pigmentation or eczema and C4b representing 
lipodermatosclerosis (LDS) or atrophie blanche. In 2004, a questionnaire study 
without photographs was sent to 3,681 phlebologists around the world. They 
concluded from 206 responders that future work would be required on discriminating 
between C1 and C2 varicose vein sizes and which C (C1-3) to assign for corona 
phlebectatica (Antignani, Cornu-Thenard et al. 2004; Uhl, Cornu-Thenard et al. 
2005). Discrepancies on the C placement of varicose veins of differing sizes were also 
apparent in an inter-observer reproducibility study between 3 clinicians on 54 limbs 
(Uhl, Cornu-Thenard et al. 2001). In that study there was disagreement between C0 
and C2 or C1 and C2 in 13 legs (24%) but only in 6 legs (11%) between C2 and C4 or 
C3 and C4. The above studies (Uhl, Cornu-Thenard et al. 2001; Antignani, Cornu-
Thenard et al. 2004; Uhl, Cornu-Thenard et al. 2005) suggested that further 
clarification should focus on the definitions of C0-3 rather than the later stages. 
Furthermore, it has been commented in an international consensus from experts that 
patients with more advanced venous disease were most reliably classified (Allegra, 
Antignani et al. 2003).  
 
3.2 Aims 
The hypothesis in this study is that skin changes (C4) are also difficult to classify and 
that any discrepancy could have greater clinical significance if it spans several points 
across the 8-point C scale. This is because wide variations in the interpretation of skin 
changes could inappropriately place a leg into a mild (C0-3) or severe (C4-6) category. 
The aim was to investigate how the definition of C4 could be improved by asking 
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dedicated phlebologists to use their judgment and experience to classify 7 colour 
photographs of skin changes using the C of CEAP.   
 
3.3 Patients and Methods 
3.31 Study design 
This was an observational study involving international experienced phlebologists 
familiar with the CEAP classification. They were asked to complete a short 
questionnaire in order to grade 7 photographs on the C of CEAP. These photographs 
were displayed on a table, placed at strategic locations, throughout the duration of 3 
international venous conferences: the Royal Society of Medicine venous forum 
(RSM-VF-2012), the European venous forum (EVF-2012) and the venous section of 
the World Congress of the International Union of Angiology (IUA-2012). Participants 
were either self-selected when they took an interest in the display table or when 
known, as prominent specialists in the venous world, were invited specifically to 
complete the questionnaire. 
   
3.32 Patients 
All 7 photographs were from patients with leg symptoms who were attending the 
venous clinic at a single public hospital. Five had duplex evidence of reflux in the 
saphenous trunks > 0.5 seconds (van Bemmelen, Bedford et al. 1989) without 
evidence of deep venous reflux. Two photographs were taken from the same patient 
(leg elevated and dependant) who had a previous calf vein thrombosis with significant 
tibial vein reflux. None of the patients had a healed venous ulcer or had received 
endovenous intervention for their condition. 
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3.33 Photographs 
The photographs were high-resolution, taken at close range and printed in colour on 
high-quality photographic A4 print-paper (Figs 3.1-3.7). Each photograph was 
cropped to highlight the gaiter and ankle areas. The first photograph of 
lipodermatosclerosis was used as a quality control to determine the standard of the 
participants at classifying skin changes and to familiarise them with the task. The 
remaining 6 were selected to highlight controversial areas in the C-class. Although 
they were considered to be representative of venous disease, it was for the participant 
to decide on the prevalence of these skin changes in their day-to-day practice.  
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Figure 3.1. The control image depicting lipodermatosclerosis. 
Survey result: C4a (39%), C4b (42%), C4 (16%). 
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Figure 3.2. Corona phlebectatica paraplantaris with an ankle flare. 
Survey result: C1 (16%), C2 (48%), C4a (28%). 
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Figure 3.3. Pigmentation over extensive varicose veins. 
Survey result: C1 (0%), C2 (29%), C4a (66%). 
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Figure 3.4. Mild pigmentation with eczema at the gaiter region. 
Survey result: C0 (32%), C2 (21%), C4a (34%). 
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Figure 3.5. Mild retro-malleolar pigmentation over a normal vein. 
Survey result: C0 (50%), C2 (16%), C4a (21%). 
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Figure 3.6. The same as shown in Fig 3.2 but the leg is now elevated. 
Survey result: C1 (86%), C4a (8%), C5 (2%). 
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Figure 3.7. Telangectasiae and reticular veins with infra-malleolar pigmentation. 
Survey result: C1 (21%), C2 (15%), C4a (56%). 
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 All 7 photographs were displayed simultaneously on a table which enabled 
each participant to pick them up and view each from different angles in order to make 
their judgment. Conferring was not forbidden and occurred occasionally. A copy of 
the clinical classification of the revision of CEAP summary was also placed on the 
table for reference purposes to remind each person of its precise wording as shown 
below (Eklof, Rutherford et al. 2004). 
 
3.34 Clinical classification (C class) 
 C0: no visible or palpable signs of venous disease 
 C1: telangiectasies or reticular veins 
 C2: varicose veins 
 C3: oedema 
 C4a: pigmentation or eczema 
 C4b: lipodermatosclerosis or atrophie blanche 
 C5 : healed venous ulcer 
 C6 : active venous ulcer 
 
3.35 Questionnaire design 
The questionnaire occupied half a page of A4 paper from which participants were 
asked to check 9 boxes and state their country of practice (Fig 3.8). This restriction on 
10 questions/replies was purposeful to prevent lapses of concentration or 
questionnaire fatigue thereby ensuring data quality with maximal completion (Rathod 
and LaBruna 2005). Participants were given 3 C-class options for each photograph 
from which to pick their answer. They also had the option of stating an alternative C-
class option or checking the “don’t know” box for whatever reason. The question on 
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whether a clinical history would influence their judgement was chosen because it is 
uncertain whether clinicians should rely on clinical appearance alone or use 
supplementary information in deciding the C of CEAP. This may be relevant because 
pigmentation could be the result of treatment. Discoloration could also be caused by 
extensive telangectasiae following a DVT. The clinical history in both of these 
situations may encourage an enthusiastic C class score of C4a rather than C0 or C1. 
 
 
 
Figure 3.8. The questionnaire which delegates were asked to complete. Picture 1 is 
Fig 3.1 and likewise for the remaining 6 illustrations. 
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 3.36 Data analysis 
The data were transferred manually from the questionnaires onto spreadsheets at the 
end of the study and then imported into the IBM® SPSS® statistics software version 
19 (IBM Corporation, Armonk, NY, 10504-1722, USA) from which the statistical 
analysis took place. The results on the C-class determination from the 7 pictures were 
reported in the way the C of CEAP is used to stratify patients in clinical trials: 
percentages in each C-class and/or stratification into mild and severe venous disease. 
That is, the results were reported in two ways. Firstly, specifically, as the percentage 
of responders choosing each C class (frequency distribution). Secondly, generally, as 
the percentage choosing mild (C0-3) or severe (C4-6) venous disease (binary outcome).   
 
3.4 Results 
3.41 Participant characteristics 
A total of 118 delegates completed the questionnaire out of the 120 that were 
returned. Two were excluded because the answers to the 7 picture questions were 
incomplete. It was interesting that 2 responders ticked multiple boxes for each 
question in line with the recommendations of the advanced CEAP. In this case the 
single highest descriptor was used for the clinical classification (Eklof, Rutherford et 
al. 2004). Delegates of 30 different nationalities completed this questionnaire, the top 
5 being: UK (17), Italy (16), USA (10), Czech Republic (8) and France (7). This 
distribution reflected the location of the conferences: London (RSM-VF: 20/118 
responders, 17%), Florence (EVF: 63/118 responders, 53%) and Prague (IUA: 35/118 
responders, 30%). 
 The experience of the delegate was determined by their number of years in 
phlebology practice which were: less than 2 (6%), between 2 and 10 (31%), between 
 116 
10 and 30 (43%), over 30 (17%) and failure to answer (3%). Of the 27 original 
members of the ad hoc committee on the revision of the CEAP classification (Eklof, 
Rutherford et al. 2004), 12 (44%) were recognized and invited in person into the 
study. Nine members completed the questionnaire and 3 were unable to take part for 
whatever reason. A further index of experience was provided by the answers to the 
quality control picture 1 depicting lipodermatosclerosis. A total of 96% of delegates 
recognized this correctly as pigmentation (C4 + C4a + C4b), with 3% as edema (C3) and 
1% checking “don’t know” for whatever reason. 
  
3.42 C class response stratification 
 
The percentage of participants checking each of the three given choices is displayed in 
the legends underneath each picture for convenience (Fig 3.1-3.7). Pictures 4, 5 and 7 
caused the greatest amount of uncertainty with the percentage of participants checking 
the “don’t know” box at 10, 5 and 4, respectively. The full spectrum is illustrated in 
Table 3.1. 
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Table 3.1.  Percentage of C classes chosen by participants for each picture. The 3 
given choices of C are highlighted in bold. 
 
 
Picture > 1 2 3 4 5 6 7 
C0 - - - 32 50 1 - 
C1 - 16 0 - 4 86 21 
C2 - 48 29 21 16 1 15 
C3 2 1 1 3 4 1 1 
C4 16 - - - - - - 
C4a 39 28 66 34 21 8 56 
C4b 42 2 1 - - - 3 
C5 - 2 - - - 2 - 
Don’t know 1 3 3 10 5 1 4 
 
 
3.43 Mild and severe response stratification 
The percentages of participants scoring mild (C0-3) and severe disease (C4-6) for each 
photograph from 1 to 7 were: mild/severe = 3/96, 65/33, 31/67, 56/34, 74/21, 89/10 
and 37/59, respectively. Apart from the control picture 1 which was classed as severe 
according to 96% of participants, there was a significant lack of agreement between 
mild and severe clinical disease for the remaining legs. There was clinical uncertainty 
in classifying picture 2 (Fig 3.2) with 32% of participants choosing advanced disease. 
However, when the same leg was elevated in picture 6 (Fig 3.6), this was reduced to 
10%. 
 
3.44 Importance of a clinical history 
In response to the influence a clinical history had to judgment of C class (Fig 3.8) the 
participants chose YES (67%), NO (26%), don’t know (3%) with 4% leaving this 
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question unanswered. The fact that two-thirds of participants stated that they would 
use a history was surprising because the C of CEAP was designed to be judged solely 
from clinical appearance. 
  
3.5 Discussion 
3.51 Limitations of CEAP as a severity classification 
The CEAP classification remains the gold standard classification of CVD. This was 
confirmed in a recent review article at which they conducted a Medline analysis 
retrieving 266 publications using CEAP (Rabe and Pannier 2012). This review also 
discussed the limitations of CEAP firstly stating that CEAP was not a severity 
classification and then pointed out the controversial areas as C0-3. The current study 
has demonstrated that the controversial areas can extend into the higher categories of 
CEAP. The reality is that C of CEAP is frequently used to group patients into 
categories and is also used to discriminate patients with mild and severe disease. The 
C4-6 group has been discussed as an individual disease (Bradbury 2010). The C 
stratification has been used in epidemiological studies (Maurins, Hoffmann et al. 
2008), longitudinal studies (Stucker, Reich et al. 2005), as a comparator to symptoms 
and signs (Chiesa, Marone et al. 2007), quality of life questionnaires (Shepherd, 
Gohel et al. 2011) and haemodynamic assessments (Lattimer, Azzam et al. 2012a). 
Many clinical papers stratify patients’ legs into mild/severe or 
uncomplicated/complicated based on this division between C0-3 and C4-6 (Navarro, 
Delis et al. 2002; Yamaki, Nozaki et al. 2002; Neglen, Egger et al. 2004; O'Hare, 
Parkin et al. 2008; Darvall, Sam et al. 2010; Rasmussen, Lawaetz et al. 2011; 
Lattimer, Kalodiki et al. 2013). This stratification is also used for rationing treatment 
in most public hospitals and in cost calculations (Ratcliffe, Brazier et al. 2006). 
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 The current research has shown that there are substantial discrepancies in the 
clinical classification of CVD using the C of CEAP and the distinction between mild 
and severe venous disease is also unclear.  
 
3.52 Analysis of photographs and scores 
Each photograph will be commented upon in turn in order to focus on the 
controversial areas. 
 Picture 3.1: (Fig 3.1) This is the control photograph which was correctly 
identified as C4/C4a/C4b by 96% of participants. A plaque of LDS is seen in the gaiter 
region with deeply situated varicose veins above this area. Although LDS is 
confirmed by palpation, this was not possible using photographs, a fact probably 
realized by 16% of participants who decided on choosing C4 alone. Nevertheless, the 
highest percentage score was C4b (42%) indicative of LDS.   
 Pictures 3.2 & 3.6: This is the same leg dependent (Fig 3.2) and elevated (Fig 
3.6) in a patient who has deep venous reflux in the calf veins following a DVT. The 
dependent ankle is discolored with a venous flare/corona phlebectatica and some 
varicose veins but on elevation pigmentation is not present which confirms the C1-2 
status of this leg. The dependent leg was reported as C4a by 28% of participants but 
this reduced to 8% after elevation. Elevation was used here to discriminate apparent 
pigmentation from venous congestion against true pigmentation from extravasation. 
Although corona phlebectatica is currently C1 there are recommendations by many 
phlebologists to consider it as C3 (Uhl, Cornu-Thenard et al. 2005). The lack of a 
marker scale prohibited the sizing of the varicose veins in order to establish if they 
were >3 mm in diameter in which case they would belong to C2. However, skin 
thickness and depth of vein should also be taken into consideration. For example it 
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would be difficult to compare vein size in Fig 3.1 with those in Fig 3.2. Interestingly, 
the venous clinical severity score (VCSS) uses a cut-off point of 4 mm adding further 
confusion (Rutherford, Padberg et al. 2000).  
 Picture 3.3: (Fig 3.3) Obvious mid-calf pigmentation over extensive varicose 
veins was reported by 66% of participants using C4a in comparison to the 29% who 
reported C2. This may be because pigmentation in CEAP is defined as “brownish 
darkening of the skin” and “occurs in the ankle region but may extend to leg and foot” 
(Eklof, Rutherford et al. 2004).  Should pigmentation arising de novo over a mid-calf 
varicose vein without having extended from the ankle be classed as C4a? Furthermore, 
pigmentation defined by the VCSS excludes this type of pigmentation by stating that 
“focal pigmentation over varicose veins does not qualify” (Rutherford, Padberg et al. 
2000) These factors may explain the reluctance of choosing C4a as an option.  
 Pictures 3.4 & 3.5: These legs demonstrate mild (Fig 3.4) and very mild (Fig 
3.5) degrees of pigmentation with eczema. This is reflected in the percentage of 
participants choosing C0 at 32% and 50%, respectively. Once again, it has been left 
for the observer to decide on what constitutes “brownish darkening” and how much 
eczema is significant to qualify as C4a. Furthermore, a “focal low intensity (tan)” is 
not considered by the VCSS as indicative of significant skin pigmentation and eczema 
is not a VCSS attribute. Both patients also had a normal looking vein present beneath 
the medial malleolus which may have prompted the choice of C2 at 21% and 16%, 
respectively.  
 Picture 3.7: (Fig 3.7) Many patients have different baseline skin colours which 
may cause additional problems in defining increased pigmentation rather than basing 
a judgment on its presence or absence. This has been highlighted in this picture of 
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gaiter telangectasiae where 56% of participants classified the accompanying 
hyperpigmentation as C4a.  
 A published limitation of CEAP is that the patient’s venous history is not 
taken into account (Cornu-Thenard, Uhl et al. 2004). It is clear from the current study 
that 67% of participants would use a clinical history in making their judgment on C. 
One participant reported that the ultrasound result would also influence her decision. 
 
3.53 Limitations of study 
This is an observational study where patients with an indeterminate C class were 
selected deliberately because they would invoke disagreement between different 
participants. However, the objective of this study was to highlight controversial areas 
because recognition of a limitation is an essential step prior to an improvement. 
Although all the patients were photographed within the same week the true prevalence 
of their leg appearances and the extent to which these patients are representative of a 
diseased venous cohort should be determined by the readers’ individual clinical 
practice.  
 A further limitation is that photographs are not patients. Differences in 
lighting, background and angles are known to have profound effects on the 
interpretation of varicose veins. However, care was taken to ensure that each 
photograph accurately represented the clinical features of each patient. This may have 
advantages over questionnaire studies which use descriptors without photographs 
(Antignani, Cornu-Thenard et al. 2004) and disadvantages in comparison to studies 
where patients are examined in a clinical setting (Uhl, Cornu-Thenard et al. 2001). 
However, the use of photographs outside a clinical setting may be beneficial because 
it standardizes the available information from which judgments are made. Clinicians 
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are therefore less likely to have their judgments on the C of CEAP influenced by the 
patients’ medical records, symptoms or duplex findings.   
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CHAPTER  4 
 
 
 
CLINICAL STUDY  II 
 
 
 
Varicose veins and severity of disease 
 
 
Things are not always as they seem;  
The first appearance deceives many. 
 
-- Phaedrus 
 
 
4.1   Introduction 
It is commonly believed that patients with extensive varicose veins (VVs) have 
greater venous insufficiency. The aim of this study was to test this belief. The venous 
clinical sverity score (VCSS) (Rutherford, Padberg et al. 2000) is an objective 
assessment of the severity of chronic venous disorder (CVD) and the Aberdeen 
varicose vein questionnaire (AVVQ) (Garratt, Macdonald et al. 1993) has been 
validated as a patient reported measure in a similar way. A question from each 
questionnaire was developed to quantify VVs. 
 The CEAP (clinical, etiologic, anatomical, pathophysiological) classification 
was first published in 1996 (Beebe, Bergan et al. 1996) following an international ad 
hoc committee on reporting standards (Porter and Moneta 1995) and has since 
undergone a detailed revision (Eklof, Rutherford et al. 2004). It classifies venous 
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disease. The clinical part, the C part, covers the spectrum with C0 representing the 
absence of venous disease and ends with C6 which is a venous ulcer. Although it is 
not a severity classification (Rabe and Pannier 2012) nonetheless it is a numerical 
score consisting of telangectasias (C1), varicose veins (C2) and ankle oedema (C3) 
through to pigmentation (C4a), lipodermatosclerosis (C4b) and lastly venous ulceration 
(C6). Furthermore, the C of CEAP is frequently used to stratify patients into severity 
groups and many publications continue to use CEAP as a severity classification 
(Chiesa, Marone et al. 2007; Shepherd, Gohel et al. 2011; Lattimer, Kalodiki et al. 
2013).  
 All phlebologists have seen patients with venous ulcers in the absence of VVs, 
irrespective of whether the cause is from deep or superficial venous reflux (Fig 4.1). 
This is often acknowledged when an endovenous saphenous ablation is performed and 
concomitant phlebectomies are not required due to their absence. Equally common are 
patients with extensive VVs and a complete absence of gaiter changes (Fig 4.2).  
 
 
Figure 4.1.  Healed venous ulcer without varicose veins but a refluxing GSV. 
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Figure 4.2.  Varicose veins without gaiter pigmentation or ulceration 
 
4.2   Aims  
The above observations led to the hypothesis that VVs are inversely related to clinical 
severity. Although not tested in this study it is possible that VVs may delay the later 
stages of venous disease. They may act as a haemodynamic cushion by redistributing 
the transmission of the reflux volume of the GSV from the sapheno-femoral junction 
(SFJ) to the gaiter area. These are controversial statements requiring investigation. 
Therefore, the first step and aim of this study was to investigate the extent and 
distribution of VVs using validated questionnaires and identify any relationship with 
clinical severity using the C of CEAP and hemodynamic severity using GSV diameter 
and air-plethysmography (APG).  
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4.3   Patients and Methods 
4.31 Study design 
This was a single centre retrospective study using baseline ancillary data collected 
from 100 patients (legs) as part of an endovenous laser ablation versus ultrasound-
guided foam sclerotherapy randomised controlled trial (Lattimer, Azzam et al. 2012b). 
All patients were awaiting endovenous treatment for a refluxing GSV. Patients with 
deep venous reflux, a history of DVT and reflux at the sapheno-popliteal junction 
were excluded. 
 
4.32 Assessment of varicose veins 
Varicose veins were assessed using question 1 of the Aberdeen varicose vein 
questionnaire (AVVQ) (Smith, Garratt et al. 1999) and question 2 of the venous 
clinical severity score (VCSS) (Rutherford, Padberg et al. 2000; Vasquez, Rabe et al. 
2010). The former is a patient reported outcome measure (Nesbitt, Wilson et al. 2012) 
where patients are requested to draw in their varicose veins on a template depicting 
the front and back of both legs as shown in Fig 4.3. A transparent grid bearing 
rectangles over identical leg drawings is placed over the completed varicose vein 
drawings from the patient. The varicose veins are then quantified by counting the 
number of transparent rectangles which are occupied by VVs. Each rectangle 
occupied scores a mark of 0.172 giving a total possible score of 22.016 (0.172 x 128 
available rectangles). Legs were then stratified into roughly 2 equal groups based on 
an arbitrary cut point of 2.  
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Figure 4.3.  Question 1 of the Aberdeen varicose vein questionnaire completed. 
 
 Question 2 of the VCSS is a physician recorded assessment where the extent 
and distribution of VVs are reported as scattered (score = 1), multiple calf or thigh 
(score = 2) or multiple calf and thigh (score = 3). This allowed patients to be grouped 
into 4 categories, none, mild, moderate and severe, with the high scores representing 
more extensive veins (Fig 4.4). 
 
 
Figure 4.4.  Question 2 of the venous clinical severity score highlighted. 
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4.33 Clinical and haemodynamic severity 
Clinical severity was assessed using the C part of the CEAP classification by 
stratifying patients into 2 roughly equal groups: mild disease (C2-3) and severe disease 
(C4-6). This is justified because patients in C4-6 category are considered as a separate 
disease entity (Bradbury 2010).  
 The GSV diameter has been validated as an index of haemodynamic severity 
(Mdez-Herrero, Gutierrez et al. 2007). It was measured in 3 places within a refluxing 
GSV using a Sonosite® Titan duplex scanner fitted with a linear 7 MHz transducer 
and averaged. Care was taken to avoid sacculated areas as well as the termination of 
the GSV when the vein usually widens with noticeable changes in size depending on 
the cycle of respiration (Lattimer, Kalodiki et al. 2012c).  
 Air-plethysmography was also used to measure severity (Christopoulos, 
Nicolaides et al. 1987). The venous filling index (VFI) quantifies the rate of venous 
filling into the calf with units of mL/sec. A value > 2.5 mL/sec is considered 
pathological. The VFT90 represents the time taken to fill 90% of the total venous 
volume in the calf and represents reflux duration (Lattimer, Azzam et al. 2013a). A 
value > 25 seconds is found in normal legs but may also represent mild clinical 
disease (Lattimer, Kalodiki et al. 2013). 
     
4.34 Statistical analysis 
Data were transferred from spreadsheets into the IBM® SPSS® statistics package 
version 19. Correlations were performed using the non-parametric Spearman rho test. 
The strength of the relationship was indicated using r where r values of < 0.3, 0.3 - 0.7 
and > 0.7 represent none-weak positive, moderate positive and strong positive 
respectively. Varicose vein assessments using question 1 (AVVQ) and question 2 
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(VCSS) were also performed by first stratifying these results into categories of VV 
extent. Differences between particular assessments were then determined on these 
categories using the Mann-Whitney U test. A P value of < 0.05 represented a 
statistically significantly correlation using continuous data as well as a statistically 
significant difference when organised into categories. A positive result was the 
presence of a significant correlation together with a significant difference.  
     
4.4   Results 
4.41 Patient characteristics 
In the 100 patients (legs) studied the median age was 46 (21-78), 42% of patients 
were male and 46% of patients had unilateral disease. The C part of CEAP was: C2 = 
35, C3 = 13, C4a = 29, C4b = 9, C5 = 7 and C6 = 7. Therefore, 48 patients had mild 
disease (C2-3) with the remaining 52 being in the severe category (C4-6). The median 
(range) AVVQ, VCSS, GSV diameter, VFI and VFT90 were 21 (1 - 53), 6 (2 - 20), 7 
(4 - 12) mm, 4.9 (0.9 – 17.8) mL/sec, 18.9 (7 – 76.1) seconds, respectively. 
 
4.42 AVVQ and VCSS versus clinical severity 
The performance of the global AVVQ and VCSS scores were evaluated first to 
confirm that there was an increase in both with severe disease (C4-6).  This is shown in 
Fig 4.5 and is in agreement with similar studies which use these questionnaires 
(Bountouroglou, Azzam et al. 2006; Shepherd, Gohel et al. 2011). This was necessary 
as a quality control in order to validate the rest of the results in this study. 
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Figure 4.5.  Significant correlations and differences of AVVQ (A) and the VCSS (B) 
between the mild and severe categories of C class. 
 
 
4.43 Question 1 of the AVVQ versus severity 
The patient reported extent of varicose veins using Question 1 did not appear to have 
any relationship between mild and severe clinical disease (Fig 4.6). Furthermore, 
patients with more extensive varicose veins scoring an AVVQ question 1 value of > 2 
did not have significantly greater GSV diameters. Similarly, as charted in Fig 4.7, 
patients with a question 1 value > 2 also did not have a significantly higher VFI or 
VFT90. Thus it would seem that question 1 is not related to severity as measured 
using C of CEAP, GSV diameter or APG parameters. 
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Figure 4.6.  AVVQ question 1 relationship to C of CEAP (A) and GSV diameter (B) 
 
 
 
Figure 4.7.  AVVQ question 1 relationship to the VFI (A) and VFT90 (B) 
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4.44 Question 2 of the VCSS versus severity 
Question 2 of the VCSS records the degree and extent of varicose veins into 4 
categories according to the physician. As shown in Fig 4.8, there was no significant 
difference between early C of CEAP and the later stages with skin changes regarding 
the proportion of legs within each of the 4 categories. According to the hypothesis it 
was anticipated that a greater proportion of legs with “protective” thigh and calf veins 
would be present in the early stages.    
 
 
Figure 4.8.  Category proportions of question 2 stratified by C class 
 
The remaining results correlated the categories of question 2 of the VCSS as well as 
the differences between these categories against haemodynamic markers of disease 
severity. These include the GSV diameter (Fig 4.9), the VFI (Fig 4.10) and the VFT90 
(Fig 4.11) all depicted as pink boxplots. Once again these are also compared alongside 
the C class stratification of mild and severe disease as a quality control (depicted as 
orange boxplots) where all correlations and differences were statistically significant 
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between the 2 clinical severity groups. Significant correlations were observed with all 
3 haemodynamic markers against the categories of question 2 and there were also 
significant differences between scattered veins and thigh or calf veins and increasing 
trends between thigh or calf veins and thigh and calf veins.  
 
 
Figure 4.9.  GSV diameter compared to question 2 (A) and clinical severity (B) 
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Figure 4.10. VFI compared to question 2 (A) and clinical severity (B) 
 
 
 
Figure 4.11. VFT90 compared to question 2 (A) and clinical severity (B). The 
horisontal dashed line (B) demonstrates that the median VFT90 in the early disease 
group is outside the inter-quartile range of the severe disease group.    
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4.5   Discussion 
4.51 Summary 
This study was set up to examine if there was a relationship between the extent and 
distribution of VVs and the severity of chronic venous disorder (CVD). It was based 
on a clinical observation that many patients with lipodermatosclerosis (LDS) and/or 
venous ulcers did not appear to have significant VVs and conversely, many patients 
without abnormal skin changes had extensive VVs. The results indicated a lack of 
relationship between VV extent and clinical severity. 
 
4.52 Validation of hypothesis 
The hypothesis that increased VVs had an inverse relationship with clinical severity 
was not proven. Furthermore a direct relationship was also not present. However, 
there was a significant relationship between the physician recorded question 2 of the 
VCSS and haemodynamic severity measured using GSV diameter and APG. This 
indicates that larger saphenous trunks with a faster rate and duration of refilling had 
more extensive varicose veins.   
 
4.53 Limitations of question 1 
The patient reported question 1 of the AVVQ had no relationship to clinical or 
haemodynamic severity. This may be because there was no real difference but may 
have occurred also because of 3 confounding variables related to the use of this 
question as an assessment. Firstly, patients often have difficulty in drawing their 
veins. They usually see their legs from above rather than enface and rarely see the 
back of them. Furthermore, personal observation has revealed that some patients also 
include areas of telangectasiae, pain and pigmentation as part of their assessment. 
 136 
Drawing skills may be lacking or just careless, evidenced by the appearance of VVs 
outside the perimeter of the translucent marking grids. Secondly, since bilateral veins 
are an intrinsic part of question 1, VVs drawn on the contralateral leg are also 
included. Thirdly, in contrast to the VCSS, the AVVQ results depend on multiple 
assessors, patient and doctor. Inter-observer variation is therefore an inherent feature 
of this questionnaire, irrespective of the actual number and distribution of VVs.  
 
4.54 Innovation in varicose vein assessments 
Although question 2 of the VCSS has the advantages of a single rater and leg the 
grading of the extent and distribution of VVs is limited to 4 categories which are 
subjective. For example, the point at which a few scattered veins become multiple 
VVs is ill defined. Likewise, there is no guidance how to score a patient with multiple 
above knee VVs when there are a few scattered VVs below the knee. One solution is 
to combine the advantages of question 1 and 2 into a separate questionnaire which 
could form the basis of future work. This questionnaire could be based on question 1 
of the AVVQ, but become physician recorded and apply only to one leg. Its 
advantages include a greater range of possible scores from 0 – 64 and allow the 
subdivision into many categories as and when required. Comparisons between this 
and a patient reported version would also be possible. 
 Most patients presenting at a varicose vein clinic do so because of their 
varicose veins (VVs). However, in the UK, gaiter pigmentation in the absence of VVs 
may remain in the domain of the primary care doctor with treatments consisting of 
various topical skin preparations. These patients may also be referred to a 
dermatologist. This may have the effect of excluding the recognition of this important 
subgroup from analysis and appropriate treatment. Changing referral patterns by 
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renaming the VV clinic to a CVD clinic may help in capturing the full spectrum of 
venous disease. Nevertheless, the current situation still provided an opportunity to 
study the relationship between the extent of VVs and the stage of progression of 
venous disease. 
 
4.55 Severity assessment 
This study has concluded that VVs have no relationship to the clinical severity of 
venous disease . This is based on a small number of patients using questionnaires 
which, although they are in common use and have been validated by many authors, 
may be inadequate for this purpose. There is no consensus as to how the severity of 
varicose veins should be recorded. The C of CEAP, AVVQ, VCSS GSV diameter and 
APG parameters all have their limitations and rarely demonstrate good correlations 
with each other. The search for a severity benchmark is awaited and opinion is 
divided whether it should be based on clinical indicators, quality of life, 
haemodynamic parameters or a combination of all three.  
 The question this study presents should be known and it is surprising that after 
extensive research into venous disease the definitive answer remains elusive. A 
multicentre equivalency trial using improvements in questionnaire design may help 
establish whether the extent of VVs bears any relationship to clinical severity or 
whether they are just a sign of CDV.   
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CHAPTER  5 
 
 
 
CLINICAL STUDY  III 
 
 
 
Responsiveness of the VCSS and the AVVQ 
 
 
All assessment is a perpetual work in progress. 
 
-- Linda Suske 
 
 
5.1   Introduction 
The venous clinical severity score (VCSS) and the Aberdeen varicose vein 
questionnaire (AVVQ) are dynamic scoring tools used to quantify the effects of 
treatment on superficial venous insufficiency (SVI). Their use is recommended in 
studies which assess the efficacy of endovenous treatments. This was highlighted in a 
joint statement by the American Venous Forum and the Society of Interventional 
Radiology (Kundu, Lurie et al. 2007).  
 The VCSS was introduced in 2000 (Rutherford, Padberg et al. 2000) and has 
been extensively validated and revised as a physician recorded outcome measure on 
venous severity (Meissner, Natiello et al. 2002; Kakkos, Rivera et al. 2003; Ricci, 
Emmerich et al. 2003; Vasquez, Wang et al. 2007; Vasquez, Rabe et al. 2010; 
Passman, McLafferty et al. 2011). Ten different attributes (categories) of severity of 
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venous disease are each given an ordinal score of 0-3, 3 representing the worse score 
within a category. The scores are then added to produce the total VCSS for that 
patient. 
 The AVVQ was introduced in 1993 (Garratt, Macdonald et al. 1993) and has 
since been validated and revised as a patient reported outcome measure on venous 
severity (Smith, Garratt et al. 1999; Darvall, Sam et al. 2010; Shepherd, Gohel et al. 
2011). There are 13 individual attributes of severity (categories) represented as 13 
questions. Each question has up to 8 responses which are quantified to 3 decimal 
places. Question 9 on bilateral ulceration, for example, has a score ranging from 0-
18.236. The scores are then added and adjusted for omitted questions to give a 
maximum possible AVVQ score of 99.658 for that patient. Since each score has been 
weighted the AVVQ represents a parametric cardinal scale of severity. 
 Both the VCSS and the AVVQ respond overall to treatment as illustrated in a 
representative recent prospective randomised controlled trial (Rasmussen, Lawaetz et 
al. 2011). This is the usual way in which these questionnaires are used. However, it is 
not clear which individual questions are the most responsive to change and the 
relationship of this change to clinical severity using the C part of the CEAP 
classification (Porter and Moneta 1995; Beebe, Bergan et al. 1996; Eklof, Rutherford 
et al. 2004). 
 
5.2   Aims 
The aim of this study was to evaluate the change in each question following 
endovenous treatment and to assess the contribution of each question to the total 
scores. This information may be useful in improving the dynamic nature of these 
assessment tools and for questionnaire committees that are planning future revisions. 
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5.3   Patients and Methods 
5.31 Study design 
This was a data analysis study to evaluate changes in answers to survey questions 
over time. The data were collected from a prospective clinical study comparing 2 
different procedures. The study has been published as a randomised controlled trial of 
100 patients who were treated with either endo-venous laser ablation with concurrent 
phlebectomies (EVLA, n=50) or ultrasound-guided foam sclerotherapy (UGFS, n=50) 
(Lattimer, Azzam et al. 2012b). The C part of CEAP was recorded and for the 
purposes of this analysis remained static throughout the treatment course (disease 
“stage”). This was irrespective of whether the dynamic elements of this classification 
improved. Patients were assessed at baseline, 3 weeks and 3 months using the VCSS 
and the AVVQ. The AVVQ was completed in a hospital environment to ensure all 
questions were answered, including question 1, where patients were asked to draw 
their veins. A face-to-face interview was avoided to prevent bias by the interviewer. 
The responses to the individual questions of each questionnaire were recorded on an 
Excel® spreadsheet.  
 Colour duplex was used to confirm eligibility with reflux in the great 
saphenous vein (GSV) > 0.5 sec but without deep venous reflux > 1 sec. The venous 
filling index (VFI) using air plethysmography was recorded after an elevation-
dependency manoeuvre in order to provide a hemodynamic assessment 
(Christopoulos, Nicolaides et al. 1988a).  
Ethics committee approval had been granted from the local ethics committee 
(No: 08/H0710) and informed consent had been obtained from participating patients. 
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5.32 Patient characteristics and stratification 
Of the 100 patients (legs), 58 were female while 60 had bilateral disease, but only the 
worst leg was enrolled in the study. All patients had exclusive superficial chronic 
venous insufficiency (CVI) involving only the GSV. Patients with evidence of a past 
or current DVT, or an incompetent small saphenous vein, were excluded. The C class 
stratification was: C2 = 34, C3 = 14, C4a = 29, C4b = 9, C5 = 7, C6 = 7. Patients were also 
stratified according to hemodynamic success at 3 months (group A, n = 38) defined as 
the complete absence of saphenous reflux with normalisation of the VFI (< 2.5 
mL/sec). The rest were in group B (n = 54). This division was based on an assumption 
that questionnaire responsiveness may parallel hemodynamic success. One patient did 
not have a follow-up APG at 3 months but had completed questionnaires. Since the 
AVVQ does not discriminate between unilateral and bilateral disease, it was also 
necessary to stratify patients in this manner. This was based on an assumption that 
unilateral veins would demonstrate a greater improvement for the patient overall in 
comparison to the patients with bilateral disease with untreated veins on the other leg. 
 
5.33 Statistical analysis 
Data were analyzed using the SPSS statistics version 17. Boxplots with median, inter-
quartile range (IQR) and range were used to illustrate the VCSS and the AVVQ. The 
Wilcoxon signed rank test was used to test for significant change within the same 
question (and same patient) between 2 time intervals (baseline versus 3 weeks, 
baseline versus 3 months) and the Friedman test was used to test for significant 
change between 3 time intervals (baseline versus 3 weeks versus 3 months). Change 
scores (responsiveness) for each question were calculated by subtracting the post-
treatment value from the baseline score. Significance was stratified according to 3 
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levels: not significant (P > 0.05), significant (P < 0.05 – P > 0.0005) and highly 
significant (P < 0.0005). The C part of the CEAP is an ordinal scale (rank and 
position) and correlations using this scale were performed using the non-parametric 
(not reliant on a quantitative scale) Spearman rho test. Although the VCSS and the 
AVVQ for the purposes of this analysis were taken to be cardinal scalar variables 
(quantifiable), correlations with the C of CEAP were necessarily non-parametric. 
 
5.4   Results 
5.41 Overall responsiveness 
The median (IQR) VCSS and the AVVQ scores significantly improved as a result of 
endovenous treatment. The VCSS decreased from 6 (4) to 3 (4) at 3 weeks (P < 
0.0005) and to 2 (3) at 3 months (P < 0.0005). The AVVQ also decreased from 21.4 
(15.1) to 18.6 (12.1) at 3 weeks (P = 0.031) and to 8.8 (13.6) at 3 months (P < 
0.0005). The improvement in the VCSS and the AVVQ was also significant 
throughout the 3 week and 3 month time intervals, P < 0.0005 and P < 0.0005, 
respectively (Friedman test) as depicted in Fig. 5.1. Whilst a global score is useful, a 
single number representing the VCSS or AVVQ is not an effective indicator as to 
which categories of patients respond the most to treatment. The results were therefore 
assessed by categorising the patients according to the C class, as demonstrated below. 
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Figure 5.1  The VCSS (A) and AVVQ (B) scores improve significantly 3 weeks and 
3 months after endovenous intervention. 
 
 
5.42 Responsiveness according to C class 
When patients were stratified according to increasing severity using the C of CEAP, 
at baseline, there was a better correlation with the VCSS (Fig 5.2A) than the AVVQ 
(Fig 5.3A), r = 0.584 and  r = 0.326 respectively, both achieving significance. The 
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VCSS and the AVVQ were also significantly responsive (baseline scores minus post-
treatment scores at 3 months) at each stage of severity (P < 0.05, Wilcoxon). When 
the responsiveness of the VCSS at 3 months (Fig 5.2A) was compared against the C 
stage, significance was achieved (r = 0.251, P = 0.015). The high VCSS change scores 
from the C6 patients, ranging from a 5 to a 14 point improvement, were responsible 
for this correlation, which would not have been significant had this category been 
excluded from the analysis. In contrast, there was no relationship between the degree 
of improvement of AVVQ and the higher C classes (Fig 5.3B). 
 
 
Figure 5.2  Increases in VCSS correlate significantly with worsening C class (A). The 
VCSS improves significantly at each stage of severity at 3 months (B), but the degree 
of improvement (excluding C6) appears static and is irrespective of C class. Dashed 
line = no change. 
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Figure 5.3  Increases in AVVQ demonstrate a weak but significant correlation with 
worsening C class (A). The AVVQ improves significantly at each stage of severity at 
3 months (B), but the degree of improvement appears static, without significant 
correlation, and is irrespective of C class. Dashed line = no change. 
 
 
These results indicate that although there was a relationship between 
increasing severity and the VCSS and AVVQ, there was no relationship between the 
degree of improvement and increasing severity (excluding C6 VCSS patients). The 
extent of improvement therefore could be attributed to the proportion of patients in the 
study cohort with C6 disease rather than a true reflection of improvement. Whilst 
subdivision according to severity is useful, it does not indicate which questions of the 
VCSS and the AVVQ are the most responsive to treatment. 
 
5.43 Responsiveness of VCSS questions 
The first 3 questions of the VCSS (Q.1 pain, Q.2 extent of varicosities, Q.3 oedema) 
contributed most to the global score at 3 months post intervention and the questions 
specific to ulceration (Q.5, Q.7, Q.8, Q.9), pigmentation (Q.4) and induration (Q.6) 
contributed least (Fig 5.4A). Since only 7/100 patients had ulcers, failure to achieve a 
significant impact on the global score was related to their small number because the 
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remaining majority (n=93) scored a zero for questions on ulceration (Fig 5.4B). 
Interestingly, Fig 5.4A appears to have an inverse relationship to Fig 5.4B. This is in 
direct contrast to the VCSS responsiveness when patients were categorized into C6 
(Fig 5.2B), since it was this group which demonstrated the greatest change with an 
improvement ranging between 5-14 points (P = 0.028, Wilcoxon).  
 
 
Figure 5.4  A wide variation in the mean change in VCSS scores at 3 months for the 
individual questions. The most responsive questions were Q.1, Q.2 and Q.3 (A). 
Small changes may be related to statistical dilution from a high proportion of patients 
scoring zero for Q.5 – Q.9 at baseline (B).   
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5.44 Responsiveness of AVVQ questions 
At 3 months, the majority of the answers to the AVVQ questions improved 
statistically as a result of intervention (P < 0.0005).  Question 3 on the use of 
analgesia was also significant (P < 0.05). However, Q.5 (stocking use) and Q.9 
(ulceration) did not have a significant impact upon the global score. When patients 
were stratified according to the C class the responsiveness of the AVVQ in C6 patients 
was significant (P=.028, Wilcoxon). The greatest mean change was demonstrated in 
Q.1 through a reduction in the distribution and extent of varicose veins (P < 0.0005) 
and in Q.10 by an improved cosmetic appearance (P < 0.0005) as depicted in Fig 
5.5A. It is likely that the lack of impact upon the global score in the ulceration group 
(n=7) is due to the small number because most patients scored a zero for Q.9 
(ulceration) at baseline as shown in Fig 5.5B.  
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Figure 5.5  The mean change in AVVQ scores at 3 months for each question 
demonstrates a wide variation, with Q.1 and Q.10 responding the most (A). The 
proportion of patients scoring zero at baseline are also illustrated (B). 
 
5.45 Subgroup analysis 
A subgroup analysis was performed according to intervention at 3 weeks and 3 
months and also according to hemodynamic success at 3 months (Group A = 38, 
Group B = 54) to determine if any of these factors changed the responsiveness of the 
individual questions.  
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There was no significant difference in the change scores (3 months) of the 
VCSS or the AVVQ when patients were stratified by treatment type P = 0.82 and P = 
0.06, respectively (Mann-Whitney U test).  Stratification by hemodynamic success 
was also not significant at P = 0.107 and P = 0.677, respectively (Mann-Whitney U 
test). Similarly there was no difference in the change scores of the AVVQ at 3 
months, when patients were stratified according to uni/bilateral disease, P = 0.495 
(Mann-Whiney U test).  
The individual questions of the VCSS and AVVQ results, across all groups, 
are summarised in Table 5.1 and Table 5.2, respectively. The changes on the first 3 
questions of the VCSS remained significant (P < 0.0005), irrespective of recovery 
time, intervention type or haemodynamic success. The score changes associated with 
the use of stockings (Q.10) were not useful, demonstrating significant deterioration at 
3 weeks, but also improvements at 3 months, and without significant change in the 
foam patients (3 weeks), laser patients (3 months) and in those patients with 
haemodynamic success. The responsiveness of Q.6 (induration) was consistently 
insignificant across all groups examined and may reflect the long time it takes for skin 
to soften, which may not happen to all patients. Despite the fact that all the ulcers 
healed or improved, most of the questions related to ulceration failed to demonstrate 
significant responsiveness across the groups because only 7 patients had ulceration. 
This was also true of Q.9 (ulceration) in the AVVQ which remained insignificant 
except for the EVLA subgroup at 3 months (P < 0.05). In agreement with the VCSS, 
the AVVQ question regarding stocking use (Q.5) was not useful and hampered the 
responsiveness of this question at 3 weeks (Table 5.2). The most consistently 
significant change at the P < 0.0005 level on the AVVQ across all groups was Q.1 
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where patients were asked to draw in their varicose veins. It was also the least likely 
question for patients to report a zero score (Fig 5.5B). 
 
Table 5.1  Level of significancea in the change scores of the individual VCSSb 
questions according to different subgroups; stratified by time, endovenous treatment 
and haemodynamic success (Group A and B). 
 
 P < 0.0005 P > 0.0005 P > 0.05 (N/S) 
3 weeks 1,2,3,4 7,8,9,10c 5,6 
3 months 1,2,3 4,5,8,10 6,7,9 
Laser 3 weeks 1,2,3,10c 4 5,6,7,8,9 
Foam 3 weeks 1,2,3 4 5,6,7,8,9,10 
Laser 3 months 1,2,3 4 5,6,7,8,9,10 
Foam 3 months 1,2,3 10 4,5,6,7,8,9 
Group A (n=38) 1,2,3 . 4,5,6,7,8,9,10 
Group B (n=54) 1,2,3 10,4 5,6,7,8,9 
 
Group A = Haemodynamic success at 3 months with the absence of reflux on duplex 
and a venous filling index < 2.5 mL/sec. Group B = Haemodynamic failure.  
 
aWilcoxon signed rank test; bVenous clinical severity score; cdeterioration. 
 
 
 
 
 
 
 
 
 
 
 
 152 
Table 5.2  Level of significancea in the change scores of the individual AVVQb 
questions according to different subgroups; stratified by time, endovenous treatment, 
uni/bilateral and hemodynamic success (Group A and B). 
 
 
 P < 0.0005 P > 0.0005 P > 0.05 
3 weeks 1,4,5c,7,8,10 2,3,6,11 9,12,13 
3 months 1,2,4,6,7,8,10,11,12,13 3 5,9 
Laser 3 weeks 1,3,5c,7,10 4,6,8,11 2,9,12,13 
Foam 3 weeks 1,4,5c 2,7,8,10,12 3,6,9,11,13 
Laser 3 months 1,2,4,6,7,10,13 8,9,11,12 3,5 
Foam 3 months 1,2,10,11,12,13 6,7,8 3,5,9 
Unilateral  4,10 1,2,6,7,8,9,11,12,13 3,5 
Bilateral 1,2,4,6,7,10,11,12,13 8 3,5,9 
Group A (n=38) 1,2,4,6,10,11,12,13 7,8 3,5,9 
Group B (n=54) 1,2,4,6,10,11,13 3,7,8,12 5,9 
 
Group A = Haemodynamic success at 3 months with the absence of reflux on duplex 
and a venous filling index < 2.5 mL/sec. Group B = Haemodynamic failure.  
 
aWilcoxon signed rank test; bAberdeen varicose vein questionnaire; cdeterioration. 
 
 
5.5   Discussion 
5.51 The VCSS and AVVQ as outcome assessments 
This study supports the use of the VCSS and AVVQ in following outcomes after 
endovenous treatments. Since they have different objectives they are not directly 
comparable. The VCSS is an easy to use, well established, physician-generated 
questionnaire that community clinicians can use to assess the results of treatment. The 
AVVQ is a patient reported quality of life (QoL) questionnaire. Although easy to 
complete, the evaluation of the scoring is labour intensive, especially Q.1, where 
patient drawings require quantification using transparent grid-lines. Advantages of the 
AVVQ include a high Cronback alpha (0.72) (Bland and Altman 1997), which 
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measures internal consistency using the correlation between questions and the 
question-total correlation. Garratt and coworkers (Garratt, Macdonald et al. 1993), in 
their validation study on the AVVQ, rejection the respective question when there was 
a poor question-total correlation (< 0.2).  
This research has demonstrated that the VCSS had a better correlation with 
clinical severity than the AVVQ, r = 0.584 and r = 0.326, respectively. The VCSS and 
the AVVQ significantly reduced after endovenous treatment and this was also true at 
each level of clinical severity. However, the degree of improvement in these 
questionnaires was not related to C class, except for the improvement in the VCSS in 
C6 patients. Some questions failed to statistically contribute overall to the scores 
because of statistical dilution with many VCSS questions recording zero scores within 
the study population. Improvement in the VCSS, for example, may be positively 
influenced by the proportion of patients with active ulceration. This observation is not 
surprising since 12 out of the 30 possible scores are specific to the severity of 
ulceration.  
 
5.52 Responsiveness of individual questions 
Questions 1, 2 and 3 of the VCSS and questions 1 and 10 of the AVVQ demonstrated 
the greatest mean change (responsiveness) at 3 months as a result of treatment. Very 
few patients scored a zero for these questions at baseline, which indicated that the 
changes are likely to be representative of the study group. Stratifying patients by 
treatment type, post procedural assessment time or haemodynamic effectiveness did 
not significantly alter these results. 
 The AVVQ was designed as a postal questionnaire (Garratt, Macdonald et al. 
1993) and consequently some questions are often left unanswered: Q.1 for example, 
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where patients are requested to draw their veins, rather than just tick a box. Lack of 
patient response may also include questions which are usually given zero scores (Q.9 
on ulceration) as well as questions which attract points (Q.1 vein drawings on legs). 
The significance of an unanswered question will therefore differ according to clinical 
severity. If an ulcer patient leaves out Q.9 it would be of greater significance than a C2 
patient who would inevitably score zero for this question. Patients should therefore be 
encouraged to fill in every question. It was part of the methodology of this study for 
patients to complete the AVVQ in a hospital environment. Furthermore, knowledge of 
the likelihood of an unanswered question being zero may result in a revision of the 
scoring adjustment policy which states: “If a question is omitted by a patient the total 
score is calculated after removing the score for that question from the denominator” 
(Garratt, Macdonald et al. 1993). The alternative policy of filling in omitted questions 
on behalf of the patient is not advised as it would be contrary to the principle of the 
AVVQ as a patient reported outcome measure (PROM) (Nesbitt, Wilson et al. 2012). 
Stratifying patients by C class and ensuring each question is answered may therefore 
improve the performance of the AVVQ.  
The observation that the scores of Q.10 of the VCSS and Q.5 of the AVVQ 
significantly deteriorated at 3 weeks interrogates the relationship between the use of 
compression and the severity of the disease. It is known that stockings are 
uncomfortable and that there is a trade-off between the symptom relief gained with 
stockings against the discomfort to wear them, the difficulty in application, erratic 
prescribing and high cost (Raju, Hollis et al. 2007; Ziaja, Kocelak et al. 2011). There 
is also the patients’ expectation that they may be free of compression following 
treatment which may artificially reduce the severity. However, the most likely 
explanation for deterioration was that patients were told to wear compression 
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following intervention. Three weeks may be too early to assess severity when the 
benefits of treatment are off-set with the discomfort of recovery. A limited review 
performed by Darvall and colleagues (Darvall, Sam et al. 2010) noted that the AVVQ 
appeared to worsen in the early weeks after surgery and EVLA, before improving by 
4 – 6 weeks The questions which relate to stocking use (VCSS Q.10, AVVQ Q.5) 
have been shown in our study to hamper responsiveness if the AVVQ is used at the 
early time of 3 weeks. 
 
5.53 Subgroup analysis 
Contrary to expectation, stratification of patients into haemodynamic success and 
failure (groups A and B, respectively) did not affect the responsiveness of the 
questions in the VCSS or the AVVQ. Haemodynamic parameters usually show poor 
correlation with clinical severity, so this result would be in keeping with similar 
studies which examine venous haemodynamics (Labropoulos, Leon et al. 1994; 
Nishibe, Kudo et al. 2006; Volkmann, Falk et al. 2008). Possible explanations for this 
include the time taken for the haemodynamic insult to be expressed clinically and that 
haemodynamic correction may also take time to become clinically noticeable. 
When patients were stratified into uni/bilateral disease the majority of the 
AVVQ questions, except Q.3, Q.5 and Q.9 (analgesia use, stocking use and 
ulceration) were responsive. It came as a surprise that the change in nearly all the 
questions in patients with bilateral disease were in the higher level of significance (P 
< 0.0005) with the responsiveness in the patients with unilateral disease at a lower 
level (P > 0.0005). Patient factors may be responsible for this finding with patients 
with bilateral disease recording severity in the contra-lateral leg before intervention 
but focusing their response to the questionnaire on the treated leg after intervention. 
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Whatever the reason, these results indicate that the responsiveness of the AVVQ may 
have more meaning if assessed in relationship to whether they had uni- or bi-lateral 
disease. 
 
5.54 Clinical integration 
The results on this study were assessed at 3 weeks and 3 months. Three weeks may be 
considered too soon to expect improvement in some of the less responsive questions. 
Analgesia use, gaiter induration, post-inflammatory hyperpigmentation and stocking 
use may be an effect of treatment, rather than an index of severity. Furthermore, it 
may take much longer than 3 months for the baseline pigmentation and induration to 
reduce to a degree that will be detected on questionnaires.   
In 2000, Rutherford and colleagues (Rutherford, Padberg et al. 2000) proposed 
the VCSS as an adjunct to venous outcome assessment. This study has examined the 
performance of the VCSS when used as adjunct to the C part of the CEAP 
classification, rather than a global score, irrespective of the clinical stage of disease. 
Since the VCSS is an ordinal scale based on the attributes of severity, rather than 
severity itself, it may be more meaningful if the VCSS was recorded for each stage of 
C. This research therefore reflects the original intention of the American venous 
forum ad hoc committee on venous outcomes assessment to use the VCSS on patients 
with similar degrees of clinical severity (Rutherford, Padberg et al. 2000).  
 Significant correlations between baseline VCSS and the C of CEAP have been 
described previously by our group (Kakkos, Rivera et al. 2003) and others (Meissner, 
Natiello et al. 2002), and are in agreement with the correlations in this study. The 
correlation between the VCSS and the C of CEAP was better than between the AVVQ 
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and CEAP, which is not surprising since the VCSS was developed in relation to 
CEAP. 
The C part of CEAP is the only widespread acknowledged classification that is 
able to stratify patients according to categories of severity based on the progression of 
CVI. Therefore, the proposal of improving the responsiveness of the VCSS and 
AVVQ according to CEAP seems valid. However, this could only be achieved 
provided the C of CEAP is used as a static scoring system for the purposes of studies, 
and provided each C stage can be precisely defined and interpreted with good inter-
observer reproducibility (Uhl, Cornu-Thenard et al. 2001; Cornu-Thenard, Uhl et al. 
2004). Since this study has demonstrated a lack of a relationship between increasing 
responsiveness with increasing C class (excluding C6) it may be valid to categorise 
patients into 2 groups based on the presence or absence of ulceration: C2-5 and C6. 
This may allow the responsiveness of the VCSS to measure a real improvement rather 
than reflect the type and percentage of venous disease in the cohort. 
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CHAPTER  6 
 
 
 
CLINICAL STUDY  IV 
 
 
 
Use of the AVVQ as a rationing tool 
 
 
However beautiful the strategy,  
you should occasionally look at the results. 
 
-- Winston Churchill 
 
 
6.1   Introduction 
 
Varicose veins are very common (Evans, Fowkes et al. 1999) and since they are a 
quality of life (QoL) issue rationing has been introduced as a means of controlling the 
public purse. The National Institute of Health and Clinical Excellence (NICE) have 
just published their clinical guidelines on the diagnosis and management of varicose 
veins (Varicose veins in the legs. http://www.nice.org.uk/nicemedia/live/14226/ 
64566/64566.pdf. Accessed on 23/08/13) 
 Treatment for varicose veins is rarely an emergency. The few urgent situations 
are haemorrhage that requires compression and transfusion, a superficial vein 
thrombosis that requires anticoagulation to reduce thromboembolic complications and 
compression bandaging for venous ulceration. These examples are less common 
presentations requiring urgent attention as they can become life-threatening. This is in 
contrast to the QoL related symptoms in VVs which comprise the elective rationing 
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process. It has been highlighted that rationing should not be performed solely for 
complications (Carradice 2012). 
 Rationing has been demonstrated as an effective measure at reducing 
workload (Harris, Davies et al. 2006). However, there is controversy whether this 
should be based on clinical criteria, leg symptoms, QoL, haemodynamic criteria or 
whether it should just be left to the judgment of the clinician taking everything into 
consideration. The Royal Society of Medicine (Recommendations for the referral and 
treatment of patients with lower limb chronic venous insufficiency (including varicose 
veins). http://www.rsm.ac.uk/academ/forvenou.php. Accessed 28/10/2012) 
recommends that referral is based on a combination of a clinical classification using 
CEAP (Eklof, Rutherford et al. 2004) as well as QoL criteria. For example in C2 
disease, “troublesome lower limb physical symptoms that are impairing QoL” should 
be “referred to a vascular surgeon” for a clinical judgment. The REACTIV trial was a 
randomised clinical study that assessed cost-effectiveness in the treatment of VVs 
(Michaels, Campbell et al. 2006). They illustrated the importance of QoL assessment 
by utilising 2 health-related quality-of-life questionnaires, the SF-36 (Jenkinson, 
Coulter et al. 1993) and the EQ-5D (Devlin, Parkin et al. 2010), as their main outcome 
measure on effectiveness.  
6.2   Aims 
The aim of this study was to identify which patient pre-treatment characteristics were 
related to the greatest improvement in QoL as a result of treatment using the 
Aberdeen varicose vein questionnaire (AVVQ) (Garratt, Macdonald et al. 1993). The 
need for further development and ongoing evaluations on QoL has been highlighted 
especially whether treatment outcomes could be predicted and to ration the treatment 
of VVs (Sarvananthan, Shepherd et al. 2010). 
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6.3   Patients and Methods 
 
6.31 Study design  
 
This was a single centre analysis on a prospectively collected database on 84 patients, 
44 (52.4%) female, median age 47.5 (22-78) years, randomised into receiving either 
endovenous laser ablation or ultrasound-guided foam sclerotherapy using sealed 
envelopes.  The study population was multicultural and multiethnic. The pre-
procedural C stratification was: C2 = 28 (33.3%), C3 = 13 (15.5%), C4a = 26 (31%), 
C4b = 5 (6%), C5 = 7 (8.3%) and C6 = 5 (6%). The AVVQ was introduced to the 
patient after treatment was guaranteed. This occurred in a hospital environment to 
ensure 100% completion. The venous clinical severity score (VCSS) (Rutherford, 
Padberg et al. 2000), venous filling index (VFI) of air-plethysmography 
(Christopoulos, Nicolaides et al. 1988a) and averaged refluxing GSV diameter 
(measured in 3 places) completed the assessment. Follow-up was at 3 weeks (100%) 
and 3 months (n = 70, 83%). 
 
6.32 Statistical analysis 
Statistical analysis was performed using SPSS® for Windows version 17. 
Improvement in the AVVQ was defined as the difference between the pre and post 
treatment scores along the validated and weighted severity scale of the questionnaire. 
Percentage change was not used since this would cause bias, for example, a 
favourable score on patients with complete resolution of minor symptoms. 
Furthermore, percentage change from baseline has been demonstrated to have a low 
statistical power and a high sensitivity to changes in variance (Vickers 2001).  
 
 
 
 
 162 
6.4   Results 
 
The median (inter-quartile range, IQR) of the AVVQ, VCSS and VFI improved at 3 months 
from 21.17 (15.83), 6 (4), 5.1 (4.3) mL/sec to 8.46 (13.2), 1.5 (4), 1.6 (1.3) mL/sec 
respectively, P < 0.0005 (Wilcoxon signed rank test) in all parameters.  This confirms that 
treatment for CVD is of benefit to most patients.  However, there was no significant 
correlation in AVVQ improvement when compared to the baseline VCSS, VFI, GSV 
diameter (Table 6.1) or clinical severity when patients were stratified into mild disease, C2,3  
(n = 36), and severe disease, C4-6 (n = 34), as shown in Fig 6.1. Therefore it would seem that 
these parameters would be of limited use in predicting those patients who would significantly 
benefit in their QoL following intervention.  
 
Table 6.1.  Improvements in quality of life (baseline scores – post treatment scores) 
using the Aberdeen varicose vein questionnaire (AVVQ) correlated against baseline 
values. 
 
 
Correlations (r) using the Spearman rho test. 
VCSS, Venous clinical severity score; GSV, Great saphenous vein  
 
 
 3 weeks (n = 84) 3 months (n = 70) 
Baseline values r correlation P value r correlation P value 
VCSS 0.233 0.033 0.130 0.284 
Venous filling index 0.187 0.089 0.159 0.188 
GSV diameter 0.070 0.529 0.124 0.306 
AVVQ 0.500 <0.0005 0.585 <0.0005 
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Figure 6.1.  There was no significant difference in the improvement of the AVVQ at 
3 months when patients were stratified into early (C2,3) and severe (C4-6) disease. 
 
 
 Similarly, there was no significant difference in QoL improvement at 3 months 
when patients were stratified into laser (n = 40) and foam (n = 30) treatment groups. The 
median (IQR) improvement in the AVVQ was 12.2 (11.0) for laser and 9.6 (11.2) for foam, 
(P = 0.084, Mann-Whitney U test). However, when AVVQ improvement at 3 weeks and 3 
months was compared to their pre-treatment values, r = 0.500 and r = 0.585, respectively, the 
results were both highly significant, P < 0.0005 (Spearman rho test). This is shown in Fig 6.2.   
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Figure 6.2.  There was a highly significant but moderate correlation between the 
improvement of the AVVQ at 3 months and worsening of the pre-treatment quality of 
life. 
 
 
  
6.5   Discussion 
 
6.1 The clinical dilemma 
Vascular surgeons are frequently faced with the dilemma of deciding which patients 
fulfill the eligibility criteria for varicose vein treatment. These vary in different areas 
of the UK and are currently determined by local Primary Care Trusts (PCTs) (Nasr, 
Budd et al. 2008). If they are based on clinical severity, patients with uncomplicated 
varicose veins (C2,3) are denied treatment even if they have a standing occupation 
which requires them to sit down to alleviate severe discomfort. Conversely, patients 
with extensive lipodermatosclerosis often fulfill the severity criteria but may decline 
intervention, even if they are told that this is a precursor for ulceration. Since 
intervention for varicose veins is designed to improve QoL then it is intuitive that 
those patients who have the greatest impairment should have priority for treatment. 
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Interestingly, this study has shown that it is precisely this group of patients which 
benefit most from an intervention. This has also been confirmed by Nesbitt and 
colleagues (Nesbitt, Wilson et al. 2012) who demonstrated that the lowest 
improvements were witnessed in patients with the lowest preoperative AVVQ scores 
(least severe symptoms). 
 
6.52 Is QoL independent of CEAP? 
Many patients present initially when their QoL has deteriorated to a point at which 
they seek treatment. This can occur at any stage of the disease process, including 
venous ulceration (C6). A recent study by Darvall and coworkers (Darvall, Bate et al. 
2012) has confirmed that QoL is significantly worse in varicose vein patients with leg 
symptoms independent of CEAP clinical grade. They concluded that the rationing of 
treatment to those with a C class of C4-6 excludes many patients who would benefit 
from intervention. The results of the current study support these findings. 
Furthermore, surgery for uncomplicated varicose veins, C2,3, has been shown to be 
cost-effective (Ratcliffe, Brazier et al. 2006). However, most leg symptoms in 
varicose vein patients probably have a non-venous cause which may invalidate 
rationing criteria based on symptoms alone (Bradbury, Evans et al. 1999). 
  
6.53 Absolute or relative assessments? 
The correct measurement of improvement is controversial. This study has used 
absolute improvement in the AVVQ as a measure of improvement in QoL. It is 
calculated by subtracting the post-treatment score from the pre-treatment score, where 
higher scores represent a worse QoL. This is justified because the AVVQ has already 
been quantified and validated as a scale upon which severity can be measured. In this 
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way those patients with the highest baseline scores have the most to gain from 
treatment.  
 Other techniques for measuring improvement include relative scores where 
percentage differences from baseline are recorded (Shepherd, Gohel et al. 2011). In 
this way each patient is treated as an individual where the questionnaire is recalibrated 
to a 100% QoL impairment at the start. The relative reductions (or increases) from 
this are then calculated, depending on the effectiveness of treatment. With this 
technique, interim assessments also require recalibration where the top score at the 
first interim point is readjusted once more to 100% in preparation for a calculation at 
the second interim point. Interpretability is the key challenge in deciding between the 
methods of relative and absolute change. For example, a patient with itchy VVs can 
achieve complete resolution after sclerotherapy (100% improvement) whereas the 
same patient may only achieve a small improvement from an absolute score. This is in 
contrast to a patient with a painful ulcer who may achieve only a 50% reduction in 
their relative score but a dramatic reduction in their absolute score.  
 Oldham’s method is another technique where the pre and post operative scores 
are averaged (Oldham 1962). It is a way of improving the reliability of the clinical 
entity of minimally important difference (MID) values (Browne, van der Meulen et al. 
2009). They make the point that baseline values are a significant factor influencing 
MID values. As an example, patients with initial low scores which return to zero 
following treatment many not have a sufficient change in their score to reach a MID. 
It could be argued that these patients should not qualify for treatment in the first place. 
Thus patients with low scores are proportionally accounted for in rationing terms 
using absolute changes in the AVVQ, because it is proportionally harder to achieve a 
MID value when baseline scores have a low value. 
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 The observation from this study that pre-operative AVVQ scores have the 
largest effect on post-operative AVVQ improvement (P < 0.0001) in comparison to 
CEAP clinical stage has been reported previously in a detailed study on 203 
unselected, non-randomised patients (Mackenzie, Lee et al. 2002). The interventions 
in that study were conventional saphenous surgery with or without subfascial 
endoscopic perforator clipping and multiple phlebectomies at the discretion of the 
surgeon. The authors stressed the need to treat every patient individually irrespective 
of the initial severity of their disease and adjusted therefore the differences in AVVQ 
baseline using a multivariate analysis. In that way the baseline differences in AVVQ 
could be factored out of the analysis. Using this analysis they found that surgery for 
C4-5 clinical stage remained a significant negative, implying that patients with 
advanced C stage improve least in terms of QoL. Adjusting for baseline therefore 
could have significant rationing implications by encouraging treatment for 
uncomplicated varicose veins (C2-3) since this group would achieve the greatest QoL 
improvement.      
 
6.54 Benefits of the AVVQ 
The AVVQ quantifies disease specific QoL. Eight questions relate to symptoms with 
the remaining 5/13 enquiring about signs. Rationing using the AVVQ is therefore not 
reliant on leg symptoms alone but a combination of symptoms and signs. This seems 
justified because for a given level of symptom severity it would be appropriate to bias 
treatment towards those patients at a worse clinical stage and therefore at a greater 
risk of ulceration. Although it has been shown that a severe C class at the outset is 
much less of a determinant to a poor generic QoL assessment than leg symptoms in 
varicose vein patients (Darvall, Bate et al. 2012), it must be remembered that QoL 
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assessment using the AVVQ includes leg symptoms as well as questions on signs 
which are closely related to CEAP clinical grade. This includes the extent and 
distribution of varicose veins (question 1, representing C2), ankle oedema (question 4, 
representing C3), telangectasiae (question 7, representing C1), eczema (question 8, 
representing C4), and venous ulceration (question 9, representing C6).  
 
6.55 Limitations of the AVVQ 
It has been argued that questionnaires may not be the ideal method for rationing 
because it depends upon the honesty of the patient who may adjust their responses to 
qualify for treatment. Whilst this may be true for some patients who seek treatment, 
many also consult the specialist solely for advice. Patients also present because of 
inappropriate fears of deterioration or with symptoms unrelated to their veins 
(O'Leary, Chester et al. 1996). It is also human nature for patients to exaggerate their 
symptoms especially if they realise they have to pass a screening test. However, it is 
unclear whether this is any different in the face-to-face consultation setting. 
Furthermore, an element of self-screening may occur, because those patients who are 
prepared to exaggerate their symptoms may have a QoL which significantly improves 
as a result of treatment. Further research is required on the extent to which these 
behavioural processes may influence a fair rationing system. A cut point for rationing 
has yet to be determined but may never become a reality because there will always be 
patients who deserve treatment yet escape rationing and vice versa. The use of an 
online AVVQ to aid the rationing and referral process is currently being explored 
(Online Aberdeen varicose vein surgery questionnaire. 
http://www.nle.nottingham.ac.uk/websites/w_survey. Accessed 23/10/12). 
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6.56 General limitations 
This is a very small study (n = 84) on National Health Service patients spread across 
the spectrum of clinical severity. Whilst efforts were made to control for a 
homogenous cohort, the treatments differed within this group. Retrospective analyses 
of larger databases from other centres are required to confirm our findings. The level 
of AVVQ severity at which treatment is permitted has not been discussed and could 
differ between treatments, especially if they are staged like in the sessional nature of 
foam sclerotherapy.  
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CHAPTER  7 
 
 
 
CLINICAL STUDY  V 
 
 
 
The VFT90 as an index of severity 
 
 
Change brings opportunity. 
 
-- Nido Qubein 
 
 
7.1   Introduction 
Reflux is the primary pathophysiological abnormality in most patients with chronic 
superficial venous insufficiency (SVI). Its measurement and quantification has been 
extensively investigated.  Reflux is conventionally measured using colour duplex over 
a target venous segment or junction.  Significant superficial venous reflux on duplex 
is defined as reflux time (RT) > 0.5 sec (van Bemmelen, Bedford et al. 1989; 
Labropoulos 2008). The two main methods of inducing reflux are a manual calf 
compression and release manoeuvre (MCCR) and pneumatic cuff inflation and release 
(PCIR) (Yamaki, Nozaki et al. 2006). These methods have both been shown to define 
significant reflux in patients with SVI but are less reliable as induction manoeuvres in 
quantifying reflux (Weingarten, Branas et al. 1993; Neglen, Egger et al. 2004). 
However, semi-quantitative duplex assessments of reflux have been attempted by 
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adding together the RTs of each involved venous segment. These have been shown to 
increase with clinical severity (Neglen and Raju 1993b). Duplex assessments of RTs 
when measured individually have been shown to decrease with clinical severity by 1-
2 seconds (Yamaki, Nozaki et al. 2002). Neglen and colleagues (Neglen, Egger et al. 
2004), in a detailed study involving duplex in 244 limbs with reflux, concluded that 
valve RT cannot be used to quantify the severity of reflux which is purely qualitative.  
 The venous filling index (VFI) measured using air-plethysmography (APG) 
has been proposed as the gold standard in the quantification of reflux (Christopoulos, 
Nicolaides et al. 1987). It increases with the severity of CVI (Christopoulos, 
Nicolaides et al. 1988b) and falls to less than 2 mL/sec after treatment aimed at 
abolishing reflux (Kalodiki, Volteas et al. 1995; Owens, Farber et al. 2000). However, 
the VFI does not measure reflux directly. It measures the rate of dependant filling of 
the calf veins following a period of venous emptying by leg elevation. Furthermore, 
with APG, the challenge test used to provoke reflux is gravitational and not the 
MCCR or PCIR induction tests that are performed whilst standing, when the venous 
reservoir is full. 
 The VFI is defined as the ratio of 90% of the total venous volume (90%VV) 
divided by the time taken to 90% of venous filling (VFT90).  Thus VFI = 
90%VV/VFT90.  The VFT90 is an estimate of global RT, provided sapheno-femoral 
junction (SFJ) reflux has been confirmed using colour duplex. It remains unclear 
whether increased RTs at the SFJ are associated with worsening CVI (Yamaki, 
Nozaki et al. 2002). The optimal APG parameter in the assessment of severity is 
currently unknown which may reflect the lack of data on the VFT90 and VV 
components of the VFI. 
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 Christopoulos and colleagues (Christopoulos, Nicolaides et al. 1988b) 
demonstrated that the VFI can provide an index of severity across the broad spectrum 
of venous disease from normal controls, patients with varicose veins, deep venous 
reflux and ulceration. Although there was significant difference between pathological 
groups there was considerable overlap without discriminatory value.    
 
7.2   Aims 
The aim of this study was to examine the relationship between APG parameters (VFI, 
VFT90 and 90%VV) in patients with isolated chronic SVI and also to determine the 
relationship and discriminatory value of these parameters against other severity 
assessments including the GSV diameter (Navarro, Delis et al. 2002; Barros, 
Labropoulos et al. 2006) the C part of the CEAP classification (Eklof, Rutherford et 
al. 2004) and the VCSS (Rutherford, Padberg et al. 2000).       
 
7.3   Patients and Methods 
7.31 Patients and study description 
Between the 1st of April 2009 and 1st of July 2010, 93 consecutive patients awaiting 
endovenous treatment for SVI at Ealing hospital were recruited. All patients had their 
affected leg staged according to the CEAP classification and were excluded if they 
were C0-1. In the 57 patients with bilateral disease, the worse affected leg was studied. 
Assessments using the VCSS and the disease specific quality of life instrument, the 
AVVQ, were also undertaken. All patients had reflux down the GSV on colour duplex 
assessment.  
 Patients with a previous history of DVT or evidence of deep venous disease 
were excluded. Other exclusion criteria included superficial venous thrombosis, 
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previous treatments for SVI, pregnancy, active malignancy, coagulation disorders, 
receiving anticoagulation and SPJ incompetence.   
 Ethics committee approval was granted from the regional ethics committee 
(REC number: 08/H0710/78) and written informed consent was obtained from 
participating patients.   
 
7.32 Colour duplex scanning 
A portable Sonosite® Titan colour duplex scanner with a linear 7 MHz transducer 
was used to assess the superficial and deep venous system. All examinations were 
performed by an experienced clinical vascular scientist (MA) with patients standing. 
Reflux was induced using a MCCR manoeuvre and reported significant if the RT was 
> 0.5 sec in the superficial veins and > 1 sec for the deep veins (Labropoulos 2008). 
Reflux was confirmed at the SFJ extending along the GSV for at least 10 cm. Patients 
with reflux in straight tributary continuations of the GSV, anterior accessory 
saphenous veins (AASV) and perforating veins were also included. The diameter of a 
refluxing GSV was measured 3 times, just below the SFJ, at mid-thigh and just above 
the knee and averaged. Focal dilatations and saphenous varicosities were excluded 
from the diameter measurements (Labropoulos, Kokkosis et al. 2010). 
 
7.33 Air-plethysmography 
The VFI, VV and VFT90 were measured using the APG® apparatus comprising a 
sensor cuff, an air-pump and software. The methodology has been described in detail 
(Christopoulos, Nicolaides et al. 1987). All constricting clothing was removed and the 
knee was slightly flexed to release any impediment to drainage at the popliteal fossa 
(Leon, Volteas et al. 1992). Calibration of pressure to volume was achieved using an 
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injection of 100 mL of air into the sensor cuff before each examination. Care was 
taken to ensure complete emptying of the veins by elevating the patient’s leg at 45 
degrees until the tracing on the monitor decreased to a steady baseline. The VFI 
measurements began from the onset of dependency until the tracing on the monitor 
reached a plateau. This elevation-dependency manoeuvre is a gravitational challenge 
(GC) test and is used as part of the APG protocol.   
 Three characteristic curves are identified with VFI measurements (Fig 7.1). In 
volunteers without duplex detectable reflux the VFI is < 2 mL/sec and the time taken 
to achieve venous filling is gradual and prolonged (Fig 7.1A). In patients with mild 
reflux the VFI increases, the curve shortens and a typical bend appears as the total 
venous volume is reached (Fig 7.1B). In patients with a high VFI and therefore rapid 
venous filling, this bend is more pronounced with a steeper and shorter curve (Fig 
7.1C).   
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Figure 7.1  Air-plethysmography tracings after a gravitational challenge in a healthy 
volunteer (A), a patient with uncomplicated varicose veins (B) and a patient with a 
venous ulcer (C). Note the progressive increase in the total venous volume (VV) on 
the vertical axis and a faster VFT90 (horizontal line with end bars). 
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7.34 Statistical analysis 
The data were analysed using the SPSS® Statistics version 17. Non-parametric data 
are presented using median and inter-quartile range (IQR), with minimum and 
maximum values and statistical outliers. The Mann-Whitney U test was used to 
demonstrate significant differences between different groups. Correlations on ordinal 
and scalar variables were achieved using the Spearman rho non-parametric test. 
Significant overlap was defined when the minimum or maximum value of one group 
corresponded within the IQR of the comparison group, and this value was taken as the 
cut-off point. Odds ratios (corrected if n = 0 for any group) and Fisher exact tests 
were used to determine the significance of cut-off points.  A P < 0.05 was statistically 
significant.  
  
7.4   Results 
7.41 Patient variables 
Ninety-three patients (93 legs) were assessed in this study. Forty-four patients 
(47.3%) were men and 36 patients (37.8%) had unilateral disease. Patients were 
grouped according to the C class of CEAP with 33 (35.5%) C2, 14 (15.0%) C3, 29 
(31.2%) C4a, 5 (5.4%) C4b, 7 (7.5%) C5 and 5 (5.4%) C6.  The median AVVQ of 
20.4 was marginally higher than that reported in other studies at 17.01 (Shepherd, 
Gohel et al. 2011) and 19.0 (Darvall, Sam et al. 2010). A summary of the baseline 
assessments and APG measurements are shown in Table 7.1.   
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Table 7.1  Baseline values in 93 patients (legs).  
 Median IQR Range 
Assessments    
   AVVQ 20.4 13.0 0.7 - 52.9 
   VCSS 6 4    2 - 20 
   GSV Diameter (mm) 7.5 3    4 - 12 
APG Measurements    
   VV (mL) 116 52  46 - 335 
   VFI (mL/sec) 4.7 4.3 0.9 - 17.8 
   VFT90 (sec) 20.2 13.7 7.0 - 88.5 
   EF (%) 48 24  12 - 134 
   RVF (%) 32 29   2 - 80 
IQR, interquartile range; AVVQ, Aberdeen varicose vein questionnaire;  VCSS, venous 
clinical severity score;  GSV, great saphenous vein;  APG, air plethysmography;  VV, 
total venous volume;  VFI, venous filling index;  VFT90, venous filling time to 90% 
of total venous volume;  EF, ejection fraction;  RVF, residual volume fraction. 
 
7.42 Components of the VFI 
The VFI is derived from the VV and the VFT90. There was no significant correlation 
between the VV and the VFT90 (r = -0.103, P = 0.324). Since elevation of the VFI is 
associated with increased clinical severity of venous disease the contribution of the 
VV and VFT90 in the calculation of the VFI was examined (Fig 7.2). Unsurprisingly, 
these correlations were statistically significant at the P < 0.0005 level (VV: r = 0.592, 
VFT90: r = -0.83). However, as the VFI increased the total venous volume (VV) also 
increased with a progressively broader range of values, whereas the VFT90 values 
reduced to a discrete range. In Fig 7.2A, the data were not linear and it could be 
argued that as the VFI=VV/VFT90 the relationship between VFI and VFT90 is 
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inversely related. The relationship between the VFI and 1/VFT90 demonstrated a very 
good correlation, r = 0.796, P < 0.0005 (Spearman). These findings may suggest that 
the VFT90 is a more discriminative marker than the VV in the makeup of an elevated 
VFI. 
 
 
Figure 7.2  Contribution of the VFT90 (A) and the VV (B) in the calculation of the 
VFI. An elevated VFI is associated with a consistently reduced and discrete VFT90 
but a wide range of increasing venous volumes. 
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7.43 Diameter of the GSV and APG parameters 
The GSV diameter is another marker of severity of chronic SVI. The GSV was the 
only refluxing vein in the thigh in 85 (91.4%) of patients, the remainder having 
concurrent thigh reflux into an AASV as well as the GSV. Increases in the VFI and 
VV, and decreases in the VFT90, significantly correlated (P < 0.0005, Spearman) 
with increasing GSV diameter: r = 0.623, r = 0.567, r = -0.432, respectively. When 
patients were stratified arbitrarily into GSV diameters < 8 mm (67.7%) and ≥ 8 mm 
(32.3%) both groups had significantly different median (IQR, range) values in VFI 
[4.2 (3, 0.9 - 14.7) versus 8.5 (5.5, 2.5 - 17.8), P < 0.0005], VV [99 (37, 46 – 259) 
versus 144 (38, 93 – 335), P < 0.0005] and VFT90 [21.8 (15.8, 7 - 88.5) versus 16.3 
(8.3, 7.1 – 42.5), P = 0.001], respectively. Thus the VFI, VV and VFT90 are 
significantly associated with an increased GSV diameter.    
 
7.44 Clinical severity and APG parameters  
The VFI, VV and VFT90 were also assessed in relation to clinical severity. Patients 
were stratified arbitrarily into Group I (C2-4a or VCSS <10) and Group II (C4b-6 or 
VCSS >9) which resulted in 76 patients in Group I and 17 patients in Group II, using 
either definition, as shown in Fig 7.3. The C of CEAP correlated significantly with the 
VFI (r = 0.4, P < 0.0005), VV (r = 0.225, P = 0.03), and the VFT90 (r = -0.343, P = 
0.001). Correlations were weaker when the VCSS was compared to the VFI (r = 
0.244, P = 0.02), VV (r = 0.145, P = 0.17) and the VFT90 (r = -0.197, P = 0.05). 
There was no statistical difference between groups in VV when patients were grouped 
by C class (Group I & II) but when patients were grouped by VCSS (Group I & II) the 
P-value was P = 0.046 (Mann-Whitney U test). However, since there was also lack of 
a discriminative cut-off point, no further analysis was performed on the VV as its 
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value in relation to severity was limited. The rest of the analysis focused on the 
VFT90 and VFI (Fig 7.3).  
 
 
Figure 7.3  The VFT90 and the VFI benchmarked against two groups of severity of 
CVI. Although the median VFI is statistically higher in the more severe groups there 
was no discrimination (B, D). However, all 17 patients in the severe groups had a 
VFT90 < 25 seconds as demonstrated by the horizontal dashed line (A, C). 
 
 The median VFT90 was 20.2 sec with 3 (3.2%) patients having reflux over 
one minute. A cut-off point of 25 seconds for the VFT90 was identified where the 
maximum value in Group II corresponded to a value within the lower quartile of 
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Group I. None of the 25 (26.9%) patients with a VFT90 > 25 sec were amongst the 17 
(18.3%) patients in categories C4b-6 or with a VCSS > 9. 
 Although a short VFT90 and high VFI were significant in the C group 
depicting severe disease (P = 0.009, P = 0.014, respectively) only the VFT90 was able 
to define patients with less severe disease in Group I (corrected odds ratio: 17.3). This 
was also statistically significant (P = 0.005, Fisher exact test). 
  
7.5   Discussion 
7.51 Clinical relevance 
This study has assessed the intrinsic relationship and discriminative value of the VFI, 
VV and the VFT90 with established markers of venous severity including the GSV 
diameter, the C part of CEAP and the VCSS. There was no correlation between the 
VV and the VFT90 which indicates that they should be regarded as independent 
variables. The VFI, VV and VFT90 were all markers of clinical severity with the VFI 
performing the best when compared to the C of CEAP and the VCSS. However, a 
VFT90 > 25 seconds could discriminate mild clinical disease. Table 7.2 suggests how 
patients may be stratified using a combination of clinical and haemodynamic scores. 
However, there is lack of longitudinal evidence whether patients with mild clinical 
disease are more likely to progress into the later stages if they have an unfavourable 
haemodynamic profile at the outset. 
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Table 7.2  Proposed stratification of patients with SVI based on clinical and 
haemodynamic assessments using CEAP & VFT90.  
 
Group Disease Clinical VFT90 Description 
S1 Mild C2-4a > 25 sec Cosmetic 
S2 Moderate C2-4a < 25 sec Risk for skin changes 
S3 Severe C4b-6 < 25 sec Ulcer prevention & treatment 
SVI, superficial venous insufficiency; S, severity group; C, C part of CEAP clinical 
etiological anatomical pathophysiological; VFT90, venous filling time to 90% of total 
venous volume.  
 
 The use of haemodynamic and quality of life markers (Darvall, Sam et al. 
2010; Shepherd, Gohel et al. 2011) as an index of clinical severity has been 
disappointing. It is not known whether the haemodynamic changes parallel or precede 
clinical severity.  
 
7.52 GSV diameter and severity of disease 
Larger GSV diameters have been shown to be associated with disease severity, an 
elevation of the VFI and therefore a faster rate of refilling (van Bemmelen, Mattos et 
al. 1993; Yamaki, Nozaki et al. 2007). This study has demonstrated that larger GSV 
diameters (≥ 8 mm) had significantly worse VFI, VV and VFT90 values than smaller 
diameter GSVs, and that there was also a good correlation between increasing 
diameter and worsening APG parameters. This relationship was highly significant 
even though the patterns of superficial venous networks in the thigh were 
heterogeneous (Philipsen, De Maeseneer et al. 2009) and the physiological reactivity 
of the GSV diameter (Criado, Daniel et al. 1995; Jeanneret, Jager et al. 2007) was not 
considered. In this study, 8 (8.6%) patients had a GSV that was only partly 
responsible for thigh reflux.   
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7.53 VFI, the VFT90 cut-point and clinical severity 
The C part of the CEAP classification and the VCSS are both assessment tools in the 
quantification of the severity of CVI. They both measure a patient’s venous status at a 
point in time during the natural history of the disease and represent the clinical 
endpoints of haemodynamic failure. This study demonstrated that worsening C scores 
and VCSSs were related to a higher VFI, a reduced VFT90 and an elevated VV. 
Furthermore, all of the 25 patients (26.9%) with a VFT90 > 25 sec had C scores of ≤ 
C4a and a VCSS of <10 (P = 0.005, Fisher exact test, adjusted odds ratio: 17.3). 
Longitudinal studies will be required to clarify whether the patients within the lower 
C categories with a VFT90 < 25 sec, if untreated, would go onto developing an 
elevation of their C score. It may also be interesting to investigate patients in the 
lower C categories who transfer to higher categories. Does this result from lessening 
of the VFT90 or from increased duration of CVI in those with an already established 
short VFT90 (severe reflux)? 
 The relationship between APG parameters [VFI, ejection fraction (EF) and 
residual volume fraction (RVF)] and clinical severity was examined by Nishibe and 
colleagues (Nishibe, Kudo et al. 2006) after one study had reported a correlation 
(Criado, Farber et al. 1998) but others had failed to confirm this relationship (Payne, 
Thrush et al. 1993; van Bemmelen, Mattos et al. 1993; Iafrati, Welch et al. 1994). The 
last 3 studies concluded that although the VFI was the most useful parameter, and 
trends between increasing VFI and severity were demonstrated, the VFI was unable to 
discriminate clinical severity due to overlap. The presence of a significant relationship 
between a high VFI and the higher C classes has been confirmed in our study and 
significant overlap has also been observed. However, the VFT90 appears to be an 
improved assessment parameter.  
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 An explanation for this observation is that the size of the venous reservoir may 
offset the discriminative ability of the VFI since VFI = VV/VFT90. Comparative VV 
measurements may be unreliable because they may depend on the size of the leg. 
Furthermore, the VFT90 may be a direct measure of the time for the anti-gravitational 
mechanisms of the leg to fail, whereas the VFI measures the rate of filling irrespective 
of the size of the reservoir. The VFT90 measures the time for the leg to reach 
maximum hydrostatic pressure (maximum venous volume) which is also the time to 
achieve the maximum haemodynamic insult. 
     
7.54 Gravitational challenge test and the VFT90  
The VFT90 is determined using a GC test. This is a physiological challenge which 
avoids external variables like hand and cuff sizes, site and duration of compression 
and speed of release. This study has shown that the GC test can produce a long range 
of VFT90 values (7.0 – 88.5 sec) which is in direct contrast to the range of duplex 
derived RTs which are much shorter (2.09 - 7.27 sec) when performed in the standing 
patient (Yamaki, Nozaki et al. 2007). Reproducibility studies, have reported that the 
mean co-efficient of variation for within-subject measurements with APG parameters 
was less than 10% (Asbeutah, Riha et al. 2005). When VFT90 coefficients of 
variation were directly assessed, in another study, they were less than the VFI (range: 
7.5% - 13.9% vs 16.3% - 22.3%, respectively) (Yang, Vandongen et al. 1997). This 
means the VFT90 had less variability when compared to the VFI.  
 
7.55 Limitations of the study 
The division of patients into 2 groups of clinical severity, using CEAP and VCSS, 
was performed retrospectively. Although this weakens the statistical power of 
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comparative tests it is an essential first step in the determination of a discriminatory 
cut-off point in a discovery cohort of patients. The cut-off point of 25 sec needs to be 
assessed prospectively in a validation cohort of patients with chronic SVI. 
 Air-plethysmography is primarily a research test and not widely available 
which limits its usefulness in a clinical situation. However, the VFT90 parameter 
represents RT using a CG test in patients with known reflux. Therefore, RT could also 
be measured in this way using duplex.  
 The number of patients studied was small (n=93). Though not identified in this 
study, it is possible for patients to have severe clinical disease with a VFT90 > 25 sec. 
Gross obesity can cause skin changes, for example, independent of reflux 
measurements (Danielsson, Eklof et al. 2002). A larger study using more patients 
would have a better weight for each CEAP class. 
 Leg dimensions were not measured which may have had a significant impact 
on VV assessments which may be one reason why the VV lacked a discriminative 
relationship with clinical severity. Patient characteristics like age, sex, BMI and 
physical activity are other determinants which could influence the results. Other 
limitations of this study include a lack of joint goniometry measurements at the ankle, 
knee and hip which may influence C class irrespective of haemodynamic compromise 
(Cavalheri, de Godoy et al. 2008) and constants like time of day, room temperature 
and caffeine intake (Stebbins, Daniels et al. 2001). 
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CHAPTER  8 
 
 
 
CLINICAL STUDY  VI 
 
 
 
Venous filling time and venous reflux time 
 
 
The quality of the connections is the key to quality per se. 
 
-- Charles Eames 
 
 
8.1   Introduction 
Air-plethysmography (APG) has been part of the haemodynamic evaluation of venous 
disease for over 25 years throughout the world. Its popularity is related to its 
capability of determining and quantifying pathology with the venous filling index 
(VFI) as a measure of reflux, outflow fraction (OF) as a measure of venous outflow 
resistance and ejection fraction (EF) as a measure of calf-muscle pump function 
(Christopoulos, Nicolaides et al. 1988a; Christopoulos, Nicolaides et al. 1988b; 
Christopoulos, Nicolaides et al. 1989; Kalodiki, Calahoras et al. 2001). These are the 
3 main haemodynamic components of global venous disease. Unfortunately, APG has 
not made its way into routine clinical practice. This may be because the measurements 
show variability (Yang, Vandongen et al. 1997), there is overlap between disease 
states (van Bemmelen, Mattos et al. 1993), a modest relationship to clinical severity 
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(Neglen, Egger et al. 2004; Nishibe, Kudo et al. 2006) and, more importantly, duplex 
has become the current standard investigation test. 
 Duplex ultrasound focuses on the anatomy and physiology of individual veins 
and as such can identify the site of pathology and the effects of treatment in patients 
with SVI. Duplex is mainly descriptive. Unlike APG it does not directly assess the 
global haemodynamic pathology of the leg in relation to inflow, outflow and pump 
efficiency.  
 Reflux time (RT) and the diameter of the GSV are the main quantifiable 
measures used in duplex. However, the RT is very difficult to quantify globally and is 
used mainly as a cut-off point to define disease (van Bemmelen, Bedford et al. 1989; 
Vasdekis, Clarke et al. 1989; Labropoulos, Tiongson et al. 2003). Larger GSV 
diameters are usually associated with severe disease (Mdez-Herrero, Gutierrez et al. 
2007), but there may be other factors like obesity (increased outflow resistance) 
(Danielsson, Eklof et al. 2002; van Rij, De Alwis et al. 2008) and poor calf muscle 
pump activity (decreased ejection fraction) (Panny, Ammer et al. 2009) contributing 
to the overall clinical severity. 
 Reflux is the main pathophysiological abnormality in patients with SVI. The 
RT or venous filling time (VFT) represents the time, in seconds, for the anti-
gravitational mechanisms in the leg to fail. It is for this reason that its quantification 
and agreement between 2 different measuring tests is of prime importance in patient 
assessment. The RT with duplex, and the VFT with APG, has never been compared 
previously using simultaneous measurements. Similarly, the rate of venous filling 
(VFI) is likely to be a function of the size of the reflux channel (GSV diameter), an 
assumption requiring concurrent testing. 
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8.2   Aims 
The aim of this study was to reconcile the venous filling time (VFT) with duplex RT 
and also to establish the relationship between the GSV diameter and the VFI. 
 
8.3   Patients and methods 
8.31 Patients and study description 
This was a prospective study on 26 patients (legs) comparing APG with duplex. They 
were all awaiting endovenous treatment for superficial CVI at Ealing hospital. 
Patients with PTS, a previous or current DVT were excluded. Patients needed to be 
reasonably agile to get off a couch and to bear the majority of their weight on the 
contralateral leg in order to perform the APG examination.  
 
8.32 Colour duplex scanning 
A portable Sonosite® Titan colour duplex scanner with a linear 7 MHz transducer was 
used to assess the superficial and deep venous system. All examinations were 
performed by an experienced clinical vascular scientist (MA) with the patients 
standing. Significant reflux duration was defined as > 0.5 sec for superficial veins and 
> 1.0 sec for deep veins (van Bemmelen, Bedford et al. 1989). The duplex 
examination was used to exclude patients with deep venous reflux or evidence of a 
previous DVT, visualised as wall thickening or obstruction. The patient was suitable 
for inclusion provided the GSV was the only refluxing vein in the thigh. Straight 
refluxing tributary continuations of the GSV were also included but patients with a 
refluxing anterior accessory saphenous vein (AASV) or SPJ incompetence were 
excluded. The rationale for such strict criteria was to provide a homogenous cohort of 
patients where the only refluxing flow into the calf was via an incompetent GSV. A 
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haemodynamic assessment of the GSV could then be made which is more likely to 
represent a global measurement of venous filling. 
 Initially, the GSV was scanned and the location of the intended measurements 
was marked as a horizontal line on the thigh skin in order to minimise the assessment 
time during the dynamic test. Care was taken to avoid focal GSV dilatations or a 
saphena varix. The refluxing GSV diameter was taken from this line, and the length 
(cm) between this line and the top of the air-cuff was also recorded.  
 
8.33 Air-plethysmography 
The APG® apparatus comprises a sensor cuff, an air-pump and software. The 
methodology has been described in detail in the original work by Christopoulos et al 
(Christopoulos, Nicolaides et al. 1987). The sensor air-cuff is placed around the calf 
and calibrated with 100 mL of air, so that any changes in pressure can be translated 
into volume. As the patient stands up following leg elevation in the supine position, 
any increases in calf volume (sensor cuff pressure) are recorded. From this the VFI 
(mL/s) and VFT90 (sec) are automatically calculated from the software. 
 
8.34 Simultaneous measurements 
The GSV diameter was measured the moment the leg became dependent by freezing 
the frame on the duplex monitor. At the onset of dependency, the calf veins began to 
fill from the refluxing GSV and this could be seen as red on duplex, diminishing in 
area until only a trace was visible in the center of the GSV. When the red trace 
disappeared this represented the termination of reflux. This point in time was marked 
as a small spike on the APG trace caused by a manual flick of the air-cuff. Duplex RT 
was defined from the APG trace as the time taken from the onset of venous filling to 
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the spike event. Thus the GSV diameter, duplex RT, VFT90 and the VFI were all 
recorded simultaneously. The set-up environment and the resulting APG trace are 
depicted in Fig 8.1 and Fig 8.2, respectively. 
 
 
Figure 8.1  (A) Simultaneous measurements of reflux time with duplex and filling 
time with APG. (B) Sequential duplex images of the GSV in cross-section taken from 
a video loop to demonstrate the termination of reflux (red). 
 
 
Figure 8.2  A representative APG tracing comparing the RT (duplex) with the shorter 
VFT90, both measured from the onset of dependency. A small spike, produced by 
manually flicking the sensor air cuff, marked the termination of RT. 
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 The corrected reflux duration (CRD) is assumed to represent the additional 
time taken for the thigh veins to full up to the level of the duplex transducer. It was 
derived as follows. The time to fill the calf was calculated by VFT90/0.9 to obtain the 
VFT100. The cross-sectional area of the deep veins waiting to be filled from the 
refluxing GSV through re-entry perforating veins (Bjordal 1972; Delis, Husmann et 
al. 2001; Zamboni, Cisno et al. 2001) was calculated by πd2/4. In this formula d is 1 
cm and represents an estimated diameter of the deep veins. The additional volume to 
fill is therefore length x πd2/4 which if multiplied by 1/(the rate of filling in mL/s) 
represents the additional time to fill the thigh veins. The CRD (seconds) is therefore 
CRD = VFT100 + (length x πd2/4 x 1/VFI). 
 
8.35 Study limitations 
This study has focused exclusively on a group of patients with SVI where the GSV 
was the only refluxing vein in the thigh. However, the presence of a refluxing anterior 
accessory saphenous vein (AASV) and other anatomical venous variations in the thigh 
are also possible (Philipsen, De Maeseneer et al. 2009). 
  
8.36 Statistical analysis 
The data were analysed using the IBM® SPSS® statistics package version 19. The 
results are given as median and range using scatter plots and boxplots to illustrate the 
data. Correlations between the VFT and duplex RT, and the VFI and GSV diameter, 
were assessed using the Spearman rho non-parametric test. Differences within these 
groups were assessed using the Wilcoxon signed rank test. A P value < 0.05 was 
considered statistically significant.   
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8.4   Results 
8.41 Patient variables 
The patient’s characteristics are shown in Table 8.1. One patient was excluded from 
the results because of an indeterminate end point of GSV reflux on duplex. Reflux in 
that patient continued intermittently and indefinitely and was attributed to 
recirculation (Bjordal 1972).  
 
Table 8.1  Characteristics of the patients studied. Figures are median and range unless 
specified otherwise 
 
Characteristic or measurement n = 25 
Age (years) 57 (25 - 78) 
Male (%) 61.5 (n = 16) 
C part of CEAP (n = 26) C1=1; C2=4; C3=8; C4=10; C5=2; C6=1 
VFI (mL/sec) 4.9 (1.3 - 15.5) 
VFT90 (sec) 24 (10 – 60) 
Duplex RT (sec) 28 (14 - 68) 
GSV diameter (mm) 7 (4 - 17) 
Length from knee to transducer (cm) 30 (19 - 41) 
CRDa 31 (13 - 80) 
 
aCRD = Corrected reflux duration. It is calculated by VFT100 + ((length x πd2/4) x 
(1/VFI)) and represents the additional time for the thigh veins to fill up to the level of 
the duplex transducer. 
 
8.42 Correlation between VFT and duplex RT 
Correlations (Spearman) between the VFT90, VFT100 and the CRD plotted against 
the duplex RT were all at the P < 0.0005 level and at r = 0.933, r = 0.933 and r = 
0.922, respectively. The correlation between the VFT100 and the RT is shown in Fig 
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8.3 which was, as expected, identical to the correlations with the VFT90 and the CRD 
(not shown).  
 
 
Figure 8.3  An excellent correlation was demonstrated between the RT (duplex) and 
the VFT100 (solid line). The line of equivalence is shown for comparison (interrupted 
line). 
 
8.43 Underestimation of VFT and duplex RT 
Although the correlations were excellent the VFT90, VFT100 and CRD were an 
underestimate of the duplex RT at 24%, 16% and 4%, respectively (Fig 8.4). There 
were significant differences (Wilcoxon) between the VFT90 and VFT100 when 
compared against the RT at P < 0.0005 and P < 0.002, respectively. However, there 
was no statistical difference between the CRD and the RT at P = 0.396. This suggests 
that the assumption of additional deep venous filling in the thigh via re-entry 
perforating veins in the derivation of the CRD may have some validity. 
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Figure 8.4  The VFT90 and the extrapolated VFT100 both significantly 
underestimate RT measured with duplex. The corrected reflux duration (CRD) was a 
closer approximation. 
 
8.44 Correlation between VFI and GSV diameter 
The correlation between the VFI and the GSV diameter was significant but moderate 
at r = 0.58, as illustrated in Fig 8.5. 
 
Figure 8.5  A moderate correlation was observed between the GSV diameter and the 
venous filling index (VFI) as shown by the solid line. The VFI can be estimated from 
the GSV diameter (d): VFI = 2(d – 5) by the gradient of the interrupted line. 
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8.5   Discussion 
8.51 Reflux and chronic venous insufficiency 
Previous studies report reflux as the main pathophysiological abnormality in patients 
with non-obstructive chronic venous disease. Reflux can define disease and precede 
the development of varicose veins (Schultz-Ehrenburg, Weindorf et al. 1992; 
Labropoulos, Giannoukas et al. 1997). Also, the anatomical extent of reflux has a 
modest correlation with clinical severity (Labropoulos, Delis et al. 1996; Passman, 
McLafferty et al. 2011). However, epidemiological studies have shown that reflux is a 
common finding in the population, but so is early venous disease, with 59% having C1 
stage of the CEAP classification (Bradbury, Evans et al. 1999; Maurins, Hoffmann et 
al. 2008). 
  
8.52 Historical evidence comparing duplex RT with VFT 
Attempts at the quantification of reflux using duplex by comparing it to APG, have 
been disappointing. In a retrospective analysis of 244 limbs undergoing sequential 
APG and duplex, the authors concluded that venous RT cannot be used to quantify the 
severity of reflux and is purely a qualitative measurement (Neglen, Egger et al. 2004). 
In that study, the peak reflux velocity (PRV) and the time of average rate of reflux 
(TAR) appeared to be more meaningful. A similar prospective study on 686 limbs 
confirmed these findings (Yamaki, Nozaki et al. 2007). The authors concluded that 
duplex RT did not improve the discrimination power between early and late venous 
disease and that PRV and peak reflux flow (PRF) were better parameters in 
quantifying both superficial and deep valvular insufficiency. Another study on 69 legs 
failed to find any correlation between duplex derived valve closure time (VCT) and 
the VFI (Rodriguez, Whitehead et al. 1996). They concluded that VCTs should not be 
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used to quantify the degree of reflux. The above studies (Rodriguez, Whitehead et al. 
1996; Neglen, Egger et al. 2004; Yamaki, Nozaki et al. 2007) all assessed reflux in the 
standing position and compared them to venous filling with APG using an elevation-
dependency challenge. Reflux quantified in this way using duplex parameters has 
been shown to represent valve deformities, as evidenced by direct angioscopy 
(Yamaki, Sasaki et al. 2002), but this did not appear to have any relationship to 
venous filling. 
 
8.53 Saphenous diameter and the VFI 
The relationship between vein diameter and the VFI has also been investigated in the 
past using sequential measurements. In a study of 32 legs (van Bemmelen, Mattos et 
al. 1993), the authors demonstrated that the VFI had a significant but weak correlation 
(r = 0.39) with the diameter of incompetent veins at the knee and a stronger 
relationship (r = 0.55) with the diameter of lower leg veins. A study of 168 limbs also 
showed that the GSV diameter and the VFI were significantly elevated in patients 
with C4-6 when compared with C1-3 stage of CEAP at P < 0.0001, for both parameters 
(Yamaki, Nozaki et al. 2007). Another study on 112 lower limbs reported that a GSV 
diameter of 7.3 mm or greater predicted critical reflux (VFI > 7 mL/sec), with an 80% 
sensitivity, 85% specificity and 84% accuracy (Navarro, Delis et al. 2002). A 
significant correlation (Pearson) of r = 0.67 was also reported between the GSV 
diameter measured at the SFJ and proximal thigh against the VFI (Barros, 
Labropoulos et al. 2006). A simultaneous haemodynamic assessment of the GSV 
diameter and the VFI in the current study demonstrated a significant but moderate 
correlation (r = 0.58) and proposed that an estimate of the VFI (mL/sec) can be 
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derived from the refluxing GSV diameter (mm) using the following formula: VFI = 2 
x (diameter - 5), as shown in Fig 8.5.  
 
8.54 To assess standing or from the start of dependency? 
Assessments of reflux using duplex are acknowledged to have better results if 
performed in the standing position following a calf compression and release 
manoeuvre. Reflux time or VCT can be precisely defined in this way and is in the 
order of fractions of a second or seconds. The current study proposes that the 
gravitational challenge test may be a better way of quantifying RT for 2 reasons.  
Firstly, VCT is a misleading term. Its use implies that reflux stops because the valve 
closes. A failed valve is an incompetent valve and will remain incompetent whenever 
there is a relative increase in post-valve pressure. Valve failure is easy to assess while 
standing when it can be detected using a cut-off point of 0.5 seconds. However, the 
difficulty in quantification is because the termination of reflux in the presence of a 
failed valve is related to the time taken to fill the venous reservoir. Reflux in this 
situation stops when there is no further capacity for reflux which occurs when the 
venous reservoir is full. A standing patient already has a full reservoir and RT in this 
situation will only represent the time taken to top this up. This is sufficient time to 
detect incompetence but not long enough to quantify reflux. 
 Secondly, this study has provided evidence that venous filling represents 
reflux and is in the order of tens of seconds, occasionally exceeding a minute. This 
provides a much longer time scale for assessment than RT measured standing with 
duplex. Furthermore, the VFT90 has previously been shown to correlate with clinical 
severity to the point of oedema and pigmentation (Welkie, Comerota et al. 1992) and 
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current evidence suggests it may also have discriminatory value (Lattimer, Kalodiki et 
al. 2013). 
 
8.55 When does reflux stop?  
This study has demonstrated an excellent correlation between the VFT90 and duplex 
RT (r = 0.933). However, the VFT90 was consistently underestimating it by a median 
of 24%. The calculated VFT100 improved the underestimate to 16% and the CRD 
was much closer at 4% with no statistical difference (P = 0.396) between the CRD 
and duplex RT. It is the first time that such a calculation has been made and the CRD 
should be taken into account in future studies. While this was significant, the CRD 
calculation was based on assumption. Volume divided by the VFI in order to produce 
the correlation may not be the best way to establish the VFT in the thigh segment of 
the vein. It assumes that there is a linear relationship on the way venous filling takes 
place that may be an oversimplification of what actually happens. There is evidence 
from venous filling traces (Christopoulos, Nicolaides et al. 1988b) and pressure-
volume studies with vein cannulation and strain gauge plethysmography (Fernandes, 
Horner et al. 1979; Clarke, Smith et al. 1989) that the rate of filling slows down with 
time. Furthermore, the cumulative diameter of the deep veins was estimated at 1cm 
and an identical level of filling of deep veins and GSV was assumed in order to define 
the termination of reflux (Fig 8.6A).  
 The precise level of deep venous filling required to terminate GSV reflux has 
never been determined. The re-entry perforating vein has been shown to play a 
significant part in suppressing GSV reflux, and the fragmentation of the hydrostatic 
column, causing columns of different heights between the GSV and deep veins, leads 
to a pressure gradient promoting reflux (Zamboni, Cisno et al. 2001). The reflux 
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elimination test (RET) (Zamboni, Cisno et al. 2001) is a clinical manoeuvre which can 
illustrate this point. The possibilities are presented in Fig 8.6. If a bidirectional 
intercommunicating venous network is assumed (Papadakis, Christodoulou et al. 
1989; Delis, Husmann et al. 2001) then GSV reflux should stop when the deep veins 
fill up to the level of the duplex transducer on the GSV (Fig 8.6A). With the 
recirculation theory (Bjordal 1972; Lurie 2009), GSV reflux should terminate when 
deep venous filling encroaches upon the re-entry perforator (Fig 8.6B). However, this 
would still leave a greater hydrostatic pressure in the GSV unopposed by undistended 
deep veins (U-tube manometer principal). In this case the level of filling must reach a 
common point at the SFJ before recirculation terminates (Fig 8.6C). Whichever 
assumption proves correct, cessation of GSV reflux is likely to depend on the level of 
deep venous filling. 
 
 
Figure 8.6  Schematic diagram representing 3 venous reservoirs at different stages of 
filling relative to the duplex transducer (T) and the knee-joint (K-J). Reflux may 
terminate (horizontal arrow) when deep venous filling reaches the level of the 
transducer (A), or at the level of the highest perforating vein (B) or at the common 
stem of the hydrostatic columns (C).  
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 Future work will determine if the excellent correlation observed between the 
VFT90 and duplex RT will be observed also in other incompetent superficial veins. 
The assumption is that the termination of GSV reflux depends upon the stage of deep 
venous filling and it should not matter which refluxing thigh vein is investigated or 
whether there is concurrent deep venous reflux. This principal, if proved, will 
highlight the importance of the examination of the GSV (or any other refluxing 
superficial vein) in reflecting the degree of gravitational reflux in the deep venous 
system. 
 
8.56 Duplex in the evaluation of global venous reflux 
The practical value of this research is that APG may not be necessary in the 
evaluation of global reflux time because a GSV assessment using duplex may provide 
similar information. However, there are 2 drawbacks with this approach. Firstly, the 
starting point of reflux was determined by the APG trace, at the start of the slope, 
which is a starting point that is difficult to determine with duplex as the patient is 
moving off the couch to stand up. Secondly, the APG trace gives feedback as to when 
the leg is fully drained, when a baseline is observed. Knee flexion can occasionally 
lower this baseline by releasing any popliteal impediment to drainage (Leon, Volteas 
et al. 1992). Another practical note is that patients must be sufficiently agile to get off 
a couch and stand bearing most of their weight on the contralateral leg which can be a 
challenge for the obese and arthritic patients. 
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CHAPTER  9 
 
 
 
CLINICAL STUDY  VII 
 
 
 
The saphenous treatment score (STS) 
 
 
Don't be trapped by dogma - which is living with the results of other 
people's thinking. 
 
-- Steve Jobs 
 
 
9.1   Introduction 
This chapter introduces the saphenous treatment score (STS). It is a novel duplex-
derived haemodynamic assessment of the GSV. Reflux, competency and occlusion 
are recorded before and after treatment, above and below the knee. Descriptive 
outcome terms like recanalisation and length of obliteration are replaced with 
numerical scores. This study will demonstrate that the STS is responsive to different 
treatments and on-going treatments and show that it may be used to complement other 
assessment tools in evaluating outcomes. 
 Endovenous treatments for varicose veins like foam sclerotherapy, laser and 
radiofrequency ablation have evolved alongside traditional sapheno-femoral ligation, 
stripping and multiple phlebectomies. Combinations of treatments are also popular 
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with one technique used for the truncal veins and a different treatment used to 
obliterate the tributaries.   
 Treatments aimed at abolishing GSV reflux can have varying results with co-
existing areas of reflux, competency and occlusion in the above knee (AK) and below 
knee (BK) segments of the same saphenous trunk. These post-treatment patterns are 
difficult to standardise with most reports relying on descriptive terms, like partial re-
canalisation, rather than using numerical scores. This is in contrast to other scoring 
systems, which have a scale upon which to quantify severity and the results of 
treatment.   
 The current duplex-derived venous segmental disease score (VSDS) 
(Rutherford, Padberg et al. 2000) has a single outcome value, 1 for reflux and 1 for 
occlusion, for the length of the GSV and consequently lacks the dynamic sensitivity to 
quantify saphenous treatments (Table 9.1). Thus a focused, dynamic scoring system 
on the effects of treatment on the saphenous trunk is proposed.   
 
 
Table 9.1  Clinical and duplex scoring systems for evaluating saphenous 
insufficiency.  The VCSS and STS are relatively more dynamic systems. 
 
STATIC  (Stage/Classification) DYNAMIC  (Change) 
                 C part of CEAP                     VCSS 
                  VSDS                      STS 
 
VCSS, Venous clinical severity score; STS, Saphenous treatment score; CEAP, 
Clinical etiological anatomical pathophysiological; VSDS, Venous segmental disease 
score.   
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 The saphenous treatment score (STS) is a duplex-derived haemodynamic 
outcome evaluation which grades the significance of co-existing haemodynamic 
patterns throughout the saphenous trunk. It is not an assessment which describes the 
length of GSV obliteration. Obliteration is a technical success but if reflux is present 
in other areas of the GSV this may result in haemodynamic failure, which will be 
recorded in the STS. The STS therefore has the potential to compare endovenous 
treatments to surgical solutions.  
 A refluxing BK-GSV has been demonstrated to be clinically significant 
(Theivacumar, Darwood et al. 2009; van Neer, Kessels et al. 2009). The extent of 
reflux below the knee leads to worse symptoms and signs, with a greater likelihood of 
residual varicose veins. If the GSV is ablated for a longer length it is associated with a 
better outcome. If a refluxing BK-GSV is neglected then there are often residual 
symptoms with an increased need for sclerotherapy (Theivacumar, Dellagrammaticas 
et al. 2008). It is therefore justified to include the BK-GSV in a scoring system 
following treatment since this is likely to have a clinical impact. 
 The STS focuses on the haemodynamic post-treatment effects on the GSV 
trunk compared to the pre-treatment value. It uses a weighting system to prioritise 
reflux, competency and obliteration, and assesses both the AK and BK segments of 
the GSV.  
   
9.2   Aims 
The aim of this study was to evaluate a haemodynamic scoring system, the STS, to 
grade different varicose vein treatments, ongoing treatments and compare them to 
other validated assessments.       
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9.3   Patients and Methods 
9.31 Study design 
This was a randomised study achieved using sealed envelopes. Sixty-six consecutive 
patients (66 legs) received either endo-venous laser ablation (EVLA) or ultrasound-
guided foam sclerotherapy (UGFS) for varicose veins during 2009 – 2010. Hospital 
rationing policy and pre-screening by the family doctor precluded treatment of 
patients with varicose veins which were only of cosmetic concern. Thus all patients 
had symptoms from their primary varicose veins and they had a C score of the CEAP 
classification of C2-6 and significant SFJ reflux extending for at least 10 cm from the 
junction as determined by duplex ultrasound. Patients with deep venous reflux, 
evidence of a current or past DVT, or SPJ reflux were excluded from the study.  
 Pre-treatment assessments included the Aberdeen varicose vein severity score 
(AVVSS), the VCSS, APG and a duplex examination. Follow-up was at 3 weeks and 
3 months and included the AVVSS, the VCSS and colour duplex examinations. 
Follow-up VFI was performed at 3 months in all patients. 
 The STS scoring system was compared in five different situations: 
a)  In all patients undergoing endovenous treatment against AVVSS and the VCSS, 
before and 3 weeks after intervention. 
b)  In the subgroup of patients requiring additional foam sclerotherapy against the 
venous filling index (VFI). 
c)  Between EVLA and UGFS patients, AK and BK, before and 3 weeks after 
treatment. 
d)  Correlations between the absolute values of the STS and the AVVSS, VCSS and 
VFI assessments 3 months after treatment. 
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e)  Improvements in the STS at 3 months compared with improvements in the 
AVVSS, VCSS and VFI measures. Improvement was defined as the difference 
between the pre and post treatment values for each assessment tool.   
 Ethics committee approval was granted from the local ethics committee (No: 
08/H0710) and informed consent was obtained from participating patients.   
 
9.32 Scoring with duplex/STS 
Scoring was performed using a portable Sonosite® Titan colour duplex scanner with a 
linear 7 MHz transducer. All examinations were performed by the same, experienced 
clinical vascular scientist (MA). Superficial and deep veins and their junctions were 
assessed for reflux, competence and occlusion. Reflux was induced using a manual 
calf compression and release manoeuvre in the standing position. Reflux duration of > 
0.5 seconds for superficial veins and > 1.0 second for deep veins was considered 
significant. Occlusion was defined as the presence of complete luminal obliteration of 
any length. The mean GSV diameter was calculated from the average of 3 
measurements taken below the SFJ, at mid thigh and above the knee. Non-refluxing 
segments of the GSV, localised dilatations or a saphena varix were avoided. 
 An STS (1-3) was given to the above-knee (AK) and the below-knee (BK) 
parts of the GSV, demarcated by the popliteal skin crease, in a standing patient.  
Straight continuing tributaries of the GSV in patients with a hypoplastic distal GSV 
were considered as part of the GSV. A refluxing anterior-accessory saphenous vein 
(AASV) was also included as part of the GSV evaluation provided reflux originated 
from the proximal GSV. A score of 1 represented complete occlusion of any length 
without reflux, 2 represented competency without occlusion or reflux and 3 
represented the presence of reflux irrespective of co-existing occlusion or 
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competency. The AK and BK scores were then added to give an STS of 2-6 for the 
leg. The STS was then repeated after each treatment. When deriving the total score 
the appropriate number was used for each segment (AK or BK) in legs with co-
existing haemodynamic patterns. The scores in the AK and BK segments were then 
combined to create the STS, as shown in Fig 9.1 and Table 9.2. 
 
 
 
 
Figure 9.1  The STS derivation before and after endovenous treatment from duplex 
reports. Combinations of downward arrows (reflux), shaded areas (occlusion) and 
upward arrows (competency) define mixed disease patterns. 
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Table 9.2  The saphenous treatment scoring system. The above knee (AK) and below 
knee (BK) segments are first individually evaluated and then combined to give the 
STS. All areas of GSV reflux and antegrade flow (competency) are assessed even if 
they occur in short segments of the GSV. 
 
GRADE  (AK or BK) 
 
1 = Occlusion (luminal obliteration) anywhere along the GSV.   
2 = Competency anywhere along the GSV 
3 = Reflux anywhere along the GSV > 0.5 sec * 
WEIGHT  (AK or BK) 
 
3 = Final score if it is present.   
It has precedence over 1 and 2. 
1 = Final score provided there is no reflux.   
It has precedence over 2 but not 3. 
2 = Final score provided there is no reflux or obstruction.   
This score should be present in health 
STS  
2 - 6 Sum of the AK and the BK score 
 
GSV, Great Saphenous Vein; STS, Saphenous Treatment Score. 
 
* This does not include ambiguous flow patterns within the GSV ‘stump’ above an 
occluded GSV (like reflux from pelvic or epigastric veins) unless there is defined 
reflux (> 0.5 sec) from this into the AASV or thigh tributary.  
 
 
 
9.33 Air-plethysmography 
This was performed using the APG-1000® apparatus comprising a sensor air-cuff, an 
air-pump and software (Christopoulos, Nicolaides et al. 1988a). The VFI represents 
the rate of venous filling of the calf when the patient stands up after lying supine with 
the leg elevated at 45 degrees. If elevated (> 2 mL/sec), it provides a global 
assessment of reflux. The VFI was measured in all patients prior to and 3 months after 
the treatment.  
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9.34 Laser treatment 
All EVLA procedures were performed with the ELVeS® PainLess diode laser 
delivering intermittent energy using a 1470 nm wavelength fibre (Biolitec, Inc. East 
Longmeadow, MA, 01028, USA). The power was set at 14 watts. Tumescent 
anaesthesia (40 ml of 0.5% bupivacaine in 1000 ml 0.9% saline) was infiltrated 
around the GSV throughout the length to be ablated and patients were placed in the 
Trendelenburg position prior to laser withdrawal. The distal access point was decided 
using a convenient location near the knee. The distal ablation end point relative to the 
knee and the energy delivered in joules/cm were recorded. Varicose tributaries were 
treated concurrently under local anaesthetic using phlebectomy hooks. Crepe 
bandages were applied for 1 day. A thigh length anti-embolism stocking (TED) was 
placed over the bandages at the time of treatment, and patients were advised to wear 
the stocking for 3 weeks, whenever ambulant.     
   
9.35 Foam sclerotherapy 
Foam sclerotherapy was initially used to treat the incompetent GSV. In only a few 
patients, access to the GSV was via a refluxing tributary. A maximum of 12 mL of 
foam was injected during a single session (Breu, Guggenbichler et al. 2008a). Foam 
was prepared according to the Tessari technique (Tessari, Cavezzi et al. 2001) by 
agitating 1.2 mL of 1% sodium tetra-decylsulphate (Fibro-Vein®) in 4.8 mL of air 
using a three-way tap and 2 syringes to produce 6 mL of foam. This was then injected 
into the saphenous trunk, at knee level, using an 18 G intravenous cannula, with the 
patient in the supine position and the leg elevated at 45 degrees. Tumescent 
anaesthesia was used for UGFS if the GSV was ≥ 8 mm in diameter. Ultrasound was 
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used to visualise the extent and direction of foam migration within the target vein. 
Sufficient foam was delivered to fill the GSV to the level of the SFJ.  
 All patients had a duplex examination at 3 weeks to screen for DVT. This 
opportunity was used to assess the need for further sclerotherapy in both groups of 
patients (EVLA and UGFS) and to determine if there was persistent AK-GSV reflux. 
Foam was also offered to all patients with BK-GSV reflux or prominent varicosities. 
The final decision was made by the patient who was informed that there was a risk of 
DVT (< 1%) and hyperpigmentation from sclerotherapy (< 10%). A full length, class 
2 (23-32 mmHg), GEC stocking with a waist attachment was fitted at the time of the 
initial and subsequent treatments with foam. Patients were advised to wear the 
stocking continuously for 3 weeks but could take it off at night during the third week.         
 
9.36 Statistical analysis 
The data were analyzed using SPSS® Statistics 17. Non-parametric data analysis was 
used to determine significance between groups (Mann-Whitney U-test), within groups 
(Wilcoxon signed rank test) and to illustrate the effects of ongoing treatments 
(Friedman test). Significance was achieved when P < 0.05. Medians with the inter-
quartile range (IQR) were used to illustrate data in charts. Means were preferred to 
illustrate STS scores because they are a discrete variable with few categories in 
comparison to medians which are an uninformative measure of location. 
 
9.4   Results 
9.41 Patient characteristics 
Thirty-eight patients were randomised to EVLA and 28 to UGFS. The C part of 
CEAP distribution in the EVLA patients was C2 (n = 16), C3 (n = 6), C4a (n = 7), C4b (n 
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= 4), C5 (n = 4), C6 (n = 2) and in the UGFS patients it was C2 (n = 8), C3 (n = 3), C4a 
(n = 13), C4b (n = 3), C5 (n = 0), C6 (n = 2). Patients were equally matched in terms of 
their baseline characteristics as shown in Table 9.3. The median GSV diameter in 
EVLA patients versus UGFS patients was 7.5 (4-12) mm versus 8 (4.5–12) mm 
respectively, P = 0.537 (Mann-Whitney). In the EVLA group, the median energy 
delivered was 69 (53-90) joules/cm. The median distal ablation end point was 4 (-8 to 
20) cm above the knee crease. The median volume of foam delivered was 12 (6-12) 
mL. Three EVLA patients and 12 UGFS patients received additional sclerotherapy at 
3 weeks. 
 
Table 9.3  Baseline values in 66 patients (legs) prior to endovenous treatment.  
Expressed in median (range, IQR) unless otherwise indicated. 
 
 EVLA (n = 38) UGFS (n = 28) P value a 
Age (yrs) 48.3  (15.2) b 50.0  (14.1) b .647 c 
Male:Female 15 : 23 13 : 15 .268 d 
Uni/Bilateral 1 : 1.53 1 : 1.8 .064 d 
AVVSS 19.38 (0.86–52.93, 11.58) 24.79  (7.5–50.06, 13.47) .078 
VCSS 6  (2 – 20, 3) 6  (3 – 17, 5) .508 
VFI (mL/s) 4.7  (1.2 – 17.8, 5.08) 4.8  (1.4 – 15.0, 3.63) .977 
STS AK 3  (3 – 3, 0) 3  (3 – 3, 0) 1.000 
STS BK 3 (1–3, 1)    2.63 (0.54) b 3 (2–3, 1)   2.79 (0.42) b .249 
STS Total 6 (4–6, 2)    5.63 (0.54) b 6 (5–6, 1)   5.79 (0.42) b .249 
 
a
 Mann-Whitney U test; b Mean (SD); c t-test for equality of means; d Chi-square test. 
 
IQR, Inter-quartile range;  AVVSS, Aberdeen varicose vein severity score;  VCSS, 
Venous clinical severity score;  VFI, Venous filling index;  STS, Saphenous treatment 
score;  AK, Above knee;  BK, Below knee;  SD, Standard deviation
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 Follow-up was complete in all assessments in 66 patients (66 legs) at 3 weeks 
and in 56 patients (56 legs) at 3 months. The VFI assessments were completed on 61 
patients at 3 months.  
 
9.42 The STS against other parameters 
Over a quarter of patients started with a competent BK-GSV (STS = 5) and almost all 
patients achieved a reduction of 2 – 4 points in the STS. The reduction in STS from 
pre-treatment values was significant both at 3 weeks (P < 0.0005) and 3 months (P < 
0.0005). The VCSS (P < 0.0005) and AVVSS (P = 0.14) improved at 3 weeks 
compared to their pre-treatment values (Fig 9.2). Although a trend was observed in 
AVVSS it failed to achieve significance. After 3 months however, the median (IQR) 
AVVSS decreased from 21.52 (15.94) to 8.16 (13.3), P < 0.0005 (Wilcoxon).  
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Figure 9.2  Improvements in the VCSS (A), AVVSS (B) and STS (C, D), three weeks 
after endovenous treatment in both groups combined. 
 
 
 At 3 months the overall VCSS, AVVSS and VFI decreased significantly, P < 
0.0005, (Wilcoxon). Correlations between the STS against the AVVSS, VCSS and 
VFI at 3 months were not significant at P = 0.724, P = 0.659 and P = 0.054 
respectively (Spearman). Similarly, correlations on improvements (pre-treatment 
scores minus post-treatment scores) at 3 months (Table 9.4) also failed to reach 
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significance except between the VCSS and the STS. However, this correlation, was 
too poor (R2 = 0.075) to derive meaningful conclusions.   
 
Table 9.4  Improvements in the STS (absolute differences between pre and post 
treatment values) at 3 months correlated against improvements with the other 
validated severity assessments (n = 56). 
 
         AVVSS           VFI          STS 
 
a P value b R2 P value R2 P value R2 
VCSS .110 .047 .051 .069 .041 .075 
AVVSS   -----   ----- .538 .007 .708 .003 
VFI   -----   -----   -----   ----- .748 .002 
 
a
 Spearman rho significance (2-tailed);  b Spearman correlation coefficient. 
 
AVVSS, Aberdeen varicose vein severity score; VCSS, Venous clinical severity score; 
VFI, Venous filling index; STS, Saphenous treatment score. 
 
 
 
 
9.43 The STS with ongoing treatments 
Fifteen patients received additional sclerotherapy. A stepwise reduction in the STS 
was observed after the first treatment and final treatment as shown in Fig 9.3 (A). The 
final treatment was able to achieve a further reduction of 1–2 points in the STS from a 
median of 4 as depicted in Fig 9.3 (B). It is interesting to note that for those patients 
who required additional treatment, the median pre-treatment VFI was 7.1 mL/sec (Fig 
9.3(C)) compared to 4.6 mL/sec for the whole group (Fig 9.3(D)).  
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Figure 9.3  The stepwise change in mean STS during two treatment sessions (A).  
The additional beneficial effect of the second treatment (B). The improvement in the 
VFI is also shown in these patients (C) compared to the whole group (D).  
 
 
9.44 The STS with different treatments 
The mean of the differences in the pre and post treatment STS evaluations (MD-STS) 
have been used to illustrate the different effects of endovenous treatments with EVLA 
and UGFS as shown in Fig 9.4 (A). The MD-STS to 2 decimal points represents a 
scale of improvement with the higher values representing the greatest difference. The 
MD-STS after EVLA was 2.79 compared to 1.86 with UGFS at 3 weeks (P = 0.001, 
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Mann-Whitney U test). Following EVLA, 26.3% of patients had a 4 point 
improvement in their STS compared to 7.1% of patients in the UGFS group at 3 
weeks, as shown in Fig 9.4 (B). 
 When the STS was separated into AK and BK components (each with a score 
between 1 and 3), the MD-STS for the AK and BK scores between EVLA and UGFS 
are illustrated in Fig 9.4 (C) and Fig 9.4 (D), respectively. With EVLA, 92.1% of 
patients achieved a 2 point STS reduction AK compared to 75.0% of UGFS patients 
(MD-STS: 1.92 and 1.57 for EVLA and UGFS respectively, P = 0.039, Mann-
Whitney U test). When the BK part of the STS was evaluated this also decreased, but 
only 26.3% of EVLA and 7.1% of UGFS patients achieved a 2 point reduction (MD-
STS: 0.87 and 0.29, respectively, P = 0.002, Mann-Whitney U test). Most of the 
UGFS patients (20/28) had no difference in the BK-STS because the primary 
treatment was directed at the AK-GSV (Fig 9.4 (D)).   
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Figure 9.4  Patients have been divided into EVLA and UGFS groups.  Three week 
improvements in the STS are illustrated (A, B). Above knee (AK) and below knee 
(BK) components of the STS have been separated in C and D respectively. 
       
   
9.5   Discussion 
9.51 The STS compared to APG and the VSDS 
The STS is a flexible, duplex-derived scoring system, which is able to quantify the 
haemodynamic effectiveness of treatments for SVI. It has the potential to complement 
the descriptive duplex evaluation with a graded haemodynamic outcome measure.  
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Statistical evaluations of variance are therefore possible which can be used to assess 
effectiveness between different treatments or further interventions. 
 Air plethysmography is another assessment tool, which can quantify 
haemodynamic improvements. It measures the rate of venous filling to the calf using 
the VFI in mL/sec (Christopoulos, Nicolaides et al. 1988b; Owens, Farber et al. 
2000). Similar to the VSDS it offers a broader assessment than measurements on the 
GSV alone because it quantifies the global haemodynamic effects in all leg veins. 
However, compared to duplex, APG is not widely available which limits its value as a 
useful assessment tool. It has been used in this study to support the haemodynamic 
improvements demonstrated by the STS.  
 
9.52 The STS in coexisting haemodynamic states 
The STS focuses on the haemodynamic effects of treatment on the saphenous trunks 
in patients with SVI. The GSV is first subdivided into AK and BK segments 
demarcated by the popliteal skin crease. The presence of co-existing reflux, 
obstruction and competency are then recorded within each segment. Since reflux is 
the primary pathophysiological abnormality in SVI it was given the maximum score 
of 3. Occlusion (luminal obliteration), anywhere within the segment, and of any 
length, was given the best score of 1, since this was the intended treatment effect. If 
several scores were present, the final score was determined using an order of 
precedence (Reflux 3 > Occlusion 1 > Competence 2).  
 
9.53 The STS for saphenous conservation 
In haemodynamic terms it could be argued that competency is a favourable outcome. 
Competency is also a treatment aim in saphenous conservation surgery where reflux is 
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abolished without saphenous occlusion. Occlusion is given the best score (score = 1) 
after EVLA and sclerotherapy since these treatments aims to obliterate the saphenous 
vein. A patent competent vein may have a greater potential for reflux (recurrence) 
later on but may also represent treatment (obliteration) failure, which is why it has 
been scored half-way between reflux (score = 3) and occlusion (score = 1). 
Furthermore, competency may be visualised as an intermediate state, which could 
“improve” (obliteration) or deteriorate (reflux). If the BK-GSV was competent and 
patent, both pre and post treatment, there would be no change in the STS.    
 Protagonists for saphenous conservation surgery (CHIVA or ASVAL) have 
the option to change the scoring by giving competency the improved score of 1 and 
occlusion a reduced score of 2. However, it is important that the order of precedence 
should remain the same with reflux prioritizing over occlusion and occlusion 
prioritizing over competency (Table 9.5). The STS can also be applied to the small 
saphenous vein (SSV). 
 
 
Table 9.5  Modifications of the standard saphenous treatment score (STS) to 
accommodate saphenous conservation surgery. The STS is flexible and could be 
modified to the aims of treatment. 
 
 
ENDOVENOUS 
OBLITERATION 
SAPHENOUS 
CONSERVATION 
SCORE   
 Reflux = 3 Reflux = 3 
 Competency = 2 Occlusion = 2 
 Occlusion = 1 Competency = 1 
PRECEDENCE   
 3 > 1 > 2 3 > 2 > 1 
                                                 Reflux > Occlusion > Competency 
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 The treatment of varicose tributaries may have indirect effects on the GSV.   
Obliteration of varicosities can restore competency in saphenous trunks which were 
originally incompetent (Zamboni, Cisno et al. 2001; Carandina, Mari et al. 2008; 
Pittaluga, Chastanet et al. 2009; Pittaluga, Chastanet et al. 2010; Zamboni, Gianesini 
et al. 2010). The STS values may change as a result and this may be useful for 
phlebologists who need to assess the haemodynamic effect of isolated phlebectomies. 
Nevertheless, the score would not fall below 1 for each GSV segment. 
 
9.54 The STS as a flexible, numerical outcome tool 
An ideal scoring system should be accurate, flexible, practical, universal, easy and 
representative of the disease and treatment being assessed. The proposed STS may 
fulfil many of these criteria but not all. If baseline assessments are undertaken then 
the greatest treatment effect would be possible only on those patients with the worst 
initial scores.  
 Occasionally patients may have a successful obliteration of the majority of the 
AK GSV but reflux can still remain within the upper or lower few centimetres of vein. 
This would be considered a failure under the STS with an AK STS score of 3 
representing reflux. Although the appropriateness of this would be controversial, the 
principle of the STS relies on a haemodynamic outcome evaluation rather than a 
success if only a few centimetres of GSV are ablated. Descriptive terms like partial 
occlusion or recanalisation are avoided and can be replaced with numerical scores of 
haemodynamic significance.   
  The use of the STS in evaluating treatment comparisons and ongoing 
treatments for SVI has been demonstrated. In common with other assessment systems 
it improves after endovenous treatment. The separate scores for AK and BK segments 
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may also be used in the evaluation of different treatments or combination of 
treatments. 
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CHAPTER 10 
 
 
 
CLINICAL STUDY  VIII 
 
 
 
The saphenous pulse and severity 
 
 
You can observe a lot just by watching. 
 
-- Yogi Berra 
 
 
10.1   Introduction 
 
Pulsatile flow in VVs has been described previously to support a causal hypothesis of 
arterio-venous (A-V) fistulae (Gius 1960). However, A-V communications have 
never been adequately visualised and direct pressure tracings within leg veins have 
been inconclusive (Murphy and Hands 2008). Nevertheless, the evidence suggests 
that GSV pulsation does occur (Haimovici 1987) but its prevalence, aetiology and 
associations remain unclear. This research re-introduces pulsation in the GSV.  
 In 2009, Hingorani and his team (Hingorani, Ascher et al. 2009) recorded the 
venous flow patterns in deep and perforating veins in patients (44 legs) undergoing 
 224 
radio-frequency stylet ablation for incompetent perforating veins The authors 
concluded that pulsation was a significant predictor of failure of the procedure. 
 Pulsation is defined as a cyclical change in velocity which can be regular or 
irregular. Pulsatile flow occurs when there is a predominant component in one 
direction. Palpability, or the detection of a pulse by touch, is not necessary to 
determine the presence of pulsation. 
 
10.2   Aims 
The hypothesis was that impalpable, pulsatile ante-grade flow is a common duplex 
finding in the GSV in patients with VVs. The aim of this study was to determine the 
prevalence and clinical impact of spontaneous saphenous pulsation (SP) in patients 
and control subjects by investigating its association with GSV reflux, GSV diameter 
and clinical severity. 
 
10.3   Patients and Methods 
 
10.31 Study design 
 
This was a prospective observational study at Ealing hospital to investigate SP. 
Twenty-three healthy ambulatory volunteers (46 legs) and 27 patients (32 legs) 
attending the VVs clinic were recruited over 3 months by 4 physicians. These were 
consecutive subjects meeting the inclusion criteria. The study group was precisely 
defined in order to reduce the number of confounding variables. Inclusion criteria 
included the GSV or a straight continuation of it as the only refluxing vein in the 
thigh, if reflux was present. Exclusion criteria were known DVT, evidence of a past 
DVT, deep venous reflux or concurrent reflux from other sources on duplex. These 
patients were excluded in order to confine this study to patients with exclusive 
superficial venous insufficiency rather than study a heterogeneous group of patients 
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with differing pathologies and sites of reflux. Reflux > 0.5 sec following a manual 
calf compression and release manoeuvre was considered a significant cut-off point 
(van Bemmelen, Bedford et al. 1989). Patients were stratified into refluxers and non-
refluxers on the basis of this test. Spontaneous reflux duration at rest was recorded, if 
present. Measurements were also taken of the GSV diameter in the mid-thigh since 
this is a known marker of clinical severity (Navarro, Delis et al. 2002; Mdez-Herrero, 
Gutierrez et al. 2007). Assessments included the C part of CEAP (Eklof, Rutherford et 
al. 2004) and the VCSS (Rutherford, Padberg et al. 2000). 
This was a study to establish whether saphenous pulsation was a common 
observation in patients with varicose veins which formed the basis of our hypothesis. 
Since the prevalence of a SP is not known there was no data in the literature from 
which a power calculation could be based. The contralateral “normal” leg was not 
used as a control because SVI is often bilateral with many patients having significant 
reflux in the absence of symptoms (Kostas, Ioannou et al. 2010). 
 
10.32 Recording the saphenous pulse with duplex 
This was performed by an experienced vascular ultrasonographer (MA) with 
volunteers and patients in the standing position. Subjects were assessed with their hips 
resting against an adjustable couch with most of their body weight on the contra-
lateral leg. The foot of the test leg was touching the ground and positioned in a 
forward direction to minimize weight bearing. This was to ensure that the venous 
reservoir was full and able to transmit the arterial impulse because hydraulic 
conductivity is diminished in partially filled collapsible tubes (Kamm and Pedley 
1989). Previous work using the VFT90 (time to fill 90% of the venous volume) of 
APG has shown that it can take over a minute to “fill” the venous reservoir in a leg 
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with SVI (Lattimer, Kalodiki et al. 2013) and over 2 minutes for healthy controls 
(Christopoulos, Nicolaides et al. 1989). 
The GSV was insonated transversely at mid-thigh using a linear 7 MHz 
transducer attached to the Phillips ultrasound machine. The mid thigh was chosen 
because it was remote from the pulsating femoral artery. The presence of a SP was 
recorded and the rate was counted from video records. Colour duplex, not the 
waveform analysis, was used to count the saphenous pulse rate. A cycle was defined 
from the start of ante-grade flow until the start of the next episode of ante-grade flow, 
irrespective of whether there was intervening cessation of flow, reflux or both. 
 
10.33 Data recording and statistical tests  
Data were collected onto spreadsheets throughout the duration of the study and 
transferred into the IBM® SPSS® statistics package version 19 at completion. Results 
are given as median (range) unless otherwise indicated. The Mann-Whitney U test 
was used to compare differences between groups. The Chi square test was used to 
compare frequencies between groups unless the expected frequency was ≤ 4 when the 
Fisher exact test was used for correction. The z-test was used to compare column 
proportions (>2) using the Bonferroni correction. The Spearman rho test was used to 
correlate individual column proportions against ordinal data from the C of CEAP. A P 
value of < 0.05 was considered significant.  
 
 
10.4   Results 
 
10.41 Characteristics of volunteers and patients 
The characteristics of the study group are illustrated in Table 10.1 where subjects 
were stratified based on the presence or absence of GSV reflux > 0.5 second (van 
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Bemmelen, Bedford et al. 1989). Unsurprisingly, reflux was rare in C0-1 and the 
absence of reflux was rare in the remaining C classes, confirming its usefulness as a 
cut-off point of disease. Spontaneous GSV reflux at rest did not occur in any of the 
volunteers. Respiratory movements occasionally induced reflux in the study group 
between 100-200 ms in duration as seen in Fig 10.1. 
 
 
Table 10.1  Characteristics of the legs in volunteers (n = 23) and patients (n = 27) 
stratified by the presence or absence of GSVa reflux (> 0.5 sec or < 0.5 sec). Results 
are given as median (range) unless otherwise indicated. 
 
 GSV reflux No GSV reflux P valueb 
Number of legs 32 46 . 
Age (years) 46 (30-80) 46 (22-69) 0.784 
Female (%) 62.5 71.7 0.389c 
C0-1 3 41 . 
C2-3 14 3 . 
C4-6 15 2 . 
GSV diameter (mm) 6.9 (2.7-9.4) 3.5 (1.5-7.2)  < 0.0005 
Detectable SPd 24/32 (75%) 3/46 (6.5%) < 0.05e 
SP rate/min 52 (22-95) 18 (16-75) 0.231 
 
aGSV = Great Saphenous Vein; bMann-Whitney U test; cChi square test; dSP = 
Saphenous Pulse; eFisher exact test  
 
 
10.42 Pulse description and waveform 
As shown in Fig 10.1, the SP when present was discrete, monophasic, of variable 
amplitude, ante-grade and irregular. The duration of ante-grade flow ranged from a 
flicker (10-20 ms) to an impulse lasting 500 ms. Occasionally 2 impulses would 
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follow in close succession with a flicker of stasis discriminating the end of the first 
pulse from the beginning of the second. The blue ante-grade impulse usually filled the 
entire cross-sectional area of the GSV but when the pulse was very brief, it was not 
unusual for this to be detected in only its central portion. Respiratory phasicity was 
observed as occasional episodic reflux which “interfered” with the recordings. In one 
patient the SP was bi-phasic: ante-grade flow followed immediately by reflux. 
The median SP rate in refluxing GSVs was 52 (22-95) beats per minute. There 
was no significant difference between these rates compared to the only 3 subjects that 
had no reflux but yet demonstrated a SP. Therefore, it appears that reflux is not an 
essential pre-requisite for pulsation to occur. 
 
 
Figure 10.1  Duplex tracing of a typical SP waveform. Each major tick represents 1 
second. The background SP (4 pulses) is discrete, monophasic, irregular and of 
varying amplitude. Reflux, coinciding with inspiration, is seen at the end of the trace. 
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10.43 Pulsation and GSV diameter 
The GSV diameter was significantly larger in legs with GSV reflux than those 
without reflux (Table 10.1). The median GSV diameter was significantly elevated in 
the presence of a SP (No pulse: 3.5 (1.5-8.1) mm, pulse: 7 (4-9.4) mm. P < 0.0005, 
Mann-Whitney U test). When the subgroup of 32 legs with GSV reflux was 
examined, a SP was present in 24/32 (75%), 23/24 of which had a GSV diameter ≥ 5 
mm. Of the non-SP legs with GSV reflux, 7/8 had a GSV diameter ≤ 6 mm.The 
presence of a SP therefore appears to be related to increases in GSV diameter.  
 
10.44 Pulsation, reflux and clinical severity 
The relationship between clinical severity versus the proportion of legs with GSV 
reflux and a SP is illustrated in Fig 10.2. There was no statistical difference in the 
proportion of legs with GSV reflux in the early (C2-3) and late (C4-6) stages of disease 
(P = 1.0) as shown in Fig 10.2A. However the proportion of legs with a SP was 
significantly higher in late disease, occurring in 94.1% of legs with C4-6 but in only 
52.9% of legs with C2-3 (P = 0.017) as shown in Fig 10.2B.  
 The relationship between reflux and the presence of a SP is further illustrated 
in Fig 10.3 when both are directly compared. Reflux occurred in 8/32 (25%) legs 
without a SP and these were all in the earlier stages of clinical severity (C0 = 2, C1 = 1, 
C2 = 3, C3 = 2). This indicates that reflux is unlikely to be associated with a SP at 
stages C0-3. It would appear therefore that reflux may be of greater value in defining 
the presence or absence of venous disease and a SP may be of greater value as a 
marker of severe disease. 
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Figure 10.2  The prevalence of reflux (A) and SP (B) across three levels of clinical 
severity. There was a significant stepwise increase in the prevalence of SP according 
to clinical severity with no detectable SP in approximately half of the subject’s legs 
with intermediate clinical severity (C2-3). 
 
  
 
Figure 10.3  Pulsation occurred in 75% of legs with GSV reflux (A). Most legs with a 
SP (89%) had reflux (B).   
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10.5   Discussion 
 
10.51 Historical evidence supporting saphenous pulsation 
        
There are several early reports of pulsatile blood flow within VVs which were used 
historically to support the concept of arterio-venous (A-V) connections in their 
aetiology. Pratt (Pratt 1949) who introduced the term “arterial varices”, reported a 
prevalence of 24% in 272 patients with advanced VVs and speculated their 
predisposition to recurrence. Gius (Gius 1960) supported the hypothesis of A-V 
anastomoses in VVs with an observational study using the operating microscope. 
When the A-V connections were divided pulsating spurts were observed. This concept 
was expanded by Haimovici (Haimovici 1985; Haimovici 1987) using serial 
arteriography and Doppler ultrasonography. He concluded that A-V shunting was 
present in 80% of VVs and at an advanced stage the saphenous trunks may also 
become affected. Studies measuring oxygen partial pressure and venous oxygen 
content in legs with VVs demonstrated significant increases consistent with 
functioning A-V shunts (Blalock 1929; Blumoff and Johnson 1977; Baron and 
Cassaro 1986). 
 More recently, a detailed investigation in 39 patients with varicose veins and 
10 control subjects revealed opposing evidence (Murphy and Hands 2008). They used 
direct VV cannulation in order to measure the venous oxygen content and pressure 
and compared this to the GSV cannulation in the controls. The mean venous pO2 in 
varicosities was 4.5 kPa (SD 1.0) in the supine position reducing to 3.9 kPa (SD 0.9) 
on standing which were not significantly different to samples from controls. 
Furthermore, pulsatile pressure tracings were not observed. The authors concluded 
that A-V shunting is unlikely to be a causative factor in primary VVs. Radiolabelled 
studies on 19 legs with varicose veins and 26 control legs using albumen 
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microparticles of various sizes (5-50 ηm in diameter) injected into the femoral artery 
failed to confirm the increased caliber A-V communications (Lindemayr, Lofferer et 
al. 1972). 
  
10.52 Tricuspid valve aetiology 
Pulsation in the GSV and varicose tributaries is rarely reported. When present this is 
usually attributed to tricuspid regurgitation as evidenced by several case reports 
(Brickner, Scudder et al. 1962; Hollins and Engeset 1989; Klein, Shachor et al. 1993; 
Blackett and Heard 1998; Moawad and Blair 1998). Table 10.2 provides a brief 
overview of the classification of SP (Brickner, Scudder et al. 1962; Hollins and 
Engeset 1989; Klein, Shachor et al. 1993; Robbs, Carrim et al. 1994; Abu-Yousef, 
Kakish et al. 1996; Blackett and Heard 1998; Moawad and Blair 1998; Eifert, 
Villavicencio et al. 2000; Abbas, Hamilton et al. 2006). 
 
Table 10.2  Classification of saphenous pulsation (SP) and the modes by which SP 
can usually be detected. The SP associated with VVs can only be detected using 
duplex. 
 
 Visible Palpable Duplex 
A-V malformations  YES/NO YES/NO YES 
A-V fistula     
   Iatrogenic (catheterisation) YES/NO YES/NO YES 
   Traumatic YES/NO YES/NO YES 
   IV drug abuse (local sepsis) YES/NO YES/NO YES 
aTricuspid valve regurgitation  YES YES/NO YES 
aRight heart failure YES YES/NO YES 
Varicose veins NO NO YES 
 
aPartial leg elevation is often required for its detection (like partial head elevation for 
the detection of the jugular venous pulse). 
 233 
 A tricuspid value (TV) aetiology for the SP, although very unlikely, was 
eliminated as a confounding variable for 5 reasons. Firstly, TV incompetence would 
promote pulsatile reflux and not ante-grade flow. Secondly, the expectation from TV 
transmission would be a regular pulsation like the cardiac cycle, not irregular. 
Thirdly, it is very unlikely that all the patients with a SP had TV insufficiency. 
Fourthly, SP can occur in the absence of GSV reflux. Lastly, in reports of pulsation in 
incompetent perforating veins (Hingorani, Ascher et al. 2009) and VVs, (Haimovici 
1985) GSV pulsation in the thigh was rare suggesting an aetiology remote from the 
TV. 
 
10.53 Relationship to severity, GSV diameter and reflux 
To our knowledge this is the first study to examine the relationship between SP 
against clinical severity, GSV diameter and reflux. This study has shown that a SP 
occurs in 94.1% of patients in C4-6 stage of clinical severity. There was also a 
significant stepwise increase in the proportion of legs with a SP (P < 0.05, z-test) with 
increasing clinical severity, and a significant correlation between the percentage of 
legs with a SP for each stage of C in CEAP (n = 8, r = 0.976, P < 0.0005, Spearman). 
Furthermore, larger diameter refluxing GSVs (> 6 mm) were more likely to have a SP 
than small diameter (< 6 mm) refluxing GSVs (P = 0.003, Mann-Whitney U test). 
However, a SP was detected in one 4 mm diameter vein but not in one 8 mm vein. 
The ease at which a SP could be detected therefore did not seem to be related to 
diameter. Although our study suggests that the presence of a SP parallels increasing 
GSV diameter this does not confirm a causal relationship. 
 When the SP was compared to GSV reflux (> 0.5 sec) only 75% of legs with 
reflux had a SP but 88.9% of legs with a SP had reflux. In contrast to SP, there was no 
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significant difference in the presence of reflux between the early and late stages of 
clinical severity (P = 0.017 versus P = 1.0, respectively, Fisher exact test). 
Furthermore, 25% of subjects with reflux did not have a SP, all of which were in stage 
C0-3. These results suggest that reflux may be the marker of the presence of SVI but 
SP may be a better marker of clinical severity. No attempts were made to quantify the 
SP or reflux. The presence or absence alone was assessed. The SP was assessed at rest 
but reflux assessments followed an un-physiological manual calf compression and 
release manoeuvre. Reflux values quantified in this way have minimum, if any, 
discriminatory usefulness in relation to clinical severity (Neglen, Egger et al. 2004). 
 This study has also shown that patients with mild clinical disease (C2-3) can be 
stratified into 2 roughly equal groups using the presence or absence of a SP. However, 
comparisons between clinical evaluation and haemodynamic parameters are usually 
poor. The C part of CEAP, for example, has a poor inter-observer correlation,(Uhl, 
Cornu-Thenard et al. 2001; Cornu-Thenard, Uhl et al. 2004) and the assumption that 
the disease progresses orderly from C1 to C6 is not always the case (Rabe and Pannier 
2012). An easily performed haemodynamic assessment of severity could therefore 
complement clinical evaluations. Further work is needed to validate the above 
statements and confirm the extent at which the changes at the tissue level are 
represented by the SP.  
   
10.54 Characteristics and aetiological considerations 
The explanation of hydraulic conductivity can be likened to a U-tube manometer with 
2 equal columns of blood, arterial and venous, connected at the U-bend by the 
microcirculation, as shown in Fig 10.4. In situations where the resistance of the 
microcirculation is reduced arterial pulses could then be transmitted to the venous 
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side. This has been termed “microcirculatory failure” for the purposes of this 
discussion. These situations include inflammation and the later stages of CVI (C4-6). 
Increased flow patterns have been demonstrated in these cases with experiments using 
venous duplex (Labropoulos, Tiongson et al. 2003) and laser Doppler (Labropoulos, 
Wierks et al. 2004). Measurements of SP correlated against changes to the resistance 
of the microcirculation are likely to provide more information on the relationship 
between the SP and the microcirculation. Experiments utilizing the veno-arteriolar 
response (Cheatle, Shami et al. 1991) and the Bayliss effect (Bayliss 1902) are future 
research projects that may unravel the degree SP is related to failure of 
microcirculatory resistance. 
 
 
 
Figure 10.4  U-tube manometer to illustrate the principal of hydraulic conductivity. 
An arterial impulse (a) is met with a corresponding venous pulse (v) provided that 
both columns are full (not collapsed) and that there is no resistance at the U-bend. 
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 The typical SP differed from the cardiac cycle in that it was irregular, with 
unequal amplitude. The explanation of this discrepancy may relate to an unproven 
assumption that the SP wave is the summation of a cardiac impulse arriving at 
different times depending on differing levels of resistance at different locations within 
the leg. Our hypothesis is that as the resistance fails the pulse becomes more 
prominent, regular and discrete. However, several other mechanisms may also 
contribute to the wide variation in duration of ante-grade flow from 10-20 ms to over 
500 ms. These include the usual forces hampering and augmenting ante-grade flow 
like changes in intra-thoracic pressure from respiration and muscular adjustments to 
maintain posture. 
 The mechanisms of venous return from the leg have been extensively 
documented and include the calf-muscle pump, the negative intra-thoracic pressure 
during the respiratory cycle and the unidirectional blood flow from venous valves. 
When these mechanisms fail then arterial drive-through from hydraulic conduction 
may start to play a significant role as the final step in forcing ante-grade venous flow. 
This can be confirmed experimentally using color duplex in a patient with isolated 
GSV incompetence. When the patient stands up from a period of leg elevation the 
first observation from the mid GSV is reflux (red) for about 10-60 seconds. This is 
followed by a few seconds of equilibration with no detectable flow (black). Then the 
SP appears with irregular impulses of ante-grade flow (blue) and occasional reflux 
(red) on a background of no flow (black). Tip-toe movements can temporarily arrest 
the SP until the venous reservoir re-fills. The SP may mark the point when all other 
anti-gravitational mechanisms of the leg cease to function. The mechanism of ante-
grade flow from the SP is unlikely to occur in normal individuals because the GSV 
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behaves like a collapsed tube with minimal resting flow, the vast majority of the 
venous return being delivered through the popliteal-femoral venous axis. 
 
10.55 Limitations of the study 
The number of volunteers and patients in this study are small. Whilst there are 
sufficient numbers to identify the presence of a SP, it is recommended that this work 
is considered as a pilot study. Any conclusions regarding the extent of the relationship 
as a marker of severe SVI, although statistically significant, should be confirmed by 
independent vascular Units. The ease of detection should make this possible for many 
phlebology practices that use duplex as a routine in their investigation of venous 
disease. Currently, measurement of SP is more of academic interest than of clinical 
severity because a SP by itself is not a sufficiently discriminating marker to determine 
whether or what course of treatment to pursue. 
 None of the subjects had echocardiography to establish the competence of the 
TV. Simultaneous recordings of the SP and heart rate were not performed and the SP 
was not assessed in relation to symptoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 238 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 239 
 
 
 
 
 
 
 
 
CHAPTER  11 
 
 
 
CLINICAL STUDY  IX 
 
  
 
Validation of the Villalta Scale 
 
 
The logic of validation allows us to move between the two limits of 
dogmatism and skepticism. 
 
-- Paul Ricoeur 
 
 
11.1   Introduction 
The Villalta scale was originally conceived by Prandoni and offered as the subject of 
Sabina Villalta’s thesis. It was first introduced as an abstract in 1994 (Villalta, 
Bagatella et al. 1994). It is a disease specific assessment questionnaire designed to 
diagnose and classify the severity of post-thrombotic syndrome (PTS) (Kahn 2009). A 
lack of standardisation of PTS was recognised as an important barrier to research 
which explained the differing incidences in previous reports. This led to a proposal for 
standardisation by the Subcommittee on Control of Anticoagulation of the Scientific 
and Standardisation Committee of the International Society on Thrombosis and 
Haemostasis (Kahn, Partsch et al. 2009). They stressed that standardisation would 
provide meaningful comparisons between studies and could also be useful in meta-
analyses on PTS. 
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 Most of the validation on the Villalta Scale has been on reproducibility and 
quality of life (QoL). Inter-observer reproducibility was evaluated in the original 
abstract as good to excellent for the total score (kappa = 0.78) as well as for 
categorising severity (kappa = 0.75) (Villalta, Bagatella et al. 1994). In a multicenter 
prospective cohort study of 646 patients (Rodger, Kahn et al. 2008), 125 of them were 
re-evaluated by study nurses after a 1-hour training period. In that study the 
reproducibility for diagnosis of PTS was also good (kappa = 0.71). Regarding QoL 
the VS has also demonstrated significant correlations with deterioration in the 
VEINES QoL measure (Kahn, Lamping et al. 2006) as well as the generic SF-36 
instrument (Kahn, Kearon et al. 2005). However, limited studies exist as to how the 
VS compares against validated clinical, duplex and haemodynamic comparators.   
 
11.2   Aims 
The hypothesis was that the VS may be as good as other more general validated 
assessments in evaluating PTS. Therefore, the aim of this study was to compare the 
VS against the VCSS (Rutherford, Padberg et al. 2000), the C of the CEAP 
classification (Eklof, Rutherford et al. 2004), the VSDS (Rutherford, Padberg et al. 
2000) and the VFI of air-plethysmography (Christopoulos, Nicolaides et al. 1987). A 
secondary aim was to determine if the symptom part of the VS had any relationship 
with the signs part of the VS. 
 
11.3   Patients and Methods 
11.31 Patients and methods 
This is a retrospective analysis on prospectively collected baseline data generated 
from a single centre clinical trial comparing Medi® graduated elastic compression 
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stocking performance on 40 legs in 34 patients with PTS. This study is presented in 
detail in Chapter 17. Ancillary data from this study were used to assess the 
measurement properties of the VS to help improve its validity. This study follows the 
example of a method in a recent publication on PTS which used a retrospective 
analysis of baseline data in order to benchmark the performance of the VS (Kahn 
2009). 
 In brief, all the legs had PTS defined as persisting leg symptoms at least 6 
months after a DVT (3 months after a recurrent DVT) with evidence of deep venous 
obstruction and/or deep venous reflux on duplex ultrasound. The CEAP classification 
was C0 = 2, C2 = 1, C3 = 3, C4a = 12, C4b = 7, C5 = 12, C6 = 3. The median (inter-
quartile range) of age, VS, VCSS, VSDS and VFI were 62 (52 - 73) years, 10 (5 - 14), 
8 (5 - 10), 5 (4 - 6.5) and 4.9 (2.8 - 7.9) mL/sec, respectively. Reflux and obstruction 
were detected in 18 (45%) legs with reflux alone and obstruction alone in 19 (47.5%) 
and 3 (7.5%) legs, respectively. None of the legs had popliteal, femoral or iliac vein 
occlusion. 
 
11.32 Statistical analysis 
Data were entered onto spreadsheets. These were subsequently imported into a 
statistical software package: IBM® SPSS® statistics package version 19 for 
Windows®. The ordinal nature of the assessment tools necessitated the use of non-
parametric statistical tests. Consequently the Spearman rho test was used for all 
correlations. The strength of association was measured using r (Spearman correlation 
coefficient). It is a better measure of size of effect than r2 which is an estimate of the 
amount of variance (D'Andrade and Dart 1990). In other words, the r is the gradient of 
the correlation line (strength) and the r squared is the scatter (variance). 
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11.4   Results 
11.41 Severity correlations 
The correlation between the VS against the VCSS and C of CEAP was good and 
highly significant as depicted in Fig 11.1 and Fig 11.2, respectively. This indicated 
that both these clinical assessments may also be of use in evaluating PTS. These 
results also give credibility to the VS as a clinical assessment but are limited in that 
there is no indication as to which assessment is best. 
 
 
 
   
  Fig 11.1.  The VS correlated against the VCSS 
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  Fig 11.2.  The VS correlated against the C class of the CEAP classification 
 
 
 Interestingly, there was no relationship between the duplex derived VSDS and 
the VS as shown in Fig 11.3.  It was expected that if the number and sites of disease 
increased, then the clinical features of PTS worsened. This was not the case. 
However, there was a moderate correlation between the VFI and the VS (Fig 11.4), 
indicating that APG may be the preferred haemodynamic assessment when compared 
to the VSDS.  
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Fig 11.3.  The VS correlated against the VSDS 
 
 
 
 
Fig 11.4.  The VS correlated against the VFI of air-plethysmography 
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11.42 Relationship between symptoms and signs 
As shown in Fig 11.5, there was no correlation between the clinical symptoms of PTS 
and the clinical signs. This was surprising because it is logical to assume that these 2 
assessments would be related.   
 
 
Fig 11.5.  The VS symptoms correlated against the VS signs 
 
 
11.43 Cross-tabulation summary 
The main correlations of this study are summarised in Table 11.1. The C of CEAP, 
VCSS and the VFI demonstrated a significant and modest correlation with the VS. 
When the VFI was used as a benchmark then the VS demonstrated the most 
significant correlation. However, the VCSS was equally significant. The VSDS did 
not seem to provide any meaningful information in the assessment of PTS severity. 
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Table 11.1.  This summarises the correlations and their significance between all the 
assessment tools of PTS severity. Significant correlations are illustrated in bold text. 
 
 CEAP VCSS VSDS VFI 
VS r = 0.556 r = 0.609 r = 0.046 r = 0.499 
 P < 0.0005 P < 0.0005 P = 0.779 P = 0.001 
CEAP ---- r = 0.822 r = 0.147 r = 0.279 
 ---- P < 0.0005 P = 0.365 P = 0.082 
VCSS ---- ---- r = 0.181 r = 0.480 
 ---- ---- P = 0.264 P = 0.002 
VSDS ---- ---- ---- r = 0.219 
 ---- ---- ---- P = 0.175 
 
 
 
11.5   Discussion 
11.51 The Villalta scale 
The VS is becoming the gold standard assessment questionnaire in the evaluation of 
PTS (Strijkers, Wittens et al. 2011). It is increasing in recognition and may soon 
become as well known as the less specific VCSS. It is a versatile scale in that it can be 
used in 4 different ways. Firstly, as a binary (yes/no) scale using a cut point where a 
score ≥ 5 defines the presence of PTS. Secondly, it can be used as a categorical scale 
with 4 categories: none (0 - 4), mild (5 - 9), moderate (10 - 14) and severe (≥ 15) 
depending on the score out of a total of 33 (Kahn, Shbaklo et al. 2008; Kahn, Partsch 
et al. 2009). Thirdly, it can also be used as a continuous scale from 0 - 33. Finally the 
symptoms can be separated from the signs to give a symptom score and a sign score 
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as has been demonstrated in the current manuscript. Although the VS has good inter-
rater reliability, opinion is divided whether a single assessment is sufficient to grade 
the patient (O'Donnell, McRae et al. 2008) or whether 2 consecutive assessments are 
required (van Dongen, Prandoni et al. 2005). In common with the VCSS, the VS has 
also been demonstrated to improve after intervention in line with a clinical 
improvement in PTS severity (Kahn, Shbaklo et al. 2008; O'Donnell, McRae et al. 
2008; Enden, Haig et al. 2012; Minichiello 2012). 
 The limitations of the VS are also widely recognised (Strijkers, Wittens et al. 
2011). The presence of venous ulceration was not included in the original scale. If 
present, patients automatically receive a score of 15 thereby placing them into the 
severe category (Kahn, Partsch et al. 2009). Venous claudication is relatively common 
in patients after an ilio-femoral DVT yet there is no provision for this in the VS. In a 
study of 39 patients with this condition, 43.6% developed venous claudication which 
was disabling in 15.4% through a compelling interruption of walking (Delis, 
Bountouroglou et al. 2004). A further limitation is the lack of weighting for each 
increment on the scale. Instead, there is the assumption that a one point change in the 
scale has the same quantitative value irrespective of which symptom or sign is being 
assessed.  
        
11.52 Innovations of this study 
This is the first study which has validated the VS using concurrent clinical, duplex 
and haemodynamic benchmarks. Whilst there has been extensive research on quality 
of life comparators and intra-rater reliability (Kahn 2009), correlations using the 
VCSS, C of CEAP, VSDS and APG are lacking. This study attempts to fill this void. 
It has shown that the VCSS correlates significantly with the VS. Furthermore, if the 
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VFI of APG is used as a haemodynamic benchmark then both the VS and VCSS 
questionnaires rate favourably when compared with each other. However, there was 
an insignificant trend that the VS could outperform the VCSS, thereby supporting 
(albeit weakly) the use of the VS as the gold standard disease specific assessment in 
the evaluation of PTS. These results therefore provide confidence to clinicians that 
they may be using the correct instrument. This will also improve the recognition of 
the VS. 
    
11.53 Limitations of this study 
A limitation of this study is that the full spectrum of venous pathology was not 
present in the study group. None of the patients had iliofemoral occlusion and only 3 
legs had obstruction without reflux. The rest of the legs either had reflux alone or 
reflux with obstruction. Since the VFI of APG represents reflux, can measure reflux 
duration and also quantify reflux (Lattimer, Azzam et al. 2013a) this test was 
therefore the appropriate benchmark for use in this study. If the majority of legs had 
iliac vein occlusion then the correlations against the VFI are likely to have been 
worse. The correct comparator in this situation would have been a reliable 
measurement of outflow resistance. However, in an ultrasound study of 1394 venous 
segments in 82 patients (Haenen, Janssen et al. 1999), most patients with severe PTS 
had a combination of deep and superficial reflux with reflux in the deep proximal 
veins as the most significant contributor to severity 
 It is known that ilio-femoral DVT is responsible for approximately 20-25% of 
leg DVT and that these patients represent the highest risk for PTS (Nyamekye and 
Merker 2012). There is therefore a likely causal relationship between proximal DVT 
and proximal deep venous reflux. Although the VSDS gives a value of 2, 1 or ½ for 
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reflux or obstruction in a specified venous segment, there is no indication from the 
total VSDS score of the site of reflux. Furthermore, reflux in the common femoral 
vein or above, or the femoral vein, has the same score as reflux in the posterior tibial 
vein (score = 1), with a score of 2 for popliteal vein reflux. The lack of higher scores 
for reflux in proximal veins may be responsible for the lack of any correlation 
observed with the VSDS in this study.   
    
11.54 Direction of future research      
More research is needed in validating the VS against other scoring instruments using 
larger numbers of patients and patients across the entire spectrum of venous disease. 
This can be achieved in prospective clinical trials which incorporate the VS in their 
PTS evaluation as well as ancillary data from retrospective studies. In particular it 
needs to be investigated whether the VS has a significant statistical advantage over 
the VCSS, a point that was not confirmed in the current study. A haemodynamic 
benchmark like the VFI of APG may be the most appropriate instrument to use in this 
situation. Furthermore, as suggested in the original article (Rutherford, Padberg et al. 
2000), the VSDS should be validated using “objective correlative data” and that 
“further modifications be done after appropriate field-testing”.   
 
 
 
 
 
 
 
 250 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 251 
 
 
 
 
 
 
 
 
CHAPTER  12 
 
 
 
CLINICAL STUDY  X 
 
 
 
Effect of methodology on cost comparisons 
 
 
Balanced budget requirements seem more likely to produce 
accounting ingenuity than genuinely balanced budgets. 
 
-- Thomas Sowell 
 
 
12.1   Introduction 
 
Despite cost comprising half of the equation in a cost-effectiveness analysis it 
receives only a small part of the research interest. In 2002 there was only a single 
paper on cost-effectiveness in varicose vein treatment (Rautio, Ohinmaa et al. 2002). 
Surgeons correctly direct most of their efforts in standardising effectiveness and 
quality, leaving cost assessment to the differing methodologies of the accountant or 
health economist (Riewpaiboon, Malaroje et al. 2007). The venous literature has 
numerous examples of effectiveness using outcomes like generic and disease-specific 
quality of life, clinical severity, saphenous occlusion rates, haemodynamic 
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improvements and recurrence rates. However, few reports remain on the way costs are 
estimated for the treatment of CVD. 
 Micro-costing is a ground-up approach (Schreyogg 2008). For example, it can 
be used to add the direct costs of consumables, staff salaries and treatment locations 
to provide a cost per patient. It is a labour-intensive process using individual data 
which can be conducted alongside randomised controlled trials (Petrou and Gray 
2011a). Reimbursement is a top-down approach where a price is calculated by the 
Department of Health (DoH) and then set as a national tariff, called payment by 
results (PbR) (DepartmentOfHealth 2010). Reference costs are collected locally and 
fed into a DoH database which then calculates the national level of reimbursement 
based on these reports. Summary data like this are used in decision analytical 
modeling, an approach used in reporting economic evaluations (Petrou and Gray 
2011b). Since the NHS is a non-profit making organisation both costing approaches 
should produce equivalent results? In reality, this is rarely the case because of the 
different ways in which direct costs, indirect costs and overheads are calculated 
(Olsson 2010). Reimbursement is often used as a surrogate for cost in economic 
evaluations even though they have been shown to be twice as high in some settings 
(Taira, Seto et al. 2003). This is to be expected in some cases as reimbursement has to 
take into account outliers that might result from complications, cancellations, wastage 
and hidden overheads. 
 Local NHS hospitals compare the actual cost of a service with the 
reimbursement it receives using the EBITDA method (earnings before interest, taxes, 
depreciation and amortisation). This is derived from the income statement of the 
annual report and is an approximate measure of the operational cash flow. It is 
broadly equivalent to profitability provided substantial interest payments are not 
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present such as a public-private partnership funded initiative (PFI). It is another top-
down approach with the local Trust as the starting point rather than the DoH. A 
positive value means that the service generates income. 
 
 
12.2   Aims 
 
The aim of this research was to quantify the impact of different cost assessments 
using data obtained alongside a recent randomised clinical trial on endovenous 
treatments for varicose veins (Lattimer, Azzam et al. 2012b). A further aim was to 
examine the costing methodologies used in the limited publications that are available 
on CVD and determine how they could influence a cost-effectiveness analysis. The 
principles used may be applied equally to non day-case procedures like 
appendicectomy which incur additional length-of-stay costs.  
 
 
12.3   Patients and Methods 
 
12.31 National data 
Data were obtained by both financial and clinical staff from patients treated for VVs 
at Ealing Hospital. The PbR reimbursement rate (tariff) and the NHS Trust reference 
costs (DepartmentOfHealth 2011) for 2010-11 were obtained from the DoH using the 
HRG code: QZ10B which is a “primary unilateral varicose vein procedure without 
complication”. The “office of population, censuses and surveys classification of 
surgical operations and procedures” (OPCS 4.6) is more granular and provides codes 
for 39 different procedures for venous disease (Connectingforhealth 2011). These 
were used to discriminate between endovenous laser ablation (EVLA) with 
phlebectomies and ultrasound-guided foam sclerotherapy (UGFS). Individual patient 
episodes were then summarised to create a mean bill per patient treated. This was then 
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subtracted from the hospital income from reimbursement, teaching etc to calculate the 
EBITDA for EVLA and UGFS. 
 
12.32 Service line report 
The service line report (SLR) represents a profit and loss account (income statement) 
of individual services. Varicose vein procedures are part of the day-case inpatient 
activity SLR for general surgery. This SLR includes reimbursement from PbR and 
teaching as well as capital costs, building, maintenance and running costs. Besides 
clinical costs and services it also includes managerial, administrative, hotel services 
and overheads from theatre usage. The SLR was adjusted by subtracting services not 
required for day surgery VVs and also by adding consumables for laser, tumescent 
and standard foam. Therefore, a final cost per treated patient could be estimated 
within these groups. 
 
12.33 Micro-costing 
A micro-costing analysis was performed alongside a recent RCT using session slots as 
well as individually timed treatments for laser (n = 50), tumescent foam (n = 27), and 
standard foam (n = 23) (Lattimer, Azzam et al. 2012b). Historical hospital data 
revealed that 2 EVLA, 3 tumescent foam and 5 standard UGFS treatments are usually 
performed in a single 210 minute (3.5 hours) session slot duration, allocated for each 
procedure. Treatments were also timed from the moment of entry into the treatment 
area until the moment of departure. This allowed the calculations on staff pay (per 
minute) and holding area costs (£11.40/hour) to be made. These were then added to 
the consumable costs, theatre overheads at £2.30/min (if relevant) with a final general 
15% overhead charge on the total cost for tumescent and standard foam. The foam 
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interventions took place, the tumescence ones in a clinical room in the day surgery 
admission ward while the ordinary foam interventions in a room in the outpatients 
department. The full calculations have been itemised in a previous publication 
(Lattimer, Azzam et al. 2012b).  
  
12.4   Results  
All data relate to the 2010-11 financial year unless specified otherwise. 
 
12.41 Earnings and profitability  
The day case elective PbR tariff was £1,098 per patient treated. The mean profitability 
and mean EBITDA were £948 and £964 per varicose vein treatment, respectively. 
This was independent of the type of intervention and excluded GEC stockings as a 
treatment. When patients were stratified according to OPCS codes the total 
profitability and total EBITDA in 2010-11 was £-18,000 and £-15,000 for EVLA with 
phlebectomies (code: L88.1; n=18) and £233,000 and £236,000 for UGFS (code: 
L86.2; n=205), respectively. The profit generated from 568 foam treatments using 
EBITDA over 3 years was over half a million pounds at £585,000. The mean 
profitability and EBITDA per treatment (3 years) is summarised in Fig 12.1.  
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Figure 12.1.  Profit and earnings (EBITDA) with laser ablation (A) and foam 
sclerotherapy (B) at Ealing hospital.  
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12.42 Top-down results from the service line report 
Using SLR data the final bill per patient treated (cost) in day surgery for all day 
surgical cases was £803. After adjustment for VVs treatment, this was calculated at 
£1,059 for laser, £603 for tumescent foam and £551 for standard foam (Table 12.1). 
 
 
Table 12.1.  Revised costs per patient (PP), bottom line, with venous interventions 
using data from the service line report (SLR) for day surgery 2010 - 11. Redundant 
services have been subtracted from the total SLR cost and procedure specific 
consumables have been added. 
 
aEndovenous laser ablation; bTumescence-assisted ultrasound-guided foam 
sclerotherapy; cDrug costs were accounted for in the consumables; dn = 3,014 for day 
surgery 
 
 
12.43 Micro-costing and review of other costing methods 
Costs derived using micro-costing methods based on individually timed treatments, 
session slots and consumables are illustrated in Table 12.2. The median (IQR) 
SLR cost adjustments £ aEVLA bT-UGFS UGFS 
Total SLR cost 2,420,000    
    Pathology services  (75,000) (75,000) (75,000) 
    Radiology services  (4,000) (4,000) (4,000) 
    
cDrug costs  (14,000) (14,000) (14,000) 
    Theatre costs   (706,000) (706,000) 
    Hotel costs    (76,000) 
Adjusted SLR cost  2,327,000 1,621,000 1,545,000 
dAdjusted SLR cost PP  772 538 513 
Consumables PP  287 65 38 
Revised cost PP  1,059 603 551 
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treatment times (minutes) for EVLA, tumescent foam and standard foam were 85 (75 
- 96), 48 (38 - 55) and 25 (23 - 33), respectively (P < 0.0005, Kruskal-Wallis test). 
The treatment times were increased using session slots at 105, 70 and 42 min 
respectively. The wide differences in cost between interventions reflected a higher 
contribution of staff, consumables and longer operating theatre times in the EVLA 
group. These differences are less apparent as the scope of overheads increase using 
top-down approaches (Table 12.2).  
 
 
Table 12.2.  Reimbursement versus micro-costing. Amounts represent cost per patient 
(2010 - 11) in UK sterling (£). The PbR and reference costs are based on HRG code: 
QZ10B. 
 
aEndovenous laser ablation; bTumescence-assisted ultrasound-guided foam 
sclerotherapy; cEVLA/UGFS ratio; dPayment by results; eService line report for day 
surgery 
 
 
Costing Method  aEVLA bT-UGFS UGFS cRATIO 
dPbR Tariff 1,098 1,098 1,098 1.0 
National Reference 1,012 1,012 1,012 1.0 
Local Reference 523 523 523 1.0 
eTotal SLR 803 803 803 1.0 
SLR (adjusted) 772 538 513 1.5 
Session slots 812 239 124 6.5 
Timed treatment 
(median) 721 (677-774) 195 (176-209) 100 (93-109) 7.2 
Consumables only 287 65 38 7.6 
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A summary of the methods used in calculating cost from other treatment units are 
illustrated in Table 12.3. 
 
 
Table 12.3.  Differences in primary costing methods used in cost-effectiveness 
analysis of clinical trials. 
 
 
aRadiofrequency ablation; bUltrasound-guided foam sclerotherapy; cEndovenous laser 
ablation 
 
 
 
 
 
12.5   Discussion  
 
12.51 Price, cost and profit 
Reimbursement is income received by a hospital and represents the price of a service. 
Cost is the expense used in the provision of this service. Profit is the difference 
between price and cost and represents the operational cash flow. This study has 
Intervention Primary  method Year Author 
Surgery, RFAa Societal, Bottom up 2002 Rautio T et al 
Surgery, Conservative Top down 2006 Ratcliffe J et al 
Surgery, UGFSb Bottom up 2006 Bountouroglou DG et al 
Surgery, EVLAc Societal, Top down 2007 Rasmussen LH et al 
EVLA, Cryostripping Societal, Top down 2009 Disselhoff BCVM et al 
Surgery, UGFS, EVLA, RFA Top down 2010 Gohel MS et al 
Surgery, RFA Societal, Bottom up 2010 Subramonia S et al 
Surgery, UGFS, EVLA, RFA Societal, Top down 2011 Rasmussen LH et al 
UGFS, EVLA Bottom up 2012b Lattimer CR et al 
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demonstrated that the EBITDA for varicose vein treatment is positive and therefore 
generates income for the hospital. However, the healthcare resource group (HRG) 
code from which the EBITDA is derived (code: QZ10B) is just for the treatment of a 
“primary unilateral varicose vein procedure without complication”. It does not have 
the granularity of discriminating between EVLA or UGFS. Since the cost of UGFS is 
less than that of EVLA and that there were more UGFS procedures performed, this 
study has shown that the UGFS contribution is responsible for the income generation.  
 
12.52 Limitations of OPCS coding 
The use of OPCS codes which separate EVLA from UGFS, rather than the global 
HRG code, may result in a more accurate calculation of reimbursement through PbR. 
However, OPCS codes lack precision and are not without their own limitations. For 
example, code L88.1 “percutaneous transluminal laser ablation of long saphenous 
vein” does not account for concurrent “avulsions of varicose veins of leg” which is 
code L87.4. Alternatively, just the single code L84.1 “combined operation on primary 
long saphenous vein” can be used in place of the above but this does not indicate that 
the patient had an EVLA procedure or whether a general anaesthetic was required. 
Interestingly, L86.2 “ultrasound-guided foam sclerotherapy for varicose veins of the 
leg” does not seem to reflect its use in the treatment of an incompetent, but non-
varicose GSV. The same code L86.2 is also used for recurrent disease, on-going 
treatment as well as primary varicose veins, irrespective of whether the patient has an 
ulcer or the treatment location. Therefore, these situations which use the same L86.2 
code can be demonstrated to have considerable variations in cost as well as different 
reimbursement levels since they all utilise different HRG codes.   
 
 261 
12.53 Effect of treatment location 
Surprisingly, varicose vein surgery in cost calculations is defined as a day case 
procedure irrespective of the actual treatment location. If foam sclerotherapy was 
accounted as an outpatient procedure, such as a minor skin procedure like a skin 
biopsy (HRG code: JC07Z) in an equivalent technical setting, then the reimbursement 
would decrease from £1,098 to just £138 (DepartmentOfHealth 2010).  
 
12.54 Societal costing and employment 
Several publications have used a societal analysis in their estimation of cost (Rautio, 
Ohinmaa et al. 2002; Rasmussen, Bjoern et al. 2007; Disselhoff, Buskens et al. 2009; 
Rasmussen, Lawaetz et al. 2011). This is the cost of the loss of productivity as a direct 
result of sick leave which represents the value of lost working days. Cost in these 
terms is dependant on the proportion of patients with CVD who seek treatment who 
are employed and the monetary value of this employment. One study noted that RFA 
was only cost effective compared to stripping when the local retired population was 
40% (Rautio, Ohinmaa et al. 2002). Treatments which reduced sick leave would only 
have economic advantages for employed patients because they could return to work 
earlier. Since geographical regions vary greatly in the proportion of patients who are 
retired, favourable cost-effectiveness analyses using a societal approach will be 
heavily dependant on local employment statistics. A national reimbursement, where 
one price fits all, may not be ideal in many settings.  
  
12.55 ICERs and QALYs 
These are abbreviations for incremental cost effectiveness ratios and quality adjusted 
life years, respectively. Cost is an integral part of an ICER. If the ICER comparing 2 
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treatments is less than a certain threshold value per QALY then that intervention is 
likely to be cost-effective. In the UK, many decisions are based using this equation 
which highlights the importance of a costing method which is accurate, standard and 
representative. Examples of this approach have been used comparing conservative, 
traditional and endovenous treatments (Ratcliffe, Brazier et al. 2006; Gohel, Epstein 
et al. 2010). Both these studies confirmed that their findings were robust by using a 
sensitivity analysis to assess the impact of variations in cost on the results. However, 
their costing methodology was primarily top-down. Micro-costing using timed 
procedures and staff pay rates were not performed.  
 
12.56 Limitations of costing methods 
Occasionally the costing analysis excludes the services which are common to the 
interventions being compared (Rautio, Ohinmaa et al. 2002; Subramonia and Lees 
2010). This may have the effect of increasing the percentage differences in cost 
between both treatments and consequently heighten the chance of significance in any 
comparative analysis. Furthermore, some publications add together reimbursement 
and cost in their final calculation of cost which provides a potential for double-
counting as additional resources are added, like ultrasound, which are assumed to be 
excluded from the case-payment (Rasmussen, Bjoern et al. 2007; Gohel, Epstein et al. 
2010; Rasmussen, Lawaetz et al. 2011). 
  
12.57 Direct, indirect and overhead costs 
Variations in cost calculation can also apply to common surgical treatments like open 
versus laparoscopic appendicectomy. Cost-effectiveness ratios comparing these 
techniques are known to depend on whether or not indirect costs have been included 
 263 
in the analysis (Long, Bannon et al. 2001). This raises an important question as to 
how wide the scope of overheads should be in cost calculations and whether this 
should be standardized. For example, should the running costs of a hospital like gas, 
electricity and building repair/maintenance be included in the cost of sclerotherapy. If 
they are then the energy efficiency of a modern block building would result in lower 
costs for varicose vein treatment than older buildings in need of repair. 
 
12.58 Local assessment of cost 
Effectiveness outcomes used to compare treatments between and within hospitals are 
recorded at a local level. If cost outcomes are used alongside then the data should be 
obtained locally, in the same way, using the same level of granularity. This is an 
approach that can be achieved using micro-costing. This is the first study which has 
compared session slots with individually timed treatments. The former may be more 
reliable because it includes patient assessment, consent, administration and set-up 
times since back-to-back treatment efficiency is rarely possible. Session slots use a 
theatre time utilization approach. Other approaches can be based on surgeons 
operating time (Rasmussen, Lawaetz et al. 2011) as well as approaches which micro-
cost the full patient episode in hospital care (Lattimer, Azzam et al. 2012b).  
  
12.59 Summary and future 
This study has shown that costing calculations can vary considerably according to the 
method from which they are derived. The costs of pre-treatment investigations, 
adjuvant treatments, follow up appointments with duplex and primary care costs were 
excluded. Societal, opportunity, teaching and agency staff costs and the cost 
reductions achieved with high throughput were also excluded from the micro-costing 
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analysis for simplicity. Motivational drivers, like recognition and ownership for work 
achieved, were also excluded since their impact on cost reduction would be difficult 
to quantify. They are arguably the most important factors for high performance. 
Departmental rewards for efficiency, such as part of the £585,000 profit from foam 
sclerotherapy in this study, could be used for service development. 
 Hospital practice has changed since the recent reorganisation of vascular 
services. Laser ablation is now performed without the assistance of a salaried trainee 
and standard foam sclerotherapy is now performed single-handed under ultrasound 
guidance thereby reducing costs. Practice settings undergo constant changes within 
and between hospitals in the same way as changes in effectiveness. The bottom-up 
approach of micro-costing has the granularity to detect these changes.   
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PART  IV 
 
 
 
ASSESSMENT INNOVATIONS ON IMPROVING SAFETY 
 
 
 
           CHAPTER  13 
 
 
 
CLINICAL STUDY  XI 
 
 
 
Assessing a Valsalva and Standardising Reflux  
 
 
Adopt the pace of nature: her secret is patience. 
 
-- Ralph Waldo Emerson 
 
 
13.1   Introduction 
This is a study which quantifies the haemodynamic effects of a standardised Valsalva 
manoeuvre (VM) at the SFJ, comments on the significance of the findings in the 
assessment of CVI and the implications this may have to the practice of UGFS.     
 Reflux duration of more than 0.5 sec is the cut point for the diagnosis of 
insufficiency in superficial leg veins (van Bemmelen, Bedford et al. 1989). It is 
typically induced using a manual calf compression and release (MCCR) manoeuvre in 
a dependent position when the venous reservoir is full. Measurements of reflux 
duration induced in this way have been shown to shorten with increasing severity of 
disease, but this does not have any discriminatory usefulness (Yamaki, Nozaki et al. 
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2002). The MCCR manoeuvre is a pre-valve SFJ challenge test. An incompetent 
valve will always remain incompetent. Reflux will stop when the reservoir is full.  
 The VM, in contrast, is a post-valve challenge test. The elevation-dependency 
test using APG is also a post-valve challenge test where reflux duration is represented 
by the VFT90 (Lattimer, Azzam et al. 2013a). Similar to a MCCR manoeuvre using 
duplex ultrasound, reflux duration using the elevation-dependency manoeuvre 
likewise decreases with disease severity (Lattimer, Kalodiki et al. 2013). The VM is a 
validated technique used to induce reflux in patients with CVI (Masuda, Kistner et al. 
1994). If it is performed in the supine position then the venous reservoir is only 
partially filled. The haemodynamic situation which terminates reflux, unlike the 
MCCR manoeuvre, has not yet been elucidated. Competent valves in the iliac and 
femoral veins (Basmajian 1952) may limit its usefulness in the assessment of GSV 
reflux which is probably why the MCCR manoeuvre is a more accepted induction 
test.   
 The UGFS procedure has become a popular endovenous treatment for both the 
saphenous trunks as well as their varicose tributaries (Bradbury, Bate et al. 2010). It 
has not however gained universal acceptance because of the risks of systemic side 
effects and complications (Gillet, Guedes et al. 2009), which, although rare, included 
stroke (Forlee, Grouden et al. 2006). Foam sclerotherapy is also acknowledged to 
have inferior GSV occlusion rates both in the short term (Rasmussen, Lawaetz et al. 
2011) and the long term (van den Bos, Arends et al. 2009) especially in patients with 
GSV diameters exceeding 12 mm (Gonzalez-Zeh, Armisen et al. 2008). Techniques 
aimed at improving the safety and efficacy of UGFS, like catheter direction (Kolbel, 
Hinchliffe et al. 2007), peri-venous tumescence (Parsi 2009) and balloon occlusion 
(Bidwai, Beresford et al. 2007) have all been shown to have advantages. Avoidance of 
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all activities which may cause a VM during and shortly after sclerotherapy may also 
help in improving the safety and efficacy of UGFS, but this has never been proven.  
 
13.2   Aims 
The hypothesis is that a VM may cause bolus foam displacement from the GSV into 
deep veins in addition to the normal seepage of micro-bubbles (Regan, Gibson et al. 
2011), a cause of potential side effects. The volume displacements in and out of the 
GSV may also cause blood-foam mixing which would inactivate foam (Watkins 
2011), especially in large calibre veins.  
 The aim of this study was to measure the haemodynamic effects of a 
standardised VM within an incompetent GSV. Quantification of the volume of blood 
displaced and other haemodynamic parameters may therefore be able to indicate the 
forces at work within the GSV. The results may also provide insights into the 
pathophysiology of venous disease in terms of reflux induced by a post-valve 
challenge test and re-circulation. 
 
13.3   Patients and Methods 
13.31 Study design 
This was a prospective observational study on 23 consecutive patients who were on 
the waiting list at Ealing hospital for endovenous treatment for their varicose veins.  
Criteria for entry included patients with C2 of the CEAP classification or greater, and 
GSV reflux extending from the SFJ down to the popliteal skin crease. Ability to 
comprehend and perform the VM was also a requirement. Patients were excluded if 
they had deep venous reflux, a history of a DVT or if they were on anticoagulation 
therapy.  The baseline characteristics of the patients were as follows: Median age = 45 
 268 
(23-78) years; M:F = 10:13; Left:Right = 12:11; Median (IQR) refluxing GSV 
diameter = 7.5 (1.9) mm.   
 
13.32 Technique of recording the VM using duplex 
The VM was standardised in time to 3 seconds in the following way. All patients were 
positioned supine on a flat examination bed with the head supported on a pillow. A 
linear duplex transducer attached to a portable ultrasound machine (Phillips) was used 
to record the haemodynamic measurements at the termination of the GSV. Patients 
were given a rehearsal on how to perform the VM. Intervals of a second (from 0 to 9) 
were counted out loud from a clock and patients were instructed to take a deep breath 
in during the first 3 seconds, strain during the next 3 seconds and relax during the 
final 3 seconds. The second and third phases of this cycle are illustrated in Fig 13.1. 
 Feedback on the adequacy of the VM was indicated by the colour flow 
patterns on duplex across the SFJ and by the change in diameter of the GSV during 
straining and relaxation, as depicted in Fig 13.2. The audio feedback also allowed the 
patient to realise a “good” technique. Once this was mastered by the patient the study 
measurements were taken off the monitor, as shown in Fig 13.3. 
 
 
Figure 13.1  The first phase of the Valsalva cycle is a 3 second inspiration from 0 - 3 
seconds – not shown. The 2nd and 3rd phases are shown, each lasting 3 seconds. 
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Figure 13.2  Differences in the GSV diameter at relaxation (a) and straining (b).                                               
 
 
 
Figure 13.3 Most of the haemodynamic values are automatically calculated on the 
monitor. 
 
 
13.33 Duplex parameters on the GSV during a VM 
The GSV diameter (d) was measured during the strain phase and also from the 
relaxation phase, from which the cross-sectional area could be calculated (π x d2/4).  
The largest diameter was measured at the termination of the GSV, for the purposes of 
this analysis, which was usually just distal to the SFJ. Volume flow (VF) in mL/min 
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was derived by multiplying the time averaged mean velocity (TAMV) in cm/s by the 
GSV diameter in cm. The strain or relaxation diameter was used appropriately for 
each of the calculations. All the above values were conveniently calculated by the 
duplex machine. The volume displaced in 3 seconds however, was obtained manually 
by multiplying the VF by 3/60 seconds (0.05).  The peak velocity (PV) in cm/s was 
also recorded because it may represent the point at which the haemodynamic forces at 
the termination of the GSV are maximal. 
 
13.34 Statistical considerations 
Data were entered into a spreadsheet and then analysed using SPSS® Statistics version 
17. Non-parametric statistical tests were used with boxplots to illustrate the medians, 
inter-quartile ranges (IQR) and ranges. The Wilcoxon signed rank test was used to 
detect differences within the patient group. A P-value < 0.05 was considered 
statistically significant. 
 
13.4   Results 
13.41 Valsalva performance and reflux duration 
Twenty-two out of the original 23 patients were able to complete the VM to a 
satisfactory standard. One patient, judged at inclusion able to perform a VM, failed to 
do so at the time of examination, despite repeated attempts at explaining what was 
required. Four patients did not have any significant reflux at the SFJ, probably due to 
the presence of iliac or femoral valves. However, reflux was significant in this region 
after a MCCR manoeuvre whilst their legs were dependant (pre-valve test). All of the 
remaining 18 patients demonstrated a reflux duration of 3.0 ± 0.5 sec during the 3 
second strain phase of the VM. The imprecision related to difficulties in the patients 
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timing their strain for exactly 3 seconds. Similarly all 18 patients had ante-grade flow 
from the GSV into the femoral vein (FV) during the relaxation phase, which 
immediately followed the strain phase. 
 
13.42 GSV diameter, area, PV and volume displaced 
The GSV diameter (mm) and calculated cross-sectional area (mm2) significantly 
increased during straining compared to relaxation as depicted in Fig 13.4A and Fig 
13.4B. The peak velocity of reflux (cm/s) was also significantly greater during 
straining than the ante-grade flow of relaxation (Fig 13.5 left). A median of 25 mL of 
blood was displaced into the GSV over 3 seconds during straining with only 9 mL of 
blood during the following 3 seconds of relaxation (Fig 13.5 right). 
 
 
 
Figure 13.4  Significant changes in GSV diameter (left) and area (right) between 
straining and relaxation. 
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Figure 13.5  Significant differences in GSV peak velocity (left) and volume 
displacements (right) between straining and relaxation. 
 
 
 
13.5   Discussion 
13.51 Previous haemodynamic studies on a VM 
The presence of significant reflux defines disease in patients with VVs from a 
haemodynamic perspective (Labropoulos, Tiongson et al. 2003; Neglen, Egger et al. 
2004). Therefore its quantification is of paramount importance in the assessment of 
patients undergoing endovenous treatment. 
 Physiological reflux and GSV diameter have been assessed previously using a 
standardised 3 second VM in healthy volunteers (Jeanneret, Labs et al. 1999). The 
reflux duration at the GSV in that study was 0.28 ± 0.4. In agreement with our study 
the GSV diameter also increased in that study with a VM compared to the relaxation 
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status, 4.3 ± 1.4 vs 3.5 ± 0.9 mm respectively. In a similar study by the same author it 
was concluded that a standardised VM could also cause an increase in the relative 
venous diameter changes at the GSV in VV patients when compared to healthy 
volunteers (Jeanneret, Jager et al. 2007).  
 
13.52 Standardisation of reflux duration 
Reflux duration has been extensively investigated using various challenge tests like 
pneumatic and manual calf compression (Yamaki, Nozaki et al. 2006), electrical calf 
stimulation (Griffin, Nicolaides et al. 2010), air plethysmography (Owens, Farber et 
al. 2000; Yamaki, Nozaki et al. 2007) and a VM (Masuda, Kistner et al. 1994). 
However, reflux duration may be an operator dependent variable, unrelated to the 
severity of the disease. This study has demonstrated that reflux can be standardised to 
3 seconds, in the majority of CVI patients using a VM. This may open the possibility 
of standardising the duration of reflux with the other tests. Controlling the filling of 
the venous reservoir by customising the deflation speed of a pneumatic cuff may offer 
one such possibility. Control using a tilt-table is another.   
 
13.53 Recirculation and reflux 
Recirculation of venous blood within the leg has been described (Bjordal 1972) but 
has never been adequately quantified. The calf-muscle pump expels blood from the 
calf veins towards the femoral vein.  In the presence of SFJ incompetence some of 
this blood may reflux back into the GSV and then the superficial veins of the calf. 
Competent re-entry perforating veins then complete the recirculation loop. This study 
has shown that a median of 25 mL of blood can reflux down the GSV during a 3 
second strain.  The proportion of venous blood involved in re-circulation remains to 
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be determined. A causal relationship between re-circulation and flow changes in 
general (Recek 2010) to venous pathologies like DVT and advanced clinical changes 
remain to be discovered. 
 
13.54 Spatial and temporal properties of duplex  
The TAMV was a key parameter in the determination of VF and the subsequent 
calculations of volume displaced. This may be an overestimate because it is reliant on 
the position of the duplex cursor at a chosen point within the cross-sectional area of 
the GSV. The centre of the GSV is chosen but this may not be representative of the 
velocity at the periphery, which may be slower. Magnetic resonance venography 
(MRV) is likely to provide a better estimate of volume displacements because it uses 
pixel shifting across the entire cross-sectional area of the vessel from a starting slice 
to a finishing slice (Meckel, Glucker et al. 2008). Spatial as well as temporal values 
can therefore be used in calculations of volume displacement (Pierce, Gatehouse et al. 
2012).  
 
13.55 Properties of blood are different to foam 
The volume shifts across the SFJ have been calculated on blood but foam has 
different physical properties. Foam is compressible and the surface tension forces 
within the micro-bubbles hamper its onward flow through the circulation. Although 
clinical endpoints in this study are desirable, it would be unethical to randomise foam 
sclerotherapy patients into a VM group. Furthermore, given the low incidence of 
systemic complications, thousands of patients would be required to achieve statistical 
significance if a clinical trial with a safety outcome was ever proposed. Nevertheless, 
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this study has quantified the volume displacements which can occur with blood. Its 
relevance to foam displacement, which is likely to be less, can only be assumed.  
 
13.56 Clinical relevance and advice 
A VM is unavoidable in patients undergoing UGFS. They need to get up off the 
couch, may move their legs, cough, and strain in various other ways and in varying 
degrees. The VM is a potential hazard in UGFS because it may be associated with 
concerns over safety and efficacy. This is because of the possibility of bolus 
displacement of foam into deep veins, and also due to neutralisation of the sclerosing 
effects of foam by blood proteins through blood-foam mixing (Watkins 2011). The 
clinician should be alerted to the problems a VM may cause and protocols should be 
in place to minimise the risks of a VM.  Patients should remain calm and still during 
and for several minutes after UGFS and avoid talking, coughing and lifting their head 
off the couch. Stockings should be placed on the patient by the physician and the 
patient should get up off the couch with the help of the physician in stages separated 
by several minutes. 
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CHAPTER 14 
 
 
 
CLINICAL STUDY  XII 
 
 
 
Haemodynamic changes during stocking application 
 
 
Make a habit of two things:  
to help or at least to do no harm. 
 
-- Hippocrates 
 
 
14.1   Introduction 
Ultrasound-guided foam sclerotherapy (UGFS) has become an established treatment 
for a refluxing GSV. An inherent part of this treatment is post-procedural 
compression. This usually involves the application of a GEC stocking in order to 
improve efficacy and reduce complications like superficial vein thrombosis and 
pigmentation. The advantages of UGFS in comparison to EVLA include reduced 
treatment time, post-procedural pain and cost (Lattimer, Azzam et al. 2012b). 
However, many controlled trials have also demonstrated that the results of UGFS on 
GSV occlusion are inferior to that of EVLA and other endovenous interventions (van 
den Bos, Arends et al. 2009; Rasmussen, Lawaetz et al. 2011). This may be because 
foam can migrate into deep veins and also become de-activated by blood proteins, 
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especially in large calibre saphenous trunks that contain more blood (Parsi, Exner et 
al. 2008; Watkins 2011). Furthermore, the transient side-effects after UGFS are often 
attributed to its escape into deeper veins (Gillet, Guedes et al. 2009). Therefore, 
strategies which mitigate the degree in which foam enters the central circulation may 
be advantageous in terms of efficacy and in the reduction of neurological side-effects.  
 It has been demonstrated previously that a standardised Valsalva manoeuvre 
can cause significant haemodynamic forces at the SFJ (Lattimer, Kalodiki et al. 
2012c). It was recommended that all activities which raise intra-abdominal pressure, 
like sitting-up and talking, should be avoided during and for several minutes after 
UGFS in order to minimize bolus foam displacement (Lattimer, Kalodiki et al. 
2012c). 
 
14.2   Aims 
The hypothesis of this study is that the application of a GEC stocking to knee level 
may flush a large amount of blood from the below-knee part of the GSV and 
connecting tributaries into the deep veins. The aim was to quantify the rate at which 
blood was displaced from the GSV into the common femoral vein (CFV) while a 
stocking is pulled-up from the ankle towards the knee.   
 
14.3   Patients and Methods 
14.31 Study design 
Twelve consecutive patients with primary VVs were recruited into the study. This 
took place in a clinical room in the out-patients department at Ealing hospital. They 
were on the waiting list for foam sclerotherapy. Informed consent was obtained from 
participating patients. Inclusion criteria were symptoms attributable to VVs, a 
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refluxing GSV throughout the thigh length and the absence of a history of DVT or 
evidence of deep venous disease on duplex examination. Significant reflux was 
defined as reversed flow > 0.5 sec following a MCCR manoeuvre (van Bemmelen, 
Bedford et al. 1989). This cut point was used to identify a pathological cohort of 
patients for investigation. 
 
14.32 Pull-up manoeuvre 
A below-knee class 2 GEC stocking (23-32 mmHg ankle pressure) was used in all 
patients. The appropriate stocking size was chosen from the manufacturer’s 
measuring chart using circumferential measurements of the calf and ankle. A below-
knee stocking was chosen as opposed to a thigh-length stocking because this was 
easier to pull-up to the knee in one swift movement.  
 
 
 
Figure 14.1  The GEC stocking in position at the ankle prior to the pull-up 
manoeuvre. Although there are no visible varicose tributaries, the below-knee GSV 
contains a reservoir of blood awaiting displacement. 
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 The stocking was initially applied on the leg, with the patient supine, over the 
toes, around the heel, and up to the level of the ankle, leaving a collar of excess 
stocking as shown in Fig 14.1. With the knee kept straight, the stocking was then 
pulled up to knee level using both hands whilst a duplex transducer was held at the 
SFJ. 
 
14.33 Haemodynamic measurements 
The GSV and SFJ were insonated by an experienced dedicated vascular scientist 
(MA) using a linear 7 MHz transducer attached to the Phillips ultrasound machine. 
Baseline measurements were taken with the patient supine and the GEC stocking 
applied at the ankle. The peak velocity (PV) in cm/sec and the volume flow (VF) in 
mL/min were recorded with the GEC at the ankle and during the pull-up manoeuvre 
to establish the change in the haemodynamic forces. The GSV diameter (d) in cm was 
also recorded before and then after the pull-up manoeuvre to determine whether the 
stocking had any influence on the calibre of the GSV. The pre pull-up diameter was 
also used in the calculation of VF. As shown in Fig 14.2, the diameter was measured 
at the termination of the GSV just before it starts to widen, which was approximately 
1-2 cm from the SFJ. Care was taken to ensure that d was representative of the thigh 
GSV by excluding any focal dilatations from the measurements. 
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Figure 14.2  Duplex recording during the pull-up manoeuvre. Volume flow is 
calculated from the diameter (Dist) and the time average mean velocity (TAMV) 
delimited by the vertical cursor bars (arrows). GSV = great saphenous vein; SFJ = 
sapheno-femoral junction. 
 
 
 
 Time average mean velocity (TAMV) in cm/sec is the average of the mean of 
all the individual velocity spikes taken during a single measurement, as shown in Fig 
14.2. The duration of measurement was taken between 2 vertical cursor lines which 
were positioned manually and coincided to the pull-up manoeuvre. The VF is the 
speed at which a given volume of blood passes across a point in the GSV. It was 
automatically calculated by the software and displayed using the following formula: 
VF = TAMV x A x 60, with A representing the cross sectional area of the GSV and 60 
representing 60 seconds. A was calculated as follows: A = π x d2 / 4. 
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14.34 Statistical analysis 
Data were collected onto spreadsheets throughout the duration of the study and 
transferred into the IBM® SPSS® statistics package version 19 at completion. Medians 
with inter-quartile ranges were used to describe the data and the results were 
illustrated using boxplots. Significant differences between volume flow (VF) and 
peak velocity (PV) at baseline and during the pull-up manoeuvre as well as GSV 
diameter differences were compared using the Wilcoxon matched-pair signed-rank 
test. 
 
14.4   Results 
14.41 Patient characteristics 
Twelve consecutive symptomatic patients were studied (female = 7). The median 
(range) age was 47 (24-76) years with 50% right legs. The CEAP classification was: 
C2-6EpAsPr, with the C stratification as follows: C2 = 5, C4a = 4, C4b = 2, C6 = 1. 
 
14.42 Peak velocity and volume flow 
Both the PV and the VF increased significantly during the pull-up manoeuvre when 
compared to baseline measurements, each with a P = 0.002, as shown in Fig 14.3. 
There was a median (IQR) 17.7 (14.2 – 23.9) fold increase in PV from a median 
(IQR) of 7.6 (6.4 - 9.8) to 150.5 (110 - 187) cm/sec and a 9.4 (7.7 – 10.3) fold 
increase in VF from 50.9 (33.8 – 78.9) to 458.7 (292.1 - 593) mL/min. This indicated 
that during the application of a GEC stocking significant haemodynamic forces are 
transmitted at the SFJ. 
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Figure 14.3.  Peak velocity (A) and volume flow (B) over the GSV increase 
significantly during the pull-up manoeuvre. 
 
 
 
14.43 Saphenous diameter 
There was also a significant decrease in the GSV diameter from a median (IQR) of 
6.9 (5.3 -8) mm to 5.8 (4.5 – 6.7) mm, respectively. As shown in Fig 14.4, this was 
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significant at P = 0.002. This indicated that the application of a below-knee stocking 
has a remote effect at the SFJ in reducing its calibre. 
 
 
Figure 14.4  The effect of below-knee compression in reducing the diameter of the 
GSV measured just below the SFJ. 
 
 
 
 
14.5   Discussion 
14.51 Prevention of foam escape into deep veins 
Several existing strategies with strong theoretical advantages that aim to prevent the 
escape of foam into deep veins have been described (Table 14.1). However, their 
implementation is limited because a trickle of bubbles migrating into the CFV is a 
common observation and the presence of intra-cardiac bubbles occurs despite all 
treatment modifications (Parsi 2011). Furthermore, small numbers of patients, the 
infrequent occurrence of side-effects (Guex, Allaert et al. 2005) and many other 
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confounding variables hamper any conclusions that recommend one technique over 
another. 
 
 
Table 14.1  Technical modifications as suggested by various authors to limit foam 
migration into deep veins 
 
Strategy Author 
Tumescence at the SFJ and GSV (Thibault 2005) 
SFJ ligation (Bountouroglou, Azzam et al. 2006)  
Intra-luminal balloon occlusion at SFJ (Bidwai, Beresford et al. 2007)  (Brodersen and Geismar 2007) 
Catheter direction using long lines (Kolbel, Hinchliffe et al. 2007) 
Transducer pressure over the SFJ (Breu, Guggenbichler et al. 2008a) 
Ultrasound control of foam distribution (Breu, Guggenbichler et al. 2008b) 
Leg elevation to promote distal migration (Hill, Hamilton et al. 2008) 
Multiple small dose foam injections (Yamaki, Nozaki et al. 2009) 
 
 
  
 The danger of a bolus displacement of foam from the GSV is likely to be more 
detrimental in terms of increased side-effects and reduced efficacy in comparison to 
slow migration of bubbles (Morrison 2008). Strategies like temporary internal or 
external compression over the SFJ may cause a proximal build-up of foam or force 
the foam though perforating veins (Almeida and Raines 2008). When the compression 
is released this results in a bolus payload (Hill, Hamilton et al. 2008). The present 
study has quantified the rate of volume displacement from the GSV during the 
application of a GEC stocking and compared this to baseline. 
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14.52 Potential hazard in the use of a stocking  
There was a 17.7 fold increase in PV and a 9.4 fold increase in VF during the pull-up 
manoeuvre. It is acknowledged that blood has different properties to foam. Foam is 
compressible and its higher viscosity discourages onward flow (Orbach 1944). 
Therefore, the displacement may be less in patients having UGFS, particularly since 
the procedure causes substantial venoconstriction along the entire treated system. 
Nonetheless, the substantial increase in volume flow to a median value of 7.6 mL/sec 
(458.7 mL/min) reflects the presence of a significant force in producing these 
haemodynamic effects. It is understandable that an injection force can cause flow into 
undesired places in the presence of a proximal balloon occlusion and be associated 
with an increased incidence of DVT (Almeida and Raines 2008). A force generated 
using the pull-up manoeuvre may likewise shift foam into deep veins via perforating 
veins especially if the saphenous outflow has been occluded by intense venospasm. 
 
14.53 Potential advantages in using a pre-applied stocking 
A pre-applied below-knee stocking significantly reduced the GSV diameter at the SFJ 
in all 12 patients (P = 0.002). This reduces the amount of blood within the GSV 
thereby limiting the neutralising properties of blood (Watkins 2011) and facilitating 
endothelial contact (Goldman 2002). It may also limit the volume of foam required 
for treatment, thereby keeping within the 10 ml maximum as recommended by the 
European guidelines (Breu, Guggenbichler et al. 2008a). The reduction in diameter 
may be explained in general terms through a reduction in flow and a diminished 
venous reservoir. Stockings have been shown to reduce the venous volume in the calf 
when measured using APG (Lattimer, Azzam et al. 2013b) and excision of varicose 
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tributaries has been shown to have beneficial effects on the GSV (Pittaluga, Chastanet 
et al. 2010). 
It is a common observation that varicose veins do not fully collapse when the 
leg is elevated. The reasons for this may include a high outflow resistance, tricuspid 
regurgitation or a reduction in the resistance of the microcirculation (Labropoulos, 
Wierks et al. 2004; Lascasas-Porto, Milhomens et al. 2008). The application of a 
stocking on an elevated leg may therefore not protect against the inadvertent 
displacement of foam, especially in patients with extensive varicose veins of the calf. 
The technique of foam injection in the presence of compression is not novel. 
Foam has been delivered via long line catheters in an elevated leg which has 
previously been wrapped in an Esmarch rubber compression bandage (Parsi 2009). 
This has been described as the ‘Alpha technique’ by Dr René Milleret (personal 
communication to K. Parsi). The use of a pre-applied below-knee stocking is also part 
of the methodology in some centers (Gillet, Guedes et al. 2009; Lattimer, Azzam et al. 
2012b). However, to our knowledge this is the first study which quantifies PV and VF 
within the GSV during the application of a GEC stocking.  
Other advantages of a pre-applied below-knee stocking include a theoretical 
reduction in the incidence of superficial vein thrombosis (SVT) by the compression of 
varicose tributaries. The flow of injected foam into the GSV is bi-directional. Foam 
usually moves down into the varicose tributaries beneath a stocking. Pre-applied 
compression reduces the amount of blood exposed to foam. Therefore, it is likely to 
decrease the extent of thrombus formation and the subsequent risk of recanalisation 
and pigmentation. However, there are no studies to date comparing compression 
before foam injection in the reduction of SVT or pigmentation.  
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14.54 Future work 
The majority of phlebologists that practice UGFS consider compression essential after 
sclerotherapy for varicose veins (Goldman 2002; Bountouroglou, Azzam et al. 2006; 
Breu, Guggenbichler et al. 2008a). The patients in this study were subsequently 
treated with UGFS and received a thigh-length GEC stocking (23-32 mmHg) with 
waist attachment which was to be worn for 2 weeks continuously and then during the 
day on the third week. Future work is required to investigate the bolus entry of foam 
into the CFV by comparing patients undergoing standard treatment, with those fitted 
with stockings in advance. 
 The procedural details are as follows. The GSV was first cannulated using 
ultrasound, the stocking was then applied to below-knee and the thigh part was then 
folded back to the ankle. As shown in Fig 14.5, the foam was injected in the presence 
of below-knee compression under ultrasound guidance. After a 5-10 minute delay the 
remainder of the stocking was applied to the thigh. 
 
 
 
Figure 14.5  A pre-applied thigh-length stocking folded back on itself prior to the 
injection of foam. 
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14.55 Study limitations 
The main limitation of this study is that the haemodynamic properties of blood have 
been measured and these results have then been extrapolated to foam without clinical 
endpoints. A clinical study is required. However, given the low incidence of 
immediate side effects, it may require several thousands of patients to achieve a 
significant difference in reducing transient events attributable to foam embolisation 
(Guex, Allaert et al. 2005). Furthermore, there are many operator and patient 
dependant variables which are difficult to standardise and which may affect the GSV 
occlusion rates. These include the quantity and quality of foam injected, the size and 
compression strength of the stocking, variable definitions of success on the GSV, 
GSV diameter and length, and the anatomical distribution of perforating veins.  
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PART  V 
 
 
 
ASSESSMENTS IN RANDOMISED CLINICAL TRIALS 
 
 
 
CHAPTER  15 
 
 
 
CLINICAL TRIAL  I 
 
 
 
Early comparisons between laser and foam 
 
 
Power is not sufficient evidence of truth 
 
-- Samuel Johnson 
 
 
15.1   Introduction 
This chapter is on a single-centre prospective randomised controlled trial comparing 
the cost and effectiveness of two popular endovenous treatments for venous 
insufficiency: EVLA with concurrent phlebectomies and UGFS to the GSV. It is 
believed that EVLA is more effective but more expensive. UGFS, on the other hand, 
is more likely to require additional treatments with foam but may be more acceptable 
in terms of pain, analgesia requirements and return to normal activities. 
This study will quantify these differences using micro-costing evaluations alongside 
duplex, functional, clinical and haemodynamic assessments leaving the clinician to 
decide which treatment is the most acceptable. 
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 Varicose veins affect approximately 25% of the western population (Callam 
1994) and are a sign of underlying CVI. Their treatment is directed at improving 
venous haemodynamics as well as obliterating symptomatic refluxing varicose 
tributaries.   
 Endovenous laser ablation (Fernandez, Roizental et al. 2008) and UGFS 
(Bradbury, Bate et al. 2010) are now established techniques at obliterating failing 
saphenous trunks, the commonest haemodynamic abnormality in SVI. Laser treatment 
requires tumescent anaesthesia, a protected environment and higher initial cost with 
the advantages of a single session of treatment. Foam sclerotherapy, in contrast, is 
acknowledged to have inferior results on the GSV (van den Bos, Arends et al. 2009), 
may require more than one extra treatment but has lower cost and is easily repeatable.  
 
15.2   Aims 
The aims of the study were to quantify the differences between EVLA and UGFS in 
terms of effectiveness, cost, complications and return to normal activities (recovery). 
 
15.3   Patients and Methods 
15.31 Study design 
This study was approved by the Regional Ethics Committee (No: 08/H0710/78) and is 
registered on a public database (www.controlled-trials.com, No: ISRCTN:03080206). 
This was a prospective, randomised controlled trial on 100 patients with primary 
symptomatic VVs at Ealing Hospital. Written consent was then obtained from suitable 
participants who met the inclusion and exclusion criteria (Table 15.1). Randomisation 
was performed with numbered sealed envelopes. Fifty patients/legs received local 
anaesthetic EVLA with concurrent phlebectomies and 50 patients/legs received UGFS 
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to the incompetent GSV.  In patients with bilateral disease, the most severely affected 
leg was treated. The flow of patients through the study is shown in the CONSORT 
(Moher, Schulz et al. 2005) flow chart (Fig 15.1). 
 
 
Table 15.1  Inclusion and exclusion criteria 
Inclusion criteria 
   Patients with primary symptomatic VVS 
   SFJ reflux (> 0.5 sec) on duplex 
   Suitability for both techniques: laser and foam 
Exclusion criteria 
   SPJ incompetence 
   GSV diameter > 12 mm 
   Previous surgery or sclerotherapy in the study leg 
   Previous or current deep vein thrombosis 
   Known coagulopathy 
   Arterial occlusive disease (ABPI < 0.8) 
   Active malignancy 
   Pregnancy 
   Known allergy to local anaesthetic or sclerosing agents 
 
 294 
 
Figure 15.1  Patient disposition. 
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15.32 Investigation protocol 
All patients underwent clinical, functional, haemodynamic and duplex assessment at 
the beginning of the study. Clinical stage was assessed using the C component of the 
CEAP classification (Eklof, Rutherford et al. 2004). The venous clinical severity 
score (VCSS) was used to assess the clinical severity before and after treatment 
(Vasquez, Rabe et al. 2010).   
 The Aberdeen varicose vein questionnaire (AVVQ) is a disease specific 
quality of life (QoL) questionnaire which was used as a patient reported outcome 
measure to assess the impact of treatment (Smith, Garratt et al. 1999). Patients were 
encouraged to fill in the questionnaire during their clinic visit and this ensured 100% 
completion. It was completed after treatment was guaranteed, to prevent its use to 
qualify for treatment. Haemodynamic measurements were quantified with the venous 
filling index (VFI) in mL/sec using air plethysmography (Owens, Farber et al. 2000). 
The calf sensor cuff was calibrated with an inflation pressure of 6 mmHg. 
 The superficial and deep leg veins, above knee (AK) and below knee (BK), 
were assessed for reflux, occlusion and competency, before and after each 
intervention. Colour duplex was performed by the same experienced operator (MA) 
using a portable Sonosite® Titan duplex scanner fitted with a linear 7 MHz transducer. 
Reflux was induced using a manual calf compression and release manoeuvre. Reflux 
was significant if the duration was > 0.5 sec for superficial veins and > 1 sec for deep 
veins. Occlusion was defined as an absence of flow with non-compressibility of any 
length across the segment of vein under investigation. Competency was defined as 
compressibility (patency) with an absence of flow or the presence of ante-grade flow. 
The diameter of the refluxing GSV, excluding dilatations, was obtained by taking the 
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average of three measurements: 2 cm below the SFJ, at mid-thigh and 5 cm above the 
popliteal skin crease.     
 
15.33 Laser procedure 
All EVLA procedures were performed in a day surgery theatre with the ELVeS® 
PainLess diode laser, delivering intermittent energy using a 1470 nm wavelength 
bare-tipped fibre. The GSV was prepared using tumescent anaesthesia (40 mL of 
0.5% bupivacaine in 1000 mL 0.9% saline) and patients were placed in the 
Trendelenburg position prior to ablation. The access site was near the knee, not 
necessarily at the distal end point of reflux. The GSV was lasered from 2 cm distal to 
the SFJ. A median (IQR) of 69 (66-76) J/cm of energy was delivered to the GSV at 20 
degrees leg elevation along a median (IQR) length of 31 (25-36) cm, at a median 
distance of 4.5 (1-10) cm proximal to the popliteal skin crease. Incompetent 
saphenous tributaries and perforating veins were treated concurrently under local 
anaesthesia using phlebectomy hooks. The stab wounds were approximated with 
adhesive strips and the leg was dressed using circumferential padding covered with 
tightly applied crepe bandages. Patients were instructed to wear a thigh length 
thrombo-embolic deterrent stocking for the next 3 weeks. 
 
15.34 Foam procedure 
The UGFS procedure took place in an outpatient consultation room and was primarily 
used to treat an incompetent GSV. Significant tributaries were treated if required, at a 
further session. A maximum of 12 mL of foam was injected during a single session in 
order to comply with the European recommendations (Breu, Guggenbichler et al. 
2008b). Foam was prepared by agitating 1.2 mL of 1% sodium tetra-decyl sulphate 
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(Fibrovein®) in 4.8 mL of air to produce 6 mL of foam. This was then injected into 
the saphenous trunk at knee level, using an 18-gauge straight intravenous cannula, 
with the patient supine and the leg elevated at 45°. The median (IQR) of foam 
injected was 12 (10-12) mL. The extent and direction of foam within the target veins 
was visualised using ultrasound. Tributaries were treated as required on a subsequent 
occasion using a 21-gauge butterfly needle. A full length, 23-32 mmHg, GEC 
stocking with a waist attachment was applied for 3 weeks.  
 
15.35 UGFS tumescence procedure 
In patients with a GSV diameter ≥ 8 mm UGFS was modified using tumescence 
(Parsi 2009) as described above. The rationale was to ensure that the pre-treatment 
preparation of the GSV in the UGFS group was the same as for EVLA since the 
tumescence and catheter may improve efficacy in larger veins (Cavezzi and Tessari 
2009). This took place in a day surgery clinical room and involved the deployment of 
foam into the GSV using a 14-gauge, 25 cm intravenous catheter (Parsi 2009). In all 
initial UGFS sessions, foam injection occurred after the GEC stocking was partially 
applied to the knee. This was in order to localise the foam and prevent potential ante-
grade displacement into deep veins which may occur during the initial pull-up of the 
stocking. In subsequent UGFS sessions, the sclerosant was usually directed at calf 
veins and the above technique was not applicable. 
 
15.36 Advice to patients 
Patients were given departmental information leaflets regarding the EVLA and UGFS 
procedures which included recovery advice. Both groups were told they could resume 
normal activity immediately and were encouraged to walk at regular intervals. 
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Patients were also asked to complete 7-day pain charts using a 100 mm visual 
analogue scale (VAS) (see Appendix I), and to record the days analgesia was taken.   
      
15.37 Costing method 
A micro-costing approach, from the ground-up, was used to assess the cost of each 
treatment (Schreyogg 2008). Consumables, staff pay, procedure location, overheads 
and individually timed treatments were included in the analysis. This approach 
provided direct comparisons between treatments and avoided the wide scope of 
overheads in the running costs of a hospital, like building maintainence, capital, 
estates, human resources, finance, teaching, managerial costs, etc. Procedures were 
timed from the entry into the treatment area until the departure as published 
previously (Bountouroglou, Azzam et al. 2006).             
 
15.38 Follow-up 
This was at 3 weeks following treatment and 3 months after the last treatment session. 
The protocol allowed a maximum of two additional treatment sessions with foam.  
The decision to offer additional treatment was based on the patient’s informed choice 
and independent of cost. Patients were warned of a < 1% risk of DVT, a 10% risk of 
pigmentation lasting a year and told that an un-occluded refluxing AK GSV was a 
failure, irrespective of symptoms. Patients therefore could decide, with the alternative 
of a 1 year review, if they needed additional treatment.  
 The follow-up evaluation included the VCSS, the AVVQ and the VFI (at 3 
months). The duplex assessment was aimed at detecting a thigh or calf DVT and 
documenting reflux, competency and degree of closure within the GSV, both AK and 
BK. The ultrasound endpoint was the absence of GSV reflux at every point, not 
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occlusion. A partially patent but competent vein was not a treatment failure. Patients 
were asked to return the 7-day post-procedural (VAS) pain score (out of 100 for each 
day), state their analgesia requirements and record the number of days to recover and 
resume normal activities.   
 
15.39 Statistical analysis 
This study was powered on a meta-analysis which showed a 5 year recurrence rate 
(GSV recanalisation) with foam of 26.5% and with laser 4.6% (van den Bos, Arends 
et al. 2009). For a type I error of 0.05 and a type II error of 0.20 the minimum sample 
size was 86.  The number of patients was increased to 100 to take into account loss to 
follow-up or protocol violation. The 3 month results of this study are reported. 
 Statistical differences were evaluated between groups at baseline using the 
independent samples t-test, chi square test, and the Mann-Whitney U test, as 
appropriate. Comparisons were made within the same group (i.e. score changes over 
time) as well as calculating improvement differences between groups (i.e. baseline 
scores minus post-treatment scores). The Mann-Whitney U-test and Wilcoxon signed 
rank test were used as the basis of the analysis. All statistical tests were two-tailed. A 
linear statistical model was assumed in each scoring system. Patients with missing 
data were removed from the analysis at the point where the data were absent. Data 
were analysed using the SPSS Statistics version 17. A P value < .05 was statistically 
significant.   
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15.4   Results 
15.41 Baseline patient characteristics 
Patients were compared across all assessment parameters as depicted in Table 15.2. 
However, there was a trend for the UGFS patients to have more severe baseline 
characteristics, but this discrepancy was not sufficient to reject the null hypothesis. 
The median baseline VCSS, AVVQ, VFI and GSV diameters were high in 
comparison to similar studies, confirming severe disease.   
 
 
Table 15.2  Demographic and baseline characteristics between the EVLA and UGFS 
groups.  Median values, range and percentages are presented unless otherwise stated. 
 
 EVLA Group UGFS Group P value 
Mean age 47.4 (21 - 74) 48.5 (22 - 78) 0.733a 
Female 31 (62%) 27 (54%) 0.418b 
Bilateral disease 28 (56%) 32 (64%) 0.414b 
C of CEAP class    
     C2 22 (44%) 10 (20%)  
     C3   7 (14%)   8 (16%)  
     C4 15 (30%) 24 (48%)  
     C5, 6   6 (12%)   8 (16%)  
   0.074c 
VCSS   6 (2 - 20)   7 (3 - 17) 0.114d 
AVVQ  20 (1 - 53) 25 (4 - 50) 0.085d 
VFI (mL/sec) 4.7 (0.9 - 17.8) 5.9 (1.1 - 15.5) 0.367d 
GSV diameter (mm)   7 (4 - 12)   8 (5 - 12) 0.115d 
BK GSV Reflux 29 (58%) 37 (74%) 0.091b 
 
a
 t-test; b Chi-square test; c Chi-square of 6.93; d Mann-Whitney U test 
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15.42 Treatment duration and cost 
The median (IQR) treatment duration of EVLA and UGFS was 85 (75 - 96) minutes 
and 35 (25 - 50) minutes respectively, P < 0.0005, Mann-Whitney U test. The median 
(IQR) treatment cost in the EVLA group overall compared with the UGFS group was 
£724.72 (676.74 – 773.85) and £230.24 (123.20 – 259.91) respectively, P < 0.0005, 
Mann-Whitney U test. The primary treatment costs and the total cost, including the 
additional treatments with UGFS, are shown in Table 15.3, with the breakdown of 
expenditure. 
 The significantly increased costs in the EVLA group did not demonstrate any 
overlap with UGFS. These costs were related to the cost of the laser kit, increase in 
procedure duration, the running costs of main theatres (£2.30 per minute), the 
increased number of staff and other consumables. The cost of the thigh-length GCS 
was the main consumable expenditure in UGFS. 
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Table 15.3  Breakdown of expenditure comparing EVLA against UGFS. 
 
Category Comment EVLA T-UGFS UGFS 
  n = 50 n = 27 n = 23 
Staff Pay per minute (£)    
   Surgeon (SPR)  0.83 0.83 0.83 
   Duplex (MA)   0.56 0.56 
   Trainee  0.50   
   Nurse (b6)  0.40   
   Nurse (b5)  0.33 0.33  
   HCA   (b2)  0.21   
 Subtotal A 2.27 1.72 1.39 
Consumables (£)    
 Laser Kit 235.00   
 Thigh stocking    27.57  27.57 
 Micropuncture set   20.23   
 Central line   16.33  
 Foam (1% STS)   10.25  10.25 
 Basic Set   10.00   
 Tumescent tubing     6.00   6.00  
 Bupivacaine (0.5%)     4.35     
 Velband & Crepe     3.78   
 1000 ml 0.9% saline     3.34   3.34  
 Sterilisation     2.77   
 Needles     1.12   1.12  
 Subtotal B 286.59 64.61  37.82 
Holding Area     
 £11.40 / hour 45.60 22.80 11.40 
Overheads     
 Theatre (£/min)  2.30   
 Percent (15%)  x 1.15 x 1.15 
Summary     
 Fixed Cost (£) 332.19   87.41 49.22 
 Variable Cost (£/min)     4.57     1.72    1.39 
 Median treatment (min)   85   48  27 
 
a Index Total b p/p (£) 720.64 195.47  99.76 
 Additional UGFS n = 3 n = 24 n = 9 
 Additional cost (£68.05) c 204.15 1633.20 612.45 
 Grand Total p/p (£) 724.72   255.96 126.39 
 
a
 Primary treatment costs; b p/p = per patient; c Total for each group. This excludes the 
cost of a new stocking. 
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15.43 Follow-up 
The median (IQR) pain score during the 7 days following treatment in the EVLA 
group was more than twice compared to the UGFS group at 33/100 (18 - 54) and 
14/100 (6 - 34) respectively, P = 0.005, Mann-Whitney U test. The daily VAS pain 
score within each group is depicted in Fig 15.2. A similar increase was also observed 
when the median (IQR) time taken to return to normal activities and recover was 
compared: 7.5 (2 - 15) days for EVLA and 3 (1 - 10) days for UGFS, P = 0.011, 
Mann-Whitney U test. The EVLA group required analgesia tablets for a median of 2 
days (0 - 21) in comparison to 0 days (0 - 14) with the UGFS group. Furthermore, 
post-procedural pain scores were significantly greater in all patients who took over 10 
days to recover (P < 0.0005, Mann-Whitney U test), as shown in Fig 15.3. 
 
 
 
Figure 15.2  Daily pain scores comparing EVLA and UGFS using a visual analogue 
scale (VAS). The differences were significant on every day. 
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Figure 15.3  Boxplots comparing time-taken to recovery and return to normal activity 
with mean 7-day post-procedural pain scores. P < 0.0005 (Mann-Whitney U test). 
 
 
 
 The results of endovenous treatment on duplex outcomes between both groups 
are demonstrated in Table 15.4. The GSV has been divided into AK and BK parts 
because the intended effect of the initial treatment was on AK outcomes. The BK 
GSV effects however, were also recorded because subsequent UGFS, if required, was 
mainly directed at the treatment of BK GSV reflux or tributary disease. At 3 months, 
AK GSV occlusion, without reflux, was achieved in 74% of EVLA patients and 69% 
of UGFS patients. This compares to an initial success rate at 3 weeks of 92% and 80% 
respectively. Below knee GSV reflux was present in 46% and 42% of patients at 3 
months, respectively. 
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Table 15.4  Ultrasound outcomes on the above and below knee GSV at 3 weeks and 3 
months.  1 = Success defined as occlusion (any length) without reflux;  2 = Patent and 
competent (no occlusion);  3 = Reflux anywhere along the GSV segment (with or 
without occlusion); 4 = Overall success, defined as occlusion (with or without reflux) 
or competency (patent and compressible with absence of flow or presence of ante-
grade flow). 5 = Overall success, defined as occlusion (with or without reflux). 
 
 EVLA UGFS 
 3 weeks 
(n=50) 
3 months 
(n=46) 
3 weeks 
(n=50) 
3 months 
(n=45) 
Above Knee     
   1 46 (92%) 34 (73.9%) 40 (80%) 31 (68.9%) 
   2   3 (6%)   3 (6.5%)   2 (4%)   5 (11.1%) 
   3   1 (2%)   9 (19.6%)   8 (16%)   9 (20%) 
   4 49 (98%) 44 (95.7%) 44 (88%) 40 (88.9%) 
   5 46 (92%)  41 (89.1%) 42 (84%) 35 (77.8%) 
Below Knee     
   1 17 (34%) 7 (15.2%) 10 (20%) 20 (44.4%) 
   2 26 (52%) 18 (39.1%) 16 (32%)   6 (13.3%) 
   3   7 (14%) 21 (45.7%) 24 (48%) 19 (42.2%) 
 
 
 
 
 Treatment was successful (absence of AK GSV reflux) in 80% of the patients 
in each group at 3 months. The patterns of closure and reflux in those patients with 
above knee reflux at 3 months (9 in each group) are explained in Table 15.5. In the 
EVLA group 7/9 refluxing patients had occlusion (absence of flow with non-
compressibility of any length) compared to 4/9 refluxing UGFS patients. 
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Table 15.5  Patterns of above knee (AK) GSV closure in patients with residual AK 
GSV reflux, at 3 months. 
 
AK reflux Occluded Partial closure      Patent Pattern of AK reflux 
EVLA  (n = 9)      7 / 9       1 / 9   1 / 9  7 / 7  (distal) 
UGFS  (n = 9)     4 / 9       3 / 9   2 / 9  3 / 4  (proximal) 
 1 / 4  (distal) 
 
 
 
 
 
 Three EVLA patients (6%) had subsequent UGFS for AK-GSV reflux, BK-
GSV reflux and AASV reflux, respectively. The duplex findings on the 28 UGFS 
patients (56%) who received additional sclerotherapy were 8 (16%) AK-GSV reflux, 
12 (24%) BK-GSV reflux, 7 (14%) tributary disease and 1 (2%) AASV reflux. 
 The median (IQR) AVVQ, VCSS and VFI at 3 months was 5.8 (2.5 - 12.2), 1 
(0 - 3) and 1.5 (1.1 - 2.4) for EVLA and 12.4 (6 - 21.9), 2 (1 - 4) and 1.9 (1.3 - 2.7) for 
UGFS, respectively. Whilst this may indicate a trend favouring EVLA, it should be 
noted that the baseline scores were also better in the EVLA patients as shown in Table 
15.2. The improvements in the AVVQ, VCSS and VFI at 3 weeks and 3 months are 
demonstrated in Table 15.6. There were no significant differences between both 
groups in terms of improvement although improvements within both groups were all 
significant (P < 0.0005, Wilcoxon) at 3 months. 
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Table 15.6  Functional, clinical and haemodynamic changes (improvements) at 3 
weeks and 3 months between EVLA and UGFS. Values represent change scores 
(baseline minus post-treatment) using median (IQR).   
 
    EVLA     UGFS 
    P* 
AVVQ  3 months      12  (11)        9  (11) 
  0.062 
VCSS  3 weeks       3  (2)        3  (5) 
  0.721 
VCSS  3 months       5  (2)        4  (3) 
  0.817 
VFI (mL/sec)  3 months    2.6  (3.3)     3.1  (4.9) 
  0.791 
 
* Mann-Whitney U Test. 
 
 
       
15.44 Side-effects and complications 
There were no serious complications (Table 15.7). Five patients re-attended before 3 
weeks due to pain. Thrombotic complications were recorded if there was severe pain 
or deep vein involvement. Four patients in the UGFS group had side effects following 
foam injection (headache n = 1, cough n = 1, dizziness n = 2) all of which disappeared 
within 30 minutes. 
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Table 15.7  Number of patients with side-effects or complications.   
 
PATIENT EVENT EVLA Group UGFS Group 
DVT (common femoral vein) * 1  
GSV thrombosis (both re-attended) 1 1 
GSV saccular thrombosis (1 re-attended)  3 
Tributary thrombosis 1 4 
Groin haematoma (1 treated by family doctor) 2  
Dermal thermal injury (1 re-attended) 2  
Phlebectomy granuloma  1  
Severe procedural pain (1 required a GA) 3  
Headache /cough /dizziness (procedural)  4 
Shingles (viral reactivation)  1 
Vasovagal episode (procedure re-sheduled)  1 
Severe stocking discomfort (re-attended)  1 
 
*Heat-induced DVT causing 30% narrowing. This disappeared within 8 weeks on oral 
Warfarin. 
 
 
15.5   Discussion 
15.51 Overall comparisons 
This is a randomised controlled trial which compares the direct procedural costs and 
early (3 month) effectiveness of EVLA versus UGFS using clinical, functional, 
haemodynamic and duplex outcome measures in our NHS treatment environment. 
The results indicate that UGFS is less expensive on the background of comparable 
effectiveness in terms of abolition of AK GSV reflux, disease specific QoL, clinical 
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severity and VFI improvements. There was also significantly shorter treatment 
duration, reduced post-operative pain, reduced analgesia requirements and an earlier 
recovery time in the UGFS group. However, 6% of EVLA patients and 56% of UGFS 
patients required additional sclerotherapy to complete their treatment which resulted 
in higher adjuvant costs for the UGFS group.   
 
15.52 Cost analysis 
The median costs for EVLA were considerably more expensive than UGFS (£724.72 
versus £230.24). These costs were calculated from the ground up (micro-costing) and 
did not include overheads from the capital and running costs of a public hospital. 
Outpatient follow-up appointments, re-attendances, opportunity costs, primary care 
costs and socioeconomic costs were all excluded from this analysis. Furthermore, 
patients in high socioeconomic classes are likely to have been treated in the private 
healthcare system, where loss of earnings from days off work would have a greater 
socioeconomic impact. Prices could not be compared because the Department of 
Health price tariff for an elective day-case primary unilateral VV procedure without 
complications was the same, irrespective of the type of treatment. This was set at 
£1,098 (HRG code QZ10B) (DepartmentOfHealth 2011). 
 Costing from the ground up allows for a sensitivity analysis, a process where 
the impact of expensive elements of a cost calculation can be assessed by their 
removal from the analysis. The cost of EVLA could be reduced if the procedure is 
performed in a clinical room in day surgery with reduced staff comprising of one 
surgeon, a nurse and a health care assistant (HCA).  The actual costs however, have 
been provided (Table 15.3) using micro-costing in our setting. In contrast to a recent 
randomised clinical trial (Rasmussen, Lawaetz et al. 2011), price (reimbursement) 
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was not added to cost. Also procedure times, not surgeons times, were used in our 
calculations.  
 Further reductions, at least in terms of disposables, could also be made if 
EVLA is performed bilaterally (Janne d'Othee, Faintuch et al. 2008). The main 
reasons for the high EVLA costs in our setting, was because the procedure was of low 
volume and performed in main theatres. It was a multi-specialty setting with multi-
disciplinary nurses and a training environment for the assistant surgeon. Furthermore, 
concurrent stab phlebectomies increased the initial procedure time. The cost for 
EVLA is likely to be less with another set-up.  
 
15.53 Duplex outcomes 
The definition of duplex success in this study was very strict as concurrent AK GSV 
reflux, even in the presence of occluded areas, was considered inadequate treatment. 
Reflux (> 0.5 sec) indicates that there may be a significant remaining varicose 
reservoir or re-entry perforating vein. This can occur at the SFJ with reflux into an 
AASV or thigh tributary from the GSV, or at the distal end with reflux into calf 
tributaries from an incompetent GSV below an occlusion (Theivacumar, 
Dellagrammaticas et al. 2008). The abolition of GSV reflux from the onset may 
reduce recurrence, a hypothesis which needs to be tested at the long term follow-up. 
 Theivacumar and colleagues (Theivacumar, Dellagrammaticas et al. 2008) 
stated that if BK-EVLA was performed in all of their study patients it may have 
improved the duplex outcomes Advances in duplex assessment criteria are justified 
because they may be able to highlight deficiencies of technique and areas of 
inadequate treatment, at least in haemodynamic terms.    
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 This study was powered, based on a meta-analysis comparing EVLA to UGFS 
(van den Bos, Arends et al. 2009). Success in these studies was defined in terms of 
occlusion, irrespective of length of obliterated GSV or co-existing areas of reflux. As 
shown in Table 15.5, 9 patients in each group had reflux within the AK-GSV at 3 
months and of these, 7 EVLA and 4 UGFS patients demonstrated occlusion across the 
entire cross-sectional area of the GSV. These occlusion results are marginally less 
than those reported in the meta-analysis cited figures at 3 months (EVLA: 89.1% 
versus 92.2%; UGFS: 77.8% versus 82.1%). A possible explanation for this may be 
that our definition of competency as an outcome was very strict and may have 
included patients which other groups would have considered as occlusion. It remains 
to be seen whether the results will be maintained after a longer follow-up. The 
expectation is that the occlusion and reflux rates will be equivalent because of the 
open access policy of further sclerotherapy to both groups, as and when required 
(Kalodiki, Lattimer et al. 2011).  
 
15.54 Quality of life 
The AVVQ, demonstrated a greater improvement in the EVLA group at 3 months 
compared to UGFS but this was not significant (P = 0.062), Table 15.6. At 3 months 
the AVVQ changes within both groups were significant (P < 0.0005) and both 
exceeded the minimally important difference value of 2.4, making them clinically 
relevant (Browne, van der Meulen et al. 2009). 
 
16.55 Pain and recovery 
It is apparent from other randomised controlled trials which report pain after EVLA 
that this occurs up to the 10th post-operative day (Shepherd, Gohel et al. 2010; 
 312 
Rasmussen, Lawaetz et al. 2011). This is in agreement with the current study where 
daily pain scores over 7 days have been charted (Fig 15.2). The time taken to return to 
normal activities however is much longer in the current study compared with others 
(Shepherd, Gohel et al. 2010; Rasmussen, Lawaetz et al. 2011), with a median of 7.5 
days for EVLA and 3 days for UGFS.  Patients were specifically asked to record the 
time taken for them to return to normal activities and recover. It may be that patients 
in pain do not feel that they have recovered from the procedure irrespective of 
whether they may be able to perform routine activities. A relationship between post-
procedural pain and time to recovery was identified in this study, as illustrated in Fig 
15.3.  Radial laser fibres and radiofrequency techniques have recently been 
acknowledged to produce less post-procedural pain which may therefore result in 
shorter recovery times (Rasmussen, Lawaetz et al. 2011). 
 
15.56 Vein calibre 
The GSV diameter was 8 mm or above in 27 patients allocated to UGFS. Foam is 
known to have inferior results in large calibre veins (Kakkos, Bountouroglou et al. 
2006; Gonzalez-Zeh, Armisen et al. 2008) and is also associated with a higher rate of 
proximal thrombus extension into the femoral vein (Lawrence, Chandra et al. 2010). 
Tumescence was used to reduce GSV calibre in UGFS patients with a GSV > 8 mm 
in diameter, with catheter direction to facilitate foam delivery into its site of action 
(Parsi 2009). This was intended to standardise the pre-procedural preparation of the 
GSV in order to make the two groups, EVLA and UGFS, more comparable. 
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15.57 Socio-economic costs 
Socioeconomic costs were excluded from the study. However, every time the 
treatment needs to be repeated, although inexpensive, the loss of work is an important 
cost for society. This fact, together with previous observations of a greater recurrence 
rate in the UGFS group (van den Bos, Arends et al. 2009; Rasmussen, Lawaetz et al. 
2011), may make the cost of UGFS to society higher in the long term. 
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CHAPTER  16 
 
 
 
CLINICAL TRIAL  II 
 
 
 
Interim comparisons between laser and foam 
 
 
Without deviation from the norm, progress is not possible 
 
-- Frank Zappa 
 
 
16.1   Introduction 
Endovenous laser ablation (EVLA) (Rasmussen, Bjoern et al. 2007; Carradice, 
Mekako et al. 2009), ultrasound-guided foam sclerotherapy (UGFS) (Darvall, Bate et 
al. 2009; Kalodiki, Lattimer et al. 2011) and radiofrequency ablation (RFA) (Vasquez, 
Wang et al. 2007; Shepherd, Gohel et al. 2010) are popular established treatments for 
VVs which may eventually replace saphenous stripping (Fischer, Linde et al. 2001; 
Winterborn, Foy et al. 2008). The early results of the present randomised clinical trial 
(RCT) comparing local anaesthesia EVLA with concurrent phlebectomies versus 
UGFS into the GSV revealed that laser was more expensive, with higher post-
procedural pain scores, greater analgesia requirements and a longer recovery time but 
the efficacy in abolishing saphenous reflux was similar (Lattimer, Azzam et al. 
2012b). The poor results of above-knee (AK) laser occlusion without reflux (73.9%) 
(Lattimer, Azzam et al. 2012b), compared to other studies (van den Bos, Arends et al. 
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2009), were attributed in part to choosing reflux abolition as the endpoint rather than 
the presence or absence of occlusion on the GSV. When success was defined as AK 
saphenous occlusion at some point, irrespective of co-existing areas of remaining AK 
reflux, then the 3 month results were 89.1% for EVLA and 77.8% for UGFS 
(Lattimer, Azzam et al. 2012b). The reality is that many studies use GSV occlusion 
ignoring the reflux status, as the endpoint of success. This makes the high AK GSV 
reflux rate in the EVLA group of the early results clearly inferior. Contrary to the 
expectation that all UGFS patients would require supplementary foam to complete the 
treatment for the varicose tributaries only 56% of the UGFS patients required 
subsequent sclerotherapy for those varicosities which were not targeted at the initial 
treatment. 
 This interim report focuses on reflux outcomes and the different ways of 
assessing and defining reflux as a clinical endpoint. Reflux is the therapeutic target 
and it would seem logical that its abolition should be the preferred outcome variable. 
This is in contrast to the occlusion endpoint that is not present at baseline.  
 
16.2   Aims 
The aim is to present the interim results of this RCT on improvements in clinical 
severity, quality of life (QoL) and to focus on assessing the abolition of saphenous, 
varicose and perforating vein reflux on ultrasound. Occlusion will be compared with 
total reflux abolition and validated against questionnaires’ assessment. 
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16.3   Patients and Methods 
16.31 Study design 
This study was a prospective RCT on patients with exclusive primary superficial 
venous insufficiency at Ealing hospital that commenced in April 2009. The early 
results were presented in Chapter 15. The primary RCT outcome was GSV occlusion. 
The hospital serves a multicultural and multiethnic population with many patients 
presenting late in their disease. A total of 191 patients were assessed for eligibility, 
110 patients (110 legs) of whom were randomised. Fifty received EVLA with 
concurrent phlebectomies under local anaesthesia and 50 received UGFS which was 
injected directly into the GSV. The CONSORT (Moher, Schulz et al. 2005) flow chart 
of patient disposition, inclusion and exclusion criteria, power calculations and the 
treatment methodology have been documented in detail in the early report in chapter 
15; therefore only a brief description will be given. This interim report focuses on 
reflux. It includes the baseline assessments, evaluations and results relating to the 44 
EVLA and 46 UGFS patients who completed their interim follow-up. It needs to be 
emphasized that the reflux is not necessarily related to the GSV treated segment. 
Reflux evaluations include all reflux in the treated lower limb, including tributaries 
and perforating veins. The outcome studied in this interim report was therefore 
differences between both groups in terms of global/total reflux abolition.  
 
16.32 Endovenous procedures 
The techniques of EVLA, UGFS and T-UGFS have been described in detail in 
chapter 2 (sections 2.51 – 2.53) and chapter 15 (sections 15.33 – 15.35). 
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16.33 Adjuvant sclerotherapy 
This was performed in the office 2 to 3 weeks after the 3 weeks follow-up visit. In the 
early report, this was performed on the UGFS group, if required, in order to complete 
their treatment of refluxing tributary disease. In both groups, the decision to offer 
adjuvant sclerotherapy was based on patient choice following the detection of reflux. 
They were informed of the duplex findings, told of the < 1% risk of a DVT and a 
<10% risk of hyperpigmentation and the need to wear a stocking for 3 weeks. An 
aggressive approach to the eradication of all areas of reflux was not advocated. Most 
foam injections were administered into tributaries using a 21-gauge butterfly needle. 
   
16.34 Duplex assessment 
All ultrasound examinations were performed using a 7-MHz linear array probe fitted 
into a Titan® portable ultrasound scanner. Non-compressibility with the duplex 
transducer head was used to confirm occlusion. Manual calf compression with release 
and Valsalva manoeuvres (Lattimer, Kalodiki et al. 2012c) were used to induce 
antegrade flow and reflux in order to determine the state of patency and competency 
of the segment of vein under examination. Reflux was defined as reverse flow lasting 
> 0.5 sec in the GSV (van Bemmelen, Bedford et al. 1989). Significant tributary or 
perforating vein reflux was defined by the ultrasonographer. The reports were drawn 
onto templates of superficial venous anatomy using in-fills to represent the length of 
occlusion and directional arrows for the extent of competency or reflux of the 
saphenous trunks and tributaries. Standardised symbols were used to annotate the 
origins of tributary and perforating vein reflux. This was supplemented with a written 
report. Patients received a duplex examination at 3 weeks after their treatment as a 
routine screen to exclude DVT. 
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16.35 Severity and quality of life outcomes 
The physician recorded VCSS (Rutherford, Padberg et al. 2000) and the patient 
reported disease specific QoL AVVQ (Garratt, Macdonald et al. 1993) were used to 
assess the impact of treatment between the 2 groups. Both were completed at baseline, 
3 weeks, 3 - 5 months and at the interim follow-up time point. At the beginning of the 
study the C part of the CEAP classification was used to determine the stage of the 
disease (Eklof, Rutherford et al. 2004). In addition, the VFI of APG (Christopoulos, 
Nicolaides et al. 1988b) and the GSV diameter (Navarro, Delis et al. 2002; Mdez-
Herrero, Gutierrez et al. 2007) were used to assess haemodynamic severity at 
baseline. At the interim period the VCSS and AVVQ were completed before the 
duplex scan and before any additional sclerotherapy, if required. 
 
16.36 Saphenous treatment score 
This is a flexible duplex-derived scoring system which evaluates the effect of 
treatment on the haemodynamic status of the GSV above and below the knee 
(Lattimer, Kalodiki et al. 2012b). Points are given for reflux = 3 competency = 2 and 
occlusion = 1, which are then prioritised, based on the objectives of treatment and the 
presence of failure. The score ranges from 2 - 6 with 6 representing the presence of 
both AK and BK reflux and 2 representing AK and BK occlusion, but only if the 
occlusion occurs in the absence of reflux. It has been shown to be useful in the 
presence of co-existing patterns of treatment effect but is limited in that the 
assessment does not take into account tributary or perforating vein reflux. However, it 
provides a more specific and detailed report on the GSV than the VSDS (Rutherford, 
Padberg et al. 2000). 
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16.37 Statistical analysis 
The data were entered into Excel® spreadsheets and imported into IBM® SPSS® 
statistics package version 19 for Windows® for statistical analysis. In patients with 
bilateral disease, only the worst leg was chosen for the analysis. The primary RCT 
outcome measure was GSV occlusion detected using duplex. This is the outcome 
from which the power calculations were based. An additional outcome measure of 
interest in this study is the difference in global venous reflux between both groups. 
Improvement was defined as the difference between the pre-treatment score and the 
interim score so the EVLA and UGFS groups could be compared using the Mann-
Whitney U test. Improvement within groups was compared using the Wilcoxon 
matched-pair signed-rank test. A multivariate logistic regression analysis was 
performed on the following 10 variables assumed to be predictive in establishing 
whether the patients required adjuvant foam treatment: treatment group, sex, age, 
GSV diameter, VCSS, question 2 of VCSS, AVVQ, question 1 of AVVQ, VFI and 
the VFT90 (venous filling time to reach 90% of the total venous volume). Most of 
these variables are markers of disease severity which is why they were chosen. 
Question 2 of the VCSS and question 1 of the AVVQ both quantify the extent and 
distribution of varicose veins (Lattimer, Kalodiki et al. 2012a).   
 
16.4   Results 
16.41 Patient baseline characteristics 
The baseline characteristics of the 44 EVLA and 46 UGFS patients who completed 
the interim part of the RCT are shown in Table 16.1. The patients were C2-6EpAsPr 
and equally matched with approximately 50% in the later stages of disease, ≥ C4 of 
CEAP, and with GSV diameters ≥ 8 mm. Although the overall Chi square was not 
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significant at baseline, the EVLA group had significantly more patients with C2 (P < 
0.05 using Chi square with Yates correction). The fact that the EVLA group had 
significantly more patients in the earlier stages of venous disease should be taken into 
account in the analysis. The median (IQR) follow-up was 15 (12-18) months. 
 
 
Table 16.1  Baseline characteristics between the EVLA and UGFS patients (legs). 
Median values, IQR and percentages are presented unless specified otherwise. 
 
 
EVLA Group 
n = 44 
UGFS Group 
n = 46 
P value 
Mean age (range) 47.3 (21-74) 49.6 (23-78) 0.486a 
Female    27 (61%)    25 (54%) 0.501b 
Bilateral disease    25 (57%)    31 (67%) 0.301b 
C of CEAP     
     C2 19 (43%)   9 (20%)  
     C3   6 (14%)   9 (20%)  
     C4 14 (32%) 21 (45%)  
  C5, 6   5 (11%)   7 (15%)  
   0.285c 
VCSSe      6 (5-7.8)      6 (5-9) 0.278d 
AVVQf     20 (14-27.9) 24.3 (16.3-30) 0.290d 
GSVg diameter (mm)      7 (6.1-8.5)      8 (6.2-9) 0.246d 
STSh      6 (5-6)      6 (5-6) 0.144d 
VFIi (mL/sec)   4.7 (3-7)   5.9 (3.5-7.9) 0.399d 
VFT90j (sec) 20.4 (14.2-23.9) 18.1 (13.6-24.3) 0.684d 
 
a
 t-test; b Chi-square test; c Chi-square of 6.23; d Mann-Whitney U test;  
e VCSS = Venous clinical severity score; f AVVQ = Aberdeen varicose vein 
questionnaire; g GSV = Great saphenous vein; h STS = Saphenous treatment score;      
i VFI = Venous filling index; j VFT = Venous filling time. 
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16.42 Duplex outcomes 
Since reflux defines disease from an endovenous treatment perspective, the absence of 
reflux was used to define technical success. Using this criterion, 18/44 (41%) EVLA 
and 20/46 (43%) UGFS patients achieved success at 15 months, as shown in Table 
16.2, which is a detailed inventory of all the sites of recurrent reflux. If GSV 
occlusion is used as an endpoint these results differ at 42/44 (95.5%) for EVLA and 
31/46 (67.4%) for UGFS in achieving success (P = 0.001, Fisher exact test). These 
and other definitions of success are shown in Table 16.3. Interestingly, 2/44 (4.5%) in 
the EVLA group and 9/46 (19.6%) in the UGFS group achieved full competency of 
their AK GSV without occlusion (P = 0.059, Fisher exact test). 
 
 
Table 16.2  Summary of duplex outcomes on 100 legs in the EVLA and UGFS 
groups at 15 months. 
 
Duplex outcome EVLA UGFS 
Lost to follow up 6 4 
Success   
   Normal (no reflux or occlusion) - 5 
   AK-GSVa & BK-GSV obliteration in the absence of reflux - 2 
   AK-GSV obliteration and no AK or BK or tributary reflux 18 12 
   BK-GSV obliteration and no AK or BK or tributary reflux - 1 
Above knee (AK) outcomes   
   AK-GSV reflux & distal thigh GSV tributary reflux - 1 
   AK-GSV reflux - 1 
   Distal thigh GSV reflux & distal thigh perforator reflux 1 - 
   AASVb reflux & distal thigh GSV tributary reflux - 3 
   Distal thigh AASV tributary reflux 1 - 
   Proximal thigh GSV tributary reflux 1 - 
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   Mid-thigh GSV tributary reflux (AK-GSV competent) - 1 
   Mid-thigh GSV tributary reflux 1 1 
   Distal thigh GSV tributary reflux 2 1 
Below knee (BK) outcomes   
   BK-GSV & proximal calf tributary reflux (AK-GSV competent) - 1 
   BK-GSV & distal calf tributary reflux (AK-GSV competent) - 1 
   BK-GSV reflux 3 2 
   BK-GSV reflux & popliteal vein reflux 1 - 
   BK-GSV reflux & proximal calf GSV tributary reflux - 1 
   BK-GSV reflux & mid calf GSV tributary reflux 1 - 
   BK-GSV reflux & mid calf perforating vein reflux 1 1 
   Mid calf perforating vein reflux 3 - 
   Distal calf perforating vein reflux 1 2 
   Proximal calf GSV tributary reflux 2 2 
   Proximal calf SSVc tributary reflux - 1 
Mixed outcomes   
   AK-GSV & BK-GSV reflux & proximal calf GSV tributary 1 - 
   AK-GSV reflux & mid thigh tributary & distal perforating vein - 1 
   AK-GSV reflux & proximal calf GSV tributary reflux 1 3 
   Mid thigh GSV tributary & BK-GSV reflux 1 - 
   Mid & distal thigh GSV reflux & calf GSV reflux - 1 
   Distal thigh GSV reflux & calf GSV reflux 1 - 
   AASV reflux & BK-GSV reflux 1 - 
   Distal thigh/distal calf GSV reflux - 1 
   Distal thigh/proximal calf GSV & mid calf perforating vein reflux 1 - 
   Distal thigh/proximal calf GSV reflux & SSV reflux 1 - 
   Distal thigh/proximal calf GSV & proximal calf GSV tributary 1 1 
TOTAL 50 50 
 
aGSV = Great saphenous vein; bAASV = Anterior accessory saphenous vein; cSSV = 
Small saphenous vein.  
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Table 16.3  Successful outcome variations on the GSVa reported with duplex after 
endovenous treatment. 
 
DUPLEX OUTCOME (15 months) EVLA 
n = 44 
UGFS 
n = 46 P value
c
 
GSV occlusion at some point in the thigh 42 (95.5%) 31 (67.4%) 0.001 
GSV occlusion of entire thigh length 35 (80%) 24 (52.2%) 0.011 
GSV occlusion thigh and upper 1/3 calf 9 (20.5%) 9 (19.6%) 1.000 
GSV occlusion without refluxing segments 29 (65.9%) 24 (52.2%) 0.267 
GSV competency of entire thigh lengthb 2 (4.5%) 9 (19.6%) 0.059 
Addition of last 2 rows 31 (70.4%) 33 (71.7%) 1.000 
 
aGSV = Great Saphenous Vein; bWithout occluded segments; cFisher exact test 
 
 
 
16.43 Validated outcome assessments 
The VCSS, AVVQ and the STS all significantly improved (P < 0.0005, Wilcoxon) at 
the interim follow-up as a result of treatment as shown in Fig 16.1. However, the 
differences between the groups at the baseline and interim time points were not 
significant and neither were the differences in improvement between the groups 
(Table 16.4). There was also no significant difference in the AVVQ between 3 
months and the interim follow-up. However, it is noteworthy that at 3 months post 
treatment the AVVQ significantly favoured EVLA (P = 0.019).    
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Figure 16.1  There was no significant difference (Mann-Whitney U test) between the 
groups at 15 months in respect of the (a) venous clinical severity score (VCSS: P = 
0.138), (b) Aberdeen varicose vein questionnaire (AVVQ: P = 0.194) or the (c) 
saphenous treatment score (STS: P = 0.749). However, all parameters significantly 
improved within both groups at P < 0.0005 (Wilcoxon). 
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Table 16.4  All patient summary of clinical, QoL and haemodynamic outcomes on 
patients randomised into EVLA versus UGFS. 
 
Improvementa EVLA (n=44) UGFS (n=46) P valueb 
3 months    
   VCSSc  5 (3 - 5) 4 (3 - 6) 0.796 
   AVVQd 14 (7.9 – 20.6) 8 (3.5 – 15.3) 0.019 
   STSe 2 (1-3) 2 (1.3 - 4) 0.148 
15 months    
   VCSS 5 (3.3 - 6) 5 (3 - 6) 0.902 
   AVVQ 12.2 (6.8 – 18) 9.5 (2.4 – 15.6) 0.276 
   STS 2 (1 - 3) 2 (1 - 3) 0.866 
 
aPre-treatment score minus post-treatment score; bMann-Whitney U test; cVCSS = 
Venous clinical severity score; dAVVQ = Aberdeen varicose vein questionnaire; eSTS 
= Saphenous treatment score. 
 
 
 
16.44 Tumescent foam outcomes 
Tumescence-assisted UGFS was performed in the 25 patients/legs with a GSV 
diameter ≥ 8 mm. Since larger veins are known to be less responsive to treatment 
(Gonzalez-Zeh, Armisen et al. 2008) the T-UGFS legs were compared to the 17 
EVLA legs with similarly sized GSVs in a subgroup analysis, as shown in Table 16.5. 
There was no significant difference in the degree of improvement in the VCSS, 
AVVQ or the STS at 15 months when compared to baseline.  
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Table 16.5  Subgroup analysis of patients having GSVa diameters ≥8 mm. Summary 
of clinical, quality-of-life and haemodynamic outcomes on patients randomised into 
EVLA versus tumescence-assisted UGFS. 
 
Improvementb EVLA (n=17) T-UGFS (n=25) P valuec 
3 months    
   VCSSd  5 (4 - 5) 4 (3 - 6) 0.554 
   AVVQe 13.6 (10.2 – 19.2) 11.3 (6.0 – 16.3) 0.230 
   STSf 1 (0 - 2) 3 (2 - 4) 0.014 
15 months    
   VCSS 4 (4 - 6) 5 (3 - 7) 0.897 
   AVVQ 12.3 (8.6 – 18.1) 13.3 (7.3 – 16.8) 0.908 
   STS 2 (0 - 3) 3 (2 - 3) 0.076 
 
aGSV = Great saphenous vein; bPre-treatment score minus post-treatment score; 
cMann-Whitney U test; dVCSS = Venous clinical severity score; eAVVQ = Aberdeen 
varicose vein questionnaire; fSTS = Saphenous treatment score. 
 
 
 
 
16.45 Adjuvant foam requirements 
A multivariate logistic regression analysis on 10 variables assumed to be predictive 
for adjuvant sclerotherapy revealed patient group UGFS as the only significant 
parameter (P < 0.0005, OR: 0.103; 95% CI: 0.035 to 0.307). The other 9 variables 
were not significant: sex (P = 0.786), age (P = 0.273), GSV diameter (P = 0.562), 
VCSS (P = 0.361), question 2 of VCSS (P = 0.072), AVVQ (P = 0.847), question 1 of 
AVVQ (P = 0.452), VFI (P = 0.155), VFT90 (P = 0.728). As shown in Fig 16.2, 10 
EVLA and 47 UGFS legs received adjuvant sclerotherapy from the beginning of the 
study making additional treatment 4.7 times more frequent in the UGFS group. The 
frequency of additional treatment decreased with time with the UGFS patients 
requiring more treatment sessions early in the follow-up. During the interim follow-up 
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period, 19/46 (41%) UGFS versus 9/44 (20%) EVLA legs received adjuvant treatment 
(2.1 times more frequent). However, by 20 months, there was equivalence with 4/12 
patients (2 from each group). 
 
Figure 16.2  The number of legs that received adjuvant sclerotherapy from the 
beginning of the study. 
 
 
 
16.46 Complications 
In contrast to the early results, there were no complications as a result of adjuvant 
sclerotherapy or stocking use. Side-effects like hyper-pigmentation and superficial 
vein thrombosis occurred in many patients. However, in the absence of strict 
definitive criteria between side-effect and treatment effect, in the 
multiethnic/multicultural study population, these could not be quantified in a 
meaningful way. None of the patients developed a DVT/PE or a neurological side-
effect after injection.  
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16.5   Discussion 
16.51 Global duplex outcome evaluations 
Heterogeneity of reporting standards in RCTs for varicose veins was highlighted 
recently with only 21/28 (75%) of trials using duplex to assess recurrence (Thakur, 
Shalhoub et al. 2010). When used, the outcome evaluation of endovenous treatment is 
usually limited to the effectiveness of a particular technology in occluding the 
saphenous trunks (not varicose veins) and using the term recanalisation as the 
definition of failure (van den Bos, Arends et al. 2009). A joint statement from the 
American Venous Forum and the Society of Interventional Radiology on 
recommended reporting standards made an important distinction between a 
“technology assessment (eg, successful ultrasound-proven ablation of the target vein)” 
and the usefulness “to report the presence or absence of reflux in other ultrasound-
evaluable major lower extremity veins” (Kundu, Lurie et al. 2007). This study has 
welcomed this recommendation by reporting both ultrasound outcomes and also 
validated this advice in 2 ways. Firstly by demonstrating that tributary and perforating 
vein reflux can occur irrespective of the treatment on the GSV and secondly by 
reporting the presence of post-treatment reflux in non-axial veins. Furthermore, the 
significance of BK reflux, frequently ignored in technology assessments, was 
highlighted by duplex evidence that reflux often commences from the distal GSV, 
supporting the ascending theory, with the thigh GSV remaining competent and 
therefore less significant to the disease process (Labropoulos, Giannoukas et al. 
1997). 
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16.52 Saphenous conservation 
The techniques of CHIVA (Pares, Juan et al. 2010) and ASVAL (Pittaluga, Chastanet 
et al. 2009) are widely practiced in Europe with an aim to restore competency in a 
refluxing GSV by focusing on the treatment of tributaries and perforating veins 
(Zamboni, Cisno et al. 2001). This study has shown that EVLA and UGFS were able 
to restore competency in the AK GSV in 4.5% and 19.6% of patients, respectively 
(Table 16.3). The mechanism of action is unknown. It may be due to GSV sclerosis 
with valve approximation (unproven) or by reducing the GSV inflow through a 
reduction in the varicose reservoir (Pittaluga, Chastanet et al. 2010). Since both 
EVLA and UGFS have the intention to occlude and abolish reflux in the treated 
segment, then according to “technology assessment” this is a complete failure. 
However, the abolition of reflux, without occlusion, is nonetheless a favourable 
outcome if reflux abolition is used as one endpoint, as it is in this study, and also 
according to a minority of European surgeons (Carandina, Mari et al. 2008). 
However, the long term results of these studies are awaited with interest to determine 
if the recurrence rate will be higher. 
 
16.53 Saphenous destruction and recurrence 
There is commercial interest in providing the best technology that destroys the GSV. 
Laser (Disselhoff, der Kinderen et al. 2011), radiofrequency (Shepherd, Gohel et al. 
2010), steam (van den Bos, Milleret et al. 2011), mechano-chemical innovations 
(Elias and Raines 2012) and glue (Proebstle and Almeida 2011) are all expensive and 
all report excellent results. However, it is not clear whether GSV occlusion hastens 
the onset of recurrent varicose veins by the expansion of alternative drainage 
pathways. This study focuses on the global assessment of the leg in terms of reflux 
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abolition and “recurrent” varicose veins (Perrin, Guex et al. 2000). It also clarifies 
why our early results of EVLA were significantly less favourable that those reported 
in other studies (Schneider 2012). A standard definition of duplex success is 
paramount in the evaluation of different technologies in treating VVs. The decision as 
to whether residual/recurrent saphenous reflux is more important to the patient than 
residual/recurrent tributary reflux is a matter for the reader to decide. However, in this 
study patients were given the option of late adjuvant sclerotherapy and after 20 
months, only 4/12 (33.3%) legs received supplementary treatment, 2 in each group 
(Fig 16.2). This reveals that duplex evidence of reflux is mostly symptomless, not 
requiring treatment, a point that was reported in a previous RCT (Kalodiki, Lattimer 
et al. 2011). In spite of the additional foam sclerotherapy requirements (n = 9/44 
EVLA, n = 19/46 UGFS) the significant increase of reflux between the early and 
interim time points was not associated with deterioration of the AVVQ. Thus the 
apparent haemodynamic deterioration had no measurable clinical impact on the QoL 
of the patients. Patients are treated initially for the symptoms of venous insufficiency 
but later on this may change for a cosmetic reason. 
 
16.54 Outcomes in comparison to other studies 
All RCTs, with few exceptions, report that the VCSS and the AVVQ improve after 
treatment. This study has confirmed this and has also reported that there were no 
significant differences in improvement between the 2 groups. The study population 
was relatively homogenous with the same number of patients as legs, an even spread 
between the early and late stages of clinical severity and the exclusion of patients with 
SPJ incompetence, deep venous reflux and recurrent disease.   
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 This study reports an interim GSV occlusion rate of 95.5% with EVLA and 
67.4% with UGFS, as shown in Table 16.3 (first row). These laser results are similar 
to the results of a recent RCT at 1 year which reported GSVs that were successfully 
treated at 94.2% for EVLA and 83.7% for UGFS (Rasmussen, Lawaetz et al. 2011). 
The estimated pooled success rates at 12 months from an earlier meta-analysis on 64 
studies from which our power calculations were based were 93.3% for EVLA and 
80.9% for UGFS at a P = 0.021 (van den Bos, Arends et al. 2009). Thus there were 
significant differences between the treatments in that RCT. The results of our study, 
using occlusion as an endpoint, were also significantly different at 15 months 
(P=.001) as shown in Table 16.3 (first row).  
 However, if the abolition of reflux in the saphenous veins, varicose tributaries 
and perforating veins in the leg are used as a measure of success, then the results are 
markedly different at 41% for EVLA and 43% for UGFS. Interestingly, the use of 
reflux abolition as an endpoint is comparable to the results with the other assessments, 
none of which were significant between the groups. On a consecutive cohort of 100 
patients following conventional surgery for 10 years, only 30% were completely free 
of recurrent VVs, although 77% reported that their symptoms were much better or 
cured (Campbell, Vijay Kumar et al. 2003). They commented that “success” rates 
vary substantially, depending on the method of assessment. 
 The early results reported the cost of each treatment using a micro-costing 
approach from the ground up based on staff pay, procedure location and overheads. In 
that study the mean cost per patient (leg) for EVLA versus UGFS was £720.64 versus 
£151.44, respectively. The cost of adjuvant sclerotherapy per patient was £68.05, 
excluding the cost of a stocking and £95.62 including one for the EVLA patients since 
they did not have a stocking to reuse. From this study the cost of the extra foam 
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sessions (10 EVLA and 47 UGFS) would compute a total cost per patient of £742.37 
(720.64 + (95.62 x 10/44)) for EVLA and £220.97 (151.44 + (68.05 x 47/46)) for 
UGFS.    
 
16.55 Limitations 
This RCT was not powered to detect differences between EVLA and UGFS regarding 
global venous reflux. However, given that there was no significant difference between 
the results in the 90 patients, if these were used in power calculations, a very much 
larger study would be required to detect significant change.  
 The extent to which refluxing tributaries and perforating veins are ascribed to 
residual veins, recurrence or the expansion of pre-existing alternative drainage 
pathways is not known. However, patients with significant reflux from a non-
saphenous or SPJ origin were excluded from the study at the outset: they all had 
significant SFJ reflux extending down to at least 10 cm of the GSV. An ultrasound 
protocol to include identification of all tributaries introduces 3 problems. Firstly, 
variations in venous anatomy make it impossible for a protocol to be consistent. 
Secondly, ultrasound criteria for reflux in tributaries and small veins do not exist. 
Thirdly, flow towards the foot is not necessarily reflux if they are drainage veins. 
Furthermore, reproducibility studies would be useful on the identification and reflux 
evaluation of specific tributaries since there are no published data in such protocols. 
Use of a newer radial laser fibre, utilising a greater wavelength, combined with an 
aggressive treatment approach to the BK part of the GSV (extended EVLA) would 
have improved the results in terms of reflux abolition (Theivacumar, 
Dellagrammaticas et al. 2008). However, the EVLA group was offered UGFS 
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(Theivacumar, Darwood et al. 2009), if required and, as shown in Table 16.2, this was 
not the cause of reflux in many of the patients at the interim follow-up period.    
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CHAPTER 17 
 
 
 
CLINICAL TRIAL  III 
 
 
 
Comparison between stocking class and length in PTS 
 
 
An approximate answer to the right question is worth a good deal 
more than an exact answer to an approximate question. 
 
-- J. W. Tukey 
 
 
17.1   Introduction 
Elastic graduated compression (EGC) stockings are an established intervention for the 
prevention (Giannoukas, Labropoulos et al. 2006; Kakkos, Daskalopoulou et al. 2006; 
Aschwanden, Jeanneret et al. 2008; Lowe 2010) and the treatment of the post 
thrombotic syndrome (PTS) (Kahn 2010). Although clinical evidence of their efficacy 
is proven, the optimal compression strength or length of stocking required to achieve 
this is not known. Furthermore, there is usually a trade-off between compression 
strength and length of stocking against compliance. Stronger or longer stockings are 
perceived to be better but are also perceived to be harder to apply and wear for longer 
periods. Many physicians are rigid in their prescribing insisting that a below-knee 
(BK) or above-knee thigh length (AK) GEC stocking is better. A class II (23-32 
mmHg) stocking is usually chosen over a class I (18-21 mmHg), and measuring charts 
are relied upon to select the appropriate size for that patient. This takes place usually 
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without the patients themselves testing and wearing the various stockings that are 
available in order to state their preference. Lack of compliance often hampers the 
results of clinical trials comparing stockings in the prevention and treatment of PTS. 
Therefore an objective assessment of stocking performance, using improvements in 
haemodynamic parameters, may provide meaningful information as to the optimal 
stocking at treating PTS. 
   
17.2   Aims 
The main hypothesis is to test a common assumption that the greater the length and 
compression of stocking, the greater the immediate reduction in reflux, the main 
pathophysiological abnormality in PTS. The aim was to examine objectively which 
strength or length of stocking was the most effective at reducing reflux. A secondary 
aim was to evaluate patient preferences as to which GEC stocking they would prefer 
to wear having tried and tested all 4 alternatives during the study session.  
  
17.3   Patients and Methods 
17.31 Study design 
This was a prospective study on 34 consecutive patients (40 legs) with PTS at Ealing 
general hospital. Ethical approval for this study was granted by the North London 
(Region 3) Research Ethics Committee (REC: 11/LO/0345). All patients invited into 
the study had a prior diagnosis of PTS using criteria based on physical symptoms and 
clinical signs as recommended (Kahn, Partsch et al. 2009). They were given a 
participant information leaflet at the time of their follow-up visit from the venous 
clinic (29 patients) or were new referrals from the anti-coagulation clinic because of 
persisting leg symptoms (5 patients, all unilateral). Patients were given a study 
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appointment a week later and requested to wear their usual compression as prescribed 
by the vascular surgeon or family doctor. Written informed consent was obtained 
from all participating patients prior to the haemodynamic measurements. Inclusion 
criteria included patients with leg symptoms (ache, heaviness, swelling, cramps, 
itching or tingling) and signs (telangiectasiae, secondary VVs, oedema, pigmentation 
and ulceration) attributable to PTS, a previous DVT > 6 months old with duplex 
evidence of deep venous disease (reflux or obstruction or both). Exclusion criteria 
consisted of a recent < 3 months recurrent DVT or venous ulceration > 1cm diameter.  
Four different stockings were used to determine the best one at reducing reflux 
in that leg. Each patient acted as their own control. The stockings (Mediven® Plus 
open toe) were applied in random order using sealed envelopes. The 4 stockings used 
were: Class I and Class II, BK and AK (thigh length). Each AK stocking had a waist 
attachment but this was not applied around the waist during the test in order to avoid 
abdominal compression as a possible confounding variable in the APG measurement. 
The stocking size for the leg was determined by measuring the ankle circumference at 
the narrowest part and the calf circumference at its widest part. The appropriate 
stocking was then selected using the manufacturer’s sizing chart.  
 The C part of CEAP (Eklof, Rutherford et al. 2004), the VCSS (Rutherford, 
Padberg et al. 2000) and the VS (Kahn 2009) are established assessment 
questionnaires and were used to grade the clinical severity of PTS. The VSDS 
(Rutherford, Padberg et al. 2000) was determined with duplex and used to identify the 
type and extent of the haemodynamic impairment. All duplex evaluations were 
carried by an accredited vascular sonographer (MA) using a 7 MHz linear transducer 
attached to the Phillips ultrasound machine. Reflux duration of  > 1 second was 
considered significant for the deep veins (van Bemmelen, Bedford et al. 1989). 
 338 
Significant obstruction was defined as occlusion or > 50% narrowing of at least half 
of the segment of the examined vein (Rutherford, Padberg et al. 2000). The study 
session lasted approximately 1 hour. At the beginning of the session patients were 
informed that they would be asked to state their preferred stocking based on comfort. 
At the end of the session each patient was offered a prescription for their chosen 
stocking which was recorded. 
  
17.32 Stocking interface pressure 
This was measured using the PicoPress® transducer. This was chosen because it had 
the least coefficient of variation and the highest accuracy compared with two other 
instruments (Partsch and Mosti 2010a). The device comprises of a 50 mm diameter 
inflatable diaphragm (sensor), 0.2 mm thick, attached to a hand held transducer via a 
narrow tube (Al Khaburi, Nelson et al. 2011b) The sensor was placed between the 
stocking and the leg, 5 cm above and 2 cm posterior to the medial malleolus. Care 
was taken to ensure the sensor was flat by pulling on the connecting tube and by 
avoiding any bony prominences (Flaud, Bassez et al. 2010; Al Khaburi, Nelson et al. 
2011a). When 2 mL of air, quantified by a pre-calibrated syringe which is an integral 
part of the transducer apparatus, was injected into the sensor, the interface pressure 
was displayed on the screen. Dynamic measurements were taken lying and standing 
without the need to recalibrate the probe.  
 
17.33 Air-plethysmography 
Air-plethysmography (APG) comprises of a sensor air-cuff, an inflation pump, a 
pressure/volume transducer and processing software. The method has been described 
and validated previously (Christopoulos, Nicolaides et al. 1987). The sensor measures 
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changes in pressure which are calibrated to reflect changes in volume. The air-cuff 
was applied around the calf directly on the skin for baseline measurements and then 
over each stocking, while the patient was in the supine position. The APG values were 
taken from continuous recordings from the point at which the patient stood up 
preceded by a period of leg elevation. The venous filling index (VFI) in mL/sec is 
derived from the venous volume (VV) in mL divided by the venous filling time 
(VFT90) in sec which is the time taken to achieve 90% of the VV. All 3 parameters 
were recorded for each of the five tests. A VFI ≤ 2 mL/s was considered normal. The 
APG was used in preference to photo-plethysmography because it has been shown to 
be a better method of evaluating reflux (Bays, Healy et al. 1994), although inherent 
variations in method error of 13.4%, in measuring the VFI, are acknowledged (Yang, 
Vandongen et al. 1997). 
   
17.34 Statistical analysis 
Data were collected onto spreadsheets throughout the duration of the study and 
transferred into the IBM® SPSS® statistics package version 19 at completion. 
Improvement using APG was defined as the difference between the initial APG 
parameter values without compression from the values recorded using each stocking. 
The non-parametric Wilcoxon signed rank test was used to assess the significance of 
an improvement. Correlations between reflux without a stocking compared to 
improvements in VFI were performed using the Spearman rho test.  
 Pilot data from our department demonstrated a stepwise reduction in VFI from 
no stocking to a BK stocking and then with an AK stocking. Power calculations for a 
type I error (alpha) of 0.05 and a type II error (beta) of 0.2 revealed that a minimum of 
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36 legs were required to demonstrate a difference of 1.5 in the VFI between a BK and 
an AK stocking with a standard deviation of 2.  
 
17.4   Results 
17.41 Patient characteristics 
Forty legs (34 male, 23 left leg) from 34 consecutive patients (28 male) with PTS 
were studied. Six patients had bilateral disease. The median age was 62 (31-81) years. 
The distribution of the C part of the C0-6EsAs,d,pPr,o classification was: C0 = 2, C2 = 1, 
C3 = 3, C4a = 12, C4b = 7, C5 = 12, C6 = 3. Severity characteristics, leg measurements 
and stocking sizes are illustrated in Table 17.1. The calf cross-sectional area at its 
widest point was calculated by: circumference2/4π. It ranged from 2.1 to 4.0 times the 
value of the narrowest ankle cross-sectional area (median 2.7, IQR 2.5 - 3). 
 
 
Table 17.1  Characteristics of 40 legs studied.  
 
 
 Median IQRa Range 
Age 62 52 - 73 31 - 81 
VCSSb 8 5 - 10 1 - 21 
Villalta scale 10 5 - 14 2 - 22 
     Patient part 4 1 - 7 0 - 11 
     Physician part 5.5 3 - 9 0 - 13 
Calf circumference/mm 40 37 - 44 33 - 55 
Ankle circumference/mm 24 22 - 26 21 - 32 
Stocking sizec 4 3 - 5 1 - 7 
 
aInter-quartile range; bVenous clinical severity score; cBased on the Mediven® 
measuring chart. 
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17.42 Pattern of haemodynamic impairment 
The median VSDS as determined using duplex was 5 (2-10) out of a theoretical total 
score of 20. The median reflux and obstruction component of this score was 4 (0-7) 
and 1 (0-5), respectively indicating that there was more reflux than obstruction in the 
legs studied. The proportions of legs with reflux, obstruction or both are shown in Fig 
17.1. Of the legs with only reflux, 9/18 (50%) had concurrent reflux in the saphenous 
trunks. This compares to 6/19 (31.6%) legs with combined reflux and obstruction. 
None of the patients had complete occlusion of the femoral or popliteal veins or 
isolated calf pathology. 
  
 
 
Figure 17.1  Type and pattern of infra-inguinal venous disease in the study group 
according to the VSDS. The number of legs are given below the percentages. 
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Attempts were also made to match stockings based on anatomical sites and the 
patho-physiology of disease. When legs were divided into calf vein pathology and 
above (n=28, 70%) or popliteal vein pathology and/or above (n=12, 30%) the 
differences between the groups were not significant at BK I (P = 0.679), BK II (P = 
0.274), AK I (P = 0.275) and AK II (P = 0.184). Similarly, when legs were divided 
into reflux alone versus reflux and obstruction the results were: BK I (P = 0.171), BK 
II (P = 0.171), AK I (P = 0.186) and AK II (P = 0.224). There was a very poor 
correlation between the VSDS score and the change in VFI with a stocking (r = 0.166, 
P = 0.035), too weak for meaningful conclusions. The inferior vena cava and iliac 
veins were not assessed. 
 
17.43 Interface pressures 
As shown in Fig 17.2, the median interface pressure either reached or exceeded the 
pressure ranges stated by the manufacturer. The interface pressure was also 
significantly higher when standing than on lying. There was a significant but weak 
correlation (Spearman) between stocking pressure measured directly with the 
PicoPress® and the VFI improvement (baseline VFI – compression VFI) with all 4 
stockings at P = 0.005, r = 0.237. 
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Figure 17.2  Interface pressure 5 cm above and posterior to the medial malleolus in 
relation to stocking class and position. The dashed lines represent the manufactures 
compression specifications.  
 
 
 
17.44 APG parameters with different stockings 
The VFI, VFT90 and VV significantly improved with all types of stocking versus no 
compression. The values of each parameter are presented in Table 17.2. 
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Table 17.2  Changes in APG parameters following the application of various 
stockings. Results are expressed as: median (IQR) percentage improvement. 
 
 VFIa  VFT90b VVc 
No compression 4.9 (5.1) 20 (17) 121 (87) 
BKd Class I 3.7 (4) 25% 23 (18) 18% 100 (69) 17% 
BK Class II 4 (4.3) 19% 27 (20) 36%  112 (80) 7% 
AKe Class I 3.6 (3.5) 27% 26 (16) 31% 119 (76) 2% 
AK Class II 3.7 (4.3) 25% 26 (16) 31% 106 (77) 12% 
 
aVenous Filling Index in mL/s; bVenous Filling Time to 90% of VV in s; ctotal 
Venous Volume in mL; dBelow Knee; eAbove Knee thigh-length. 
 
 
Regarding VFI: 
1) The number (percentage) of legs with a normal VFI (≤ 2 mL/sec) without a 
stocking was 4/40 (10%). The number of legs with a normal VFI with a stocking in 
place was: BK class I: 11/40 (27.5%), BK class II: 7/40 (17.5%), AK class I: 12/40 
(30%) and AK class II: 10/40 (25%). This indicated that a GEC stocking was unable 
to abolish reflux in the majority of patients.  
2) The VFI reduced in 28/40 (70%) of legs irrespective of the class or length. 
When stratified by stocking type, a reduction in VFI was demonstrated in 32, 31, 33 
and 32 legs, with a BK class I, BK class II, AK class I and AK class II, respectively. 
This indicated that a GEC stocking was successful in reducing reflux in most patients. 
 
17.45 APG improvements and correlations with reflux 
As seen in Figs 17.3, 17.4 and 17.5, each stocking succeeded statistically in 
improving all APG parameters (VFI, VFT90 and VV) compared without 
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compression. However, there was no statistical difference between the magnitudes of 
improvement between stockings. This indicated that stocking class or length were 
unrelated variables in reducing reflux. 
 
Figure 17.3  Significant reductions in VFI in relation to class and length of stocking. 
The dashed line represents no improvement.  
 
 
 
Figure 17.4  Significant increases in VFT in relation to class and length of stocking. 
The dashed line represents no improvement.   
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Figure 17.5  Significant reductions in Venous Volume in relation to class and length 
of stocking. The dashed line represents no improvement. 
 
 
 The degree of improvement in the stocking VFI appeared to correlate with the 
pre-stocking VFI (Fig 17.6 and Table 17.3) indicating that greater reflux at baseline 
resulted in more benefit with compression. The correlations were all moderate-poor, 
but significant, with no difference between stocking class or length. 
  
 347 
 
Figure 17.6  Significant correlation between the degree of reflux without compression 
and the improvement of the VFI with GEC. In 2 patients/4 legs (filled circles), the 
VFI significantly deteriorated. 
 
 
 
Table 17.3  Correlation between baseline VFIa against the change in VFI (baseline 
VFI – stocking VFI) following the application of various stockings. 
 
 VFI Improvementb r  valuec P valuec 
Class I (18-21 mmHg) 1.10 (0.3 – 2.18) 0.420 < 0.0005 
Class II (23-32 mmHg) 1.05 (0.2 – 2.08) 0.350 0.001 
Below Knee 1.0 (0.13 – 2.08) 0.327 0.003 
Above Kneed 1.10 (0.4 – 2.38) 0.452 < 0.0005 
All stockings summary 1.10 (0.2 - 2.10) 0.390 < 0.0005 
 
aVenous Filling Index in mL/sec; bmedian and inter-quartile range; cSpearman rho 
test; dthigh-length. 
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17.46 Patient preferences 
Patients were questioned on their use of compression by question 10 of the VCSS in 
order to determine compliance. The results were: not used (7/34, 20.6%), intermittent 
use (3/34, 8.8%), most days (3/34, 8.8%) and full compliance (21/34, 61.8%). On 
arrival for the study 8 legs had no compression, 2 legs were in compression bandages, 
1 had a mid-calf GEC stocking and 1 had a BK flight stocking. The complete 
stratification of compression and the number of subsequent changes are illustrated in 
Fig 17.7. After the study session, patient preferences and physician insistence that a 
stocking was necessary resulted in a change or a new stocking prescription in 31 legs 
as follows: AK = 9, BK = 9, class change = 4, size change = 7 and a change to a 
closed toe = 2. Interestingly, 21 (52.5%) patients indicated they wanted to change 
their compression and 38% of these (8/21 patients, 9/21 legs) preferred an AK 
stocking.  
Short term follow-up on whether these changes actually took place did not 
occur and was not part of the study protocol. However, these results indicate that 
significant changes (length, class or size) are required in determining a suitable GEC 
stocking in 29/40 (72.5%) of legs and that an AK stocking may be preferable by many 
patients.  
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Figure 17.7  Significant changes (strength, length or size) to compression as a result 
of the study environment. The numbers on the lines indicate the number of changes. 
The 7 changes in stocking size (6 BK, 1 AK) are not shown. 
 
 
 
17.5   Discussion 
17.51 Historical overview of stocking performance 
To our knowledge, this is the first study to examine the haemodynamic performance 
of GEC stocking strength as well as stocking length using APG in patients with PTS. 
The combination of circumference measurements, interface pressure and APG as an 
evaluation technique was suggested in a consensus paper from members of the 
International Compression Club (Partsch, Clark et al. 2008). Although this paper was 
written in relation to compression bandages the usefulness of these measurements 
were illustrated.  
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 The use of APG in evaluating the performance of compression was 
documented as early as 1987 (Christopoulos, Nicolaides et al. 1987) and since then 
there have been studies comparing stockings in relation to manufacturer (Zajkowski, 
Proctor et al. 2002) and compression strength (Ibegbuna, Delis et al. 1997). There is a 
systematic review on 14/29 randomized controlled trials comparing knee length 
versus thigh length thrombo-embolic deterrent (TED) stockings for the prevention of 
DVT (Sajid, Tai et al. 2006). They concluded that they were equally effective but the 
former may offer advantages in terms of patient compliance and cost. Compression 
strength or haemodynamic parameters were not reported in that analysis.  
Two previous studies are noteworthy. In one study 11 patients were randomly 
allocated to a sequence of 4 brands of knee-high, 30-40 mmHg stockings (Zajkowski, 
Proctor et al. 2002). They found that stockings decreased the VFI and VV with an 
increase in the VFT90, in support of the current study, but in contrast none of the 
parameters studied were statistically significant. Another study on 19 female patients 
(20 legs) with moderate varicose veins used lightweight compression stockings of 7, 
10 and 14 mmHg (Ibegbuna, Delis et al. 1997). They found that the mean VFI 
decreased from 5.7 mL/sec without stockings to 4.6, 3.9 and 3.4 mL/sec, respectively 
(P < 0.0002), indicating that even lightweight compression can have a significant 
effect on venous haemodynamics. 
 
17.52 Impairment of stocking performance 
In our study, 10% of the PTS legs had a normal initial value of VFI without 
compression. Approximately 25% of patients with PTS did not improve as a result of 
wearing a GEC stocking and only 25% - 30% had a VFI which returned to normal. 
The reasons for this are likely to be multi-factorial. Firstly, the properties of a GEC 
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stocking are that it must be graduated with decreasing pressure from the ankle 
upwards. Whilst this is strictly adhered to by the manufacturer ex vivo, the situation is 
often different on the leg of a patient. In an open study of 50 patients with CVD using 
round knitted GEC stockings and interface pressure measurements at 5 defined points 
only 66% had a continuous distal-proximal descending pressure gradient (Reich-
Schupke, Gahr et al. 2009). In another study in 89 patients following hip or knee 
replacement a reversed pressure gradient was detected in 54% of patients wearing a 
BK-GEC stocking (Best, Williams et al. 2000). Its presence was associated with a 
significantly higher incidence of DVT (25.6% versus 6.1%, P = 0.026). Reverse 
pressure gradients could also hamper venous return resulting in adverse changes to the 
VFI, VFT90 and VV.  
 Secondly, stockings can cause band-like constrictions if they roll down, form 
overlapping pleats with poor application or constrict from wide discrepancies in the 
cross-sectional areas of the leg. The current study observed a range in cross-sectional 
area from a factor of 2.1 to 4.0, comparing the point at the narrowest part of the ankle 
to the widest part of the calf. Thirdly, the reason for a failure to restore the VFI to 
normal may relate to ineffective compression strength. A study on 12 patients with 
venous ulcers and popliteal vein reflux > 1 sec on duplex, revealed that a reduction in 
VFI was achieved only with a thigh pressure of 60 mmHg, intolerable with elastic 
material but tolerated using inelastic compression (Partsch, Menzinger et al. 2002). 
They concluded that the compression exerted using a thigh length class II stocking, 15 
mmHg at the thigh, is too low to produce significant haemodynamic effects, although 
narrowing of the femoral vein was observed using MRI with a pressure of 7 mmHg in 
the supine position (Partsch, Mosti et al. 2010b). A recent duplex study on eight 
patients with refluxing GSVs, without deep venous reflux, revealed that an ankle 
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pressure of between 90-100 mmHg was unable to abolish reflux in 5/8 patients 
(Cornu-Thenard, Benigni et al. 2012). This pressure was achieved using three 
sequentially applied 30-35 mmHg stockings. It is likely that such high pressures will 
not be tolerated by patients, they increase the difficulty in application and result in 
skin trauma with prolonged use. Our study was limited to class I and class II stockings 
since this is the most common type of stocking prescribed. 
 
17.53 Improving compliance 
In the present study, approximately 72.5% of legs needed to have their compression 
re-evaluated with 8 (20%) presenting at entry into the study without any form of 
compression and an extra 2 (5%) with inadequate compression, despite earlier clinical 
advice. There are several reasons for non-compliance in the literature. In a population 
based study of 16,770 patients with CVD the reasons for discontinuation at a follow 
up visit were: high cost (33.0%), sweating (27.3%), itching (13.6%), cosmetic 
(13.6%), edema (6.8%), exudation (3.4%) and difficulty with application (2.3%) 
(Ziaja, Kocelak et al. 2011). In another study of 3,144 CVD patients referred to a 
tertiary practice the reasons for non-usage were: none specified (30%), none 
prescribed (25%), no benefit (14%), cutting-off of the circulation (13%), too hot to 
wear (8%), soreness (2%), cosmetic (2%), application difficulty (2%), itch or 
dermatitis (2%) and other (2%) (Raju, Hollis et al. 2007). They concluded that the 
reasons for non-compliance can be grouped into wear-comfort factors and an 
intangible sense of restriction imposed by the stocking.  
A questionnaire survey on 110/200 (55% response rate) consecutive CVD 
patients reported side effects of dry skin (58.5%), slipping (29.1%) and constriction 
(24.5%) with only 29.1% voting the stocking as “comfortable” (Reich-Schupke, 
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Murmann et al. 2009). Another questionnaire survey on 150/207 (72% response rate) 
PTS patients reported a 74% daily compliance rate with the main reasons of non-
regular use as difficulty in application, discomfort and their appearance (Roche-
Nagle, Ward et al. 2010). Furthermore, it is also known that control visits can increase 
the frequency of GEC stocking use by 37.4% (Ziaja, Kocelak et al. 2011).  
 The present study has shown that poor compliance may be attributed to rigid 
prescribing patterns based on a belief that a particular length or strength of stocking is 
better for the patient. Relying on a manufacturer’s chart and the experience of the 
fitter to select the size is important. However, a stocking testing environment, 
analogous to a fitting room in a department store, allowing patients to choose their 
own stocking based on comfort is strongly recommended. This has been shown in this 
work to result in a change or a new prescription in 72.5% of legs. Although not part of 
this study it is likely that such a patient orientated approach to stocking selection will 
improve overall compliance. Customisation, based on circumferential leg 
measurements at standardised locations, may reduce the number of patients with 
reverse pressure gradients, improve comfort and ultimately result in better 
compliance. The option to order measure-to-made GEC stockings may be required 
more often than it is used in day-to-day practice. 
  
17.54 Limitations 
This study has focused on the effectiveness of stockings at controlling reflux by using 
the VFI, VFT90 and VV parameters of APG on the assumption that a reduction in 
reflux will reduce the morbidity associated with PTS. The reasons for selecting reflux 
were firstly that it is the most useful diagnostic APG parameter to study 
(Christopoulos, Nicolaides et al. 1988b; Criado, Farber et al. 1998; Ting, Cheng et al. 
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1999; Nishibe, Kudo et al. 2006) and secondly because stockings are likely to be more 
effective at controlling reflux than improving calf-muscle pump function (Zajkowski, 
Proctor et al. 2002). A third factor likely to determine the morbidity of PTS is the 
degree of mechanical or functional obstruction to venous return, for example in 
obesity (Danielsson, Eklof et al. 2002).  It is not known how GEC stockings may 
influence this other than by an improvement in calf-muscle pump function or a 
reduction in VV. To date, there are no useful diagnostic tests which can quantify 
outflow resistance, although measurements of outflow fraction with APG can be 
meaningful in some situations (Kalodiki, Calahoras et al. 2001). Ambulatory venous 
pressure measurement is considered the gold standard test in assessing venous 
function but was not performed in our cohort for ethical reasons (Payne, Thrush et al. 
1993).   
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PART  VI 
 
 
 
CHAPTER  18 
 
 
 
DISCUSSION 
 
 
Discussion is just a tool. 
The final goal must be a decision 
-- Harri Holkeri 
 
                 
18.1 Main discussion 
 
The work contained in this thesis is a critical evaluation of the assessment of chronic 
venous disorder. Innovations have been proposed, validations of existing assessment 
tools have been made and limitations have been highlighted. The chapters were 
chosen specifically to reflect those areas in the assessment of CVD which the author 
considered required an in-depth examination. The last 3 chapters include these 
assessment tools in clinical trials comparing treatments for SVI and the efficacy of 
GEC stockings in PTS thereby bringing the chapters of the thesis together in context. 
 The clinical C part of the CEAP classification is the most well known and 
published way of classifying CVD. It is accepted as a gold standard assessment tool 
and a bench mark upon which other assessments are measured. Although not intended 
for use as a means of staging the severity of CVD into eight separate categories (C0, 1, 
2, 3, 4a, 4b, 5, 6) it is nonetheless a widely-accepted way of grouping patients into 2 
categories of severity. These are early or mild disease, represented as C0-3, and late or 
advanced disease, represented as C4-6. This separation into 2 categories has been given 
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great importance in clinical research, controlled clinical trials, the Department of 
Health and NICE. Indeed, the mission statement of NICE is to develop a series of 
national clinical guidelines to secure consistent high-quality evidence based care for 
patients treated under the NHS. Therefore, a failure to categorise patients into mild 
and severe disease may lessen the impact of research conclusions and DoH policy 
decisions.    
 Chapter 3 reports the results of an international survey where delegates at 
venous conferences were asked to classify photographs of legs into mild and severe 
based on the C of CEAP. Most images depicted varying degrees of pigmentation. This 
study was undertaken following the revision of CEAP where C4 was further 
subdivided into C4a, representing pigmentation or eczema, and C4b representing 
lipodermatosclerosis or atrophie blanche (Eklof, Rutherford et al. 2004). Despite very 
few participants checking the “don’t know” box on the questionnaire, there was a 
considerable lack of agreement in discriminating mild from severe disease. The 
conclusion was that inter-observer variations on classifying pigmentation using the C 
of CEAP were unreliable. Furthermore, clinical trials using the C class as a means of 
stratifying legs into mild and severe clinical disease should be interpreted with caution 
because of the difficulties in weighting the importance of pigmentation based solely 
on appearance. This questions the value of the recent CEAP revision proposal to 
subdivide C4. The results of this work have also indicated that the C of CEAP may be 
improved by using the same rater throughout clinical studies and by using leg 
elevation to discriminate between telangectasiae and pigmentation.  
 It must be noted that the questionnaire participants were given very little 
clinical information other than the patient attended a venous clinic. There was no 
clinical history and contralateral legs were not shown as comparators. This was in-
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keeping with the original intentions of the C of CEAP as being an assessment based 
solely on appearance. However, two-thirds of the participants stated that a clinical 
history would influence their classification. The reality is that any classification into 
mild or severe using C of CEAP, whether for research or policy decision making, will 
be made by the majority of clinicians on additional assessment information. This is 
may include symptoms, quality of life data, duplex scan reports and personal 
judgement.        
 The relationship between VVs and CVD is imprecise. They may be the focus 
of the pathology or an adaptive collateral response to facilitate venous return. Patients 
with venous ulceration may have minimal, if any, varicose veins to accompany a 
refluxing saphenous trunk. Furthermore, patients with severe longstanding PTS may 
have deep venous reflux as their only source of pathology. The above observations 
suggest that VVs are an incidental finding running concurrently with CVD. It has not 
been disproven that their development may be an adaptive response by the organism 
to off-set the progression of CVD.   
 The link between VVs and CVD was examined in chapter 4 in 100 patients 
awaiting treatment for their VVs. Quantification of the extent and distribution of VVs 
was achieved using question 1 of the AVVQ and question 2 of the VCSS. These were 
then compared to severity questionnaire results and hemodynamic measurements of 
severity namely, the GSV diameter and the VFI of APG. The results indicated the 
lack of a relationship between VVs and clinical severity of CVD. This pointed away 
from a common assumption that extensive large VVs imply a greater severity of 
CVD. This leads to 2 questions: Firstly, should VVs be removed from severity 
questionnaires?  Secondly, should the treatment aim be to remove all significant 
varicose veins or to treat CVD? If assessment questionnaires are based on the 
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evaluation of VVs then it is fait accompli that their ablation or removal will result in 
an improvement of disease severity. Recurrent VVs may be a marker that the 
underlying CVD has returned or not been adequately treated. 
 In contrast, when the haemodynamic parameters were used as an index of 
severity, namely the GSV diameter, the VFI and the VFT90, there was a significant 
and direct relationship with question 2 of the VCSS. This means that with increasing 
haemodynamic severity there were more VVs recorded by the physician. Perhaps 
haemodynamic assessments therefore should occupy a more prominent place in the 
evaluation of CVD if VVs are considered the focus of the pathology and treatment. 
Interestingly, this is the principle of ASVAL (Pittaluga, Chastanet et al. 2010). In 
minor CVD it has been shown that a refluxing GSV can be restored to competency by 
removal of the varicose reservoir. 
 The work concluded that VVs are a marker of venous disease but their number 
and distribution do not appear to be related to clinical severity. As a result, the 
importance of assessing VVs should be reduced since they are an incidental finding 
whose treatment is based solely on their appearance. If this is the case, VVs need not 
be treated concurrently with a refluxing saphenous trunk. Patients should be assessed 
primarily for CVD since this encompasses a group of diseases with differing patho-
physiological elements. For example: reflux, outflow resistance and calf muscle pump 
dysfunction. A change in the assessment paradigm may be helpful with a focus on 
treating CVD rather than VVs per se. 
 Questionnaires are useful tools in the assessment of venous disease. They can 
measure the response to treatment, provide baseline data on severity of disease and 
compare the effectiveness between different interventions and at different hospitals. 
Prior to the widespread acceptance of a questionnaire it must undergo rigorous 
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validation tests and field testing and finally overcome the test of time. Both the VCSS 
(Rutherford, Padberg et al. 2000) and the AVVQ (Garratt, Macdonald et al. 1993) 
have survived these rigorous tests and are now part of the common venous language. 
They are included in most clinical trials on CVD. The ten question VCSS measures 
clinical severity and is recorded by the physician. The 13 question AVVQ measures 
disease specific (really VV specific) QoL and is reported by the patient. Interestingly, 
they are used rarely for PTS despite this being a major component of CVD and a 
common aftermath of a DVT. 
 Chapter 5 examines the responsiveness of the individual questions of the 
VCSS and the AVVQ to endovenous treatment. This was necessary because a global 
improvement in a questionnaire is often taken at face value without an examination of 
the elements. For example, an unchanged AVVQ may be related to a reduction in the 
number of VVs (a lower score for question 1) but a corresponding increase in pain or 
hyperpigmentation (higher scores for question 2 and 10), facts which remain hidden 
when using global scores. Similarly, if question 1 is answered because patients are 
reluctant to draw veins on a postal questionnaire, then this may conceal improvement. 
This chapter attempts to answer which questions are the most or least responsive and 
the effect this has on the overall score. The aim was to provide a transparent 
interpretation as to why the total scores changed after intervention on 100 patients.  
 Unsurprisingly, the total VCSS and AVVQ scores improved after treatment. 
The VCSS improved on the whole because of a reduction in the first 3 questions on 
pain, varicose veins and oedema. However, the most responsive group was the 
patients with venous ulceration which had healed, since this was 40% of the 
questionnaire. Unfortunately, this had no impact on the global reduction of the median 
VCSS because of statistical dilution since there were too few patients with ulcers in 
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the study cohort. On the basis of this it can be suggested that if the VCSS is used then 
patients could be categorised into ulcer and non-ulcer groups because of the great 
increase in responsiveness of the former group.  
 The AVVQ improved on the whole because of a reduction in the number and 
appearance of VV (lower scores for questions 1 and 10). In contrast to the VCSS, 
when patients were categorised using the C of CEAP the responsiveness was broadly 
equivalent, irrespective of C. This is not too surprising because the AVVQ is heavily 
weighted in the assessment of VVs. In fact only 3 questions of the AVVQ do not have 
the word “varicose veins” in the question itself. So if all the visible VVs are removed, 
the remaining 10 questions no longer apply resulting in a dramatic improvement in 
the total score. The converse might also be true if venous ulcers are successfully 
treated in patients without VVs. This group will be expected to undergo the least 
improvement with only 1 question on ulceration (question 9). This makes an 
argument, as with the VCSS, for patient separation into ulcer and non-ulcer groups. 
However, the scoring for the AVVQ has been partially adjusted for this purpose by 
giving ulceration the second highest score of the 13 questions, 18.236 out of 100.  
 As expected patients with bilateral disease responded differently to those with 
unilateral disease, but this is already a known limitation of the AVVQ. The inclusion 
of the question on stocking use did not provide any meaningful information in relation 
to responsiveness or severity of disease in either the VCSS (question 10) or the 
AVVQ (question 5). Its deletion from the questionnaires may be a point to consider 
for the next revision committee.   
 In summary, stratification by C class into C1-5 and C6 may improve the 
interpretation of the VCSS and AVVQ. Furthermore, reporting the changes in the 
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individual questions may improve the usefulness and transparency of both 
questionnaires. 
 The NHS is funded by the public and was set up to provide state treatment for 
all UK nationals. Its funds are limited so it makes sense to restrict treatment to those 
patients who suffer the most with their CVD rather than provide treatment for 
everyone; including those whose VVs are an occasional minor inconvenience. The 
AVVQ has been proposed as such a rationing tool, but its use in this respect is 
controversial. Chapter 6 has evaluated the AVVQ in relation to rationing in 84 
patients who received endovenous treatment for varicose veins. The outcome was that 
the baseline AVVQ seemed to be the best predictor in identifying those patients who 
improved the most after VV intervention. Thus the use of the AVVQ as a rationing 
tool was supported by this study. 
 However, the conclusions reached rely on three main assumptions which are 
mentioned below. Firstly, the AVVQ was assumed to be able to quantify QoL 
impairment as a result of the patient’s VVs. Since patients on the whole present for 
treatment at a time when the perceived benefit of treatment outweighs the 
inconvenience at that stage in their lifetime then the threshold for presentation, or 
level of QoL impairment, should be similar in all patients. This is not usually the case 
with patient’s presenting with widely differing AVVQ scores and clinical CEAP 
classes. The second assumption is that the QoL scale is accurate, so those patients 
with a low score have a better quality of life than those with a higher score. If this is 
true then a return to zero score would be appreciated more in the high scorers. 
Absolute differences in scores will therefore be a more appropriate measurement of 
improvement that percentage differences. This was the way improvement was 
measured in the study. The final assumption is that patients perceive the questionnaire 
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as a way of determining how much they are likely to benefit from treatment. If they 
arrive at the conclusion that this is a rationing instrument they are likely to exaggerate 
their responses in order to qualify for treatment. This was not an issue in the current 
study because patients completed the questionnaires after treatment was guaranteed. 
 The baseline cut-off point below which patients are denied intervention will 
depend on the DoH as to the percentage of patients who should be treated. The lower 
the threshold the more will pass the screening criteria. However, it must be noted that 
patients with a low initial AVVQ can only improve down from their initial level of 
severity. Despite the rationing proposal there will always be patients who improve 
minimally, or even deteriorate, irrespective of a high initial score. Retrospective 
analyses from databases on larger studies may improve the level of cut-off and predict 
the percentage of patients who will improve minimally or deteriorate.  
 Complications like SVT, haemorrhage or skin ulceration require treatment like 
LMWH, blood transfusion and compression in addition (or instead of) VV ablation. 
These are more complex problems with a different treatment paradigm and a case can 
be made therefore to remove those patients from an elective rationing process. 
 The next four topics in the discussion focus on innovations on the use of 
duplex ultrasound and APG in the assessment of SVI. The first topic examines a 
novel marker, the VFT90, as an index of disease severity. It is covered in chapter 7 of 
this thesis. The need for a haemodynamic marker of severity is highlighted by the fact 
that clinical makers of severity demonstrate poor correlation with each other with high 
inter-observer variability and, as detailed in the previous chapters, they have different 
interpretations depending on the characteristics of the study cohort. Furthermore, the 
haemodynamic impairment (elevated venous pressure) is probably uncomfortable so 
symptoms may precede the development of the clinical manifestations used to gauge 
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severe disease. It is also well known that most patients presenting with venous disease 
may have leg symptoms from a non-venous origin (Bradbury, Evans et al. 2000). 
Thus poor correlations exist between clinical and haemodynamic severity. The 
VFT90, like the VFI, provides a severity number for the leg but, in contrast to the 
VFI, it was shown also to have discriminatory value. Correlation exercises with other 
severity scoring systems, such as those performed in chapter 7, have helped validate 
the VFT90 as a severity index. 
 It is universally agreed that the VFI of APG is a reliable parameter. The VFI 
and the 2 components from which it is derived, the VV and the VFT90, were all 
shown to be markers of severity in patients with SVI. In contrast to the VFI and the 
VV, a VFT90 > 25 sec had discriminatory value in the identification of patients with 
mild clinical disease. Therefore, patients with early clinical disease could be divided 
into 2 groups based on this cut-off point of 25 seconds. The study concluded that a 
low VFT90 may be of value in identifying patients with early disease who are likely 
to progress into the later stages of clinical severity, whereas those with a VFT90 > 25 
sec may cease to progress. Longitudinal natural history studies will be required to 
confirm this hypothesis.  
 The rationale behind the use of the VFT90 as a marker of severity is that it 
may represent the time taken for the global anti-gravitational mechanisms in the leg to 
fail. The longer the VFT90, the greater the protection the leg has to the full effects of 
hydrostatic pressure from gravity. The VFT90 is defined as the time taken for the leg 
to fill to 90% of the venous volume (VV) from dependency, after an initial period of 
elevation. Immediate rapid filling means immediate susceptibility to the full 
hydrostatic insult. The VFT90 can be considered as a surrogate marker of global 
reflux duration. The evidence for this statement is provided in the next section.    
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 The VFI of APG historically has never shown a good relationship with duplex 
derived reflux parameters. This is because the VFI measures the rate of global 
dependant filling to the calf after a period of elevation whilst duplex measures reflux 
duration and is performed on a single vein with the subject already in the standing 
position. Furthermore, simultaneous recordings have never been performed. The first 
study to compare the relationship between APG venous filling time (VFT90) and 
duplex venous reflux time (RT) is reported in chapter 8. This was a prospective study 
on 26 legs in patients awaiting intervention for SVI. All legs had a refluxing GSV as 
the only refluxing vein in the thigh. The duration of reflux (red colour on colour 
duplex demonstrating flow towards the probe) was marked on the VFI chart from the 
point of rise to the termination of the red colour. This was marked as an event on the 
VFI chart.  
 There was an excellent correlation between the VFT90 versus duplex RT, 
thereby validating the use of both tests in the quantification of reflux. There was also 
a significant but moderate correlation between the VFI and the refluxing GSV 
diameter. Whilst duplex RT performed standing can diagnose diseased veins, the 
elevation-dependency manoeuvre provided an improved method for quantifying 
reflux, irrespective of the investigation. Reflux times with this manoeuvre are in the 
order of tens of seconds rather than fractions of a second in a standing patient which 
may allow for a greater discrimination. The global assessment of reflux in patients 
with a single refluxing GSV in the thigh can now be performed using either of the two 
tests. This may be of benefit to physicians who do not have APG in their vascular 
laboratory. 
 Further research is required to determine the event which terminates reflux in 
a patient with SVI and whether this is related to the level of re-entry perforating veins 
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or whether it ceases simultaneously, at all levels, in all incompetent leg veins. It is 
also not known whether the correlations between the VFT90 and duplex RT are 
maintained in the assessment of deep venous reflux or combined deep and SVI. 
However, it is clear that valves can only close when they are competent. If reflux 
stops in an incompetent vein it is likely to be at the point of maximum venous filling. 
Evaluation of the mechanisms of reflux cessation will provide insights into how they 
may be manipulated by intervention. It may also help in the understanding of the 
pathological venous recirculation and the significance of re-entry perforating veins 
before and after treatment.  
 In health the GSV, when assessed using duplex, is a small calibre tube that is 
competent with antegrade flow. When diseased in SVI its diameter enlarges and its 
valves become incompetent with retrograde flow > 0.5 sec. Despite these simple 
differences between health and disease there remains great controversy as to the 
duplex endpoint of a successful intervention. Whilst restoration of competency with 
normalisation of calibre seems to be the ideal objective it is only accepted by the 
minority of phlebologists who practice CHIVA or ASVAL. Furthermore, restoration 
of competency is considered a duplex failure if the primary intention was to ablate the 
GSV thereby removing all trace of flow, antegrade as well as reflux. In contrast, an 
occluded vein is usually considered to be pathological. A typical example is a 
saphenous vein thrombosis. However, after treatment, occlusion it is accepted by most 
practicing phlebologists as a success, with shrinkage and closure better than a 
distended thrombotic occlusion. Then there is also the debate on the length of 
occlusion and whether a remaining refluxing below knee GSV is as significant as 
claimed. Perhaps the preferred outcome should just be based on the abolition of 
reflux, irrespective of the presence of occlusion. Therefore there is clearly a need for a 
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universal duplex-derived outcome evaluation system that could be used to score all 
patients whatever method of intervention is performed. The saphenous treatment 
score may fulfil some of these objectives. 
 The third of the 4 haemodynamic topics examines the saphenous treatment 
score (STS) which is also the content of chapter 9. The STS is a quantitative, flexible, 
duplex-derived, scoring system, which has the potential to assess the haemodynamic 
effectiveness of treatments for SVI. This research has shown that the STS can score 
and differentiate between the therapeutic impact of EVLA and UGFS, AK and BK 
treatment effects, as well as assess the benefit of further interventions. The STS has 
been shown to grade the haemodynamic effects of different treatments as well as 
ongoing treatments on the GSV. 
 Briefly, with the STS the GSV has numerical values assigned to it for 
competency (= 2), reflux (= 3) and occlusion (= 1) before and after treatment, above 
and below the knee. These values depend on the preferred treatment outcome but 
reflux always = 3, the worst score. Then, depending on the patterns of flow co-
existing within the saphenous trunk, there is an order of precedence as to which of the 
three states (competency, reflux or obstruction) has their value counted towards the 
total score. The presence of reflux will dominate over occlusion which in turn will 
dominate over competency, irrespective of the aim of treatment. With saphenous 
conservation where the best outcome is competency (= 1) this is given a better score 
than occlusion (= 2). The STS may be the first universal scoring system that can be 
used to compare the success of conventional ablation techniques with preservation 
techniques. The very least the introduction of the STS into standard practice will 
achieve is a formal upgrade of reporting standards through the evaluation of the GSV 
before and after treatment with respect to the 3 co-existing states. 
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 The fourth and last haemodynamic innovation is the finding of saphenous 
pulsation as a marker of the severity of SVI. Pulsation is rarely recognised in veins 
and its presence is usually associated with a direct arterial communication like an 
arteriovenous malformation or a femoral vein/femoral artery fistula resulting from 
intravenous drug misuse.  Furthermore, a pulse is often taken as a palpable finding 
such as the radial pulse. Therefore, the high prevalence of pulsatile ante-grade 
saphenous flow may be a surprising observation in patients with severe chronic SVI. 
 The SP is easy to record at the mid-thigh level in the non-weight bearing leg 
of a standing patient with colour duplex. Impulses of blue antegrade flow are 
observed against a background of black, representing stasis, or even red, representing 
reflux. The SP is not palpable, it is irregular and does not correspond to the heart rate.  
Although its aetiology is unknown, the results from chapter 10 have shown that it 
appears to parallel clinical severity and its presence is related to increases of the GSV 
diameter.  
 Hydraulic transmission from the arterial circulation may be a plausible 
aetiological hypothesis. In pathological states, like chronic SVI, the microcirculation 
may fail resulting in a diminished capillary resistance. Consequently, the arterial pulse 
may be transmitted through to the venous side of the circulation and present itself as 
an impulse recordable along the saphenous vein. The irregular nature of the pulse can 
be explained by damping from the remaining capillary resistance. A delay of 
transmission in some parts of the leg may cause impulses to reach the GSV at various 
different time points. The SP is assumed to be the sum of these discordant waves. 
 Future work will be required to define the relationship between 
microcirculatory failure and the appearance of a SP and to establish the clinical 
relevance of the SP in terms of CVD progression, recurrence after treatment, and as a 
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haemodynamic marker of severity. For example, does the presence of a SP in patients 
with mild CVD result in a rapid progression to skin changes?  Furthermore, do 
patients with a SP have a greater likelihood of recurrence after treatment because of a 
decompensated microcirculation? In the absence of a functioning calf-muscle pump is 
the SP the default means of superficial venous return to the heart? These and many 
other questions about the SP require formal evaluation with clinical studies. 
Measurement of the SP could be performed on all patients as a research tool to 
supplement duplex assessments of reflux until its true significance and value in 
clinical practice is known. 
 The post-thrombotic syndrome forms a significant part of CVD and the 
Villalta Scale has been proposed as the means to define and classify the severity of 
PTS (Kahn 2009). Chapter 11 attempts to validate the VS by comparing it against 
other assessment tools in 40 legs from 34 patients with PTS. The results showed that 
the VS, in agreement with other studies, was able to classify PTS into mild, moderate 
and severe categories. Furthermore, there were good correlations identified between 
the VS against the VCSS, the C of CEAP and the VFI of APG. The evidence provided 
supported the use of the VS as the gold standard, disease-specific clinical evaluation 
of PTS, especially when the VFI was used as a haemodynamic benchmark. 
Nevertheless, the VCSS also showed good correlations with the VS and the VFI, and 
there was very little to discriminate between either questionnaire. 
 Limitations of the VS are well known and include the lack of a score for 
venous claudication and venous ulceration (Strijkers, Wittens et al. 2011). The current 
study has highlighted 3 further limitations. The first concerns the diagnosis of PTS 
which is defined as a score of ≥ 5. In the current study 17.5% of legs did not have 
PTS despite the presence of leg symptoms/signs, duplex evidence of deep venous 
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disease and the patients’ attendance in the venous clinic. This definition is important 
because it is required to determine the true incidence of PTS after a DVT. Precise 
definition of a study cohort allows data comparisons across studies and meta-analyses 
and should limit the wide range of reporting differences in the rates of PTS. 
 The second limitation is there is no provision in the VS for assessing the 
degree of venous ulceration. Its sole presence defines PTS and places the patient into 
the severe category. It has been recommended that patients with ulceration with a VS 
< 15 should be upgraded to a score of 15 (Kahn, Shrier et al. 2008). Therefore, a 
single small superficial ulcer could have the same score as chronic multiple large 
ulcers. Furthermore, ulcer patients with minimal symptoms would be expected to 
have the greatest improvement in the VS score once their ulcers heal. The upgrade in 
the score from these ulcers will increase the pre/post difference in the VS 
(improvement) which may overemphasize performance reporting. Studies should 
report the percentage of patients who have ulceration and clarify the number of ulcer 
patients with unadjusted low scores. Alternatively, they could be evaluated as a 
separate cohort for analysis. 
 The third limitation relates to the correlation exercise as a means of validating 
the VS. Correlations between assessment instruments are useful to identify the 
strengths and weaknesses of a scoring system. However, they should not be over 
interpreted. Excellent correlations are strong arguments for validation purposes. 
However, if the correlations are too good then this equivalence may justify the use of 
either of the two instruments on its own. Furthermore, strong correlations are 
expected if the questions between the questionnaires are similar.  
 Assessing the efficacy of treatment in CVD relies on a wide variety of 
outcome measures. These include a reduction in clinical severity, post-procedural 
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pain, recovery, improvement in QoL, abolition of reflux and a lowering of the VFI. 
The same broad scope of measurements should be applied also in assessing the cost of 
treatment, but this is noticeably absent from clinical trials. Chapter 12 examines the 
effect of different methods on cost comparisons between EVLA and UGFS and 
concluded that the differences were dependant on the methodology used in the 
calculations. Top-down approaches demonstrated less of a difference in cost between 
the treatments when compared to bottom-up approaches. The scope of the overheads 
was a principle variable in the calculations. The point is made that as cost forms an 
integral part of a cost-effectiveness analysis it should also undergo the same breadth 
of analysis as effectiveness.  
 A sensitivity analysis is used frequently to test the robustness of a cost 
calculation. The variance is then reported using the mean and a standard deviation. 
The process also involves inputting the uncertainty of a costing element directly into 
the equation so that to assess the impact of variations in cost on the results. However, 
this usually validates a single costing approach rather than an examination into the 
variations between different costing methods.   
 The difference between price (reimbursement) and cost has been overlooked 
in a recent cost-effectiveness publication on VV treatment where both price and cost 
seem to have been added to calculate the overall cost (Rasmussen, Lawaetz et al. 
2011). This technique provides a potential for double-counting when additional 
services are duplicated, like ultrasound, which are assumed to be excluded from the 
case-payment. Cost in economic terms should be the price paid minus the profit 
received, since PROFIT = PRICE - COST. It is clear from the results of chapter 12 
that using the hospital accounting systems of profitability and EBITDA that these 
were both positive for UGFS and negative for EVLA. 
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 The use of HRG and OPCS codes in costing evaluations are misleading. They 
are usually too generic for the treatment like the HRG code QZ10B which is unable to 
differentiate EVLA from UGFS being defined as a “primary unilateral varicose vein 
procedure without complication”. Furthermore, the OPCS code L86.2 “ultrasound-
guided foam sclerotherapy for varicose veins of the leg” is used for primary VVs, 
recurrent VVs as well as on-going treatment, irrespective of whether the patient has 
an ulcer or the treatment location. 
 A final comment on costing a procedure relates to the scope of overheads used 
in the calculation. For example should non-NHS costs be included like productivity 
loss, patient’s travel costs, over the counter expenses and lost leisure time? Should 
indirect NHS costs be included like the running costs of a hospital, gas, electricity, 
water and building repair/maintenance and parts of the salary of senior management? 
Since these all have a significant impact on cost it may be prudent to use several 
methods of costing in cost-effectiveness analyses of VV treatments. 
 The next 2 chapters assess a potential risk in the technique of UGFS which is 
used to justify the innovation of partially applying a GEC stocking before foam 
treatment to an incompetent GSV. This technique is promoted in an attempt to 
minimise potential foam displacements which may occur in a patient during an 
inadvertent Valsalva manoeuvre and the antegrade milking effect whilst the doctor 
dons the stocking. If the GEC stocking is already in-situ, then the risk may be 
minimised. Chapter 13 assesses the volume displacements at the SFJ during a 
Valsalva manoeuvre and chapter 14 assesses the flushing of blood up the GSV during 
a stocking pull-up manoeuvre. If these assessments are performed prior to UGFS in 
patients with SVI then, if the haemodynamic effects are great, extra vigilance in 
technique and donning a stocking to knee level may be required on order to minimise 
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risk and improve efficacy. These 2 chapters in this thesis assess potential risk and 
efficacy in patients with CVD prior to their treatment. 
 Chapter 13 has shown that a VM can cause significant haemodynamic effects 
at the SFJ where a median total of 40 mL of blood can be displaced during a 3 second 
strain followed by a 3 second relaxation cycle in patients with chronic SVI. The 
described volume changes may be responsible for blood-foam mixing, foam 
inactivation and bolus foam displacement into deep veins. These findings may also 
provide a causal factor as to why systemic side effects may occur following UGFS 
and provide an explanation as to why the occlusion results of UGFS are inferior to 
other endovenous techniques. Patients should avoid all activities which may cause a 
VM. Patients should remain still and calm during and immediately after treatment. A 
pre-applied below knee stocking may be of benefit before the foam injection because 
this has been shown in the results to reduce the calibre of the GSV in the thigh. It may 
also limit any straining by the patient in helping the doctor apply the stocking. This 
study has also shown that reflux duration following a VM can be determined by the 
physician and less by the pathology of the disease. The significance of assessing 
reflux duration, therefore, may depend on the nature of the induction test as well as 
the degree of venous incompetence or the clinical severity.  
 Chapter 14 concluded that the manoeuvre of pulling up a GEC stocking results 
in a significant increase in the PV and VF within the GSV and that these 
haemodynamic forces could be avoided by the partial application of a GEC stocking 
up to the level of the injection site. Future work is required to determine if these 
forces are haemodynamically or clinically significant in patients with VVs undergoing 
foam sclerotherapy. However, it may be unacceptable by an ethical committee to 
conduct a large randomised clinical trial comparing efficacy and side-effects between 
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the two different techniques of applying a stocking before or after injection. It is 
anticipated that patients would prefer to be in the “safer” group rather than risk foam 
displacement.  
 To avoid overreaching any conclusions it must be remembered that foam 
sclerotherapy has the potential of causing substantial venospasm of the GSV. If this 
occurs then foam displacement, back and forth across the SFJ during a VM or a 
stocking pull-up manoeuvre may be minimal, if at all. The reported results apply to 
blood, not foam. The haemodynamic properties of foam in vivo after sclerotherapy are 
not known and this needs to be the subject of future research. Haemodynamic forces 
like a VM or GEC pull-up are more likely to be detrimental before the onset of 
venospasm, so it is advisable to wait for this to take place. This can be checked on 
duplex easily by noting the width of the acoustic shadow emanating from the foam-
filled GSV. 
 The remaining 3 chapters focus on validating scoring tools in the context of 
clinical trials. The first and second are the early and intermediate results in treating 
SVI by comparing patients randomised to EVLA and UGFS. In the final chapter the 
haemodynamic efficiency of 4 stockings, assigned in random order, were compared in 
patients with PTS using the VFI of APG. 
 Chapter 15 reports the early results of a RCT comparing cost and effectiveness 
of EVLA with phlebectomies against UGFS in patients with SVI. This trial concluded 
that there were no significant difference between the two treatments at 3 months in 
terms of improvements in the clinical, QoL, duplex and haemodynamic values. 
However, there were significant differences in favour of UGFS in treatment duration, 
post-procedural pain scores, analgesia requirements and time to recovery. 
Furthermore, UGFS was shown to be 3.15 times less expensive than EVLA (£230.24 
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versus £724.72) with comparable effectiveness but 56% (versus 6%) required 
additional foam. The study report commented that although the initial cost-saving 
with UGFS cannot be ignored in public health care systems, these results are too early 
to take into account the treatment costs of later recurrences. 
 The study reported that at 3 months the above-knee GSV occlusion rate, 
without co-existing reflux, was not significantly different between the two groups: It 
was 74% with EVLA and 69% with UGFS (P = 0.596). A major comment of this 
RCT was the high rate of reflux remaining within the GSV in the EVLA treated group 
(Schneider 2012). In particular, the observation that 26% of subjects in the laser arm 
had reflux that was much greater than any previous study. The comment continued by 
stating that, in general, the rate of reflux in those precedent studies is 10% or less even 
at two years and the authors cite a meta-analysis with a figure of 4.6% at 5 years (van 
den Bos, Arends et al. 2009). The concluding remark of this commentary was an open 
invitation to explain why the results with EVLA were so discrepant from the 
precedents. The author’s reply (unpublished) is below which highlights a significant 
limitation in the duplex assessment of CVD – a standard duplex outcome measure. 
 Firstly, the meta-analysis from which the RCT was based used the term 
recurrence (GSV recanalisation) and not rate of reflux as cited in the invited 
commentary. This is important because recanalisation implies a re-opening of the 
GSV throughout its length after it has been sealed. Secondly, the current RCT 
tabulated the “failures” as patterns of closure in patients with residual above-knee 
reflux. Seven out of the 9 failures had a GSV occlusion in the upper part of the GSV 
with reflux further down, one had partial closure (recanalisation from groin to knee) 
with only one patient demonstrating reflux with co-existing groin to knee patency. If 
the endpoint of “occlusion at some point above the knee” was added to the existing 
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“successes” then the combined success rate would be 89.1% which is in keeping with 
other studies on EVLA and the cited meta-analysis at 3 months (92.2%). Finally, the 
commentary stated correctly that the “precedents may have used a more forgiving 
definition for haemodynamic treatment failure” because they may have “graded a 
procedure as a success if reflux was no longer present in the SFJ and adjacent upper 
GSV”.  
 It was commented in public at the ESVS in 2011 that the failures using EVLA 
may have been caused by an inexperienced operator because of the high rate of lower 
thigh reflux and residual below knee reflux despite occlusion up to the SFJ 
(Theivacumar, Darwood et al. 2009). It is true that most procedures were carried out 
by a junior registrar but it is unlikely that this influenced the results. The site of GSV 
access was described in the study as a convenient location at the knee and this was 
performed irrespective of the experience of the operator. This was not necessarily 
below the point of reflux and may have been a few centimetres above the knee or 
below the knee. In many patients reflux extended down to the ankle with 53% having 
pigmentation or a higher clinical stage. Had our definition of failure as a result of 
above knee reflux changed to above the mid-thigh level then, as illustrated above, our 
results would have been similar to other studies. The importance of a clear definition 
of duplex success in assessing outcomes is necessary.  
 The treatment of below knee GSV reflux remains controversial. It is not 
reimbursed in the USA where above knee ablation remains accepted practice. 
Furthermore, in patients with advanced lipodermatosclerosis, it is difficult to maintain 
an adequate margin of tumescence between a superficial GSV and the dermis. In 
some patients the saphenous nerve is incorporated into the adventitia of the vein wall 
at this level making tumescence separation impossible and neuronal injury likely 
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(King 2010). A parasthesia rate of 4/50 (8%) has been reported if the BK GSV is 
treated with laser (Timperman 2007). Despite these real considerations below knee 
GSV ablation with laser has also been reported as a safe and effective procedure 
(Theivacumar, Dellagrammaticas et al. 2008). 
 Post-procedural pain was less with UGFS than with EVLA. It was 
acknowledged that if the study were to be repeated with higher wavelength, radial 
fibres this may have reduced pain and therefore also recovery time. Procedure 
duration was also high in the EVLA group in comparison to other studies. The likely 
explanation is that the duration recorded was from the moment of entry into the 
procedure room to the moment of departure. This included WHO checks, set-up 
times, draping, bandaging, computer work and paperwork. Comparative studies just 
include the surgeons operating time which is therefore necessarily shorter 
(Rasmussen, Lawaetz et al. 2011). Once again the point is made of standardisation in 
assessing treatment for CVD. 
 A structured abstract summarising the RCT results has been published on the 
Centre for Reviews and Dissemination (CRD) NHS Economic Evaluation Database. 
This was set up in 1994 to provide the NHS with information on the effectiveness and 
cost-effectiveness of treatments and can be referenced at 
http://www.york.ac.uk/inst/crd (entered on 9/1/13). They acknowledged that the 
methods of the study were good and the authors’ conclusions appeared to be 
appropriate. However, the main deficiencies were in relation to an economic 
evaluation, namely: price years, ICERs and sensitivity analyses which were not 
included in the costing calculations. The study did not set out to assess the impact of 
inflation and deflation, though important, which may justify the absence of a price 
year. Several different cost figures could have been inputted into an ICER calculation 
 377 
but this was not performed in an attempt to keep the data transparent and 
understandable. Without a universally accepted way of calculating cost and 
determining effectiveness an ICER calculation, if performed, would have been 
misleading. Regarding sensitivity analyses the study did report medians and inter-
quartile ranges as well as the effects of changing the variables in costing to determine 
its effect on cost overall. However, the principle determinant of cost is the costing 
approach (top-down or bottom-up) and the scope of the overheads, rather than the 
variability associated with a sensitivity analysis of a single costing methodology.  
 Chapter 16 reports the interim results of the EVLA versus UGFS RCT 
focusing on reflux as an endpoint in the assessment. At a median follow-up of 15 
months, occlusion at some point in the above-knee GSV occurred more often with 
EVLA at 42/44 (95.5%) versus 31/46 (67.4%) for UGFS (P = 0.001, Fisher exact 
test). However, duplex success measured using the absence of any residual/recurrent 
reflux anywhere did not demonstrate any significant difference between the 2 groups 
at 41% for EVLA and 43% for UGFS. Reflux was present in the majority of patients, 
irrespective of treatment type, and occurred in the saphenous trunks, varicose 
tributaries and perforating veins. Although both groups of patients had equal access to 
adjuvant foam sclerotherapy this was given 4.7 times more often in the UGFS group. 
In addition to ablation, residual and recurrent sites of reflux should be reported as an 
outcome measure in order to complete the evaluation of endovenous treatments on the 
leg and enable meaningful comparisons. This was an original recommendation in a 
joint statement by the American Venous Forum and The Society of Interventional 
Radiology (Kundu, Lurie et al. 2007). Interestingly, the presence of reflux at these 
sites did not result in a significant deterioration in the patient’s quality of life. 
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 Many successful GSV outcomes are possible. The RCT reported 6 different 
successful outcome variations on the GSV as well as a detailed inventory of all the 
sites of venous reflux within the leg. This gave the results a greater degree of 
transparency between the 2 groups especially when the saphenous treatment score 
was included in the outcome assessment. The justification for this approach was that a 
single duplex outcome may favour one endovenous intervention whereas a number of 
different duplex assessments provide a global and balanced perspective. For example, 
how does thigh-length GSV occlusion with co-existing below-knee GSV reflux 
compare, in terms of success, to complete restoration of competency throughout the 
full length of the GSV? Interestingly, this study has shown that EVLA and UGFS 
were able to restore competency in the AK GSV in 4.5% and 19.6% of patients, 
respectively. The 5-year results will determine whether these veins become refluxive 
or maintain their competency.   
 Chapter 17 assesses stocking performance in patients with PTS by comparing 
below-knee stockings with above-knee stockings of class I and II. The stockings were 
applied in random order and APG was used to assess performance. The results 
demonstrated that compression stockings significantly improved haemodynamic 
performance in patients with PTS. This was evidenced by a reduction in the rate of 
venous filling and venous volume with an improvement in reflux duration. The extent 
of improvement correlated with the initial magnitude of reflux irrespective of the class 
or length of stocking. There was also a significant but weak correlation between the 
interface pressure measured with a PicoPress and the extent of improvement assessed 
using the VFI of APG.  
 Interestingly, 72.5% of legs required a change of GEC or new prescription 
with 8/21 (38%) patients preferring an AK stocking. The research environment may 
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have been seen by patients as analogous to a fitting room in a department store. The 
opportunity to try out different stockings to see which is more comfortable and fits the 
best may have influenced their decision to change. Since stocking length or strength 
did not have significantly different haemodynamic profiles between them when tested 
on patients it seemed fair to conclude that the results support the liberal selection of a 
GEC stocking based on the preference of the patient. 
 A criticism of the study was that performance was based exclusively on the 
ability of the stocking to reduce the venous inflow or reflux and the venous volume 
(VV). Tests assessing the performance of a stocking at improving the venous outflow 
were not performed. The elastic recoil of the stocking could have been tested in 3 
ways. Firstly, by measuring the volume ejected over the total VV on release of an 
occlusive thigh-cuff (termed the outflow fraction) when wearing a GEC stocking. 
Secondly, by measuring the time taken to eject 90% of the total VV on thigh-cuff 
release. Thirdly, by recording the thigh cuff pressure required to prevent venous 
return. Stronger stockings would be expected to overcome higher thigh-cuff inflation 
pressures. However, the use of these outflow challenge tests in patients with PTS 
would not be without criticism since they are mainly used to assess iliac/femoral 
obstruction rather than the elastic recoil of a stocking. Furthermore, reflux was the 
overriding pathology in the PTS study patients and therefore, correctly, the efficacy of 
a stocking at reducing reflux was the parameter that was assessed. 
 
 
18.2 Summary 
 
Ten proposed recommendations resulting from this work are listed below: 
 
  1) Improve the C class by a consensus on hyperpigmentation regarding C4a 
 
  2) Focus on CVD rather than varicose veins in the NHS 
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  3) Improve the interpretation of the VCSS, AVVQ and the VS by separating out  
 those patients with venous ulceration 
  4) Use of the baseline AVVQ score to provide rationing thresholds 
 
  5) Use of the STS in assessing outcomes after endovenous interventions. 
 
  6) Use of the saphenous pulse in assessing the severity of CVD 
 
  7) Widespread use of VFT90 of APG to quantify global venous reflux duration 
 
  8) Inclusion of more than one costing approach, like micro-costing, in cost- 
 effectiveness evaluations 
  9) Application of a pre-applied stocking prior to sclerotherapy 
 
10) Assessing compression stockings at their effectiveness prior to prescription 
 
 
 
18.3 Future research 
 
Given resources and opportunity the direction of future research will occur along 
three separate paths. The first is to develop and validate the innovations studied within 
the thesis. For example, collaboration with saphenous conservation groups to 
determine whether the STS is able to evaluate outcomes in comparison to 
conventional ablation in SVI. Another example is to determine the relationship 
between the SP and the cutaneous microcirculation using laser Doppler. This device 
can be used to study the veno-arteriolar reflex thereby testing the hypothesis of 
microcirculatory failure in the generation of the SP. Future work along the ideas 
covered in the thesis are discussed in more detail at the ends of the respective 
chapters. 
 The second path is to collect the 5 year follow-up data for the EVLA versus 
UGFS RCT that commenced in 2009. This will be useful to compare the various 
assessment tools in their performance. Duplex endpoints will be compared to APG 
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parameters like the VFT90, VV and VFI to see how they change with time after the 
respective treatments. The significance of reflux in the saphenous trunks, perforating 
veins and tributaries at the 5 year mark will be compared against severity scores and 
QoL assessments.  
 The third path will be to develop assessments of venous outflow resistance and 
evaluate the mechanisms of venous return from the leg to the heart. Once the relative 
contribution of the forces driving antegrade flow within veins is established then the 
forces hampering normal venous return can be studied and corrected. This is a grossly 
under researched area in CVD in comparison to research on reflux.  
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The C part of the CEAP classification (Eklof, Rutherford et al. 2004) 
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Aberdeen varicose vein questionnaire (Garratt, Macdonald et al. 1993) 
Questions 3 and 7 were removed from the final instrument  
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Venous clinical severity score (Rutherford, Padberg et al. 2000) 
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Villalta scale (Strijkers, Wittens et al. 2011) 
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Venous segmental disease score (Rutherford, Padberg et al. 2000) 
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Visual analogue pain score 
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ADDENDUM 
 
The following comments have been added to supplement the discussion. They have 
arisen as a direct result of the viva voce examination held at the Academic Section of 
Vascular Surgery, Charing Cross Hospital, London, by Professor Alun Huw Davies 
and Professor Gerard Patrick Stansby. They addressed some of the drawbacks of the 
study design and methodology and have given constructive input in improving the 
interpretation of this work. Their reservations have been divided into 4 categories, as 
recommended, below. 
 
Compression using stocking class 
Patients’ legs are of different shapes and it is apparent that the classification of 
compression strength by the manufacturer at the single narrowest circumference of 
the gaiter region may not be representative of the compression achieved throughout 
the length of the stocking. The purpose of a GEC stocking is to provide a graduation 
of pressure which is maximal at the ankle and reduces in pressure gradually towards 
the thigh. If a single measurement is used, there is no indication if there are reversed 
pressure gradients or areas of compression loss or constriction.  
 
Chapter 17 compared stocking class and length at reducing reflux. If stocking 
interface pressures were measured at set intervals along the full length of the stocking 
then more meaningful information could have been derived from this study. In 
particular, reversed pressure gradients and constrictions would have been detected and 
these may have had a negative impact on stocking performance. This advice has been 
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of great value in a subsequent project which will measure stocking interface pressures 
along the length of the stocking. 
 
Stocking interface pressures can be used to test for graduation along the length of a 
stocking. Equally important is the observation that interface pressures may vary at the 
same level. Stockings are not uniform and neither are legs which have non-circular 
perimeters in cross-section surrounding tissues of different consistencies. 
Manufactures attempt to accommodate for this by matching stocking shape to leg 
contour. However, there is considerable scope for unequal pressure gradients. For 
example, pressures will be higher over bones and tendons and lower in the recesses 
created by these prominences. In practice, consistent measuring points should help to 
overcome these difficulties.  
 
It was also pointed out that the use of the term “class” differs between countries and 
manufactures. For this reason pressures in mmHg are the preferred way of defining 
the compression properties of stockings rather than a “class” which may be subject to 
different interpretations. Pressure in mmHg has been used throughout the thesis to 
avoid any misunderstandings. 
 
Economic evaluations 
The methodology recommended by NICE in all economic studies on cost-
effectiveness is the use of a quality adjusted life year (QALY). The analysis involves 
looking at the total cost of a treatment and then to assess this against how much 
someone’s life can be improved. The costs and effects are then combined into an 
incremental cost-effectiveness ratio. Decision analytical models, like the Markov 
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model, facilitate this process. If the cost of a treatment is more than £20,000 - £30,000 
per QALY it would not be regarded as cost-effective by NICE.  
 
Although cost and effectiveness were used in chapter 15 regarding the early 
comparisons between laser and foam, a formal health economic evaluation was not 
performed. This was seen as a weakness to the study and an explanation was required 
why this did not take place. Interestingly, part of the data generated by the study was 
evaluated by NICE as part of their decision making process although they 
acknowledged the lack of QALYs. Nevertheless, the study was included in the NHS 
Centre for Reviews and Dissemination (CRD) on 9th January 2013 (accession number: 
22012018967) as a critical abstract of an economic evaluation. It was acknowledged 
that the cost estimates were from one hospital which might limit the generalisation of 
the results across the UK. 
 
It was not the original intention for the study on laser versus foam to undergo high 
levels of data processing for inclusion into UK decision making policy and it was a 
surprise that this happened. In contrast, the aim of this thesis was to go into the 
opposite direction by taking a granular approach in the many ways how CVD is 
assessed. This was achieved with cost by using a micro-costing analysis from the 
ground up, and with effectiveness by examining the responsiveness of individual 
questions of QoL questionnaires.  
 
High impact, expensive, professionally designed, resource intensive, multicenter trials 
are underway comparing treatments for varicose veins using approaches 
recommended by NICE. The need for repetition from a small, low cost trial in a single 
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unit using these approaches would be unimaginative and have little impact. 
Furthermore, using a well trodden pathway was not likely to make any significant 
advances in our understanding of the methods used in cost and effectiveness. For this 
reason a grass roots approach was used where the data is unprocessed, more 
understandable and transparent.       
 
Validations on the Villalta scale 
All studies on validation should include a patient reported QoL questionnaire in order 
to give an additional scope of value. Furthermore, QoL is arguably the most important 
criterion for assessing venous disease and subsequent treatments. It was noted that 
chapter 11, validation of the Villalta scale, was deficient in this regard and an 
explanation was required as to why this had been left out of the study. A recent 
analysis of RCTs which assessed reporting standards highlighted the deficiency that 
QoL was not evaluated in 11/28 studies deemed eligible (Thakur, Shalhoub et al. 
2010). 
 
The lack of a disease specific QoL instrument for the post-thrombotic syndrome 
(PTS) made this pitfall particularly difficult to answer. Suitable contenders include the 
AVVQ, the SF-36 and the VEINES-QOL/Sym. Whilst the AVVQ is specific for 
varicose veins it is not intended for use in the PTS. The SF-36 is a generic 
questionnaire which is not specific for any type of venous disorder and consequently 
has not been tailored to assessing the PTS directly. However, the VEINES-QOL/Sym 
has been validated as a questionnaire which covers the entire range of venous disorder 
and would have been the best choice. It should have been used to improve the quality 
of the subsequent published manuscript and it is with regret that this was not 
 427 
achieved. However, it should be noted that many of the questions in the patient 
reported part of the VS are similar to the VEINES-QOL/Sym. We cannot be sure 
without further experiment, but if the VEINES-QOL/Sym was used then the 
correlations would be expected to be excellent, provided that the patients were 
consistent in their answers and did not suffer with questionnaire fatigue. 
 
In the published version of chapter 11 (Lattimer, Kalodiki et al. 2014) it is stated in 
the study limitations that “there were no disease-specific QoL instruments used ... like 
the VEINES-QOL/Sym”. Disease specific in this context was venous disease rather 
than PTS. Further research may be required in developing a QoL questionnaire that is 
specific for the PTS.    
 
Power calculations on sample size 
It is customary to calculate sample size using a power calculation at the start of a 
study. This is to ensure that enough patients are recruited to achieve statistical 
significance and reduce the risk of a study being underpowered. Sample size 
calculations were not reported at the start of the majority of the projects and the 
reasons for this required explanation. However, it was noted that PART V of the 
thesis entitled “Assessments in randomised clinical trials” (Chapters 15 - 17) had 
power calculations performed prior to their commencement.  
 
Chapters 4, 5, 6, 7, 9, 11 and 12 used ancillary data collected alongside the studies 
from PART V and thus a repository of information was available for analysis. 
Whenever a research idea was conceived the existing data provided the means to test 
the hypothesis. The advantage of this approach is that it maximises the information 
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collected during a study. The disadvantage, of course, is that new endpoints and 
hypotheses are determined after study completion and this may be open to statistical 
bias. It is acknowledged that retrospective analyses on existing databases have less 
impact in terms of level of evidence than data collected prospectively as part of the 
study design. The studies which did not use power calculations for sample size and 
were unrelated to PART V will be discussed below. 
 
Chapter 3 on inter-observer variations in the C of CEAP was a questionnaire study. 
The aim was to get as many responders as possible from 3 international conferences. 
An arbitrary value of n=100 was decided. If this was not achieved then the 
questionnaire would have been be used at a fourth conference. Ten would have been 
too few to make a conclusion that delegates lacked agreement in discriminating mild 
(C0-3) from severe (C4-6) disease. One thousand would have been in excess of 
requirements in making the point because of the limited nature of the study. This is 
because the study was observational using photographs chosen deliberately to invoke 
disagreement. Thus any conclusions drawn are based on the presented photographs. 
The value of any conclusion from this chapter relies on the degree in which the 
photographs are representative of a patient population. 
 
Chapter 8 correlating venous filling time using APG with duplex derived reflux time 
is an innovation. Simultaneous measurements have never been performed and there is 
no information in the literature on the range of values obtained of venous reflux 
duration using an elevation-dependency manoeuvre. Thus any formal sample size 
calculations would require a great deal of assumption and have limited value. In 
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retrospect, the chosen sample size of 26 was enough in achieving sufficient power (P 
< 0.0005, r = 0.933). 
 
Likewise, chapter 10 on the relationship between saphenous pulsation (SP) and 
severity of disease is an innovation. Few practitioners have recognised SP and none 
have attempted to establish a connection to clinical severity. Seventy-eight legs were 
tested which was an arbitrary number decided by our research team. This study was 
investigative and the hypothesis was very general, trying to establish if SP is common 
and what role it plays in the assessment of chronic venous disorder. It is anticipated 
that future researchers on SP will use the data obtained from this study for their 
sample size calculations. 
 
The remaining chapters 13 and 14 were measurement studies. The former measured 
the volume across the sapheno-femoral junction during a Valsalva manoeuvre (VM) 
and the latter the volume flow during the pull-up of a GEC stocking. The former used 
an arbitrary value of 23 patients (legs) and the latter used 12 patients (legs). Greater 
numbers would have improved the confidence of the measurements. The information 
obtained from the results of chapter 13 is that a Valsalva manoeuvre can displace a 
large volume of blood (median of 40 mL) across the SFJ in 3 seconds. Chapter 14 has 
shown an 18 fold increase in peak velocity and a 9 fold increase in volume flow 
during a pull-up manoeuvre. Huge effects like these do not require large sample sizes. 
These should be reserved for studies where the anticipated effects are marginal. 
Furthermore, given the variability of how a VM is performed by the patient and the 
variability of how stockings are pulled up by the physician it is doubtful whether 
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larger sample sizes would significantly affect the usefulness of the information 
obtained from this study.  
 
 
